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Summary 
Background 
The syndrome of heart failure is common, and is associated with high morbidity 
and reduced life expectancy.  Patients can experience high symptom burden, low 
mood, and impaired quality of life.  Repeated, and often prolonged, 
hospitalisations due to exacerbations of heart failure and other co-morbidities are 
common.  Over the last 25 years, the evidence base for the treatment of heart 
failure has increased, with an associated improvement in prognosis.  However, 
many patients with heart failure still have a poor prognosis.  International 
guidelines for the treatment of heart failure now suggest referral to palliative care 
services, particularly in patients thought to have a poor prognosis and impaired 
quality of life.  Despite these recommendations, few patients with this condition 
have access to specialist palliative care services in the United Kingdom.  However, 
not every patient with heart failure will have palliative care needs, therefore the 
extent of the problem of unmet palliative care needs in patients with heart failure 
is unknown. 
I systematically reviewed the published literature to identify studies describing the 
palliative care needs, including prevalence, of patients with heart failure.  
Although my search identified over 60 publications describing the palliative care 
needs of patients with heart failure, most of the studies were of highly selected 
cohorts, did not include descriptions of therapy, or descriptions of severity of 
heart failure such as ejection fraction, natriuretic peptides, prognostic scores or 
clinical outcomes.  Most studies used a cross-sectional approach to describe the 
potential palliative care needs, and therefore, were unlikely to appreciate the 
variable clinical course of patient with heart failure.  Although the studies 
identified were informative, a definitive description of the prevalence of palliative 
care needs in a well described, contemporary cohort of patients with heart failure 
is lacking.  My systematic review also identified a number of preliminary 
randomised controlled clinical trials, assessing the effect of early palliative care in 
patients with heart failure.  However, these studies included small numbers of 
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participants, and only had qualitative endpoints such as change in quality of life 
measures without assessment of clinical outcomes such as death or hospitalisation. 
Again, although these preliminary trials are informative, a definitive evidence base 
comparing palliative care to standard care in heart failure is not available. 
Aims 
The primary aim of this study was to inform the design of a randomised controlled 
clinical trial of palliative care in patients with heart failure.  The first step in this 
process was to define the clinical problem and identify a suitable target population 
by describing the prevalence of patients with heart failure who have palliative 
care needs.  I then aimed to describe whether these patients could be identified 
from data collected during an index hospital admission.  The final aim of my study 
was to identify useful outcome measures which could be used in a randomised 
controlled clinical of palliative care in heart failure.   
Methods 
This was a prospective, longitudinal study of the prevalence of possible palliative 
care needs, defined using quantifiable patient reported outcome measures.  An 
unselected cohort of patients admitted to hospital with a primary diagnosis of 
heart failure were recruited and extensively characterised.  The World Health 
Organisation definition of palliative care was used to identify patients with heart 
failure who had palliative care needs.  I made objective assessments of quality of 
life (using the Kansas City Cardiomyopathy and Short Form 12 questionnaires), 
mood disturbance (using the Hospital Anxiety and Depression Scale), symptom 
burden (using the Edmonton Symptom Assessment Scale), and caregiver strain 
(using the Zarit Burden Interview questionnaire).  These assessments were made at 
baseline and repeated every four months for the duration of the study.  Patients 
were identified as having palliative care needs if they had persistently severe 
impairment of any patient reported outcome measure without improvement, or 
severe impairment of any patient reported outcome measure followed by death.  
End-of-life care was assessed using the Views Of Informal Caregivers Evaluation of 
Services questionnaire, and by comparing preferred place of end of life care to 
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actual place of death.  Multivariate logistic regression analysis was used to 
determine if baseline prognostic markers, physician completed assessments, or 
patient reported outcome measures could identify patients with palliative care 
needs. 
Results 
Between January 9th 2013 and December 1st 2014, 313 near consecutive patients 
with heart failure were enrolled in the study.  Of these, 272 (86.9%) completed 
patient reported outcome measures at baseline and agreed to attend study visits.  
Patients were elderly, with a median [interquartile range] age of 76 [70-82] years, 
and 47% of participants were female.  56% of patients did not have a previous 
diagnosis of heart failure.  Most participants had heart failure with reduced 
ejection fraction (67.3%) compared to heart failure with preserved ejection 
fraction (32.7%).  Use of disease modifying pharmacotherapy was high, especially 
in participants with heart failure with reduced ejection fraction.  
Participants suffered from a number of physical and psychological symptoms, as 
recorded using patient reported outcome measures.   The most common physical 
symptoms were shortness of breath and fatigue, followed by drowsiness and lack of 
appetite.  Although less frequent, pain and nausea were also common.  
Participants reported higher scores for depression and anxiety compared to studies 
using similar mood assessments in the general population.  Quality of life was 
impaired in most participants at baseline, with 77.9% of participants being 
classified as having moderate or severe impairment as assessed by the Kansas City 
Cardiomyopathy questionnaire.  At baseline, 114 (41.9%) participants scored severe 
in at least one patient reported outcome measure.  Of these, 95 (83%) participants 
scored severe on the Kansas City Cardiomyopathy Questionnaire.   
Participants were invited to attend study visits, or have home study visits, every 
four months for the duration of the study.  The minimum number of study visits 
offered was two for the last participant enrolled.  A total of 691 study visits were 
performed.  37% of these assessments were home visits.  Participants were also 
followed up passively using record linkage to report number and cause of 
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hospitalisations, and cause and location of any deaths.  Participants were followed 
up for a minimum of one year.  During follow-up, 217 (79.8%) participants were re-
admitted to hospital.  The median number of admissions was 3.  Most 
hospitalisations were due to non-cardiovascular causes.  During passive follow-up 
until December 1st 2015, there were 103 (37.8%) deaths. Most (60.2%) deaths were 
due to cardiovascular causes.   
73 (26.8%) participants met my criteria for having palliative care needs.  These 
patients had worse summary scores at baseline for all patient reported outcome 
measures.  Patients who met my definition of palliative care needs spent fewer 
days alive and out of hospital than the group who did not meet the definition of 
palliative care needs.  The median [IQR] days alive out of hospital in the group 
meeting the definition of palliative care needs was 394 [172-586], compared to 638 
[420-809] in the group not meeting the definition of palliative care needs 
(p<0.001).  After adjusting days alive out of hospital for quality of life, patients in 
the palliative care needs group had fewer days of good health as a percentage of 
total follow-up, median 12 [3-22] % of potential follow-up, compared to 47 [25-68] 
% in those not meeting my definition of palliative care needs (p<0.001). 
Most participants expressed a wish to spend the end of their life at home, but 
despite this, most died in hospital.  17 caregivers completed the Views Of Informal 
Caregivers Evaluation of Services questionnaire.  Overall care in the last few 
months of life was assessed as fair or poor by 35.3%.  Of the 272 participants who 
participated in the whole study, 33 (12.1%) had access to specialist palliative care 
services.  Of the 73 participants who met the definition of PC needs, 19 (26.0%) 
accessed specialist PC services.  6 (2.2%) participants used hospice care during the 
duration of the study. 
Using multivariate logistic regression analysis, a low Kansas City Cardiomyopathy 
Questionnaire summary score and a low Australia Modified Karnofsky Performance 
Scale (a physician completed assessment) score, were predictive of patients with 
palliative care needs.  Conventional prognostic markers, such as natriuretic 
peptides or ejection fraction, were not predictive of patients with palliative care 
needs.  Physicians, using their clinical judgement, were only modestly accurate at 
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predicting patients with heart failure who had or would go on to develop palliative 
care needs.  Physicians were better at predicting prognosis than need for palliative 
care. 
Conclusions 
Palliative care needs were common in patients with heart failure admitted to 
hospital with heart failure, with 26.8% of participants meeting my definition of 
palliative care needs.  This study has shown there is an unmet need for palliative 
care in many patients with heart failure, with a marked discrepancy between the 
patients who met the definition of palliative care needs and those who accessed 
specialist palliative care services.  I have also shown that patients with heart 
failure who go on to develop palliative care needs can be identified during a 
hospitalisation, using a combination of a patient reported outcome measure and a 
physician completed assessment.  Patients who met my definition of palliative care 
needs had 40% fewer days alive and out of hospital than those who did not.  The 
quality of days alive out of hospital was much worse.  This thesis also provides 
important pilot data describing the quality of life adjusted days alive out of 
hospital of a “real life”, unselected, and therefore, generalisable cohort of 
patients with heart failure.  I hope that these data, including the detailed 
description of a suitable target population, will inform the design of a randomised 
controlled clinical trial assessing the benefit of early palliative care in patients 
with heart failure. 
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Chapter 1 Introduction 
1.1 What is heart failure? 
Heart failure is a clinical syndrome, the definition, management, and prognosis 
of which has changed dramatically over the years.  Although one of the first 
descriptions of heart failure in the medical literature was in 1930s by Thomas 
Lewis, who described heart failure as “a condition in which the heart fails to 
discharge its contents adequately” , it was not until as recently as the 1980’s 
that a fuller understanding of some of the aetiologies and pathophysiological 
processes led to the description of heart failure as a clinical syndrome .1 The 
classical definition of heart failure by Eugene Braunwald describes heart failure 
as “the pathophysiological state in which an abnormality of cardiac function is 
responsible for failure of the heart to pump blood at a rate commensurate with 
the requirements of the metabolizing tissues.”2 The clinical syndrome of heart 
failure has been further defined by the European Society of Cardiology (ESC) as 
the presence of typical symptoms and signs (see Table 1-1) resulting from an 
abnormality of cardiac structure or function.3  
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Table 1-1 Typical signs and symptoms of heart failure 
Symptoms Signs 
Typical More specific 
Ankle swelling 
Elevated jugular venous pressure 
 
Orthopnoea 
 
Hepatojugular reﬂux 
Paroxysmal nocturnal dyspnoea 
 
Third heart sound (gallop rhythm) 
Reduced exercise tolerance 
 
Laterally displaced apical impulse 
Breathlessness 
 
Cardiac murmur 
Fatigue, tiredness, increased time to 
recover after exercise 
 
Less Typical Less Specific 
Nocturnal cough 
Peripheral oedema (ankle, sacral, 
scrotal) 
Wheezing 
 
Pulmonary crepitations 
Weight gain (>2 kg/week) 
Reduced air entry and dullness to  
percussion at lung bases (pleural  
effusion) 
Weight loss 
(in advanced heart failure) 
Tachycardia 
Bloated feeling 
 
Irregular pulse 
Loss of appetite 
 
Tachypnoea (>16 breaths/min) 
Confusion 
(especially in the elderly) 
Hepatomegaly 
Depression 
 
Ascites 
Palpitations 
 
Tissue wasting (cachexia) 
Syncope 
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1.1.1 Aetiology and pathophysiology of heart failure 
The syndrome of heart failure can be caused by a number of conditions.4 
Ischaemic heart disease (especially in myocardial infarction) is by far the most 
common and best-understood cause of heart failure in developed countries, 
particularly in the context of left ventricular systolic dysfunction.  Other 
common causes of heart failure include hypertension, valve disease, inherited 
cardiomyopathies (dilated, hypertrophic, arrhythmic right ventricular 
cardiomyopathy, and left ventricular non-compaction), and congenital heart 
disease.  Rarer causes of heart failure include arrhythmia, infection, infiltrative 
conditions such as amyloidosis or sarcoidosis, iatrogenic causes such as 
chemotherapy, pericardial diseases, metabolic diseases, endocardial disease, 
conduction disorders, and high output states.   
As there are many causes of the syndrome of heart failure, there is no unifying 
pathophysiological process.  However, a number of pathological mechanisms and 
pathways have been described in detail, particularly in the context of heart 
failure with a reduced ejection fraction (HF-REF).  Following an insult and 
reduction in cardiac output and/or increased wall stress of the left ventricle, 
caused by one of the aforementioned aetiologies of heart failure, a number of 
compensatory mechanisms are activated to maintain sufficient cardiac output 
and reduce ventricular wall stress. These compensatory mechanisms include 
activation of the adrenergic nervous system with increased circulating levels of 
noradrenaline, the renin-angiotensin aldosterone system (RAAS), and the 
cytokine system.5, 6  Consequently there are increased levels of neuro-hormonal 
and autocrine/paracrine mediators of hypertrophy such as noradrenaline, 
angiotensin II, endothelin 1, fibroblast growth factor, transforming growth 
factor-β, tumour necrosis factor-α, and interleukin-1β amongst others.6  
Sustained up-regulation of these systems results in hypertrophy of the cardiac 
myocytes.7  Although initially protective, many of these mechanisms and 
pathways eventually result in pathological structural changes to the left 
ventricle, known as ventricular remodelling.8 As well as increased levels of the 
vasoconstrictors noradrenaline and angiotensin II, both of which directly 
stimulate myocyte hypertrophy but also increase afterload on the ventricle, 
there is, over time, loss of the beneficial effects of the endogenous counter 
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regulatory vasodilators such as nitric oxide, natriuretic peptides, prostaglandins, 
and kinins.5, 6, 9   
There have been three broad patterns of ventricular remodelling described: 
concentric remodelling, caused by increased myocyte thickness in response to 
increased pressure load on the left ventricle; eccentric remodelling, caused by 
myocyte lengthening in response to increased volume load on the left ventricle; 
and myocardial infarction, where tissue is dilated, damaged, and stretched, 
resulting in a combination of pressure and volume load on the rest of the 
ventricle.8  In eccentric remodelling and the remodelling changes seen post-
myocardial infarction there is progressive left ventricular dilation, sphericity, 
left ventricular wall thinning, and mitral valve incompetence.5  These changes to 
left ventricular geometry, particularly eccentric remodelling, can result in 
further pressure and volume load to the left ventricle, with resultant 
exacerbation of the afore mentioned compensatory mechanisms.  Other 
pathological changes that occur in failing hearts include changes to the extra-
cellular matrix, with increased collagen and fibrous deposition, reduced myocyte 
contractile function, cell apoptosis and death.  The pathological processes 
involved in heart failure with preserved ejection fraction (HF-PEF) are not as 
clearly described, although concentric left ventricular remodelling and 
hypertrophy in response to increase pressure load, with resultant impaired 
diastolic function and impaired left ventricular filling are thought to be 
important.10  Although left ventricular hypertrophy alone does not explain the 
presence of the heart failure syndrome in those with a preserved ejection 
fraction.11 
All of these changes result in a progressive spiral of reducing cardiac function 
and worsening of the pathological processes.  This spiral of ventricular 
remodelling was once thought to be un-modifiable, and thus palliative.  
However, some contemporary treatments have been shown to impede12-15 and in 
some instances reverse16 both eccentric left ventricular remodelling and 
concentric remodelling (when caused by aortic stenosis).17 
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1.1.2 Incidence, prevalence and prognosis of heart failure 
Prevalence of heart failure in the community 
Heart failure is common, affecting between 1-2% of the general population.18-21  
The prevalence of heart failure increases with age, with over 10% of the general 
population over the age of 80 suffering from heart failure.19, 21  A number of 
studies have used echocardiography and symptom status to estimate the 
prevalence of heart failure in the general population.  The first of these studies 
was carried out in Glasgow in the mid-1990s, where a cross-sectional sample of 
2000 men and women from the community were assessed using 
echocardiography, biomarkers, questionnaires, and medical examination.18  They 
found the prevalence of left ventricular dysfunction was 2.9% overall, and those 
with signs and symptoms of heart failure and left ventricular dysfunction was 
1.5%.  These data were similar to the Echocardiographic Heart of England 
Screening Study (ECHOES), where 6286 randomly selected patients over the age 
of 45 had an echocardiogram, history and examination.19  Prevalence of heart 
failure (based on symptoms and signs) was present in 2.3%, with 41% of these 
patients having an ejection fraction less than 40%.  Redfield et al performed a 
similar cross-sectional study of 2042 randomly selected adults over 45 years in 
Olmstead County.20  Each participant had an echocardiogram and the 
Framingham criteria for diagnosis of heart failure was applied to confirm the 
diagnosis.22  Using these methods, 2.2% of the study population had confirmed 
heart failure, with 56% having a reduced ejection fraction.  The Rotterdam Study 
enrolled 7983 participants from a potential population of 10275 in the town of 
Ommoord, in the Netherlands.21  They found the prevalence of heart failure in 
this cohort to be between 6-7%, perhaps reflecting the older age cut-off used as 
inclusion criteria.  The prevalence of heart failure ranged from 0.9% in subjects 
aged 55-64, to 17.4% in those aged over 85 years. 
Incidence of heart failure  
Incidence rates of heart failure have been reported in a number of community 
studies.21, 23  The Rotterdam Study reported an incidence rate of 14.4 per 1000 
person-years, with a much higher rate in men versus women with rates of 17.6 
and 12.5 per 1000 person-years respectively.   The incidence increased with age, 
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with those aged 55-59 having a rate of 1.4 per 1000 person-years compared to 
47.4 per 1000 person-years in those over the age of 90.  This trend was seen in 
both men and women.  The Hillingdon epidemiology study recorded incident 
cases of heart failure identified through referral to a heart failure diagnostic 
pathway.  They reported much lower incidence rates of 1.3 cases per 1000 
person-years.  Incidence again was higher in elderly subjects, with rates of 0.02 
per 1000 person-years in those ages 25-34, and 11.6 in those over 85 years.  The 
discrepancy between these two studies can perhaps be explained by the 
methodology used, where the Rotterdam Study attempted to screen a whole 
population, and thus unselected cohort, the Hillingdon Study was a much more 
selected population by utilising a referral pathway.  Two population studies in 
the United States reported incident rates at several time points and allow 
observations to be made regarding the possible changing incidence of heart 
failure.24, 25  Levy et al reported incidence rates of heart failure in The 
Framingham Heart Study between 1950-69, 1970-79, 1980-89, and 1990-99.  The 
incident rate for development of heart failure did not change significantly in 
men over these time periods, although there was a significant reduction in 
incident rate for women of 30-40%.24   The Rochester Epidemiology Project, 
conducted in Olmsted County, Minnesota, recorded incident cases of heart 
failure over a time period of 20 years.25  The incidence rate was higher amongst 
men (378 per 100 000 persons) compared to women (289 per 100 000 persons), 
and did not change over time amongst men or women.  Jhund et al studied the 
incidence rates of first hospitalisation for heart failure by analysing the 
electronic record system in Scotland between 1986 and 2003.26  All discharge 
diagnoses and causes of death were coded according to the International 
Classification of Diseases.  The age adjusted incidence rate per 100 000 persons 
for men increased between 1986-1994, from 124 to 162.  This trend changed 
after 1994, with a falling incidence rate for first hospitalisation for heart failure.  
A similar trend was seen in both men and women.  Similar trends for first 
hospitalisation for heart failure have been observed in other countries, such as 
The Netherlands, Sweden, and England.27-29  This fall in incidence of 
hospitalisation for heart failure, but not for incidence of community heart 
failure, could be as a result of improved prescribing of heart failure therapy and 
the introduction of heart failure nurses.26  Although community incident rates 
have not declined, the ageing population, combined with better survival from 
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myocardial infarction and heart failure itself, will likely result in an overall 
increase in prevalence of heart failure, particularly in the elderly.30   
Prognosis of patients with heart failure 
Short and long-term prognosis for patients diagnosed with heart failure remains 
poor, although with each successive new therapy survival has improved.  In the 
Co-operative North Scandinavian Enalapril Survival Study (CONSENSUS), 
published in 1986, which enrolled 253 patients with New York Heart Association 
(NYHA) class IV and reduced ejection fraction, 44% and 52% of the placebo arm 
were dead at 6 and 12 months, respectively.31 This is a stark contrast to the 
most recent large randomized controlled trial in heart failure with reduced 
ejection fraction (HF-REF), the Prospective Comparison of ARNI [Angiotensin 
Receptor–Neprilysin Inhibitor] with ACEI [Angiotensin-Converting– Enzyme 
Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure 
Trial (PARADIGM-HF), which was published in 2014 and enrolled 8442 patients 
with NYHA II-IV and HF-REF.32  In this study participants were on good 
contemporary therapy, with over 90 %, 54%, and 14% of participants receiving a 
beta-blocker, mineralocorticoid receptor antagonist, and implantable 
cardioverter defibrillator, respectively, at baseline.  All participants were on an 
ACEI during the run in phase of the study.  The overall mortality for both 
treatment groups was under 30% after 3.5 years of follow up.  Although 
randomised controlled clinical trials (RCTs) are useful in terms of estimating 
prognosis in patients with heart failure, they do not adequately reflect real-
world patients in the community, who are generally older and with more co-
morbidities.  One contemporary study that provides important prevalence and 
mortality data in a community population is the ECHOES study.33  This 
prospective study screened over 6000 members of the public in England with 
echocardiograms and performed detailed characterisation of each participant.  
These patients were followed up for over 10 years for vital status, thus providing 
useful insight into prognosis of community patients with heart failure in the 
United Kingdom.  They found that patients with heart failure, both HF-REF and 
HF-PEF, had much worse 5 and 10 year survival rates.  54% of those with heart 
failure were alive after 5 years follow up, compared to 90% of those without 
heart failure.  When these patients were followed up to 10 years, only 28% of 
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those with heart failure compared to 76% of those without heart failure were 
alive.  Patients admitted to hospital because of heart failure are at even higher 
risk of death.  Using hospital discharge records linked to death certificates 
through Information Services Division (ISD) of the National Health Service (NHS) 
Scotland, Jhund et al were able to describe 30 day, 1 year, and 5 year mortality 
following a hospitalisation for heart failure.  They were also able to describe 
change over time between 1986 and 2003 in Scotland.26  In 1986, 30 day 
mortality for men and women was 24 and 21 %, respectively, 1 year mortality for 
men and women was 33 and 31 % respectively, and 5 year mortality was 74 and 
70 % respectively.  These mortality rates improved over time, and in 1999, 30 
day mortality for men and women was 20 and 19 % respectively, 1 year mortality 
for men and women was 28 and 28 %, respectively, and 5 year mortality was 66 
and 64 % respectively.  Although these trends for improving mortality were 
highly statistically significant, clearly the prognosis for patients with heart 
failure is still poor.  
The natural history of heart failure is unpredictable at an individual patient 
level.  Some patients will respond very well to therapy and will have a life 
expectancy approaching that of the normal population, whereas others will 
remain highly symptomatic and experience multiple hospital admissions with 
AHF and a shortened life expectancy.  There are numerous risk prediction 
models for both patients in the community and those hospitalised because of 
heart failure, however, although these models are good at predicting prognosis 
at population level, they are not good at predicting individual patient 
prognosis.34 
Where and how do patients with heart failure die? 
Most patients with heart failure die from cardiovascular (CV) causes and the 
majority due to either worsening heart failure or sudden death.35  There is some 
evidence that patients with more severe symptoms of heart failure are more 
likely to die from worsening heart failure, whereas less symptomatic patients 
are more likely to suffer a sudden death from arrhythmia.36, 37   The majority of 
heart failure patients die in hospital.  Place of death was recorded in the 
Assessment and Treatment with Lisinopril and Survival (ATLAS) trial and more 
than 50% of patients died in hospital and those who died out of hospital were 
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more likely sudden deaths.38  This was similar to the results of the Sudden 
Cardiac Death in Heart Failure (SCD-HeFT) trial where 58% died in hospital, 29% 
died at home, and 7% in an extended care facility.39  Although these clinical 
trials are informative, they had a number of exclusion criteria and were not 
based on consecutive patients.  Therefore, they are not truly reflective of the 
general population with heart failure.  A recent analysis of data gathered from 
death certificates from England and Wales reported over 60% of patients dying 
from heart failure died in hospital and less than 20% died at home.40  However, 
as heart failure is potentially under-reported on death certificates, this may not 
be truly reflective of patients with HF in the general population.40, 41    Preferred 
place of death was described in a study of 80 patients hospitalised with heart 
failure which reported that 50% wished to be cared for at home when recovery 
seemed unlikely, and 40% wished to remain in hospital.42  Data from prospective 
follow up of unselected, consecutive patients comparing preferred place of 
death to actual place of death is lacking in patients with heart failure.  Patient 
preference for end of life care has been identified as a priority for research into 
palliative care (PC) need in patients with heart failure.43, 44  Previous studies 
suggest that patients often change their mind about preferred place of death 
and there is also poor agreement with their carer on this issue.45  Patients also 
change their mind about resuscitation status.46, 47   A recent study has confirmed 
that patients with heart failure are willing to discuss end of life issues and also 
found that patients change their mind regarding resuscitation.48  The same group 
also found that patients in this trial were willing to trade quality of life for 
length of life, which is contrary to previous studies.   Although these studies are 
informative, they are based on clinical trial cohorts, and therefore represent a 
selected population. 
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1.1.3 Types of heart failure syndromes 
Acute versus chronic heart failure 
The syndrome of heart failure can present in two ways, as an emergency 
requiring hospital admission, often termed ‘acute heart failure’ (AHF), or in a 
more insidious fashion in the community, often called ‘chronic heart failure’ 
(CHF).  Patients presenting to hospital with AHF are often known to have a 
diagnosis of CHF which has acutely deteriorated with worsening symptoms.   The 
Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with 
Heart Failure (OPTIMIZE-HF) registry included data describing over 48 000 AHF 
hospitalisations in 259 hospitals across the United States.49   52% of patients in 
this registry were known to have heart failure prior to admission.50 Common 
precipitating factors identified in those patients presenting with AHF included: 
arrhythmia (14%); uncontrolled hypertension (11%); ischaemia (15%); worsening 
renal function (7%); pneumonia (15%); non-adherence to medication (9%); non-
adherence to diet (13%).  Many patients had more than one factor that 
precipitated admission.  Patients presenting to hospital with AHF often have 
signs and symptoms of pulmonary or peripheral oedema or congestion, or a 
combination of both of these.  In extreme cases, patients can present in 
extremis and in cardiogenic shock.   Acute pulmonary oedema is extremely 
distressing for patients and often a medical emergency.  Acute pulmonary 
oedema results when increased left ventricular end-diastolic pressure, which is 
initially compensatory and increases pre-load and cardiac output, causes 
increases in pulmonary venous and ultimately capillary pressure.  When the 
capillary pressure raises above the point where colloid osmotic pressure and 
alveolar basement membrane can keep fluid within the arterial and venous 
system, then fluid starts to accumulate in the pulmonary interstitium, alveoli, 
and ultimately airways.51   Pulmonary oedema is often acute onset, on a 
background of a few days of increasing dyspnoea. Treatment with oxygen, 
diuretics, and vasodilators, usually resolves acute pulmonary oedema quickly 
over a few hours.  However, some patients do not respond to these treatments 
and acute pulmonary oedema can be a terminal event.  Other patients with AHF 
present with a more insidious deterioration with peripheral fluid accumulation 
over weeks or months, which ultimately gets to a point where this cannot be 
managed at home.  The pathophysiological mechanisms of peripheral fluid 
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accumulation of cardiac origin are thought to be related to the heightened 
neurohormonal response seen in heart failure and to reduced renal perfusion.52 
Ultimately elevated levels of renin, aldosterone, natriuretic peptides, growth 
hormone, anti-diuretic hormone and cortisol result in sodium and water 
retention and oedema.52  Peripheral oedema usually develops in the feet and 
ankles first, then as more sodium and water retention occurs, this increases to 
thigh level and ultimately ascites and pleural effusions.  Patients often have 
many litres of excess fluid.  Patients presenting to hospital with gross oedema 
and fluid overload require treatment with intravenous diuretics and are often 
hospitalised for numerous days.  During the most recent audit of over 40 000 
heart failure admission in England and Wales between 2012 and 2013, the 
median length of stay was 8 days.53 
To determine the common presentations of patients with AHF, 452 consecutive 
admissions were retrospectively analysed at the Brigham and Women’s Hospital 
between 1996 and 1999.54  The authors found four common types of presentation 
in AHF based on the presence or absence of adequate perfusion and the 
presence or absence of congestion.  Congestion was deemed present if patients 
had orthopnoea, jugular venous distention, pulmonary rales, hepatojugular 
reflux, ascites, peripheral oedema, leftward radiation of the pulmonic heart 
sound, or a square-wave blood pressure response to the Valsalva manoeuver.  
Patients were classified as either adequate perfusion (warm), inadequate 
perfusion, congested, or uncongested.  27% were well perfused and 
uncongested, 49% were well perfused and congested, 20% were congested and 
under-perfused, and 4% were under-perfused and uncongested.  Patients that 
presented with signs and symptoms of congestion had a poorer prognosis. 
CHF is a state where patients have been relieved of congestion, usually with 
adequate treatment with diuretics, and have been started on long-term therapy 
for heart failure.  The typical symptoms experienced by patients with CHF are 
predominantly dyspnoea and fatigue, although a variety of other symptoms can 
be experienced including chronic oedema.  Severity of symptoms is often graded 
using the NYHA classification, Table 1-2.55  Although this scoring system is the 
most widely used and is predictive of prognosis, there are limitations.  Namely, 
the scoring system does not equate to ventricular function at rest and often it 
not clear if NYHA classification has been applied by the physician or the patient.  
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Often there is a discrepancy between physician and patient estimates of 
functional limitation.56 
Table 1-2 NYHA classification 
Class Symptoms 
I No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea. 
II Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea. 
III Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. 
IV Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest.   
As previously discussed, patients with heart failure who are admitted to hospital 
with AHF have a worse short and long term prognosis than those in the 
community.  This higher mortality risk is not entirely related to the acute 
presentation, as most patients survive to discharge, but more reflects that these 
patients are a much higher risk group perhaps with more advanced disease.  In 
the OPTIMIZE-HF registry, there were 1834 (3.8%) deaths during the index 
admission.49  Although this was lower than that seen in England and Wales, 
where in hospital mortality was reported at 9.4%.53 
Heart failure with reduced versus preserved ejection fraction 
Heart failure is now further categorised by both the ESC and the American Heart 
Association according to cardiac function.3, 57  Specifically, patients are 
categorised according to the most widely used estimate of ventricular systolic 
function, called ejection fraction.  This is most commonly measured using 
echocardiography.  HF-REF is defined by the ESC as an ejection fraction of less 
than 50% and HF-PEF as greater than or equal to 50%.  Analysis of community, 
hospitalised and RCT cohorts reveals a distinctive difference in phenotype 
between these two groups.58  Patients with HF-PEF are generally older, more 
often female and tend to have a higher body mass index.  The number and type 
of co-morbidities in these two types of heart failure would appear to differ as 
well. Hypertension, atrial fibrillation, and chronic lung disease appear to be 
more common in patients with HF-PEF compared to HF-REF, where the converse 
is true regarding coronary artery disease.   Other commonly reported medical 
conditions such as chronic kidney disease and anaemia appear to have similar 
prevalence between HF-PEF and HF-REF.  Historically, the perception has been 
that HF-PEF is a more benign phenotype than HF-REF, although two large cohorts 
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(one community and one hospital) have suggested that not only is HF-PEF as 
common as HF-REF, but associated with a similar prognosis.59, 60  Although, a 
meta-analysis of over 41 000 patients from a variety of cohorts showed that HF-
REF has a poorer outcome.61 The most striking and clinically relevant difference 
between the two phenotypes of heart failure is the response to therapy, where 
HF-REF has one of the strongest evidence bases for treatments which reduce 
mortality, there has been no therapy proven to improve survival in HF-PEF.3 
1.1.4 Management of heart failure 
1.1.4.1 HF-REF 
The management of HF-REF has changed dramatically over the past 25 years, 
with a resultant increase in survival for patients.  Many of the key treatments in 
HF-REF are aimed at interrupting the pathological neurohormonal cascade that 
occurs in heart failure, namely increased noradrenaline and the RAAS system.  
The first agent to be shown to reduce mortality in these patients was the ACEI 
enalapril.  This was used in the key RCTs CONSENSUS and Studies of Left 
Ventricular Dysfunction (SOLVD)- Treatment trials, which enrolled 256 and 2569 
participants with NYHA IV and II/III, respectively.31, 62  There was a relative risk 
reduction (RRR) in mortality of 27 and 16% with use of an ACEI in CONSENSUS and 
SOLVD-Treatment, respectively.  Further improvements in survival in patients 
with HF-REF were demonstrated in large RCTs of beta-blockers.  These landmark 
trials were the Cardiac Insufficiency Bisoprolol Study II (CIBIS II), Metoprolol 
CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF), 
and Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) 
trials.63-65  Further improvements in survival were demonstrated through use of 
the mineralocorticoid receptor antagonists (MRAs) spironolactone and 
eplerenone in the Randomized Aldactone Evaluation Study (RALES) and 
Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure 
(EMPHASIS-HF) trials.66, 67  These studies enrolled 1663 and 2737 patients with 
HF-REF and NYHA class III and II respectively.  There was a RRR in mortality of 
30% in RALES and a RRR in cardiovascular mortality of 37% in EMPHASIS-HF.  In 
the Valsartan Heart Failure (Val-HeFt) and Candesartan in Heart failure: 
Assessment of Reduction in Mortality and morbidity (CHARM) Added and 
Alternative trials, angiotensin receptor blockers were effective at reducing heart 
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failure hospitalisation in patients intolerant of ACEI, or in addition to ACEI, but 
did not reduce all-cause mortality.68-70  Another therapy for HF-REF which has 
been shown to reduce heart failure hospitalisation but not mortality is the If 
channel blocker ivabradine.71  In the Digitalis Investigation Group (DIG) trial of 
6800 participants with HF-REF, digoxin was shown to reduce heart failure 
hospitalisation, but not mortality.72  The combination of hydralazine and 
isosorbide dinitrate was shown to reduce mortality in a selective population in 
the African-Americans with Heart Failure Trial (A-HeFT).73 
These dramatic reductions in mortality in HF-REF with pharmacotherapy, 
particularly ACEI, beta-blockers and MRAs, have been further improved upon 
with the addition of device therapy.  Implantable cardioverter defibrillators 
(ICDs) are one such device, which detect malignant ventricular arrhythmias and 
deliver an electrical shock, aimed at cardioverting the patient back to sinus 
rhythm.  The SCD-HeFT trial enrolled 2521 patients with HF-REF (ejection 
fraction ≤ 35%), NYHA class II/III, no history of ventricular arrhythmias, and 
either non-ischaemic or ischaemic cardiomyopathy.74  Treatment with ICD, in 
addition to ACEI (96%) and beta-blocker (69%) therapy resulted in a 23% RRR 
compared to treatment with amiodarone.  These results were supported by the 
Multicentre Automatic Defibrillator Implantation Trial II (MADIT-II), which 
enrolled 1232 patients with a previous myocardial infarction and a low ejection 
fraction (<30%).75  Participants were randomised to receive conventional medical 
therapy or ICD, and those receiving ICD had a 31% RRR in mortality.  Patients 
with HF-REF (ejection fraction ≤ 30%), in sinus rhythm, a prolonged QRS 
duration, and left bundle branch block (LBBB) morphology have improved 
survival with the addition of cardiac resynchronization therapy (CRT) by pacing 
both sides on the heart.76, 77  The improved survival seen CRT use in NYHA class 
III/IV patients was also seen in addition to ICD therapy in patients with HF-REF 
and NYHA I-III.78, 79  Patients with advanced heart failure, who have severe 
symptoms despite optimal medical therapy should be considered for heart 
transplantation.80  For those who are ineligible, there is evidence from the 
Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive 
Heart failure (REMATCH) study that ventricular assist devices improve survival.81  
This study randomised 129 patients with NYHA class IV heart failure, ejection 
fraction less than 25%, a peak oxygen consumption of ≤ 12 ml per kilogram of 
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body weight per minute or a need for continuous intravenous inotropic support, 
decreasing renal function or worsening pulmonary congestion.  Patients 
randomised to long-term left sided ventricular assist device (LVAD) had a 48% 
RRR of death compared to medical therapy.  However, the survival for the LVAD 
group was only 25% at two years.   
Unlike the dramatic improvements in mortality seen over the last 25 years in HF-
REF, no study has shown a survival benefit in HF-PEF, despite numerous large 
RCTs.82-86  A similar trend has been also been seen in RCTs of therapies for 
patients with AHF, where no survival benefit has been demonstrated.87-94 
1.2 What is palliative care? 
The PC movement in many ways originated from the hospice movement.  The 
modern hospice movement was founded by Dame Cicily Saunders when she 
founded St Christopher’s Hospice in 1967.95  Dame Saunders developed the 
principle of “total pain” and essentially incorporated holistic practice by 
assessing and managing physical, emotional, social, and spiritual distress.  As 
well as developing the principle of total pain, she developed the principles of 
good end of life (EOL) care, where dying patients should be treated with 
compassion, dignity and respect.  In the 1980’s, the PC movement began to 
develop formally, building on the experiences of those in the hospice movement. 
This involved the establishment of a scientific journal,96 a medical association, 
and ultimately formal recognition of the specialty of palliative medicine in 
1987.97 
Perhaps the most widely used and accepted definition of PC is provided by the 
World Health Organisation (WHO), in which PC is defined as “an approach that 
improves the quality of life of patients and their families facing the problem 
associated with life-threatening illness, through the prevention and relief of 
suffering by means of early identification and impeccable assessment and 
treatment of pain and other problems, physical, psychosocial and spiritual.”98  
The complete definition of PC by the WHO is detailed in Table 1-3.   
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Table 1-3  WHO definition of PC 
WHO definition of palliative care98 
Palliative care is an approach that improves the quality of life of patients and 
their families facing the problem associated with life-threatening illness, through 
the prevention and relief of suffering by means of early identification and 
impeccable assessment and treatment of pain and other problems, physical, 
psychosocial and spiritual. Palliative care: 
 Provides relief from pain and other distressing symptoms;
 Affirms life and regards dying as a normal process;
 Intends neither to hasten or postpone death;
 Integrates the psychological and spiritual aspects of patient care;
 Offers a support system to help patients live as actively as possible until
death;
 Offers a support system to help the family cope during the patients illness
and in their own bereavement;
 Uses a team approach to address the needs of patients and their families,
including bereavement counselling, if indicated;
 Will enhance quality of life, and may also positively influence the course of
illness;
 Is applicable early in the course of illness, in conjunction with other
therapies that are intended to prolong life, such as chemotherapy or
radiation therapy, and includes those investigations needed to better
understand and manage distressing clinical complications.
The Scottish Palliative Care Guidelines, published on-line in 2014, provide a 
complimentary description of PC, highlighting the use of PC early on in a 
patient’s illness and not just at the end of life: “Good palliative care is not just 
about supporting someone in the last months, days and hours of life, but about 
enhancing the quality of life for both patients and families at every stage of the 
disease process from diagnosis onwards.  A palliative care approach should be 
considered alongside active disease management from an early stage in the 
disease process.  Palliative care focuses on the person, not the disease, and 
applies a holistic approach to meeting the physical, practical, functional, social, 
emotional and spiritual needs of patients and carers facing progressive illness 
and bereavement.”99 
1.3 Palliative care in other conditions 
PC is more established in other terminal conditions in the United Kingdom (UK), 
particularly cancer.  Of all of the patients accessing hospice care or specialist PC 
services in the England and Wales in 2013-14, 88% had a diagnosis of cancer.100  
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Improving EOL and access to palliative care has been established as a priority by 
the Department of Health in the UK.  EOL care was recently assessed in England 
using the Views Of Informal Carers for the Evaluation of Services (VOICES) 
questionnaire.101, 102 This specifically designed questionnaire is sent to bereaved 
relatives and asks for their opinion regarding different areas of EOL care.  The 
latest EOL survey in England, was in November 2015.  The VOICES questionnaire 
was sent to 49 558 adults who had registered a death between 4 and 11 months 
previously.103  21 320 (43%) responses were received. 25% of patients died from 
cardiovascular disease, 28% from cancer, and 46% from other conditions.  Place 
of death was recorded as part of the questionnaire: 21% died at home, 46% died 
in hospital, 27% died in a care home and 6% died in a hospice.  Overall quality of 
care in the last three months was reported in 95% of responses.  12% reported 
this care as outstanding, 30% as excellent, 33% as good, 15% as fair and 10% as 
poor.  Patients with cancer were more likely to receive better overall quality of 
care, as assessed by their caregiver, and were more likely to die in their 
preferred place of EOL. 
While the use of PC in terminal conditions is intuitive, designing and executing 
an RCT to formally investigate the pros and cons is challenging.  IN cardiology 
very few therapeutic approaches are adopted without RCT evidence.  RCTs have 
been performed in other terminal conditions, namely cancer.  Temel et al 
performed a single centre RCT of 151 participants with metastatic non-small-cell 
lung cancer to receive either early PC in conjunction with standard therapy or 
standard therapy alone.104  The main outcome measures were change in quality 
of life (QOL) and mood as assessed by the Functional Assessment of Cancer 
Therapy-Lung and the Hospital Anxiety and Depression Scale (HADS) 
questionnaires, at 0 and 12 weeks, respectively.  Patients assigned to early PC 
had better QOL and fewer depressive symptoms.  Interestingly, patients in the 
early PC arm had statistically significant better median survival, at 11.6 versus 
8.9 months in the standard care arm.  These preliminary results were followed 
up by Zimmerman et al, who performed a multi-centre cluster-RCT of early 
referral to PC plus standard care versus standard care alone in patients with 
cancer.105 Patients were considered eligible if they had advanced cancer and an 
estimated clinical prognosis of 4- 24 months.  461 participants were randomised 
(228 to early PC and 233 to standard care).  Outcome measures were QOL, 
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symptom severity (as measured by the Edmonton Symptom Assessment Scale 
[ESAS]), satisfaction with care, and problems with medical interactions.  These 
patient reported outcome measures (PROMS) were assessed at baseline and 
monthly for 4 months. The primary outcome measure was change in QOL, as 
measured by the Functional Assessment of Chronic Illness Therapy-Spiritual Well-
Being scale, at 3 months.  This study did not corroborate the previously 
described study by Temel et al, as there was no significant difference in the 
primary end point of change in QOL. 
1.4 Palliative care use in heart failure 
There is little doubt that, for some patients, heart failure is a terminal condition 
associated with poor QOL and high morbidity with multiple hospitalisations.  The 
poor prognosis in heart failure has led to comparisons with cancer, and heart 
failure has been described as “more malignant than cancer”.106  Again, it would 
seem intuitive that these patients would benefit from a palliative approach.  
Indeed, guidelines and consensus documents from both the ESC and American 
Heart Association recommend referral to palliative care services for certain 
patients, although these recommendations are based on expert opinion rather 
than evidence.3, 107  Despite these recommendations, very few patients in the 
United Kingdom access PC.  The latest National Heart Failure Audit of England 
and Wales, between April 2012 and March 2013, included over 43 000 patients 
admitted to hospital due to heart failure .108  The median age of these patients 
was 80, and most patients were highly symptomatic, 44 and 35% were NYHA class 
III and IV respectively.  Overall, these patients were a high risk group, with 30 
day and 1 year mortality rates of 15 and 25%.  Despite these patients having high 
symptom burden and reduced life expectancy, only 4% were referred to PC.  
These findings are different to those reported from the Rochester Epidemiology 
Project from Minnesota, USA.109  The Rochester Epidemiology Project enrolled 
1369 Southeastern Minnesota residents with heart failure into a longitudinal 
cohort study between 2003 and 2011.  During this time there were 698 deaths.  
Over the time period studied, the proportion of patients with heart failure who 
were referred to palliative care increased from 10.8% between 2003-2006 to 
43.6% between 2010-2012.  There was also an increase in hospice access from 
28.6% to 42.2% from between 2003-2006 and 2010-2012, respectively.  This was 
associated with a reduction in patients with heart failure who died in hospital, 
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with 32.8% between 2003-2006 and 22.4% between 2010-2012.  This study 
provides a stark contrast to the National Heart Failure Audit, reflecting a 
difference in healthcare practice.   
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Chapter 2 Systematic review of PC needs in 
patients with HF 
The main aim of this systematic review was to critically analyse and appraise the 
current evidence base describing the palliative care needs of patients with heart 
failure.  Specifically, I wanted to assess the available quantifiable data 
describing what the potential PC needs are in patients (and their caregivers) 
with heart failure and assess the prevalence of these needs.  The secondary aim 
of this systematic review was to describe the evidence base, specifically RCTs, 
for a palliative intervention in this population. 
2.1 Methods 
Data sources and searches 
I collected data from observational study and trial data, where available, which 
described patient and caregiver perceived experiences and PC needs.  I searched 
the online databases Medline, Embase, CINAHL, and PsycINFO using the terms 
“heart failure” or “congestive cardiac failure” or “advanced heart failure” or 
“end stage heart failure” in abstracts, titles, or as keywords.  This search was 
combined with the search terms “palliative care” or “end of life” in abstracts, 
titles, or as keywords.  Citations of studies identified, review articles and 
guidelines were searched for any potential additional studies.  The search was 
initially performed on the 27th October 2013, and updated on 7th May 2014.  A 
summary of the search is provided in Figure 2-1. 
Study selection 
Studies were limited to those of adult humans, and published in English. Titles 
and abstracts were then reviewed to exclude duplicates and studies not 
assessing patients with heart failure.  The search was further limited to include 
only original research by excluding letters, editorials, reviews, guidelines, case 
reports, and conference abstracts (Figure 2-1).  As this systematic review aimed 
to assess patient and caregiver perceived needs, surveys of health professionals 
and publications describing service provision were excluded.  Studies assessing a 
PC intervention were included if a description of PC needs was provided.  Full 
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text was then reviewed of the remaining articles to assess inclusion and 
exclusion criteria, Figure 2-1. 
Figure 2-1 Systematic review and study selection 
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Data extraction and quality assessment 
Data from the methods and results section of each publication was reviewed and 
tabulated.  Authors’ comments and opinions were not included in data 
extraction or synthesis.  Specifically, the number of participants with heart 
failure, number of caregivers (where relevant), mean age, sex, proportion of 
participants according to NYHA status, and mean ejection fraction were 
extracted and assessed.  Other data collected from the methods section 
included the setting of recruitment of each patient, whether the recruitment 
was selected or unselected, whether a description of the diagnostic criteria used 
to define heart failure was used, and whether HF-PEF was included in the 
cohort.  The study design and outcome measures were recorded.     
 
2.2 Results 
2.2.1 Study characteristics 
 
The search criteria identified 65 original research publications primarily aimed 
at assessing PC needs of patients (and their caregivers) with heart failure.46, 110-
172  Of these, 32 studies used quantitative outcome measures and research 
methodology (supplementary table 1-A), and a further 33 used qualitative 
outcome measures (supplementary table 1-B).  The majority of the studies were 
carried out in the USA, UK, or Europe.  Studies were published between 1997 
and 2014.  Overall, the median number of patients with heart failure studied 
was 45 (interquartile range [IQR] 20-76).  For studies using quantitative outcome 
measures, the median number of participants was 60 (IQR 46-111).  The studies 
using qualitative outcomes had a median number of participants of 24 (IQR 13-
45).  Weighted mean age for all studies identified was 71 (SD 7.4).  The weighted 
mean age for those enrolled in qualitative studies was 72 (SD 7.1), and for those 
enrolled in quantitative studies was 71 (SD 7.4).  12 studies did not provide a 
mean or median age.  Most of the participants were male (weighted mean 
overall 65%), although 8 studies did not report sex of participants.  Of the 65 
studies identified, only 19 reported an ejection fraction, 12 reported how the 
diagnosis of heart failure was made, and only 5 mentioned whether patients with 
HF-PEF were included in their sample.  Only 4 studies used an unselected cohort 
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of patients, with three of these studies using prospective recruitment.    The 
majority of studies targeted patient population that were thought to have higher 
PC needs, such as exclusively NYHA class III/IV, physician’s estimated limited life 
expectancy, or elderly patients. 
2.2.2 Qualitative studies 
Although results from qualitative studies are less generalisable than quantitative 
studies, important preliminary themes can be identified through such research, 
therefore it is important to critically assess these studies also.  33 of the studies 
identified utilised qualitative methodology.  Of these, 8 performed assessments 
longitudinally, with the rest utilising a cross-sectional approach.  As described 
above, most of the qualitative studies were highly selected cohorts, with small 
numbers of participants.  Only 3 studies enrolled over 100 participants. 
A number of common themes were identified in these studies.  One of the most 
common themes was the issue of communication between healthcare 
practitioner and patients and caregivers.  Patients and caregivers often reported 
a need for greater disclosure of information regarding their diagnosis, treatment 
options, and particularly prognosis.115, 119, 135, 155, 159, 162  Patients with heart 
failure, and their caregivers, had less of an understanding of their prognosis and 
fewer discussions regarding EOL care than patients with cancer.155, 171  
Understanding prognosis was considered an important aspect of having a ‘good 
death’,171 as was dying at home.164  Preference, when asked, for where EOL care 
should take place was often at home.42  Many patients asked would not want 
active resuscitation,46, 42 although the Study to Understand Prognoses and 
Preferences for Outcomes and Risks of Treatments (SUPPORT) study investigators 
found that when patients were asked this question serially, they often (40%) 
changed their mind.  A common sub-theme within the overall theme of 
communication was the lack of EOL care discussions in patients with heart 
failure.  Patients with heart failure were less likely to discuss EOL care, wishes, 
or anticipatory care plans than patients other conditions such as cancer.138, 145,
162, 167, 172  Although many studies drew attention to the potential EOL care needs 
in heart failure, rarely was the opinion of EOL care, following death, from the 
relatives and caregivers reported.  One notable exception was the study by 
Formiga et al, who asked the caregivers of deceased relatives with heart failure 
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to reflect on the standard of care received at the EOL.133  Although 67% were 
satisfied with the EOL care received, 45% felt symptoms could have been better 
managed. 
Another common theme identified was the effect heart failure had on patient 
and caregivers’ daily lives.  Patients with heart failure often experienced 
feelings of hopelessness, isolation, and loss of confidence and independence.154, 
170  Patients reported feeling like a burden to relatives or caregivers, and 
caregivers themselves also felt socially isolated and struggled with the physical 
demands of caregiving.123, 139 
Physical symptoms were commonly experienced by patients with heart failure 
and included dyspnoea, falls, fatigue, insomnia, headaches, oedema, 
palpitations, and fatigue.  Less common symptoms included pain.119, 126, 139, 160 
The unpredictable nature, and fluctuant course of heart failure was often 
highlighted in the studies identified.  Murray et al assessed, qualitatively, 
changes in social, spiritual, psychological wellbeing every 3 months in patients 
with heart failure and cancer thought to be in the last year of life.  They found 
no clear terminal phase in heart failure, as opposed to cancer, but greater 
fluctuation in spiritual and psychological wellbeing.155 
2.2.3 Quantitative studies 
32 studies assessing PC needs in patients with heart failure which utilised 
quantitative outcome measures were identified.  Of these studies, 21 (65%) used 
a cross-sectional approach and the remaining 11 (34%) used a longitudinal 
methodology.  A number of different aspects of PC needs were assessed using 
quantitative outcome measures.  These included physical symptom assessment, 
quality of life, mood assessment, spiritual well-being, performance status, 
caregiver burden and care dependency, and EOL care.  Most studies assessed one 
or two of these individual components, but no study assessed all components. 
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Physical symptom assessment 
13 of the 32 quantitative studies made an assessment of physical symptoms using 
PROMs.  The PROMs used included: Edmonton Symptom Assessment Scale (ESAS) 
(6 studies); Memorial Symptom Assessment Scale (3 studies); Brief Pain Inventory 
(one study); Visual Analogue Scale (one study); and the McCorkle Symptom 
Distress Scale (one study).  One study used an investigator-designed 
questionnaire, specifically designed for the study to assess physical symptom 
burden, which had not validated in an external cohort.  Physical symptoms were 
common, and often reported as severe by patients.168, 169   The classic symptoms 
of heart failure, dyspnoea and fatigue, were commonly reported in the 
quantitative studies identified, although dyspnoea perhaps not as frequently as 
expected.  Reported dyspnoea ranged from 25-76% of patients in the studies 
identified.  Fatigue was more commonly reported (50-85%).  Pain and anorexia 
were also frequently reported (41-78% and 30-50%, respectively).  Pain was more 
commonly reported in those with higher NYHA class.131  When compared to 
cancer populations, patients with heart failure had a similar distribution of 
physical symptom burden.120, 156   
Quality of life 
QOL was measured using heart failure and generic PROMs in 13 and 7 studies 
respectively.  The heart failure specific questionnaires included Minnesota Living 
with Heart Failure questionnaire (four studies) and the Kansas City 
Cardiomyopathy Questionnaire (KCCQ) (9 studies).  The generic QOL PROMs used 
were the Short Form-36 (four studies), the Short Form-12 (SF-12) (two studies), 
and the Quality of Life Index questionnaire (one study).  4 studies utilised both a 
generic and a heart failure specific questionnaire.  Generally QOL was reported 
as poor, particularly on the subscales of physical function and general health.  
Evangelista et al showed that patients who experienced pain were more likely to 
suffer from poor QOL.131  Studies that compared QOL in patients with heart 
failure and cancer found similar QOL, although better social function sub-scores 
were found in patients with heart failure.156  Allen et al monitored QOL 
longitudinally in 1458 patients admitted to hospital because of heart failure and 
found that in this high risk population (33% 6 month mortality), 13.2% suffered 
from persistently unfavourable QOL as measured by the KCCQ.112   Brunner La 
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Rocca et al asked 622 patients with heart failure (as part of a RCT) if they would 
consider trading time (life expectancy) for improved QOL, and found that most 
(74%) would not be willing to trade any time which is perhaps contrary to 
popular belief.48  
Mood assessment 
13 studies used a quantifiable patient reported outcome measure to report mood 
disturbance.  The measures used were Geriatric Depression Scale (four studies), 
Hospital Anxiety and Depression Scale (four studies), Patient Health 
Questionnaire (four studies), and the Mental Health Inventory questionnaire (one 
study).  Anxiety and depression were common in the patients studied, reported 
levels ranging between 33-50% and 30-50% respectively.  Fitzsimmons et al 
reported common depression, but not at clinically significant levels.132  This was 
contrary to Bekelman et al, who reported 30% prevalence of clinically significant 
levels of depression.117  Studies that compared mood disturbance between 
patients with heart failure and cancer found no difference in prevalence of 
anxiety or depression.117, 156  Scott et al assessed mood disturbance in 20 highly 
selected patients, receiving out-patient infusions of inotropes, and 18 caregivers 
using the mental Health Inventory.161  They showed that not only was depression 
and anxiety common in patients, 45 and 50% respectively, but more so in their 
caregivers at 65 and 55% respectively.  
End of life care 
Of the 7 studies using quantifiable or semi-quantifiable outcome measures to 
describe EOL care, most focused on documentation of anticipatory care plans 
(ACP), cardiopulmonary resuscitation (CPR) preferences, and preference for ICD 
deactivation at EOL.  Strachan et al asked 106 patients with heart failure their 
preferred place of death, resuscitation preference, and their preference for 
knowledge about their prognosis.165  Most patients, when asked, would prefer to 
die at home.  Patients thought obstacles to achieving this preferred place of 
death were no caregiver available, uncontrolled pain, and lack of home services. 
46% of patients would want to know their predicted prognosis, and 50% of 
patients wanted to discuss CPR preferences.  Dunlay et al assessed 
documentation of ACP by reviewing 608 unselected patients’ case records 
 46 
 
retrospectively.128  Of these, 249 had an ACP documented in the case record.  
However, less than half of these addressed CPR, haemodialysis or mechanical 
ventilation.  Many patients would want to have discussions regarding ICD 
deactivation at the EOL, although most had no recollection of having any such 
discussion.140, 141, 158  Herman et al reported that of 109 selected patients with 
HF attending a tertiary referral centre, only 7% had any recollection of 
discussing ICD deactivation at EOL, although 40% would have wanted more 
information, 26% refused to have any further discussions on the topic. 
Caregiver burden / strain 
The influence of heart failure on the caregiver’s well-being or strain/ burden 
was assessed by quantifiable measures in four studies identified through the 
search criteria.  The quantifiable PROMs used to assess caregiver strain were the 
Caregiver Reaction Assessment (one study), Care Dependency Scale (one study), 
Family Appraisal of Caregiving Questionnaire for Palliative Care (one study), and 
the Zarit Burden Interview (one study).  Scott et al studied 20 patients with end 
stage heart failure attending secondary care for outpatient inotrope infusions 
and their caregivers (n= 18), and found not only high levels of depression and 
anxiety in caregivers, as described above, but reported one third of caregivers 
felt unprepared for the stress associated with caring for someone with heart 
failure.161  Not all studies focused on the negative aspects of caregiving, Jansen 
et al and Malik et al reported on the positive aspects of caregiving, with many 
participants reporting caregiving positively.148, 152  Furthermore, Malik et al 
compared caregiver strain between caregivers of patients with heart failure and 
cancer, and found that most caregivers (90%) reported no or only mild levels of 
caregiver burden.152   Janssen et al further described dependency on care, using 
the Care Dependency Scale, and found similar levels of dependency in patients 
with heart failure and chronic obstructive pulmonary disease (COPD).148  Patients 
with COPD were more likely to develop increasing care dependency over time 
compared to patients with heart failure.   
Other assessments- spiritual well-being and palliative performance scale 
Spiritual well-being was assessed in two studies using quantifiable PROMs, both 
studies using the Functional Assessment of Chronic Illness Therapy- SPiritual 
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well-being (FACIT-SP) questionnaire. Greater spiritual well-being was associated 
with less depression as measured by the Geriatric Depression Scale.116  Patients 
with heart failure were found to have similar scores for spiritual well-being when 
compared to patients with cancer, and regardless of ejection fraction.120   
Two studies measured functional capacity using the Palliative Performance Scale 
(PPS), of these two studies one described the proportion of patients with low 
functional levels.151  Kaveralitos et al compared 334 selected patients with heart 
failure to 697 patients with cancer attending a PC service, all of which had a PPS 
assessment performed.  This assessment rates functional capacity across five 
domains.  Patients with heart failure had similar functional levels to patients 
with cancer.  28 and 46% of patients with heart failure had low and medium 
functional levels respectively, whereas 34 and 42% of patients with cancer had 
low and medium functional levels respectively. 
2.2.4 Randomised controlled trials 
3 RCTs that assessed an early PC intervention in patients with heart failure were 
identified.  The first published study in 2007 recruited terminally-ill, housebound 
patients with either heart failure, cancer, or COPD.173  297 patients were 
enrolled (97 with heart failure), with 145 being randomised to early PC and 152 
to standard care.  The main outcome measures were satisfaction with care, 
healthcare utilisation, and place of death.  Patients in the early PC group were 
less likely to die in hospital, had higher patient satisfaction, and less secondary 
care healthcare utilisation.  Patients with heart failure were not analysed 
separately from the whole cohort and there was no clear description of how the 
diagnosis of heart failure was made or influence of ejection fraction or other 
prognostic markers on outcomes. 
In 2014 72 patients with chronic heart failure, from a single centre in Sweden, 
were randomised to either standard care or early PC.122  The primary endpoint 
was change in QOL as measured by the KCCQ and Euro Quality of life (EQ-5D) 
questionnaires, and symptom burden as measured by the ESAS.  A good 
description of the participants, including ejection fraction was provided.  The 
standard care group differed from the early care by being significantly older at 
baseline.  There was no statistically significant difference between the groups in 
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mean symptom burden as measured by the ESAS or in QOL as measured by the 
KCCQ.  However, there were greater improvements in nausea (measured by 
ESAS), physical symptom burden (measured by KCCQ), self-efficiency (measured 
by KCCQ), or QOL (measured by KCCQ) in the early PC group.  NYHA functional 
class was significantly better in the early PC group when assessed at 6 months.  
There was less resource utilisation in the early PC group, in particular 
hospitalisations (15 vs 53, p = 0.009). 
When the literature review was performed, the most recent RCT of an early 
palliative intervention in patients with heart failure was reported by Sidebottom 
et al in 2014.163  The study recruited patients admitted to hospital with heart 
failure and randomised participants to early PC before discharge or standard 
care.  The primary outcome measures were change in symptom burden (as 
measured by ESAS), QOL (as measured by MLHF), and mood (as measured by 
patient health questionnaire).  Secondary endpoints included use of anticipatory 
care planning, repeat hospitalisation at 30 days, hospice use, and death.  The 
study was powered for 500 patients, but only managed to recruit 232 patients, 
the most common reason for screening failure being refusal of consent.    There 
was very little baseline characterisation of patients with heart failure.  There 
was no description of NYHA class, distribution of ejection fraction, how the 
diagnosis of heart failure was made, or mention of whether patients with HF-PEF 
were included.  At baseline, patients in the early PC arm were statistically 
older, by a mean of 5 years, than the standard care arm.  Despite being 
underpowered, patients in the early PC arm had significantly better symptom 
burden, QOL, and mood, at both one and three months.  Patients in the early PC 
arm were more likely to have an anticipatory care plan than standard care, but 
there was no other difference in the other secondary endpoints.  This study 
suffered from loss to follow up, with only 79% of patients who were known to be 
alive completing study assessments at both study visits. 
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2.3 Discussion 
2.3.1 Summary of literature describing potential palliative care needs 
in patients heart failure 
The primary purpose of this systematic review was to critically appraise the 
available literature describing PC needs in patients with heart failure, with a 
secondary aim of reviewing the current evidence base for a palliative 
intervention.  The number of publications describing PC needs has increased, 
particularly in the last ten years.  Over half of the studies identified through my 
search criteria used qualitative methodology.  Although less generalisable than 
studies using quantitative methodology, these studies are none the less 
informative, particularly in identifying common themes which can be further 
studied using quantifiable methods.  The common themes highlighted from these 
studies include the variety of physical and psychological symptoms experienced 
by not only patients, but also by their care-givers.  Poor communication, 
particularly about disease prognosis and EOL care and issues was consistently 
flagged as an issue. 
The quantitative studies provide further insights into the potential PC needs in 
this patient population.  A number of studies described and quantified the 
frequency and severity of physical symptoms, and also psychological mood 
disturbance in these patients.  Many made comparisons to similar terminal 
conditions, such as cancer, COPD, and renal failure, and found similar symptom 
burden.  EOL communication and planning was assessed using quantifiable 
measures and often there was a lack of anticipatory care planning in patients 
with heart failure.  Some patients with heart failure were found to have 
impaired QOL, similar to other terminal conditions such as COPD or cancer.   
2.3.2 Summary of randomised controlled clinical trial evidence 
The three studies identified through the search criteria provide good 
preliminary, although tentative, evidence that an early palliative intervention in 
heart failure is possible and potentially effective.  Brumley et al showed that PC 
for housebound terminally ill patients can potentially reduce unplanned hospital 
admissions, and cost of care, while improving patient satisfaction with care, and 
increasing the likelihood of a home death.173  The study by Brannstrom et al did 
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not show a statistically significant difference in the primary outcome measures 
of QOL and symptom burden at 6 months, although the early PC group used less 
healthcare resources including hospitalisations.122  In contrast to this study, 
Sidebottom et al showed statistically significant better scores in QOL, symptom 
burden and mood at 3 months.163   
2.3.3 Limitations of current evidence base 
Most studies, both qualitative and quantitative, recruited highly selected 
patients based on known or expected poor prognosis or because of the 
established presence of predictors of poor prognosis, such as NYHA status.  Other 
studies recruited exclusively from patients already attending PC services.  These 
studies are therefore, although informative, less generalisable than an 
unselected, real-world cohort. Therefore, the prevalence of PC needs in the 
general population with heart failure cannot be extrapolated from these studies. 
Most of the studies identified were small, with a median of 45 participants.  
Many studies did not describe in detail the heart failure population that was 
studied.  Specifically, ejection fraction, NYHA class, whether patients with HF-
PEF were included, or what criteria was used to make the diagnosis of heart 
failure, were rarely described.  It is important to describe these findings for a 
number of reasons.  Firstly, a description of factors which may influence 
prognosis is crucial when describing the PC needs of a population, and therefore 
ejection fraction and NYHA status, amongst other characteristics, should be 
included in the description of the cohort. Another limitation of the current 
evidence base describing the PC needs of patients with heart failure is the lack 
of longitudinal data.  When this was described, e.g. by Murray et al or Barnes et 
al,114, 155 patients with heart failure were found to have a fluctuating course, and 
a single one off assessment seems unlikely to describe the needs adequately in 
these patients.  A further limitation of the evidence base was the number of 
facets of PC needs assessed.  Although many different aspects were assessed 
using quantitative measures, such as QOL, symptom burden, EOL care, caregiver 
burden, and mood disturbance, no one study assessed all of these. 
The RCTs were limited in terms of size, particularly the study by Sidebottom et 
al, who failed to meet their target sample size by over 50%.163  Although Brumley 
et al enrolled almost 300 participants, only 97 had heart failure, and like many 
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of the studies describing potential PC needs, there was no description of the 
heart failure cohort.173  Two of the three studies had statistically significant 
differences between groups at baseline, namely large differences between mean 
ages, possibly as a result of small numbers of participants and under-
recruitment.  An adequate description of the inclusion of HF-PEF was also 
lacking in all three studies, again potentially limiting the generalisability of the 
results. 
2.3.4 Conclusion  
There are a number of studies describing the PC needs of patients with heart 
failure, and a fledgling evidence base evaluating benefit of early PC intervention 
in RCTs in this group.  Patients with heart failure can suffer from a variety of 
physical symptoms, not just dyspnoea and fatigue.  The patients described in the 
studies often suffered from psychological disturbance as well, particularly 
anxiety and depression, sometimes at clinically significant levels.  Mood 
disturbance was also reported at high levels in caregivers, although caregiving 
was not universally seen as a negative experience.  Communication breakdown 
in EOL planning was a common theme in both qualitative and quantitative 
studies.  Despite the number of studies identified in this systematic literature 
review, there were no systematic studies with detailed descriptions of the 
patients with heart failure, describing the prevalence of PC needs.  
Furthermore, there were no studies using quantitative measures which assessed 
all of the different potential facets of PC needs.  This study and thesis will 
provide these essential data, which will both describe whether there is a need 
for further RCTs, by describing the extent of the problem, and also help inform 
the design of any future trials. 
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Chapter 3 Methods 
Although there have been descriptions of unmet supportive and PC needs of 
patients with heart failure, these needs have not been described using 
reproducible and quantifiable measures in a ‘real world’ heart failure 
population.  Any such description should take into account the WHO definition of 
PC (Table 1-1),98 and therefore not only make an assessment of EOL care needs, 
but also the QOL of patients and their caregivers, mood and symptom burden.  In 
this section I will describe how I will make objective, quantitative assessments 
and describe the rationale for using each chosen patient reported outcome 
measure.   I will then describe the target study population, how the diagnosis of 
heart failure was confirmed, and then describe the study protocol used in detail. 
3.1 Study Aims 
1. Describe the prevalence of PC needs, and what these needs are including
EOL issues, in a contemporary cohort of patients (and their caregivers)
with heart failure.
2. Assess whether patients who have, or are likely to develop, PC needs can
be identified.
3. Explore potential outcome measures which could be used as end-points in
a RCT of PC use in heart failure.
3.2 Study population 
I studied patients admitted to hospital with a primary diagnosis of heart failure.  
This group of patients, rather than community based or patients with chronic 
heart failure, were chosen as they are at particularly high risk of readmission 
and death.26  To reduce selection bias, I recruited prospectively, and aimed to 
recruit a near consecutive population.  A truly consecutive, prospective cohort is 
not possible, due to refusal or inability of some patients to participate.  
Therefore, I screened all patients identified as possibly having a primary 
diagnosis of heart failure and invited those who met the inclusion criteria to 
participate.   
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3.2.1 Confirming the diagnosis of heart failure 
Making the diagnosis of heart failure is difficult.  The criteria required to 
diagnose heart failure have changed over the past two decades, with more of an 
emphasis on demonstrating, using objective measures, abnormalities in the 
structure and function of the heart, particularly the left ventricle.  The ESC sets 
different criteria for different phenotypes of heart failure based upon ejection 
fraction.3   The 2012 ESC guidelines were used as these were the most up to 
date when participants were enrolled.  Patients with HF-REF require the
following three conditions to be met: typical symptoms of heart failure; typical 
signs of heart failure; and reduced left ventricular ejection fraction (<50%).  The 
diagnosis of HF-PEF is met if the following criteria are met: presence of typical 
symptoms of heart failure; typical signs of heart failure; normal or mildly 
reduced ejection fraction ( ≥ 50%); and relevant structural heart disease
indicating diastolic dysfunction 
(Table 3-1).   As well as the typical symptoms and signs of heart failure, 
investigations are crucial in making the diagnosis, particularly in confirming the 
presence of structural and functional abnormalities of the heart. First line 
investigations, as directed by the ESC, in the assessment of suspected heart 
failure include electrocardiography (ECG) and chest x-ray (CXR).  An ECG may 
reveal evidence of structural heart disease such as left ventricular hypertrophy, 
previous myocardial infarction with pathological q waves, inter-ventricular 
conduction delay, or arrhythmias.  Although CXR is not deemed to be as useful 
in chronic heart failure, it is an important test in acute heart failure.   Firstly, 
CXR can exclude other conditions which could be causing a patient’s symptoms, 
for example pneumonia.  Secondly, CXR can provide objective evidence of 
congestion and pulmonary oedema, which are often pathognomonic of acute 
heart failure.  Other findings that may support the diagnosis of heart failure 
include cardiomegaly and pleural effusions.  
Echocardiography allows assessment of heart structure through two-dimensional 
measurement of left ventricular wall thickness, chamber volumes, and valve 
structure.  Assessment of systolic and diastolic function of the left ventricle, 
either or both of which must be abnormal to meet the ESC definition of heart 
failure, are possible through two dimensional and Doppler echocardiography.  
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 Use of Doppler echocardiography also allows estimation of left ventricular 
filling pressure.  Echocardiography allows identification of pericardial disease, 
which can mimic the presentation of heart failure.  A summary of the 
echocardiography features which are commonly found in heart failure and 
make the diagnosis more likely are detailed in Table 3-1. 
Another important test that can aid the physician in making the diagnosis of 
heart failure is natriuretic peptide testing.174  Natriuretic peptides are released 
by the heart in response to pressure and volume overload of the atria and 
ventricles.174  There are three major natriuretic peptides, atrial natriuretic 
peptide (ANP), Brain-type natriuretic peptide (BNP), and C-type natriuretic 
peptide (CNP).  ANP and BNP are released from the heart and act as circulating 
hormones which have beneficial vasodilatory, natriuesis and diuretic 
properties. 
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Table 3-1Echocardiography protocol 
Protocol Measurement 
Window Doppler 2D / M-mode 
Parasternal 
Long axis MV & AV colour flow IVSd, LVEDD, LVPWd 
IVSs, LVESD, LVPWs, LVOT, LA 
LV end diastolic dimension (cm/m2) 
LV end systolic dimension (cm/m2) 
RV inflow TV CW + colour flow 
Short axis 
Base AV, TV & PV colour flow 
MV MV colour flow 
Papillary muscle 2D endocardial & epicardial area LV mass index (g/m2) 
apex 
Apical 
4 chamber MV annulus TDI + LV inflow PW 
MV colour flow, TV colour flow 
LV volume diastole + systole, LAA LV EF (%) 
LV diastolic volume (ml/m2) 
LV systolic volume (ml/m2) 
LV stroke volume (ml) 
Cardiac output (L/min) 
LV diastolic parameters (E, E/e’, IVRT, E/A) 
Left atrial volume (ml/m2) 
Valve assessment of structure and function 
2 chamber MV colour flow LV volume diastole + systole, LAA LV EF (%) 
Left atrial volume (ml/m2) 
LV diastolic volume (ml/m2) 
LV systolic volume (ml/m2) 
5 chamber AV CW + PW + IVRT, AV colour flow 
Long axis MV colour flow 
RV TAPSE, RAA TAPSE 
RAA (mm2) 
Subcostal 
4 chamber 
IVC & hepatic veins IVC diameter RVSP 
AV= aortic valve; CW= continuous wave; E= early diastolic filling; e’= early lengthening velocity; E/A= IVC+ inferior vena cava; IVRT= isovolumic relaxation time; IVSd= intraventricular septal diastole; IVSs= intraventricular septum systole; LVEDd= left ventricular end-diastolic dimension; 
LVESD= left ventricular end-systolic dimension; LVOT= left ventricular outflow tract; LVPWd= left ventricular posterior wall diastole; LVEDs= left ventricle posterior wall systole; EF = ejection fraction; LAA= left atrial area; LV= left ventricle; MV= mitral valve; PV= pulmonary valve; PW= 
pulsed wave; RAA= right atrial area; RV= right ventricle; RVSP= right ventricular systolic pressure; TAPSE = tricuspid annular plane systolic excursion; TV= tricuspid valve. 
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BNP is particularly useful in the diagnosis of heart failure, as it is synthesised 
and secreted in bursts in response to volume and/ or pressure overload of the 
left ventricle.  The use of BNP has been incorporated into guidelines on the basis 
of a number of observational studies and randomised controlled trials.3  In the 
landmark Breathing Not Properly Multination Study, BNP was measured in 1586 
patients presenting to the emergency department with acute shortness of 
breath.175  This study showed that BNP measurement on admission had a higher 
area under the receiver-operating characteristic curve than the emergency 
physician at diagnosing heart failure.  This study demonstrated a cut-off of 100 
pg/ml had a sensitivity and specificity for the diagnosis of acute heart failure of 
90% and 76% respectively.   The ESC stipulate a rule-out value of BNP of <100 
pg/ml in the setting of suspected acute heart failure.3  Other conditions can also 
cause elevation of natriuretic peptide including: increasing age; renal 
dysfunction; acute coronary syndromes; pulmonary disease (acute respiratory 
distress syndrome or cor pulmonale); pulmonary embolism; high output states 
(anaemia, cirrhosis, hyperthyroidism); and atrial fibrillation.  Therefore, the 
combination of natriuretic peptide and echocardiography are recommended by 
the ESC, taking into consideration signs and symptoms of heart failure.3 I used 
this evidence based and objective approach to confirm the diagnosis of heart 
failure in every participant in this study. 
3.3 Outcome measures 
I have chosen to use quantifiable PROMs as the main outcome measures in this 
study.  This will enable me to make generalisable, objective assessments of PC  
need. PROMS are outcomes reported directly by the patient, without 
interpretation or influence from the clinician, caregiver, or researcher.  PROMs 
inform researchers and clinicians regarding the influence of disease, or the 
response of treatment, on morbidity and disease burden on individual patient 
lives.  More importantly, these outcome measures reflect the patients’ opinion 
of their own health and potential suffering, rather than the investigators’.  The 
ESC has recently released a position statement recommending that PROMs be 
incorporated into not only clinical trial design and reporting, but also clinical 
practice, as well as RCT design.176 
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3.3.1 Assessing Quality of Life in heart failure 
It is unclear which QOL tool is best in patients with heart failure, although a 
combination of a heart failure specific and a generic questionnaire may be 
optimal.177  Both generic and heart failure specific QOL PROMs have recently 
been systematically reviewed by the Oxford Patient Reported Outcome Group, 
on behalf of the UK Department of Health.178  A number of different PROMs were 
identified in the systematic review, and the evidence base describing construct 
validity, test-retest reliability, and responsiveness was also critically appraised.  
Another important aspect of any PROM is acceptability to the patient, this was 
also reviewed.  One of the more commonly used HF specific questionnaires is the 
KCCQ.179  The KCCQ was one of two disease specific QOL PROMs recommended, 
the other being the Minnesota Living with Heart Failure questionnaire 
(MLHFQ).180  Although both of these assessments are well validated, there is a 
suggestion that the KCCQ may be more sensitive to change in QOL than the 
MLHFQ.178  The KCCQ is a 23-item, self-administered questionnaire that 
quantifies symptoms (including severity, frequency, and change), self-efficiency, 
knowledge, physical function, and QOL.  The KCCQ generates an overall 
summary score derived from combining each of the afore mentioned domains.  
Each sub-set score and overall summary scores are out of 100, with higher scores 
indicating better function. 
Over 34 studies describing the use, construct validity, reliability, and 
responsiveness of the KCCQ are available.178  This strong evidence base has 
shown The KCCQ have excellent test-retest reliability, with an interclass 
correlation coefficient (ICC) of 0.88, in a study testing the psychometric 
properties of the KCCQ in patients with both anaemia and heart failure.181  
Assessment of construct validity of the KCCQ has been demonstrated previously 
with a strong correlation between NYHA class and KCCQ overall score, lower 
KCCQ overall scores associated with worse NYHA class.182 The KCCQ overall score 
has been shown to discriminate between patients with and without symptoms of 
depression.117, 183  The KCCQ overall score has also been shown to be predictive 
of prognosis, with those scoring less than 25 being five times more likely to die 
at one year than those scoring over 75.  The responsiveness of the KCCQ has 
been demonstrated in a multi-centre study of 476 patients with heart failure, 
where the KCCQ was found to have the highest C-statistic for monitoring 
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individual patients, followed by NYHA class and 6-minute walk test.182  
Responsiveness of KCCQ was also demonstrated in an analysis of the Eplerenone 
Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study, 
where change in KCCQ summary score had a linear association with all-cause 
mortality.184  This linear relationship was also true for each 5 point reduction in 
KCCQ summary score.  Patient acceptability of the KCCQ is good, and in one 
study there was an 80% response rate to a posted questionnaire survey.185     
A variety of generic QOL assessment tools are available and one of the more 
widely used is the SF-36,186 which has been validated in a variety of populations 
including HF.187, 188   This has been shortened to a 12 question format, while 
retaining construct validity, in the form of the SF-12.189, 190  The SF-12 is a 12-
item questionnaire which assesses both physical and mental components of QOL.  
Test-retest reliability is assessed as moderate, with a ICC of 0.59.191 
Responsiveness of the SF-12 has been shown to be good, particularly for the 
physical component score.192  One particular advantage of utilising the SF-12 
questionnaire is the high acceptability, particularly when compared to the more 
extensive SF-36.  One study found completion rate of 99%.191  SF-12 also has 
normative data and data from patients with heart failure for comparison and 
interpretation purposes.193 
HF not only affects patients’ QOL, but also that of their caregivers.194 Caregiver 
QOL can be readily assessed using a generic tool, such as SF-12, but assessing 
‘caregiver burden’ within a family as a result of heart failure can also be 
assessed using the Zarit Burden Interview.195 This is the most widely used and 
validated caregiver assessment tool.196  The validity and reliability of the Zarit 
Burden Interview has been demonstrated in caregivers of patients with heart 
failure.197  This tool also includes an assessment of financial strain placed on the 
caregiver.  This is an important question, as patients within the last 6 months of 
life are potentially entitled to financial support in some countries.   
3.3.2 Assessing mood disturbance 
The WHO definition of PC states that PC should identify and treat psychosocial 
as well as physical problems.  Therefore, any assessment of PC needs should 
detail how QOL, symptom burden, and EOL care potentially affect a patient’s 
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mood.  The review of PROMs undertaken by the Oxford Patient Reported 
Outcomes Group in 2009 highlighted that neither of the preferred disease 
specific PROMS (KCCQ or MLHFQ) adequately covered the psychological domain 
or the whole range of symptoms.178  They therefore suggest concomitant use of a 
dimension-specific measure of psychological well-being.   This has become 
standard practice in other conditions, and in one RCT of PC use in lung cancer, 
mood assessment was used as an outcome measure.104  Depression, which is 
common in HF,198 can affect QOL199 and is associated with higher morbidity and 
mortality.200-202  A validated screening questionnaire for depression is the 
HADS.203 HADS is a 14-item screening questionnaire, comprised of 7 questions 
relating to anxiety and 7 to depression.  A summary score is generated for both 
anxiety and depression, which are interpreted independently.  The HADs 
questionnaire can be administered by an interviewer or self-administered.  
Summary scores for anxiety and depression can categorise patients as normal, 
mild, moderate, or severely impaired.  The test-retest reliabilty, internal 
consistency , and validity of the HADS have been assessed and supported by 
previous reviews.204, 205  HADS has been used in a variety of populations,205 and is 
validated in HF.206  This, together with the reduced patient burden, combines 
two aspects of psychological assessment into one PROM and make HADS an 
appropriate and objective tool for this study. 
3.3.3 Assessing symptom burden 
Assessing on-going symptoms should also form part of an assessment of potential 
PC needs in patients with heart failure.  Heart failure RCTs tend to focus on the 
symptoms of dyspnoea, fatigue and oedema.  However, my systematic review 
highlighted that patients with HF can suffer from other symptoms including pain, 
anxiety, low mood, constipation, anorexia, nausea, insomnia, and persistent 
cough.207, 208  There are recognised tools to help make an objective measurement 
of symptom burden but these have not been extensively evaluated in heart 
failure (although they have been in other diseases).  The ESAS209 is one such 
PROM which has been validated in cancer210, 211 and has previously been used in a 
studies of patients with heart failure.157  The ESAS comprises 10 separate 
questions regarding different symptoms, where respondents mark a score 
between 0 and 10 for each symptom, with zero being no symptom and 10 
representing the worst.  There is also the possibility to generate a total score 
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out of 100, with higher scores representing higher overall symptom burden.  
Scrutiny of the content of the ESAS and prior studies suggest that it can quantify 
many of the symptoms experienced in HF, and importantly, has low patient 
burden.    
3.3.4 Assessing end of life care 
Assessment of EOL care is essential in making any assessment of PC need.  For 
this reason, I made an assessment of the patients’ preferences for EOL care and 
also a retrospective assessment of the caregivers’ (where available) opinion of 
EOL care.  Patient preference for EOL care has been identified as a priority for 
research into PC need in heart failure.3, 43  Previous studies suggest that patients 
often change their mind about preferred place of death and there is also poor 
agreement with their caregiver on this issue.45  Patients also change their mind 
about resuscitation status.46, 47  A recent study showed that patients with heart 
failure were willing to discuss EOL issues and that patients were willing to trade 
QOL for length of life,48 which is contrary to previous studies.212, 213   Although 
these studies are informative, they are based on selected cohorts of patients 
and this issue requires further research. 
In this study I asked participants, in a sensitive way, to consider their preferred 
place of care, death and resuscitation preference.  Specifically patients were 
asked “ If your health was to deteriorate in the future, such that you required 
other people to care for you, where would you prefer that care to take place?”  
Patients were then given the following options to choose from (after explaining 
this was a hypothetical discussion): in their own home; a nursing or care home; 
hospital; hospice; or undecided.  Patients were then asked to consider their 
preferred place of care for EOL treatment, specifically, patients were asked “If 
you were to think about the last few days of hours of life, would you have a 
strong opinion or preference for where that care took place?”  Patients will then 
be given the following options to choose from (again, after explaining this is a 
hypothetical discussion): in their own home; a nursing or care home; hospital; 
hospice; or undecided.  Finally, patients were asked, after an explanation of 
what resuscitation is, to consider their preference for resuscitation.   
Specifically, patients were asked “Do you have a strong opinion or preference to 
be resuscitated or not to be resuscitated in the event of a cardiac arrest”.  
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Patient were asked to pick an option from “for active resuscitation, not for 
resuscitation, or undecided”.   
Any EOL assessment should not only assess preference for and actual place of 
death, but also the patient and caregiver experience of dying, wherever that 
occurs. The VOICES postal questionnaire has been designed to evaluate relative’s 
experience of EOL care of the patients in the last few months of life.101  A recent 
review by the Department of Health has identified the VOICES questionnaire as 
the tool of choice in a survey of EOL care.214  I used this questionnaire to assess 
the caregivers’ (where available) perspective on EOL care.  The VOICES 
questionnaire was posted to relatives of deceased participants between 6 and 12 
months after a death.   
3.3.5 Identification of patients with palliative care needs 
Before a RCT of PC use in HF can be planned, there is a need to further explore 
how patients with PC needs can be identified and which patients require the 
additional services of a specialist PC service.  Heart failure guidelines suggest 
using the following factors to identify patients PC needs: frequent admission to 
hospital with decompensated heart failure; weight loss and cachexia; the need 
for frequent or on-going intravenous therapy; chronic poor QOL with NYHA class 
IV symptoms; and a clinical judgement that the patient is close to the EOL.3, 44  
However, predicting prognosis (and specifically mortality) is notoriously difficult 
and is recognised as a barrier to PC referral in heart failure.215  A number of 
prognostic models for mortality have been described from various heart failure 
cohorts.34  Unfortunately, most models were developed in chronic ambulatory 
populations (as opposed to acutely hospitalised patients) and many were based 
on patients not receiving contemporary pharmacotherapy or did not include 
important prognostic factors such as renal function, BNP216 (or NT pro BNP) or 
troponin.217, 218  Use of prognostic models has been suggested as a way of 
identifying patients with heart failure who are approaching EOL.219  However, 
while these models may predict death there is no evidence to suggest that 
prognostic models for mortality correlate well with PC needs.220   For example, 
patients who are clinically stable and then die suddenly probably are not 
candidates for PC.  This question requires further exploration.221 
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One approach to try and specifically identify and assess the PC needs of patients 
with heart failure is to use tools currently in development for cancer patients, 
acknowledging that these require validation in patients with heart failure. The 
Needs Assessment Tool (Progressive Disease – Cancer) (NAT-PD-C),222 has been 
designed specifically to assess and monitor PC needs in cancer patients.  It was 
designed based upon a literature review of needs of patients and their 
caregivers.  This assessment is made on a single page and completed by the 
patient’s healthcare professional.  The NAT-PD-C has been validated in cancer 
patients223, 224 and has been adapted for use in heart failure with the creation of 
the Needs Assessment Tool Progressive Disease Heart Failure (NAT-PD-HF), with 
reliability testing and construct validation.225  However this tool has yet to be 
evaluated in a substantial cohort of patients with heart failure and its value in 
identifying PC needs in patients with heart failure is as yet unconfirmed.  I will 
assess the usefulness of the NAT-PD-HF as part of this study.  
Performance status has been used by PC clinicians in both clinical practice and 
research as an indication for the likely need for PC services.226-228  The Karnofksy 
Performance Scale (KPS)229 is regarded by many as the gold standard tool for use 
in cancer patients.227, 228  This instrument has been simplified and validated in 
the form of the Australia-Modified Karnofksy Performance Scale (AKPS).230  The 
AKPS has been developed for use in cancer, and review of it suggests that it 
should also provide a suitable assessment of performance status in patients with 
heart failure. 
Current guidelines suggest using the physician’s own assessment of prognosis and 
need for PC to guide who to refer to PC services.3, 43, 219  I therefore, where 
available, asked the treating physician to estimate whether the patient had a 
prognosis of more or less than one year, and also to estimate whether they 
thought the patient had PC needs. 
 
  
63 
3.4 Study protocol 
This was a prospective observational study of near-consecutive patients 
admitted to hospital with a primary diagnosis of heart failure.  Patients were 
extensively characterised during their inpatient stay by collecting 
echocardiographic, demographic, biomarker and physiological data, as well as a 
detailed past medical history, (Appendix 3).  Patient symptom burden, mood and 
QOL were assessed during the index admission and repeatedly at study visits 
using PROMs as described above (Appendix 4). The burden on caregivers assessed 
using the Zarit Burden Interview PROM (appendix 4). Patient preference for 
place of care and death, as well as resuscitation preference, were recorded 
during the index admission.   
Patients had study assessments performed at baseline during their index 
admission to hospital, and then at 4 monthly intervals for a minimum of 8 
months and a maximum of 2.5 years. 
3.4.1 Patient recruitment and consent 
Near-consecutive patients admitted to the Western Infirmary in Glasgow with 
suspected HF were screened for inclusion in the study. The Western Infirmary 
acted as a community hospital for the North and West of the city, serving a 
population of about 250,000.  I screened all case notes of patients admitted to 
the medical receiving and cardiology wards at the Western Infirmary.  All new 
patients admitted through the medical receiving wards, unless admitted directly 
to the coronary care unit, were screened.  I screened medical admissions every 
morning, Monday to Friday.  On a Monday, I reviewed a list of admissions from 
the previous two days and case notes reviewed.  In addition to reviewing case 
records, I reviewed CXRs and ECGs of any potentially eligible patients.  I also 
screened echocardiogram referral requests and referrals to the Heart Failure 
Liaison Service, to ensure a rigorous screening process.  Any patients with signs 
and symptoms suggestive of heart failure were invited to participate in the study 
and have a BNP screening test performed. 
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I used a two-staged consent process.  The patient information sheets and 
consent forms are detailed in Appendix 2.  The first stage involved asking 
permission to access patients’ medical records and to link their record through 
NHS Scotland Information Services Division (ISD), allowing identification and 
cause of hospital readmission and death (including place of death), and to allow 
a sample of plasma to be tested for BNP.  A finger prick (12 microlitre) sample of 
blood was analysed for BNP using a validated, point of care, capillary blood 
sample analysis (Alere HeartCheck System). Those with a BNP less than 100 
pg/mL were excluded.3 In addition to elevated BNP, patients had to meet the 
ESC echocardiographic criteria for the diagnosis of HF.3, 231  Patients with a 
confirmed diagnosis of HF were invited to participate in the study and asked to 
complete the PROMs.  A full echocardiographic examination was carried out 
according to the European Association of Echocardiography guidelines and 
assessment of known prognostic variables were recorded (Table 3-1).232 Left 
ventricular ejection fraction was measured using Simpson’s biplane method.233  
Echocardiograms were blindly analysed by two cardiologists to ensure validity of 
the diagnosis and findings.  If an ejection fraction was not possible through poor 
echocardiographic acoustic window, an estimated ejection fraction was given.  
Inclusion and exclusion criteria are detailed in Table 3-2. 
Table 3-2 Inclusion and exclusion criteria 
Inclusion Criteria Exclusion Criteria 
 Admitted to hospital with a primary
diagnosis of acute decompensated
HF
 Age ≥ 18 years
 Fulfilling the ESC diagnostic
criteria for the diagnosis of HF
 HF-REF, HF-PEF and valvular HF
will be included.
• Refusal to participate
• Unable to provide informed 
consent/ complete study 
assessments
o Confusion/ dementia
o Learning difficulties
o Unable to read or write 
English language
o Moribund
• Already in study
• Geographical reasons, not from 
catchment area
• Isolated cor pulmonale
• Acute coronary syndrome 
complicated by pulmonary oedema 
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3.4.2 In-patient assessment 
A representation of the patient flow through the study is shown in Figure 3-1. 
I gathered detailed clinical data and data used in validated models of mortality 
prediction in HF during the index hospitalisation from history and examination of 
the patient, and review of the case record. Before discharge from hospital, 
patients completed the PROMs: the KCCQ and SF-12 questionnaires to assess 
QOL; the ESAS questionnaire to assess their current symptom burden; the HADS 
questionnaire to assess mood.  Patients were given a questionnaire pack 
(Appendix 4) and given 24 hours to complete the questionnaires.  Patients’ 
caregivers, where available, were invited to complete the Zarit Burden Interview 
to assess caregiver burden.  Performance status was evaluated using the AKPS.  
The NAT-PD-HF was used to assess the palliative needs of the patient.   
3.4.3 Study visit 
Following discharge patients with HF-REF were reviewed at an outpatient clinic 
by a cardiologist, a Heart Failure Liaison Nurse (HFLN), or both, where evidence-
based therapy were optimised in accordance with ESC guidelines.3   Patients 
were invited to attend for study assessments at 4 monthly intervals following 
discharge for a maximum follow-up period of 2.5 years. Participants were also 
offered the option of a home visit instead of attending in person, to increase 
study retention.  At these visits the PROMs were completed, to detail any 
potential change in QOL, mood, and symptom burden over time.   At these study 
assessments, prognostic markers were updated and the NAT-PD-HF was 
reassessed.  A physical examination and assessment of medications and 
symptoms was also made (Appendix 3).    
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Figure 3-1 Study schedule 
BNP= Brain type natriuretic peptide; ESAS= Edmonton Symptom Assessment Scale; DN= district nurse; 
GP= general practitioner; HFLN= heart failure liaison nurses; KCCQ= Kansas City Cardiomyopathy 
Questionnaire; SF-12= Short Form 12; HADS= Hospital Anxiety and Depression Scale; NAT-PD-HF= 
Needs Assessment Tool- Progressive Disease- Heart Failure; VOICES= Views Of Informal Carers 
Evaluation of Service.  
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3.4.4 Follow up 
All consenting patients were followed-up passively using record linkage though 
Information Services Division and the Safehaven record linkage services at NHS 
Scotland and NHS Greater Glasgow and Clyde, respectively.  This ensured as 
complete follow-up as possible.  All participants were followed up for a 
minimum of 12 months.   The number of hospital admissions, length of stay, 
date, cause and location of death were extracted.  Cause of hospital admission 
and death were determined using the primary cause of death or discharge 
diagnosis.  These were coded using the International Classification of Diseases 
version 10 classification.   
Relatives of deceased patients were asked to complete the VOICES EOL postal 
questionnaire.   This was posted to relatives between 6 months and 1 year 
following the death of a patient.  This recommendation (from the 
questionnaire’s authors) on timing of posting the questionnaire is aimed to 
reduce any potential upset caused by receiving an EOL questionnaire too soon 
after a death, but not so long after the death as to reduce recall of the events 
surrounding the death. Relatives were written to and given the opportunity to 
opt out prior to the questionnaire being posted to minimise any potential 
emotional upset from this questionnaire. 
3.4.5 Data handling 
All data were managed by the Robertson Centre for Biostatistics (RCB) at the 
University of Glasgow, the Data and Biostatistics Centre of the UK Clinical 
Research Collaboration Glasgow Clinical Trials Unit (CTU).  Baseline and follow-
up data (including patient and carer PROMs) was entered into case report forms 
(appendix 3) and then into the study database by experienced data entry staff.  
All data was stored, and managed according to CTU standard operating 
procedures that comply with appropriate legal and regulatory requirements.   
3.5 Statistical analysis  
Much of the analyses in this study are descriptive.  Normally distributed 
continuous variables are expressed as mean with associated standard deviation 
described.  Nonparametric continuous variables were summarised and expressed 
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as median with associated interquartile range.  Comparison of categorical 
variables was performed using Fisher’s exact test, and comparison of non-
parametric continuous variables using the Mann-Whitney U test.  To test the 
relationship between baseline prognostic variables, baseline PROMs, and 
physician completed assessment, multivariate logistic regression analysis was 
used.  Time to event analysis for mortality were analysed using the Kaplan-Meier 
survival analysis. This analysis was used to determine if patients who went on to 
meet the definition of PC needs could be identified from the baseline dataset.  
Statistical analysis were made using STATA 13 (College Station, TX, USA). 
3.5.1 Severity of patient reported outcome measures 
Summary scores from each PROM were categorised according to severity.  Where 
available, cut-offs used were based upon published normative data.  Cut-offs 
used are detailed in 
 
Table 3-3.  KCCQ overall summary score was categorised as none/mild, 
moderate, and severe impairment of QOL using the scores 51-100, 25-50, and 
less than 25 respectively.  An overall score of less than 25 has previously been 
shown to not only correlate with severe symptom burden according to NYHA 
classification, but also with poorer prognosis.181, 184, 234  Furthermore, a summary 
score of less than 25 has recently been shown to be associated with higher 
likelihood of persistently impaired QOL or death at 12 weeks following 
discharge.112  Indeed, this was the strongest predictor of any variable in a 
multivariable model.  SF-12 summary scores for physical and mental component 
scores are based upon normative data of more than 8000 individuals in the 
United Kingdom, with moderate and severe impairment being classified as one 
and two standard deviations from the mean respectively.193 Summary scores for 
both anxiety and depression HADS PROM can be used to categorise patients into 
severity of mood impairment with scores of <8 indicating normal, 8-10 mild, 11-
15 moderate, and >15 severe impairment. These cut-offs have been 
complimented and corroborated by normative data.203, 235   There are no 
published data categorising ESAS overall scores by severity.  However, as the 
ESAS is composed of 10 Likert scales for each individual symptom, with a 
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minimum of 0 and a maximum of 100, I chose to define mild symptom burden as 
ESAS total score of <34, moderate as 34-66, and severe as >66.  As each 
individual PROM would not assess QOL, symptoms, or mood, and taking into 
account that patients could be severe in one, but not other PROMs, I made an 
overall assessment of severity.  I defined severe overall as any patient who was 
categorised as severe in at least one PROM.   
Table 3-3 Severity category patient reported outcome measures 
Score Severity Cut-off 
HADS Depression None/mild ≤ 10 
Moderate 11-15 
Severe ≥ 16 
HADS Anxiety None/mild ≤ 10 
Moderate 11-15 
Severe ≥ 16 
KCCQ Summary Score None/mild > 50
Moderate 25-50
Severe < 25
ESAS Summary Score None/mild 0-33
Moderate 34-66
Severe 67-100
SF-12 PCS None/mild > 40.28
Moderate 30.56-40.28
Severe < 30.56
SF-12 MCS None/mild > 40.28
Moderate 30.56-40.28
Severe < 30.56
Overall severity category Severely impaired Severe in any PROM category 
ESAS= Edmonton Symptom Assessment Scale; HADS= Hospital Anxiety and Depression 
Scale; KCCQ= Kansas City Cardiomyopathy Questionnaire; SF-12= Short Form 12. 
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3.5.2 Defining palliative care needs 
There is no tool currently available to classify the presence of absence of PC 
needs.  I have therefore used the WHO definition of PC as a basis on which to 
categorise patients who likely had PC needs and those who were less likely to 
have palliative care needs.  To do this, I have elected to identify those patients 
with the worst QOL, symptom burden, and mood.  Given the fluctuating nature 
of heart failure, I have taken into account potential change in status over time.  
My definition of PC needs, which is a practical interpretation of the WHO 
definition of PC, is shown in Table 3-4.  I have chosen to try to identify the 
patients with the worst symptom, QOL and mood burden as these are the 
patients who would likely benefit most from a palliative intervention.  
Table 3-4 Definition of PC needs 
Either 
1- Severely impaired status* preceding death, without known improvement of 
status. 
2- Persistently severely impaired status*, defined as two or more consecutive study 
visits, without known improvement. 
*Severely impaired status = severe in any patient reported outcome measure 
 
 
3.5.3 Days alive and out of hospital analysis 
To test whether the definition described above was appropriate for identifying 
patients with PC, further analyses of the patient journey were performed.  I 
used three different analyses.  Firstly, I calculated the number of days spent 
alive and out of hospital (DAOH), as patients in the PC needs group would likely 
have a poorer prognosis and a higher morbidity (including longer length of initial 
hospitalisation and more subsequent hospitalisations), and therefore have fewer 
DAOH.  DAOH is a useful metric as it provides a quantifiable combination of both 
morbidity and mortality.  This allows comparison of the patient journey between 
two groups.  DAOH was calculated by subtracting one day from the total time 
from recruitment to study completion, for each day spent in hospital or lost to 
death.  I then calculated the proportion of DAOH compared to the potential 
DAOH for each participant.  The second sensitivity analysis I used was to adjust 
DAOH for QOL.  This metric assesses not only days lost due to death or 
hospitalisation, but estimates days lost due to poor QOL.  This metric has been 
used to describe the patient journey in heart failure previously.236  To calculate 
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QOL adjusted DAOH I first calculated the number of DAOH between each 
assessment.  I then used the KCCQ overall summary score to weight each DAOH.  
For example, if a KCCQ summary score was 75, and there were 100 DAOH, this 
would be calculated as 0.75 x 100 days, resulting in 75 days of good health.  I 
then calculated the proportion of QOL DAOH compared to the potential DAOH.  
The third sensitivity analysis performed was similar to the QOL adjusted DAOH 
calculation, but using symptom adjusted DAOH.  I used the ESAS summary score 
to estimate the number of days lost to symptom burden.  As a higher score on 
ESAS was associated with worse symptom burden, I subtracted the total ESAS 
score from 100 before calculating the symptom adjusted DAOH.  For example, a 
patient with an ESAS summary score of 75 and 50 DAOH would have ((100-
75)/100) x 50 DAOH, resulting in 12.5 symptom free DAOH.  If the definition used 
for PC needs is robust, then the PC needs group should have lower DAOH, QOL 
adjusted DAOH, and symptom adjusted DAOH. 
3.6 Ethical considerations 
This study was conducted according to the principles outlined in the Declaration 
of Helsinki.237  The study protocol was approved by the West of Scotland 
Research Ethics Committee.  All participants were given over 24 hours to read 
the patient information letter and consider if they wish to participate before 
provide written consent.  Patient burden and load were considered, and PROMs 
were specifically chosen to limit the burden placed on participants.  Burden of 
follow up study visits was reduced by offering participants home visits or 
providing door to door transport. 
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Chapter 4 Recruitment and baseline 
characteristics 
In this chapter I will describe the number of patients with suspected heart 
failure that I screened, and describe the proportion who met the inclusion 
criteria and agreed to participate in the study.  I will also describe the baseline 
characteristics of the cohort recruited, including medical history, physical 
examination findings, laboratory findings, and results of baseline investigations 
including echocardiography.  I will then compare the cohort recruited to other 
published hospitalised cohorts of patients with heart failure and reflect on the 
generalisability of this cohort. 
4.1 Recruitment 
4.1.1 Screening 
All patients admitted to the medical receiving and cardiology wards at the 
Western Infirmary Glasgow, were screened for eligibility for inclusion.  I 
discussed with the physicians and nurses on each ward to identify any possible 
new cases of suspected heart failure.  I also reviewed the case notes for all new 
admissions, looking for any patients with potential signs or symptoms of heart 
failure.  In addition to this, I reviewed the chest X-ray and ECG for each patient, 
again looking for any evidence of an underlying diagnosis of heart failure.  As a 
further screening method, I reviewed all of the requests for echocardiography, 
looking for any requests that queried heart failure as a diagnosis.     
I screened new admissions between January 9th 2013 and December 1st 2014.  I 
did not routinely screen on Saturday or Sunday, but attempted to review all 
potential patients admitted over this period each Monday morning.  I screened 
an unselected population of patients admitted to hospital with suspected heart 
failure.  Consecutive admissions were screened for inclusion in the study on the 
days that I was present.  Using this method of screening patients, I was able to 
approach a near-consecutive, unselected population, thus increasing the 
generalisability of this study.   Potentially eligible patients were initially 
approached and given preliminary information about the study and the potential 
diagnosis of heart failure.  They were asked for consent to B-Type natriuretic 
73 
peptide testing and also for access to medical records and ISD record linkage.  
Patients were then given 24 hours to consider participation in the study.  Those 
consenting to participate and with an elevated natriuretic peptide were invited 
to participate in the full study, including completing patient reported outcome 
measures and follow up assessments.   
4.1.2 Screening log 
I screened over 15 000 acute medical admissions to the Western Infirmary, 
Glasgow, between January 9th 2013 and December 1st 2014.  Of these acute 
admissions, 829 patients had suspected heart failure based on the receiving 
physician’s initial assessment, or from reading the case notes (Figure 4-1).  
During further screening through use of history, examination, natriuretic 
peptide, and echocardiography, 165 patients were excluded as they did not 
meet the inclusion criteria.  That is, heart failure was not the primary reason for 
admission, or an alternative diagnosis was found.   
The reasons for exclusion included: primary presentation with acute coronary 
syndrome complicated by pulmonary oedema; elevated natriuretic peptide, but 
no objective evidence of structural heart disease on echocardiography; low 
natriuretic peptide levels; iatrogenic pulmonary oedema caused by giving 
intravenous fluids; and one case of neurogenic pulmonary oedema in the context 
of a sub-arachnoid haemorrhage.  Many of the patients with elevated natriuretic 
peptide, but no objective evidence of heart failure had a diagnosis of likely or 
confirmed cor pulmonale, others a diagnosis of pulmonary embolism, renal 
failure, or sepsis.  Of a total of 664 patients identified as having probable heart 
failure, 351 patients were excluded.  The most common reason included 
readmission and already in the study (n = 154).  The next most common reason 
for exclusion was those that were unable to participate for language, 
geographical, or cognitive issues (n = 124).  A further 52 patients refused 
consent to participate in the study.  21 patients were deemed too unwell, or 
were in fact, moribund, and thus not approached for inclusion.   
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Figure 4-1 Screening 
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A total of 313 patients met the inclusion criteria, and met the ESC definition of 
heart failure.  Of these patients, 272 agreed to complete the questionnaire pack 
of PROMs and to attend study visits every four months for the duration of the 
study.  On average, 3.6 patients were recruited per week over the duration of 
study enrolment (Figure 4-2). 
 
Figure 4-2 Recruitment per week 
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4.2 Baseline results 
313 patients agreed to participate in the study.  Of these, 272 agreed to 
complete PROMs and attend further follow-up visits.  All 313 patients consented 
to long term follow up via electron records regarding vital status, cause of 
death, number and cause of hospitalisations.   The median time from admission 
to recruitment was 2 days [IQR 2, 4].  Most patients survived until discharge, 
with only 4 deaths during the index admission for those that were able and 
willing to participate in the study.  The median length of stay was 9 [5-15] days. 
4.2.1 Baseline demographics clinical features 
Demographics and past medical history are displayed in Table 4-1.  Patients 
were elderly, with a median age of 77 [IQR 71-83] for the whole cohort.  
Patients who did not complete PROMs or consent to attend study visits were 
older than those who did with a median age of 84 [IQR 79-88] and 76 [IQR 70-82] 
respectively.  Female sex was more common in patients who declined to 
participate in the questionnaire and active follow-up components of the study 
(63 versus 47%), although there was no statistically significant difference 
between groups.  The majority of participants were of Caucasian decent, 
reflecting the patient population that attended the Western Infirmary, Glasgow.  
Many patients were hypertensive on admission, in keeping with acute heart 
failure, with the overall cohort having a median systolic blood pressure of 134 
[IQR 117-155].  Patients who participated were similar physiologically in terms of 
blood pressure and pulse rate on admission.  There was a statistically significant 
difference between the two groups in body mass index, with those not 
completing PROMs having a lower body mass index at 24 kg/m [IQR 21.3-27.1] 
versus 27.0 [IQR 23.5-31.6] in those who did.   
As expected, common symptoms experienced in heart failure were extremely 
common in the overall cohort.  The most prevalent symptom was ankle swelling 
(76%), followed by paroxysmal nocturnal dyspnoea (71%), and orthopnoea (74%).  
Patients participating in the full study with follow-up and PROMs reported a 
higher prevalence of these symptoms, although this was not statistically 
significant. 
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Table 4-1 Baseline demographics 
 All participants Completed  
PROMS 
Did not complete 
PROMS 
p  
 n = 313 n =272 n = 41  
Age- yr 77.1 [70.6, 83.4]  76.0 [69.8, 82.4]  84.2 [79.1, 87.8]  < 0.001  
Female sex- n (%) 154 (49.2)  128 (47.1)  26 (63.4)  0.051  
Race or ethnic group- n (%)    0.065  
White 304 (97.1)  266 (97.8)  38 (92.7)   
Black 1 (0.3)  1 (0.4)  0 (0.0)   
Asian 7 (2.2)  5 (1.8)  2 (4.9)   
Other 1 (0.3)  0 (0.0)  1 (2.4)   
     
Systolic blood pressure- 
mmHg 
134 [117, 155]  134 [118, 155]  129 [112, 154]  0.370  
 
Diastolic blood pressure- 
mmHg 
75 [63, 89]  75 [64, 90]  71 [61, 83]  0.111  
 
Heart rate- beats/min 82 [68, 103]  82 [68, 102]  77 [67, 106]  0.536  
Body-mass index- kg/m 26.5 [22.9, 30.9]  27.0 [23.5, 31.6]  24.0 [21.3, 27.1]  0.001  
     
Symptoms- n (%)     
NYHA functional class    0.713 
Class I 0 (0.0)  0 (0.0)  0 (0.0)   
Class II 95 (30.4)  82 (30.1)  13 (31.7)   
Class III 160 (51.1)  141 (51.8)  19 (46.3)   
Class IV 58 (18.5)  49 (18.0)  9 (22.0)   
HF symptoms     
Orthopnea  232 (74.1)  204 (75.0)  28 (68.3)  0.346  
PND  221 (70.6)  194 (71.3)  27 (65.9)  0.467  
Ankle swelling  237 (76.0)  208 (76.5)  29 (72.5)  0.558  
Wheeze  65 (20.8)  62 (22.8)  3 (7.3)  0.022  
Palpitations  11 (3.5)  10 (3.7)  1 (2.4)  1.000  
     
Signs- n (%)     
Elevated JVP (> 4cm)  208 (74.0)  176 (73.0)  32 (80.0)  0.438  
Third Heart Sound  63 (20.2)  59 (21.8)  4 (9.8)  0.094  
Murmur  174 (55.8)  149 (55.0)  25 (61.0)  0.504  
Pulmonary crackles  239 (76.8)  212 (78.5)  27 (65.9)  0.110  
Basal§  237 (99.2)  210 (99.1)  27 (100.0)  1.000  
Middle§ 55 (23.0)  45 (21.2)  10 (37.0)  0.087  
Apex§ 10 (4.2)  9 (4.2)  1 (3.7)  1.000  
Pleural effusion  107 (34.5)  95 (35.3)  12 (29.3)  0.486  
Right  67 (62.6)  59 (62.1)  8 (66.7)  1.000  
Left  66 (61.7)  59 (62.1)  7 (58.3)  1.000  
Peripheral Oedema  236 (75.9)  206 (76.3)  30 (73.2)  0.696  
Ankle*  236 (100.0)  206 (100.0)  30 (100.0)  NA  
Knee*  141 (59.7)  125 (60.7)  16 (53.3)  0.551  
Thigh*  72 (30.5)  64 (31.1)  8 (26.7)  0.678  
Sacrum*  47 (19.9)  43 (20.9)  4 (13.3)  0.464  
Abdomen*  38 (16.1)  35 (17.0)  3 (10.0)  0.432  
Ascites  44 (14.1)  40 (14.8)  4 (9.8)  0.478  
Continuous variables expressed as median [ interquartile range]. 
HF= heart failure; JVP= jugular venous pressure; NYHA = New York Heart Association; PND= paroxysmal 
nocturnal dyspnoea. 
§ percentage of patients with pulmonary crackles 
* percentage of pateints with peripheral oedema 
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No patients were NYHA classification I by definition, as such patients would be 
symptom free and not present to hospital or have heart failure.  Most patients 
were NYHA III (51%), with 30% NYHA II and 19% NYHA IV.  This represents a very 
high disease and symptom burden when using the most commonly utilised 
functional assessment.  Those completing PROMs and the full study were very 
similar in terms of NYHA classification compared to those who did not, with the 
exception of a numerically higher proportion of NYHA IV in those who did not 
complete the PROM component of the study (although this was not statistically 
significant).   
Physical signs of heart failure were common.  Signs of elevated venous pressure 
were particularly common, with 74% overall having an elevated jugular venous 
pressure.  There was similar proportion of patients with elevated jugular venous 
pressure in both those who completed PROMs and those who did not (73 and 
80%, respectively).  Auscultation of the heart frequently identified a murmur 
(56%), although a gallop rhythm or third heart sound was only detected in 20% of 
patients.  Clinical evidence of pulmonary congestion, in the form of pulmonary 
crackles or rales, was present in 77% of patients, with no statistically significant 
difference between those participating and those who did not.  27% of patients 
presented with marked signs of pulmonary congestion, with pulmonary rales to 
the mid-zones or more.  35% of patients had clinical evidence of a pleural 
effusion, either uni- or bi-lateral.  Peripheral oedema was another common 
physical finding, present in 76% of patients at admission.  Most of these patients 
presented with oedema extending to the knees (60%), whereas 20 and 16% 
presented with oedema extending to the sacrum and abdomen, respectively. 
4.2.2 Past medical history 
Overall, most patients had not been diagnosed with heart failure previously 
(57%); this was true for both patients completing the PROM aspect of the study 
(56%) and those who did not (61%).   Of the 136 patients with a previous 
diagnosis of heart failure, 80 (59%) had previously been admitted to hospital 
with a primary discharge diagnosis of heart failure.  Most were under the care, 
or had previously been under the care, of a cardiologist (77%).  Only 24 patients 
had been admitted to hospital due to heart failure in the previous 6 months.    
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Co-morbidities were highly prevalent in the overall cohort, and those completing 
PROMs (Table 4-2).  Ischaemic heart disease was particularly common, with 40% 
suffering from previous myocardial infarction, 13% having had percutaneous 
coronary intervention, and 15% coronary artery bypass grafting.  Most patients 
had a previous diagnosis of, or were being treated for, hypertension (68%).  A 
past history of atrial fibrillation was also common, reported in 53% of patients.  
Of these 165 patients, atrial fibrillation was persistent or permanent in 80% and 
paroxysmal in 19%.  Other commonly reported cardiovascular co-morbidities 
included stroke (19%) and peripheral vascular disease (14%).  Permanent 
pacemakers were uncommon, with only 21 patients with some form of pacing 
device.  Of these 21 patients, only 8 had cardiac resynchronisation therapy.  
Implantable cardioverter defibrillators, either in combination with cardiac 
resynchronisation therapy or as a stand-alone system, were also very rare with 
only 10 patients having these devices.  Non-cardiovascular co-morbidities were 
frequently reported, with 100 patients (32%) reporting a diagnosis of, or were 
treated for, diabetes.  Of these, most were on oral hypoglycaemic medication 
(65%) or insulin (29%), with 23% being treated with diet alone.  A history of 
anaemia was also prevalent at 28%.  Many patients had a history of chronic lung 
disease, with 25 and 8 % reporting a history of chronic obstructive pulmonary 
disease and asthma, respectively.  43 patients reported, or were on treatment 
for, depression, with 28% of these patients reporting current depression.   
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Table 4-2 Past medical history 
 All participants Completed  
PROMS 
Did not 
complete 
PROMS 
p  
 n = 313 n =272 n = 41  
History of HF- n (%)     
HF diagnosis prior to 
admission 
136 (43.5)  120 (44.1)  16 (39.0)  0.614  
Previous HF 
hospitalisation 
80 (25.6)  73 (26.8)  7 (17.1)  0.279  
HF hospitalisation 
preceding 6 months 
24 (7.7)  22 (8.1)  2 (4.9)  0.752  
     
Cardiovascular- n (%)     
Treated Hypertension  212 (67.7)  184 (67.6)  28 (68.3)  1.000  
Myocardial Infarction  126 (40.3)  111 (40.8)  15 (36.6)  0.733  
PCI  42 (13.4)  38 (14.0)  4 (9.8)  0.624  
CABG  47 (15.0)  42 (15.4)  5 (12.2)  0.814  
Hypercholesterolaemia  94 (30.0)  88 (32.4)  6 (14.6)  0.027  
Atrial Fibrillation/Flutter  165 (52.7)  144 (52.9)  21 (51.2)  0.868  
Cerebrovascular disease 
(CVA/TIA)  
59 (18.8)  52 (19.1)  7 (17.1)  1.000  
Peripheral Vascular 
Disease  
43 (13.7)  37 (13.6)  6 (14.6)  0.810  
Primary prevention ICD  5 (1.6)  4 (1.5)  1 (2.4)  0.508  
Pacemaker  21 (6.7) 18 (6.6) 3 (7.3)  
Conventional§  13 (61.9)  10 (55.6)  3 (100.0)  0.257  
CRT-P§  3 (14.3)  3 (16.7)  0 (0.0)  1.000  
CRT-D§  5 (23.8)  5 (27.8)  0 (0.0)  0.549  
Valve replacement  16 (5.1)  11 (4.0)  5 (12.2)  0.044  
     
Non-cardiovascular-n (%)     
Diabetes Mellitus  100 (31.9)  89 (32.7)  11 (26.8)  0.590  
COPD  77 (24.6)  69 (25.4)  8 (19.5)  0.560  
Asthma  24 (7.7)  23 (8.5)  1 (2.4)  0.339  
Depression  43 (13.8)  37 (13.7)  6 (14.6)  0.811  
Cancer  41 (13.1)  31 (11.4)  10 (24.4)  0.043  
Hypothyroidism  44 (14.1)  35 (12.9)  9 (22.0)  0.145  
Osteoarthritis  29 (9.3)  27 (9.9)  2 (4.9)  0.396  
Anaemia  86 (27.5)  77 (28.3)  9 (22.0)  0.457  
CABG= coronary artery bypass graft; COPD= chronic obstructive pulmonary disease; CRT-P= cardiac 
resynchronisation therapy- pace; CRT-D= cardiac resynchronisation therapy- defibrillator; CVA= 
cerebrovascular accident; HF= heart failure; ICD= implantable cardioverter defibrillator; PCI= percutaneous 
coronary intervention; TIA= transient ischaemic attack. 
§ percentage of patients with pacemaker 
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4.2.3 Drug history- medications started prior to admission 
Drug history is detailed in Table 4-3.  Polypharmacy was common.  Although, 
only 43% of all patients had a known diagnosis of heart failure, many were 
already prescribed the common therapies used in chronic heart failure, although 
heart failure was not necessarily the indication for these medications.  Over half 
of all participants were on an ACEi (41%), or an ARB (15%) prior to admission.  
The most commonly prescribed ACEi were ramipril (60%), followed by enalapril 
(17%), and lisinopril 16%).   ARBs prescribed prior to admission were losartan 
(50%), candesartan (41%), and irbesartan (9%).   Beta blocker therapy was also 
very common prior to admission, with 56% of participants taking this class of 
drug.  Patients were prescribed bisoprolol (74%), atenolol (17%), carvedilol (9%), 
and metoprolol (1%).  25 (8%) of participants were already prescribed a MRA.  
Other heart failure therapies which have been shown to reduce morbidity were 
less commonly prescribed, with only 8 and 1 patients prescribed hydralazine and 
ivabradine, respectively.  Drug therapy that is often used for symptomatic 
treatment in heart failure, loop diuretics (in the form of furosemide) and 
digoxin, were also frequently prescribed prior to admission, with 64 and 10% 
respectively taking these medications.  Many patients were prescribed 
pharmacotherapy often used in the treatment of ischaemic heart and 
cerebrovascular disease, with 63% taking a statin, 42% taking aspirin, and 10% 
taking clopidogrel prior to admission.  Calcium channel blockers (CCB) were 
often prescribed prior to hospitalisation, with 25% of participants on this class of 
medication.  The most common CCBs were amlodipine (68%), verapamil (14%), 
and diltiazem (9%).  The anti-anginal medications nicorandil and long-acting 
nitrates were prescribed in 9 and 12% of participants, respectively.  Warfarin 
prescription was relatively low (28%) compared to the proportion of participants 
with a past history of atrial fibrillation (53%).   
Unsurprisingly, a high proportion of participants were receiving some form of 
diabetic therapy, reflecting the high prevalence of diabetes mellitus in this 
cohort.  26% of all participants were taking some form of diabetic therapy.  Of 
these, the most commonly prescribed were insulin (35%), sulphonurea (49%), or 
biguanide (57%).    
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Non-cardiovascular medications were common, again reflecting the high co-
morbid burden in the cohort.  The most common non-cardiovascular medications 
were respiratory medications/ bronchodilators and anti-depressants, at 30 and 
16% respectively.  85% of patients on respiratory medications were prescribed a 
beta-agonist inhaler, with a further 58 and 54% prescribed steroid and anti-
cholinergic inhalers respectively.  The most frequently prescribed anti-
depressants were selective serotonin reuptake inhibitors (37% of those taking 
anti-depressants) and tricyclic antidepressants (41% of those taking anti-
depressants). 
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Table 4-3 Medications prior to admission 
All participants Completed 
PROMS 
Did not 
complete 
PROMS 
p 
n = 313 n =272 n = 41 
Cardiovascular - n (%) 
ACE-Inhibitor  128 (40.9) 108 (39.7) 20 (48.8) 0.308 
ARB  46 (14.7) 40 (14.7) 6 (14.6) 1.000 
Beta-blocker  176 (56.2) 152 (55.9) 24 (58.5) 0.866 
MRA  25 (8.0) 23 (8.5) 2 (4.9) 0.756 
Hydralazine  8 (2.6) 8 (2.9) 0 (0.0) 0.603 
Ivabradine  1 (0.3) 1 (0.4) 0 (0.0) 1.000 
Anti-arrhythmic  4 (1.3) 4 (1.5) 0 (0.0) 1.000 
Calcium channel-blocker 79 (25.2) 68 (25.0) 11 (26.8) 0.847 
Long-acting nitrates  37 (11.8) 33 (12.1) 4 (9.8) 0.799 
Statin  197 (62.9) 171 (62.9) 26 (63.4) 1.000 
Diabetic medication  82 (26.2) 70 (25.7) 12 (29.3) 0.703 
Insulin§ 29 (35.4) 27 (38.6) 2 (16.7) 0.198 
Sulphonylurea§ 40 (48.8) 33 (47.1) 7 (58.3) 0.543 
Biguanide§ 47 (57.3) 41 (58.6) 6 (50.0) 0.754 
Glitazone§ 3 (3.7) 3 (4.3) 0 (0.0) 1.000 
Other§ 9 (11.0) 8 (11.4) 1 (8.3) 1.000 
Diuretics  199 (63.6) 172 (63.2) 27 (65.9) 0.862 
Digoxin  31 (9.9) 26 (9.6) 5 (12.2) 0.577 
Aspirin  130 (41.5) 112 (41.2) 18 (43.9) 0.737 
Clopidogrel 32 (10.2) 26 (9.6) 6 (14.6) 0.403 
Warfarin  89 (28.4) 78 (28.7) 11 (26.8) 1.000 
Nicorandil  28 (8.9) 25 (9.2) 3 (7.3) 1.000 
Non-cardiovascular -n (%) 
Bronchodilator  93 (29.7) 86 (31.6) 7 (17.1) 0.067 
Steroid tablets*  9 (9.7) 9 (10.5) 0 (0.0) 1.000 
Beta-agonist 
inhalers*  
78 (84.8) 71 (83.5) 7 (100.0) 0.590 
Anti-cholinergic 
inhalers*  
50 (54.3) 45 (52.9) 5 (71.4) 0.448 
Steroid inhalers* 53 (57.6) 48 (56.5) 5 (71.4) 0.695 
Antidepressants 49 (15.7) 42 (15.4) 7 (17.1) 0.818 
SSRI± 18 (36.7) 17 (40.5) 1 (14.3) 0.238 
TCA±  20 (40.8) 19 (45.2) 1 (14.3) 0.216 
MAOI ± 3 (6.1) 3 (7.1) 0 (0.0) 1.000 
Other±  10 (20.4) 5 (11.9) 5 (71.4) 0.002 
NSAIDs  11 (3.5) 8 (2.9) 3 (7.3) 0.163 
Vitamins 32 (10.2) 28 (10.3) 4 (9.8) 1.000 
Antihistamines 12 (3.8) 11 (4.0) 1 (2.4) 1.000 
Osteoarthritis  29 (9.3) 27 (9.9) 2 (4.9) 0.396 
ACE= angiotensin converting enzyme; ARB= angiotensin receptor blocker; MRA= mineralocorticoid receptor 
antagonist; MAOI= monoamine oxidase inhibitor; SSRI= selective serotonin reuptake inhibitor; TCA= tricyclic 
antidepressant. 
§ percentage of diabetic medication
* percentage of bronchodilator medication
± percentage of antidepressant medication
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4.2.4 Drug history- medications started during admission or on 
discharge 
Almost all participants were treated with the loop diuretic furosemide (98%).  Of 
these patients, most received intravenous furosemide.  One bolus of intravenous 
furosemide was received by 22% and regular boluses on more than one day by 
74%.  279 (90%) patients went on to have regular oral furosemide prescribed.  
Another loop diuretic that was prescribed was bumetanide (n= 17, 5%), often 
orally after intravenous furosemide.  Intravenous vasodilators and inotropic 
agents were prescribed infrequently.  Intravenous nitrate was prescribed in only 
2% of participants, and only 3% and 1% received dobutamine and dopamine 
respectively. 
ACEi and ARB prescription increased during hospital admission, with 70% of 
patients on one of these medications at discharge.  The proportion of patients 
on ACEi which have been shown to reduce mortality in patients with heart 
failure was higher than admission, with 32% of patients who were on an ACEi 
being prescribed enalapril.  Most other patients who were prescribed an ACEi 
were prescribed Ramipril (53%).  The most common ARBs prescribed were 
candesartan (52%) and losartan (41%).  Beta blocker prescription increased 
following admission, with 69% of being prescribed this class of medication.  
Again, cardio-selective beta blockers were favoured, with a higher proportion 
being prescribed specific beta blockers which have been shown to reduce 
mortality in patients with heart failure.  By far the most commonly prescribed 
beta blocker was bisoprolol (84%), followed by carvedilol (11%).  MRA 
prescription increased, with 32% of patients being prescribed either 
spironolactone (67%) or eplerenone (33%).  A similar proportion of patients 
continued or were prescribed hydralazine and ivabradine compared to 
admission, with 9 and 1 patients respectively prescribed these medications.  The 
number and proportion of patients prescribed digoxin increased from admission 
from 10% to 28%.  Warfarin prescription saw a similar increase in prescription 
from admission from 29 to 37%. 
There were no significant differences in prescription between patients who 
participated in the full study and those who did not, either on admission or 
medications prescribed during admission. 
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Table 4-4 Medications started in hospital or at discharge 
 All participants Completed  
PROMS 
Did not 
complete 
PROMS 
p  
 n = 313 n =272 n = 41  
Cardiovascular - n (%)     
ACE-Inhibitor  178 (56.9)  152 (55.9)  26 (63.4)  0.401  
ARB  42 (13.4)  37 (13.6)  5 (12.2)  1.000  
Beta-blocker  217 (69.3)  192 (70.6)  25 (61.0)  0.275  
MRA  100 (31.9)  91 (33.5)  9 (22.0)  0.155  
Hydralazine  9 (2.9)  9 (3.3)  0 (0.0)  0.612  
Ivabradine  1 (0.3)  1 (0.4)  0 (0.0)  1.000  
Anti-arrhythmic  7 (2.2)  7 (2.6)  0 (0.0)  0.600  
Calcium channel-blocker  32 (10.2)  28 (10.3)  4 (9.8)  1.000  
Long-acting nitrates  35 (11.2)  30 (11.1)  5 (12.2)  0.792  
Statin  184 (59.0)  160 (59.0)  24 (58.5)  1.000  
Diuretics (exc. 
Furosemide)  
25 (8.0)  22 (8.1)  3 (7.3)  1.000  
Furosemide  306 (97.8)  265 (97.4)  41 (100.0)  0.600  
IV once-off  57 (18.2)  49 (18.0)  8 (19.5)  0.817  
IV regular  209 (66.8)  182 (66.9)  27 (65.9)  0.893  
Oral once-off  4 (1.1)  3 (1.1)  1 (2.4)  0.478  
Oral regular  279 (89.1)  242 (89.0)  37 (90.0)  0.807  
Digoxin  86 (27.5)  76 (27.9)  10 (24.4)  0.711  
Aspirin  109 (34.9)  96 (35.4)  13 (31.7)  0.727  
Clopidogrel  38 (12.2)  31 (11.4)  7 (17.1)  0.307  
Warfarin  116 (37.2)  106 (39.1)  10 (24.4)  0.083  
Nicorandil  23 (7.4)  18 (6.6)  5 (12.2)  0.203  
Inotropes / vasodilators      
IV Nitrate  7 (2.2)  6 (2.2)  1 (2.4)  1.000  
Dobutamine  4 (1.3)  4 (1.5)  0 (0.0)  1.000  
Dopamine  10 (3.2)  9 (3.3)  1 (2.4)  1.000  
IV other  6 (1.9)  6 (2.2)  0 (0.0)  1.000  
ACE= angiotensin converting enzyme; ARB= angiotensin receptor blocker; MRA= mineralocorticoid receptor 
antagonist; IV= intravenous.  
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4.2.5 Investigations 
 Electrocardiogram 
All participants had an ECG performed during admission, often within the first 
hour of admission.  A summary of the ECG findings are detailed in Table 4-5.  As 
expected, the ECG often suggested underlying structural heart disease and was 
often abnormal.  Half of all participants were in atrial fibrillation, in keeping 
with the high prevalence of atrial fibrillation in the past medical history.    A 
bundle branch block pattern was present in 29% of all participants, more often a 
left bundle branch block pattern (70%).  QRS duration was 100 [IQR 88-128] ms 
and corrected QT duration was 468 [441-495] ms. Pathological Q waves were present 
in almost one quarter of patients (24%) and evidence of left ventricular hypertrophy in a 
further 19%.  Patients who participated in the whole study and completed PROMs were 
similar to those who did not, other than a higher proportion of atrial fibrillation in those 
who did not. 
Table 4-5 Electrocardiogram 
All participants Completed 
PROMS 
Did not 
complete 
PROMS 
p 
n = 313 n =272 n = 41 
ECG during admission 313 (100) 272 (100) 41 (100) 
Sinus rhythm 151 (48.2)  138 (50.7) 13 (31.7) 0.029 
AF/flutter  158 (50.5)  131 (48.2) 27 (65.9) 0.044 
BBB  92 (29.4)  81 (29.8) 11 (26.8) 0.854 
Right§ 28 (30.4)  26 (32.1) 2 (18.2) 0.494 
Left§  64 (69.6)  55 (67.9) 9 (81.8) 
Paced  19 (6.1)  16 (5.9) 3 (7.3) 0.724 
Pathological Q waves 75 (24.0)  66 (24.4) 9 (22.0) 0.846 
LVH  60 (19.2)  54 (19.9) 6 (14.6) 0.527 
QRS duration 100 [88, 128]  102 [88, 129] 96 [88, 128] 0.488 
QTc duration 468 [441, 495] 470 [441, 497] 458 [440, 490] 0.314 
Values are expressed as n (%) or median [inter-quartile range]. 
AF= atrial fibrillation; BBB= bundle branch block; LVH= left ventricular hypertrophy. 
§ percentage of BBB
Chest X-ray 
Most participants (98%) received a CXR as part of standard clinical care for 
patients admitted to hospital with suspected heart failure.  A summary of the 
key findings from the CXR is detailed in Table 4-6.  CXRs were often abnormal 
with signs suggestive of underlying cardiac disease and congestion in most.  
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Cardiomegaly was present overall in 91% of patients, with a higher proportion of 
cardiomegaly in the group completing the PROMs versus those who did not, 93 
versus 81% respectively.  Evidence of pulmonary congestion was common, but 
not universal.  Most patients CXR showed upper lobe venous diversion (91%), 
with a further 42 and 38% showing evidence of interstitial oedema (with Kerley 
B-lines) and alveolar oedema (with patchy consolidation), respectively.  Just 
over half of all patients who had a CXR had evidence of pleural effusions, with 
most (68%) being bilateral.  Other than cardiomegaly, there were no statistically 
significant differences between those who participated in the full study and 
those who did not. 
Table 4-6 Chest X-ray findings 
 All participants Completed  
PROMS 
Did not 
complete 
PROMS 
p  
 n = 313 n =272 n = 41  
CXR during admission  308 (98.4) 267 (98.2) 41 (100)  
Cardiomegaly (CTR > 0.5)  281 (91.2)  248 (92.9)  33 (80.5)  0.016  
Upper lobe venous 
diversion  
279 (90.6)  245 (91.8)  34 (82.9)  0.084  
Interstitial oedema (kerley 
B lines)  
128 (41.6)  112 (41.9)  16 (39.0)  0.865  
Alveolar oedema (patchy 
consolidation)  
118 (38.3)  104 (39.0)  14 (34.1)  0.608  
Pleural effusions  160 (51.9)  140 (52.4)  20 (48.8)  0.738  
Right§  33 (20.6)  31 (22.1)  2 (10.0)  0.468  
Left§  19 (11.9)  16 (11.4)  3 (15.0)    
Bilateral§ 108 (67.5)  93 (66.4)  15 (75.0)   
Values are expressed as n (%). 
CTR= cardiothoracic ratio; CXR= chest X-ray.  
§ percentage of patients with pleural effusions 
  
Laboratory results 
A summary of the laboratory results, which were collected on the day of 
enrolment, and often within 24-48 hours of admission, are detailed in Table 4-7.  
A detailed biochemistry and haematology profile was tested in every participant.  
This included known prognostic markers in heart failure including BNP, sodium, 
haemoglobin, haemoglobin A1c, urea, creatinine, estimated glomerular filtration 
rate, thyroid function, urate, troponin, and lymphocyte count.  As a BNP value 
of >100 pg/ml was used as part of the inclusion criteria, as per ESC Guidelines, 
BNP was elevated in all participants.  BNP is one of the most powerful prognostic 
marker in heart failure and is also a marker of congestion.  BNP levels were 
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generally extremely high, as expected in patients presenting to hospital with 
acute decompensated heart failure, with a median BNP of 749 pg/ml [IQR 424-
1424] for the whole cohort.  Although the median BNP was higher in the patients 
who did not participate in the whole study and complete PROMs than those who 
did, 888 pg/ml versus 724 pg/ml respectively, this difference did not reach 
statistical significance.   
Another powerful predictor of prognosis in heart failure, amongst other 
conditions, is troponin.  Over half of all participants had detectable troponin on 
admission to hospital.238-240   This was often at very low levels, with a median 
level of 0.04 µg/L (IQR 0.02-0.12).  Although troponin is often associated with 
myocardial ischaemia and infarction, the levels seen in this cohort were much 
lower than would normally be seen when ischaemia is the main driver for 
admission.  Chronic troponin leak is often seen in heart failure, particularly in 
the acute setting.  Patients with extremely high troponin levels (> 1.0 µg/L) and 
a history or ECG consistent with ischaemia were excluded as per the inclusion / 
exclusion criteria. 
Although sodium levels were within the normal range for most participants 
(normal range 136 -145 mmol/L) with a median level of 138 mmol/L, one 
quarter of all participants were hyopnatraemic with a level of 135 mmol/L or 
less.  Hyponatraemia is the most common electrolyte abnormality in acute 
decompensated heart failure, with a number of pathophysiological processes 
identified.241  These processes in heart failure can broadly be divided into 
dilutional and depletional hyponatraemia.  Hyponatraemia is associated with 
worse outcomes including all-cause mortality in patients admitted to hospital 
with heart failure.242 Impaired renal function is an independent prognostic 
marker in heart failure, both in patients with reduced and preserved ejection 
fraction.243  Renal function was abnormal (estimated glomerular filtration rate 
[eGFR] < 60 mL/ min/ 1.73m2) in 185 (59%) participants on admission blood 
testing.  One quarter of the whole cohort had at least moderately impaired renal 
function assessed by eGFR.  Liver function tended to be within the normal range 
for the whole population, and although there were statistically significant 
differences between those completing the PROMs and those who did not, median 
results for these values (and inter-quartile ranges) were within normal limits.  
Thyroid stimulating hormone levels were similar between those completing 
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PROMs and those who did not, however, there was a higher proportion of 
patients with low free T4 in the group completing PROMs.  The significance of 
this is uncertain, as a recent analysis of a large randomised controlled trial data 
set has shown that thyroid status is not an independent predictor of outcome 
(all-cause mortality).244  Serum Albumin levels were generally low in many 
patients with 50% of total participants having levels on or below the lower 
reference limit for serum albumin (reference range 35-50 g/l).  
Hyopalbuminaemia is common in heart failure with a prevalence of 
approximately 25%, and is associated with worse outcomes.245-247  The cause of 
low albumin in acute heart failure is multifactorial, potentially reflecting a 
chronic disease state, advanced heart failure, or dilutional component secondary 
to volume overload.   
Not only is diabetes an important, independent predictor of prognosis in heart 
failure, but so is HBA1c, even when not at diagnostic levels.248  Many patients in 
this cohort had abnormal random serum glucose on presentation, with 50% of all 
participants having a random glucose of at least 6.5 mmol/l.  HBA1c was also 
elevated in many patients and into the diagnostic range for diabetes in at least 
25% of participants.  Although there was a statistically significant difference (p= 
0.032) between those participating in the whole study and those who did not, 
this likely reflects that only 14 (33%) of those who did not complete PROMs had 
HBA1c available, compared to 238 (88%) in the group who completed PROMs.  
This discrepancy was due to the two staged consent process, in which consent to 
draw additional blood samples was given.  The high prevalence of abnormal 
random serum glucose and HBA1c are to be expected given the high prevalence 
of diabetes in heart failure in general and specifically this cohort.   
Anaemia is an important and common co-morbidity in heart failure, and is an 
independent predictor of adverse outcomes.249  Anaemia is multi-factorial in 
heart failure, with anaemia of chronic disease thought to play an important role.  
An analysis of the CHARM Program revealed a prevalence of anaemia of 25%, 
with similar prevalence between both HF-PEF and HF-REF phenotypes.249   The 
median haemoglobin was 121 g/L (IQR 107-136).  There were no significant 
differences between the group of patients who completed the whole study and 
those who did not.   
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Table 4-7 Laboratory results 
 All participants Completed  
PROMS 
Did not complete 
PROMS 
p  
 n = 313 n =272 n = 41  
Biochemistry      
BNP level (pg/ml) 749 [424, 1424] 724 [420, 1405] 888 [481, 1635] 0.333 
TnI (ug/l) 0.04 [0.02, 0.12] 0.04 [0.02, 0.12] 0.05 [0.02, 0.09] 0.704 
TnI ≥ 0.04 ug/L - n(%) 149 (50.5) 130 (50.0) 19 (54.3) 0.753 
Sodium (mmol/l) 138 [135, 140] 138 [135, 140] 139 [137, 141] 0.108 
Potassium (mmol/l) 4.2 [3.8, 4.6] 4.2 [3.8, 4.6] 4.2 [3.9, 4.6] 0.643 
Chloride (mmol/l) 104 [99, 106] 103 [99, 106] 104 [100, 107] 0.580 
Urea (mmol/l) 8.6 [6.4, 12.4] 8.5 [6.4, 12.4] 9.0 [6.5, 13.2] 0.589 
Creatinine (umol/l) 99 [73, 133] 99 [73, 136] 101 [79, 120] 0.985 
eGFR (ml/min/1.73 m2) 59 [41, 80] 62 [40, 82] 57 [45, 68] 0.347 
eGFR <= 60 ml/ 
min/1.73 m2 - n(%) 
185 (59.1) 159 (58.5) 26 (63.4) 0.611 
Bilirubin (mmol/l) 15 [10, 23] 16 [10, 23] 13 [8, 21] 0.044 
AST (mmol/l) 24 [18, 34] 24 [18, 34] 22 [17, 29] 0.228 
ALT (mmol/l) 19 [13, 34] 20 [13, 36] 17 [11, 23] 0.046 
Alk Phos (mmol/l) 95 [73, 127] 99 [76, 128] 82 [68, 112] 0.047 
Albumin (g/l) 34 [31, 36] 34 [31, 36] 34 [31, 36] 0.967 
TSH (mU/l) 1.55 [0.95, 2.60] 1.60 [0.94, 2.60] 1.49 [1.11, 2.08] 0.890 
T4 (pmol/L) 14.00 [0.24, 
16.00] 
14.00 [0.19, 
16.00] 
15.50 [13.00, 
16.90] 
0.006 
Urate (mmol/l) 0.51 [0.41, 0.65] 0.51 [0.41, 0.65] 0.49 [0.44, 0.64] 0.877 
Glucose (mmol/l) 6.5 [5.6, 8.3] 6.5 [5.6, 8.3] 6.5 [5.3, 7.7] 0.424 
 
Haematology  
    
Haemoglobin (g/L) 121 [107, 136] 122 [109, 136] 119 [103, 127] 0.120 
WCC (x10/l) 8.1 [6.5, 10.6] 8.1 [6.4, 10.6] 8.3 [6.6, 10.7] 0.539 
HbA1c (mmol/mol) 41 [38, 50] 41 [38, 48] 54 [40, 61] 0.032 
MCV (fl) 91.0 [86.0, 95.6] 90.9 [86.1, 95.5] 92.1 [85.6, 96.6] 0.692 
Platelets (x10) 216 [166, 270] 216 [164, 273] 222 [186, 250] 0.798 
Lymphocytes (x10/l) 1.20 [0.85, 1.60] 1.20 [0.83, 1.60] 1.30 [0.92, 1.70] 0.252 
Values are expressed as median [interquartile range] unless specified. 
ALT= alanine aminotransferase ; AST= aspirate aminotransferase; eGFR= estimated glomerular filtration rate; 
HbA1c= haemoglobin A1c; MCV= mean corpuscular volume; BNP= Brain-Type natriuretic peptide; TnI= troponin 
I; TSH= thyroid stimulating hormone. 
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Echocardiography 
I performed a detailed echocardiogram in every participant to confirm the 
diagnosis of heart failure.  The protocol for the echocardiogram is detailed Table 
3-1.  In summary, detailed measurements based on standard echocardiographic 
views were performed to provide a systematic evaluation of left and right 
ventricular structure and function, valve structure and function, left and right 
atrial size, and left ventricular diastolic function.  A summary of the key 
echocardiographic findings are detailed in Table 4-8.  Overall, there were 
multiple abnormalities noted on echocardiography examination.  This is entirely 
expected as abnormality of left ventricular systolic and or diastolic function is 
required to make the diagnosis of heart failure.3    
Left ventricular systolic function is most commonly quantified by measuring 
ejection fraction, as described in chapter 3.  Ejection fraction is calculated using 
the modified Simpson’s Biplane method, which requires visualisation of the 
endocardial border in systole and diastole, in both apical four and two chamber 
views.  This was attempted in every patient, however, due to body habitus, or 
poor acoustic window, a formal ejection fraction was possible in 245 (78%) of 
participants.  The remainder of ejection fractions were estimated.  The mean 
ejection fraction for the cohort was 39% (±16.55).  When using the ESC definition 
of HF-PEF as  50%, 104 (33%) patients were in this category.  This is much lower 
than the 50% of cases often quoted in the literature, although this is in keeping 
with the proportion of these patients that are seen in the catchment area from 
which the cohort was recruited.59, 60  A similar proportion of HF-PEF was found in 
a previous study of near-consecutive patients with admitted to hospital in 
Glasgow.250  
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Table 4-8 Echocardiography 
 All 
participants 
Completed  
PROMS 
Did not 
complete 
PROMS 
p  
 n = 313 n =272 n = 41  
LV structure     
LViDDi, cm/m2 2.97 ±0.56 2.96 ±0.56 2.98 ±0.54 0.829 
LViSDi, cm/m2 2 ±1 2 ±1 2 ±1 0.852 
LVDVi, ml/m2 74 ±31 75 ±32 67 ±27 0.216 
LVSVi, ml/m2 48 ±30 49 ±31 43 ±25 0.284 
LV mass index, mg/ m2 118 ±38 119 ±37 109 ±46 0.216 
LV systolic function     
LVEF biplane 
assessment 
245 (78.3) 218 (80.1) 27 (65.9) 0.044 
LVEF estimated 68 (21.7) 54 (19.9) 14 (34.1) 0.044 
LVEF, % 39.93 ±16.55 39.63 ±16.55 41.98 ±16.55 0.397 
HF-PEF 104 (33.2) 89 (32.7) 15 (36.6) 0.722 
S-Lateral, m/s 5.58 ±1.96 5.54 ±1.99 5.84 ±1.71 0.401 
LV diastolic function     
E, m/s 1.05 ±0.35 1.05 ±0.34 1.05 ±0.41 0.926 
a, m/s 0.75 ±0.35 0.73 ±0.34 0.91 ±0.37 0.053 
E/a ratio 1.65 ±1.11 1.69 ±1.12 1.41 ±1.08 0.346 
E’-Lateral, m/s 0.08 ±0.05 0.08 ±0.05 0.07 ±0.03 0.160 
E’-Septal, m/s 0.05 ±0.05 0.06 ±0.05 0.05 ±0.02 0.498 
E’-Average, m/s 0.07 ±0.07 0.07 ±0.08 0.06 ±0.02 0.117 
E/E’, cm/s 17.61 ±7.79 17.45 ±7.57 18.80 ±9.29 0.337 
DT, ms 196.6 ±77.38 194.1 ±72.94 212.8 ±101.3 0. 271 
LAVi, ml/m2  57 ±19 57 ±18 62 ±24 0.210 
RV structure/ function     
RViDD, cm 3.54 ±0.74 3.53 ±0.72 3.57 ±0.83 0.349 
TV Peak Gradient, ms 2.86 ±0.57 2.85 ±0.57 2.96 ±0.58 0.852 
RV Systolic Pressure, 
mmHg 
48.47 ±14.73 48.29 ±14.34 49.63 ±17.21 0.622 
IVC Diameter, mm 2.22 ±0.57 2.24 ±0.56 2.12 ±0.58 0.457 
TAPSE, mm 18 ±6 18 ±6 17 ±5 0.629 
RA Volume, ml 23 ±8 23 ±8 22 ±8 0.168 
Valvular disease     
Valve disease 266 (85.0) 228 (83.8) 38 (92.7) 0.165 
Significant Valve 
Disease* 
74 (23.6) 65 (23.9) 9 (22.0) 1.000 
Significant TR§ 23 (7.3) 21 (7.7) 2 (4.9) 0.751 
Continuous variables are expressed as mean ± standard deviation unless specified, categorical variables are expressed as n (%). 
DT = deceleration time; HF-PEF= heart failure with preserved ejection fraction; IVC = inferior vena cava; LAV ; left atrial volume index; LV = 
left ventricle; LVEF ; left ventricular ejection fraction; LViDDi= left ventricular internal diastolic dimension indexed; LVDVi = left ventricular 
diastolic volume indexed; LVISDi= left ventricular internal systolic dimension indexed; LVSVi = left ventricular systolic volume indexed; RV = 
right ventricle; RViDD= right ventricular internal diameter diastole; TAPSE = tricuspid annular plane systolic excursion; TV= tricuspid valve;  
*  Defined as ≥ moderate-severe left sided valve disease. 
§ defined as ≥ moderate-severe left tricuspid regurgitation. 
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Mean left ventricular size, assessed by measuring left ventricular internal 
diameter in diastole, was at the upper limit of normal, when indexed for body 
surface area, at 2.97 (±0.56) cm/m2 (normal range 2.2-3.1 cm/m2).  Similar 
findings were found when measuring left ventricular size by different methods, 
such as left ventricular internal diameter in systole, left ventricular diastolic and 
systolic volumes, all adjusted for body surface area, Table 4-8.  As described in 
chapter 1, in heart failure, whether there is impaired ejection fraction and 
increased left ventricular volume or preserved ejection fraction with reduced 
ventricular volume, there is usually increased left ventricular mass as a result of 
pathological remodelling of the ventricle with either concentric or eccentric 
remodelling. This was clearly shown in the patients studied with a mean left 
ventricular mass (adjusted for body surface area) of 118 g/m2 (normal range 50-
102 g/m2).   The two broad phenotypes of heart failure, HF-REF and HF-PEF, are 
clearly demonstrated in Table 4-9.  Patients with HF-REF had larger ventricle 
sizes and volumes, when adjusted for body surface area. Mean left ventricular 
diastolic volume index was 84 ml/m2 in patients with HF-REF compared to 49 
ml/m2 in patient with HF-PEF (normal range 35-75 ml/m2). Left ventricular mass 
was also higher in patients with HF-REF compared to HF-PEF at 122 (±39) and 
109 (±37) g/m2 respectively. 
Features of diastolic impairment were present in most patients.  Mean left atrial 
volume, indexed for body surface area, was severely enlarged at 57 (±19) ml/m2, 
with no significant difference between patients with HF-PEF and HF-REF.  E/E’, 
which, when elevated >15, is associated with increased pulmonary capillary 
wedge pressures and elevated left ventricular end diastolic pressures.  This 
metric implies high filling pressure of the left ventricle.  Mean E/E’ was 
markedly elevated with a mean of 17.61 (± 7.79), with no significant difference 
between patients with HF-PEF or HF-REF, or between those who completed the 
whole study or not.   
Right ventricular size was mildly enlarged, mean right ventricular internal 
diameter in diastole 3.54 (±0.74) cm.  Other common features included dilated 
inferior vena cava, right atrial enlargement, and moderately elevated right 
ventricular systolic pressure (mean 49 ±15 mmHg).  Right ventricular systolic 
function overall was preserved as measured by tricuspid annular plane systolic 
excursion (TAPSE), although those with HF-REF had lower TAPSE at 16 (±5) mm 
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versus 21 (±6) mm in those with HF-PEF.  There were no differences in right 
ventricular size and function between those who participated in the whole study 
and those who did not.   
A large proportion of participants had valve disease detected during 
echocardiography.  74 (24%) of participants had significant left sided valve 
disease, defined as  moderate-severe left sided valve disease.  There was no 
difference between those participating in the whole study and those who did 
not.  There was a higher proportion of patients with significant left sided valve 
disease in the HF-PEF group.    
 95 
 
Table 4-9 Echocardiography by ejection fraction 
 All 
participants 
EF < 50% EF  50% p 
 n = 313 n =209 n = 104  
LV structure     
LViDDi, cm/m2 2.97 ±0.56 3.14 ±0.53 2.60 ±0.44  < 0.001  
LViSDi, cm/m2 2 ±1 3 ±1 2 ±0 < 0.001  
LVDVi, ml/m2 74 ±31 84 ±30  49 ±18  < 0.001  
LVSVi, ml/m2 48 ±30 61 ±28  20 ±9  < 0.001  
LV mass index, mg/ m2 118 ±38 122 ±39  109 ±37  0.019  
LV systolic function     
LVEF biplane 
assessment 
245 (78.3) 171 (81.8)  74 (71.2)  0.032  
LVEF estimated 68 (21.7) 38 (18.2)  30 (28.8)  0.032  
LVEF, % 39.93 ±16.55 30.12 ±9.66  59.65 ±7.29  < 0.001  
S-Lateral, m/s 5.58 ±1.96 4.94 ±1.63  6.83 ±1.95  < 0.001  
     
LV diastolic function     
E, m/s 1.05 ±0.35 0.96 ±0.29  1.22 ±0.38 < 0.001  
a, m/s 0.75 ±0.35 0.69 ±0.32  0.87 ±0.37  0.007  
E/a ratio 1.65 ±1.11 1.67 ±1.20  1.62 ±0.92  0.811  
E’-Lateral, m/s 0.08 ±0.05 0.08 ±0.06  0.09 ±0.03  0.061  
E’-Septal, m/s 0.05 ±0.05 0.05 ±0.05  0.06 ±0.02  0.020  
E’-Average, m/s 0.07 ±0.07 0.07 ±0.09  0.08 ±0.02  0.351  
E/E’, cm/s 17.61 ±7.79 17.70 ±7.58  17.45 ±8.22  0.793  
DT, ms 196.6 ±77.38 184.2 ±66.75  220.0 ±90.08  < 0.001  
LAVi, ml/m2  57 ±19 56 ±18  60 ±20  0.149  
     
RV structure/ function     
RViDD, cm 3.54 ±0.74 3.56 ±0.72  3.49 ±0.77  0.430  
TV Peak Gradient, ms 2.86 ±0.57 2.79 ±0.53  3.02 ±0.62 0.002  
RV Systolic Pressure, 
mmHg 
48.47 ±14.73 46.65 ±13.34  52.26 ±16.73  0.005  
IVC Diameter, mm 2.22 ±0.57 2.24 ±0.58  2.18 ±0.55  0.475  
TAPSE, mm 18 ±6 16 ±5  21 ±6  < 0.001  
RA Volume, ml 23 ±8 23 ±8  24 ±7  0.157  
     
Valvular disease     
Valve disease 266 (85.0) 175 (83.7)  91 (87.5)  0.381  
Significant Valve 
Disease* 
74 (23.6) 41 (19.6)  33 (31.7)  0.018  
Significant TR§ 23 (7.3) 13 (6.2)  10 (9.6)  0.282  
Continuous variables are expressed as mean ± standard deviation unless specified, categorical variables are expressed as n (%). 
DT = deceleration time; IVC = inferior vena cava; LAV ; left atrial volume index; LV = left ventricle; LVEF ; left ventricular ejection fraction; 
LViDDi= left ventricular internal diastolic dimension indexed; LVDVi = left ventricular diastolic volume indexed; LVISDi= left ventricular 
internal systolic dimension indexed; LVSVi = left ventricular systolic volume indexed; RV = right ventricle; RViDD= right ventricular internal 
diameter diastole; TAPSE = tricuspid annular plane systolic excursion; TV= tricuspid valve;  
*  Defined as ≥ moderate-severe left sided valve disease. 
§ defined as ≥ moderate-severe left tricuspid regurgitation. 
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4.2.6 Summary 
I believe the cohort studied has a number of strengths.  Firstly, and most 
importantly, it is a generalisable cohort.  I believe this is a generalisable cohort 
as I tried to eliminate selection bias wherever possible.  I recruited 
prospectively, and approached consecutive admissions of suspected heart 
failure.  A further strength of this study is the robustness of the diagnosis of 
heart failure.  I adhered to the most current guidelines available when deciding 
whether a patient met the inclusion criteria for the study.  I used natriuretic 
peptide to screen and excluded patients with low natriuretic peptides.  I also 
used detailed echocardiography, in accordance with the most up to date 
guidelines to confirm the presence of a structural or functional abnormality in 
keeping with the diagnosis of heart failure.  I also had access to ECG and CXRs 
for almost every potential patient, further aiding the diagnosis.  Although, as 
anticipated, some patients declined to participate in the full study and complete 
PROMs and attend follow-up visits, the proportion of such patients was relatively 
small (13.1%).  The main differences between those who participated in the 
whole study and those who did not were in age and body mass index.  Those who 
declined to participate in the PROMs and follow-up part of the study were older, 
median age 84.2 versus 76.0 (p <0.001), and had a lower body mass index, 24.0 
versus 27.0 kg/m.  This would perhaps suggest that those patients who did not 
participate in the whole study were more elderly and frail.  There were very few 
statistically significant differences between those who did and did not 
participate in the full study and completed the PROMs, in terms of 
echocardiographic, ECG, CXR, clinical examination findings, past medical 
history, or drug history.  This suggests that the cohort completing PROMs is 
representative of patients admitted to hospital with heart failure. 
An important test of generalisability would be to make comparisons between this 
cohort and other cohorts of patients hospitalised with a primary diagnosis of 
heart failure.  When comparing to one of the largest heart failure cohorts, the 
American Get With The Guidelines (GWTG) cohort, which reported on the 
characteristics of over 110 000 consecutive patients admitted to hospitals across 
the United States of America between 2005 and 2010.251  The cohort recruited in 
my study was very similar to the GWTG cohort in terms of age (median age 77 
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and 74, respectively) and sex (49 and 47% female sex respectively).  Similarly 
high proportions of co-morbidities were seen in both cohorts, particularly 
hypertension, coronary artery disease, cerebrovascular disease, and diabetes.  
One notable difference was the ethnicity of patients, with the 97% being of 
white ethnicity in my cohort compared to 66% in the GWTG cohort.  However, 
this reflects the demographics of the local population which the Western 
Infirmary, Glasgow, served.  There were similarities in key objective, markers of 
disease severity, namely natriuretic peptides and ejection fraction.  Median 
(IQR) BNP levels were similar between the GWTG and my cohort at 749 (424-
1424) and 821 (386-1690) pg/ml, respectively.   Regarding the two broad 
phenotypes found in heart failure based on ejection fraction, HF-REF and HF-
PEF, key similarities were again seen between these cohorts.  The median (IQR) 
ejection fraction in the GWTG cohort was 40 (25-55) %, compared to 38 (26-
54)%.  A very similar proportion of patients were classified as HF-PEF in both the 
GWTG and my cohort, at 36 and 33%, respectively.   Another important cohort to 
make comparisons with comprised 1003 near-consecutive patients admitted to 
hospital with a primary diagnosis of heart failure, from three local hospitals 
(Glasgow Royal Infirmary, Glasgow Western Infirmary, and Royal Alexandria 
Hospital).250  This study prospectively enrolled patients admitted to hospital 
between 2006 and 2009, and utilised natriuretic peptides to screen for 
eligibility.    Of these 1003 patients, a further 648 went on to have microvolt T-
wave alternans testing and were described in detail.  My cohort and this cohort 
showed very similar prevalence of co-morbidities.  Mean ejection fraction (± SD) 
was similar again between this and my cohort at 40.2 (12.2) and 39.9 (16.6), 
respectively.  
Use of disease modifying therapy is an important metric in this study, as these 
medications could improve life expectancy and quality of life, both of which are 
key components when assessing the potential PC needs of any population.  High 
proportions of patient were started or continued on disease modifying therapies, 
namely ACEi/ ARB,beta-blocker or MRA.  Overall, 70, 69 and 32 % of participants 
in this study were started on ACEi/ARB, beta-blocker and MRA, respectively.  
The proportion of patients with HF-REF, that is, the patients who would benefit 
most from these therapies, was much higher.  79, 70, and 40 % of participants 
were started on ACEi/ARB, beta-blocker, or MRA. These proportions compare 
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favourably with patients with a reduced ejection fraction (<40%) in the GWTG 
cohort, with 74, 87, and 26 % taking ACEI/ARB, beta-blockers, or MRA 
respectively.  Overall, the patients in my cohort were started on high 
proportions of disease modifying therapy.   
In summary, the cohort studied had limited selection bias as it was near-
consecutive and prospective.  The cohort is highly generalisable for this reason, 
and this is confirmed by the consistencies seen with other large cohorts of 
hospitalised heart failure cohorts.  This cohort also benefits from a very rigorous 
screening process, in which the definition of heart failure was adhered to 
stringently, and natriuretic peptides and echocardiography were used to make 
the diagnosis, therefore, I can say with confidence that all patients in the study 
met the ESC definition of heart failure.3  Furthermore, the cohort was treated 
very well, with a very high proportion of participants being started or continued 
on disease modifying therapies, which is crucially important when assessing if a 
patient has PC needs. 
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Chapter 5 Results- Baseline Patient reported 
outcome measures  
In this chapter I will report the findings from the PROMs used, namely the HADS, 
the KCCQ, the ESAS, and the SF-12 questionnaires.  I will also report the 
caregiver burden questionnaire, the Zarit Burden Interview.  All of these PROMs 
were given, in the form of a pack of questionnaires (appendix 4), to each 
participant who agreed to take part in the whole study.  Each participant was 
encouraged to complete the questionnaire pack without any assistance from 
anyone else.  If a participant had visual problems such that they could not read 
the questionnaires, then these were read out by a study nurse, with particular 
attending being paid to reduce any attempt to influence the participant.  This 
was only necessary for a minority of participants.  Participants were given 24 
hours to complete the questionnaire pack.  Questionnaires were administered at 
the beginning of the admission to hospital, at the time of consent.  The median 
[IQR] time from admission to recruitment for those completing questionnaires 
was 2 [2-4] days. 
5.1 Hospital Anxiety and Depression Scale 
The HADS is a 14 point, 7 anxiety and 7 depression, screening questionnaire 
designed to be completed by patients.  The HADS generates two summary 
scores, one for depression and one for anxiety.  These scores can then be used 
to categorise patients into potential severity of depression and anxiety (mild, 
moderate, and severe).   
HADS- anxiety 
263 participants completed all of the questions in the HADS anxiety 
questionnaire.  The questions and distribution of responses at baseline for the 
anxiety component of the HADS questionnaire are shown in Figure 5-1.  All of the 
questions in HADS have four potential answers, from which the patient picks the 
answer which is most appropriate for them.   For the question “I get sudden 
feelings of panic”, most participants responded either “not at all” or “not very 
often”, with 109 (40.5%) and 87 (32.3%), respectively.  46 (20.8%) and 17 (6.3%) 
of participants responded that they experience sudden feelings of panic “quite 
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often” and “very often indeed”, respectively.  A similar distribution of responses 
were reported to the question “I feel restless as if I have to be on the move”, 
with 71 (26.1%) and 23 (8.5%) experiencing reporting this symptom “quite a lot” 
and “very much indeed”, respectively.   
 
Figure 5-1 Distribution of HADS anxiety responses 
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A higher proportion of participants reported minimal frequency for the symptom 
“I get a sort of frightened feeling like butterflies in the stomach”, with 83.2% 
reporting these symptoms either only “occasionally” or “not at all”.  195 (72.5%) 
of participants answered “I can sit at rest and feel relaxed” “usually” or 
“definitely”.  With 74 (27.5%) reporting being able to sit at rest and feel relaxed 
“not often” or “not at all”.  A high proportion reported “worrying thoughts go 
through my mind” “a lot of the time” or “a great deal of the time”, at 53 
(19.5%) and 30 (11.0%, respectively.  103 (38.0%) reported feeling “I get a sort of 
frightened as if something awful is about to happen” either “yes, but not too 
badly” or “very definitely and quite badly”.  168 (62.0%) reported experiencing 
this symptom either “a little, but it doesn’t worry me” or “not at all”.  78 
(28.7%) of participants reported feeling “tense or wound up” “a lot of the time” 
or “most of the time”, with 142 (52.2%) reporting this symptom “from time to 
time, occasionally”, and 52 (19.1%) “not at all”.  Overall, most questions had a 
similar distribution of responses regarding proportion of participants who had 
moderate or severe frequency, with roughly between one quarter and one third 
of participants.  The exception was to the symptom “I get a sort of frightened 
feeling like butterflies in the stomach”, where only 16.8% reported 
moderate/severe frequency.   
HADS- Depression 
267 participants completed all of the questions in the HADS depression 
questionnaire.  The questions and distribution of responses to the depression 
component of the HADS questionnaire are detailed in Figure 5-2.   183 (68.5%) of 
participants reported “I still enjoy the things I used to enjoy” “not quite so 
much) or “definitely as much”, with 85 (31.5%) reporting “only a little” or “not 
at all”.  Most participants in the study felt they had retained their sense of 
humour, with 57% reporting they could “laugh and see the funny side of things” 
“as much as I always could”, and 31.3% “not quite so much now”.  Most 
participants described feeling cheerful, with 234 (86%) reporting “I feel 
cheerful” “sometimes” or “most of the time”.  Most participants reported 
moderate- severe impairment in response to the statement “I feel as if I have 
slowed down”, with 262 (96.7%) reporting having slowed down to some degree, 
and most feeling slowed down “nearly all the time” or “very often”.  Although 
 102 
 
this question could reflect a somatisation of depression or depressive symptoms, 
physical symptom burden from heart failure could also contribute to the high 
burden reported.  Just over a quarter (26.9%) of participants reported “I have 
lost interest in my appearance” “definitely as much now” or “I don’t take as 
much care”.  A further 28.4% of participants reported mild impairment to this 
question.  Only 99 (33.5%) of participants reported optimism for the future, 
reporting “I look forward with enjoyment to things” “as much as I ever did”.  82 
(30.1%) responded to this question with either “definitely less than I used to” or 
“hardly at all”.  However, most participants did appear to get enjoyment from 
common leisure activities, with most reporting “I can enjoy a good book or radio 
or TV program” “often” or “sometimes”, with 178 (65.7%) and 60 (22.1%), 
respectively.   
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Figure 5-2 Distribution of HADS depression responses 
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HADS summary scores 
Both HADS-Anxiety and HADS-Depression questionnaires generate a summary 
score, which is perhaps easier to understand and compare to other cohorts of 
patients.  Each question has a range of responses from 0-3, with a total for both 
subscales being 21, with a minimum score 0.  The test’s authors suggest a score 
of 8-10 is indicative of mild cases of anxiety or depression, 11-15 moderate, and 
>16 suggests severe.203   The distribution of scores for both anxiety and 
depression are shown in Figure 5-3 and Figure 5-4, respectively.  The range for 
the HADS anxiety summary score was 0-21, with the mean (SD) and median [IQR] 
being 7.33 (4.76) and 7.00 [4-11], respectively.  The range for the HADS 
depression summary score was 0-21 again, with the mean (SD) and median [IQR] 
being 7.02 (4.17) and 7.00 [4-10], respectively.  As seen in Figure 5-3 and Figure 
5-4, neither score was normally distributed, but positively skewed, with most 
participants having lower scores.   The proportion of participants with 
none/mild, moderate and severe anxiety and depression summary scores is 
shown in Figure 5-15.  74.5 and 81.6% of participants scored in the none/ mild 
category for anxiety and depression, respectively.  19.0 and 14.6% scored in the 
moderate category for anxiety and depression, respectively.  Only 17 (6.5%) and 
10 (3.7%) participants scored in the severe mood disturbance range for anxiety 
and depression, respectively.   
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Figure 5-3 Histogram of total anxiety score 
 
Figure 5-4 Histogram of total depression score 
 
Comparison of selected baseline characteristics, per severity group, for both 
HADS Anxiety and Depression summary scores are shown in Table 5-1 and Table 
5-2, respectively.   Patients in the moderate or severe categories for HADS-
Anxiety were more likely to be younger (p<0.001).  A similar trend was seen 
regarding the HADS Depression, with patients in the moderate or severe groups 
being younger (p=0.0253).  There were very few differences between the three 
groups of HADS Anxiety severity in terms of past medical history, examination 
findings, sex, echocardiographic or laboratory findings.  Notable exceptions 
included NYHA class, with higher proportions of participants being NYHA class 
III/IV in the moderate or severe groups (p=0.024).  There was a trend, albeit not 
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statistically significant, for patients with lower ejection fraction to have higher 
HADS-Anxiety scores.  Patients in the severe group of HADS-Anxiety had larger 
ventricles, as measured by left ventricular internal diameter in diastole and 
adjusted for body surface area.  Median scores for all of the other PROMs were 
worse in patients in the severe HADS-Anxiety group.   
Unsurprisingly, there was a statistically significant higher proportion of 
participants with a past medical history of depression in the severe versus 
moderate, versus none/mild groups (p 0.0004).  Other baseline characteristics 
were similar between the three groups of HADS-Depression severity.  There were 
no differences in known markers of prognosis at baselines, such as B-type 
natriuretic peptide level, ejection fraction, left ventricular size, or NYHA 
classification.  Similar to HADS-Anxiety groups, participants in higher severity 
groups of HADS-Depression had worse median scores for all other PROMs.  The 
only was the mean SF12-Physical summary score, where there was no 
statistically significant difference between the groups of HADS-Depression 
severity.  
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Table 5-1 Baseline demographics per HADS Anxiety severity group 
 None/ mild Moderate Severe p  
 n=196 n=50 n=17   
Age- yr 76.53 ± 10.16 69.95 ± 10.16 70.86 ± 11.88 <0.0001 
Female sex- n (%) 90 (45.9) 23 (46.0) 10 (58.8) 0.5883 
Systolic blood pressure- 
mmHg 
137.08 ± 28.95 140.22 ± 22.31 132.12 ± 23.65 0.5586 
Heart rate- beats/min 86.68 ± 24.99 89.41 ± 28.19 89.35 ± 21.87 0.7559 
Body-mass index- kg/m 27.67 ± 6.02 29.43 ± 7.55 27.75 ± 10.10 0.2778 
Past Medical history- n(%) 
Hypertension 134 (68.4) 31 (62.0) 12 (70.6) 0.6626 
Myocardial infarction 74 (37.8) 25 (50.0) 5 (29.4) 0.1941 
Atrial fibrillation 111 (56.6) 21 (42.0) 7 (41.2) 0.1099 
Diabetes 60 (30.6) 22 (44.0) 6 (35.3) 0.1984 
CVA/TIA 41 (20.9) 8 (16.0) 3 (17.6) 0.7192 
COPD 42 (21.4) 15 (30.0) 8 (47.1) 0.0398 
Depression 21 (10.8) 8 (16.0) 6 (35.3) 0.0149 
Symptoms- n (%)     
NYHA functional class    0.024 
Class I 0 (0.0)  0 (0.0)  0 (0.0)   
Class II 63 (32.1) 13 (26.0) 4 (23.5)  
Class III 103 (52.6) 27 (54.0) 5 (29.4)  
Class IV 30 (15.3) 10 (20.0) 8 (47.1)  
Examination- n (%)     
Elevated JVP (> 4cm)  126    (72.8) 32     (71.1) 11     (73.3) 0.9713 
Third Heart Sound  40     (20.5) 11     (22.0) 7      (41.2) 0.1441 
Pulmonary crackles  152    (78.4) 39     (78.0) 15     (88.2) 0.6218 
Pleural effusion  67     (34.5) 18     (36.0) 8      (50.0) 0.463 
Peripheral Oedema  146    (75.3) 41     (82.0) 11     (64.7) 0.3291 
Echocardiography     
Ejection fraction, % 39.99 ± 16.75 39.88 ± 16.11 34.76 ± 13.72 0.4522 
LVIDD/BSA2 2.92 ± 0.54 2.91 ± 0.53 3.44 ± 0.66 <0.001 
LV mass/BSA2 116.99 ± 38.05 119.20 ± 33.07 143.24 ± 40.13 0.0551 
E/e’ 17.15 ± 7.52 18.33 ± 8.60 18.18 ± 4.88 0.5954 
Laboratory     
Sodium (mmol/l) 138.0 [134.5, 140.0] 137.0 [135.0, 139.0] 138.0 [135.0, 140.0] 0.7934 
Urea (mmol/l) 8.9 [6.4, 12.5] 7.7 [6.2, 12.2] 7.8 [7.3, 11.5] 0.5625 
Creatinine (umol/l) 101.5 [72.5, 141.5] 91.0 [72.0, 129.0] 92.0 [75.0, 110.0] 0.71 
BNP (pg/ml) 738.5 [465.5, 1454.0] 616.5 [287.0, 1001.0] 1192.0 [378.0, 2010.0] 0.0599 
Haemoglobin (g/L) 121.0 [109.0, 137.0] 124.0 [109.0, 136.0] 117.0 [102.0, 126.0] 0.5259 
PROMS     
HADS-A score 5.11 ± 2.97 12.64 ± 1.52 17.35 ± 1.22 <0.0001 
HADS-D score 5.69 ± 3.55 10.17 ± 3.06 12.94 ± 4.02 <0.0001 
KCCQ summary score 39.00 ± 20.94 25.48 ± 16.74 10.00 ± 9.84 <0.0001 
ESAS summary score 33.79 ± 19.06 51.98 ± 19.87 66.60 ± 20.89 <0.0001 
SF12-physical score 30.62 ± 9.60 31.19 ± 8.41 24.24 ± 4.29 0.028 
SF12-mental score 45.37 ± 10.84 33.63 ± 8.83 25.33 ± 8.00 <0.0001 
Continuous variables are expressed as mean± standard deviation or median [ interquartile range], categorical variables are expressed as n (%). 
BNP= Brain-Type natriuretic peptide; BSA= body surface area; CVA= cerebrovascular accident; ESAS= Edmonton Symptom Assessment Scale;    
HADS-A= Hopsital anxiety and depression scale- anxiety; HADS-D= Hospital anxiety and depression scale- depression; JVP= jugular venous pressure; 
KCCQ= Kansas City Cardiomyopathy Questionnaire; LVIDD = left ventricular internal diameter diastole; NYHA = New York Heart Association; 
PROMs= patient reported outcome measures; SF12= Short Form 12 questionnaire; TIA = transient ischaemic attach.   
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Table 5-2 Baseline demographics per HADS Depression severity group 
 None/ mild Moderate Severe p  
 n=218 n=39 n=10   
Age- yr 75.83 ± 10.52 72.22 ± 9.14 69.16 ± 9.85 0.0253 
Female sex- n (%) 106 (48.6) 12 (30.8) 7 (70.0) 0.0392 
Systolic blood pressure- 
mmHg 
138.22 ± 27.88 136.64 ± 28.56 127.20 ± 26.83 0.4651 
Heart rate- beats/min 86.87 ± 25.13 87.03 ± 25.57 100.30 ± 38.70 0.2737 
Body-mass index- kg/m 27.69 ± 6.41 29.35 ± 8.36 28.27 ± 5.69 0.3883 
Past Medical history- n(%) 
Hypertension 143 (65.6) 30 (76.9) 9 (90.0) 0.1201 
Myocardial infarction 84 (38.5) 24 (61.5) 2 (20.0) 0.0103 
Atrial fibrillation 118 (54.1) 18 (46.2) 6 (60.0) 0.5949 
Diabetes 67  (30.7) 18 (46.2) 3 (30.0) 0.1652 
CVA/TIA 38 (17.4) 11 (28.2) 3 (30.0) 0.2037 
COPD 49 (22.5) 15 (38.5) 4 (40.0) 0.0605 
Depression 23 (10.6) 9 (23.1) 5 (50.0) 0.0004 
Symptoms- n (%)     
NYHA functional class    0.1547 
Class I 0 (0.0)  0 (0.0)  0 (0.0)   
Class II 70 (32.) 6 (15.4) 4 (40.0)  
Class III 112 (51.4) 25 (64.1) 3 (30.0)  
Class IV 36 (16.5) 8 (20.5) 3 (30.0)  
Examination- n (%)     
Elevated JVP (> 4cm)  139 (72.4) 26  (74.3) 7 (77.8) 0.9199 
Third Heart Sound  45 (20.7) 6 (15.4) 6 (60.0) 0.0077 
Pulmonary crackles  172 (79.3) 30 (76.9) 6 (66.7) 0.6445 
Pleural effusion  79 (36.4) 9 (23.1) 5 (62.5) 0.072 
Peripheral Oedema  161 (74.2) 35 (89.7) 7 (77.8) 0.1071 
Echocardiography     
Ejection fraction, % 39.64 ± 16.73 39.97 ± 16.42 36.70 ± 15.15 0.8503 
LVIDD/BSA2 2.94 ± 0.54 2.97 ± 0.63 3.32 ± 0.67 0.1156 
LV mass/BSA2 116.86 ± 37.99 130.24 ± 36.66 128.57 ± 25.32 0.1951 
E/e’ 17.55 ± 7.76 16.99 ± 6.75 15.69 ± 6.06 0.7451 
Laboratory     
Sodium (mmol/l) 138.0 [134.0, 140.0] 138.0 [135.0, 140.0] 138.0 [135.0, 139.0] 0.7338 
Urea (mmol/l) 8.7 [6.4, 12.6] 8.5 [6.9, 12.2] 8.4 [6.4, 14.2] 0.9577 
Creatinine (umol/l) 100.5 [73.0, 140.0] 102.0 [72.0, 133.0] 89.0 [75.0, 110.0] 0.9067 
BNP (pg/ml) 735.0 [451.0, 1418.0] 749.0 [254.0, 1268.0] 780.0 [358.0, 3000.0] 0.4042 
Haemoglobin (g/L) 121.0 [109.0, 136.0] 124.0 [110.0, 134.0] 120.5 [96.0, 136.0] 0.9019 
PROMS     
HADS-A score 6.17 ± 4.00 12.00 ± 4.39 13.50 ± 5.46 <0.0001 
HADS-D score 5.56 ± 2.85 12.38 ± 1.41 17.90 ± 1.37 <0.0001 
KCCQ summary score 38.08 ± 20.30 21.91 ± 18.42 8.69 ± 8.11 <0.0001 
ESAS summary score 35.65 ± 20.06 54.00 ± 16.73 62.61 ± 23.97 <0.0001 
SF12-physical score 30.81 ± 9.44 29.16 ± 6.71 24.37 ± 6.07 0.0648 
SF12-mental score 44.16 ± 11.02 32.87 ± 10.34 23.57 ± 10.12 <0.0001 
Continuous variables are expressed as mean± standard deviation or median [ interquartile range], categorical variables are expressed as n (%). 
BNP= Brain-Type natriuretic peptide; BSA= body surface area; CVA= cerebrovascular accident; ESAS= Edmonton Symptom Assessment Scale; 
HADS-A= Hopsital anxiety and depression scale- anxiety; HADS-D= Hospital anxiety and depression scale- depression; JVP= jugular venous 
pressure; KCCQ= Kansas City Cardiomyopathy Questionnaire; LVIDD = left ventricular internal diameter diastole; NYHA = New York Heart 
Association; PROMs= patient reported outcome measures; SF12= Short Form 12 questionnaire; TIA = transient ischaemic attach.   
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Normative data from the United Kingdom are available for comparison.235   This 
study administered the HADS questionnaire to a sample of 1792 participants 
from the general population (978 males, 810 females).  The mean HADS anxiety 
score in this population was 6.14 (±3.76), with a median of 6.  The mean HADS 
depression score was 3.68 (±3.07), with a median of 3.  Unsurprisingly, there 
were higher mean scores for both anxiety and depression in my cohort of 
patients admitted to hospital because of heart failure.   The prevalence of 
depression has previously been described in heart failure, and the effects of 
depression on all-cause mortality.252   This meta-analysis demonstrated a 
significant influence of depression on all-cause mortality.  Although the above 
review analysed 26 studies with over 80 000 combined patients, the assessment 
tool for assessment of depression varied, with the most common depression 
screening tool being the Beck Depression Inventory and the Patient Health 
Questionnaire.  However, the HADS has been used in a number of studies which 
allows for comparison.  A particularly useful comparison is the study by Junger 
et al, of 209 patients with chronic heart failure as this not only provides mean 
HADS depression and anxiety scores, but also a description of potential severity 
based on summary scores.253  The mean total depression score and anxiety scores 
were 6.4 (± 4.3) and 7.0 (± 4.0), showing similar results to the participants in my 
study.  30.1% of all participants in the study by Junger et al had a HADS 
depression score of ≥8, and 21.5% had a HADS anxiety score of ≥10.  Although the 
mean total scores in my cohort were similar, a larger proportion of participants 
had higher scores in the depression sub-scale, with a 25% having a score of ≥10.  
A similar trend was seen in anxiety scores, with 25% having a score of ≥11.  The 
larger proportion of patients with both higher anxiety and depression scores 
perhaps reflects my cohort being admitted to hospital rather than a community 
sample.   Overall, prevalence of high scores of depression and anxiety were seen 
in my cohort when compared to both community heart failure cohorts and 
normative data. 
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5.2 Kansas City Cardiomyopathy Questionnaire 
The KCCQ is a heart failure, disease specific questionnaire which is self-
administered by patients.179  Patients are given instructions to reflect on the 
preceding two weeks when completing the KCCQ.  The KCCQ comprised 23 
questions, each of which contributes to a different sub-domains including: 
Physical Limitations Score; Symptom Stability Score; Symptom Frequency Score; 
Symptom Burden Score; Self-efficacy Score; Social Limitations Score; and Quality 
of Life Score.  For each sub-domain a score is calculated between 0-100, with 
higher scores representing better quality of life and lower symptom burden.  
These sub-domain scores are then used to calculate additional summary scores 
including: Total Symptom Summary Score, Clinical Summary Score, and an 
Overall Summary Score.  The Total Symptom Summary Score is a combination of 
Symptom frequency and severity.  The Clinical Summary Score combines Physical 
Limitations Score with Total Symptom Score.  The Overall Summary Score 
combines all domains and represents a mean of Physical Limitation Score, Total 
Symptom Score, Quality of Life Score, and Social Limitation Score.  A detailed 
description of how to score the KCCQ is provided in appendix 5. 
Physical Limitations 
The first 6 questions in the KCCQ comprise the Physical Limitations sub-domain.  
The responses given at the baseline assessment are detailed in Figure 5-5.  
Patients are asked to reflect on how much their physical symptoms of heart 
failure (dyspnoea, fatigue, or oedema) have restricted them from doing physical 
activities.  The specific physical activities remarked upon include getting 
dressed, showering/ bathing, walking one block on flat ground, doing yard work/ 
housework/ carrying groceries, climbing one flight of stairs without stopping, 
and hurrying or jogging.     There was a higher proportion of participants who 
felt extremely limited by more strenuous activities.  Most participants (51.2%) 
were not limited at all or only slightly limited when dressing.  A further 93 
(34.9%) participants were moderately or quite a bit limited when dressing, with 
33 (12.4%) being severely limited.  This compares to 12 (4.5%) reporting only to 
be slightly limited or not limited at all, with a further 40 (14.9%) being 
moderately or quite a bit limited, and 191 (71%) being extremely limited.  Most 
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patients reported some degree of physical limitation, with most reporting 
marked limitation on mild- moderately strenuous activity.     
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Figure 5-5 KCCQ summary of physical burden at baseline
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Symptoms 
The physical symptoms that the KCCQ asked patients about are fatigue, 
dyspnoea, and peripheral oedema. Patients were asked to reflect on how often, 
in the previous two weeks, they had been limited by these symptoms.  The 
frequency of these symptoms are detailed in Table 5-3.  The most common 
symptom described by participants was fatigue, with almost every participant 
who completed this question reporting fatigue at least once per week and only 
2.3% denying any fatigue in the previous two weeks.     Dyspnoea was also 
extremely common, limiting all participants who completed this question at 
least once in the previous two weeks, with only 11 (4.1%) denying any limitation 
due to dyspnoea.  A larger proportion of participants, 62 (23.0%), did not 
describe any peripheral oedema.  However, half of all participants reported 
oedema every morning (137 participants, 50.9%).  A further 52 participants 
(19.3%) reported peripheral oedema either one to two times per week or three 
or more times per week.  A high proportion of participants reported limitations 
due to either fatigue or dyspnoea (or both) on a daily basis.  41 (15.4%) 
participants reported fatigue at least once per day, with 38 (14.2%) reporting 
limitation due to dyspnoea at least once per day.  A further 89 (33.5%) of 
participants reported fatigue limiting them several times a day, with 73 (27.4) 
feeling fatigue limited them all the time.  94 (35.1%) participants reported 
limitation due to dyspnoea several times per day, with 83 (31.0%) reporting 
feeling limited by dyspnoea all the time.   Another specific symptom which is 
reported is paroxysmal nocturnal dyspnoea or orthopnoea.  The KCCQ asks 
participants to report how often they have been “forced to sleep sitting up or 
propped up due to shortness of breath”.  101 (37.4%) participants reported to 
experiencing this symptom every night, with 40 (14.8%) reporting three or more 
times per week, 18 (6.7%) 1-2 times per week, 22 (8.1%) less than once a week, 
and 89 (33.0%) never over the previous two weeks. 
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Table 5-3 KCCQ symptom frequency 
 Oedema  Fatigue Dyspnoea 
 n (%) n (%) n (%) 
n  269  266 268 
Every morning 137 (50.9) - - 
All the time - 73 (27.4) 83 (31.0) 
Several times per day - 89 (33.5) 94 (35.1) 
At least once per day - 41 (15.4) 38 (14.2) 
Three or more times a week 28 (10.4) 29 (10.9) 14 (5.2) 
One to two times a week 24 (8.9) 11 (4.1) 14 (5.2) 
Less than once a week 18 (6.7) 17 (6.4) 14 (5.2) 
Never over the past two weeks 62 (23.0) 6 (2.3) 11 (4.1) 
 
The KCCQ also asks patients to reflect on the burden each of these three 
symptoms (oedema, fatigue, and dyspnoea) creates.  The distribution of 
responses is displayed in Figure 5-6.    
 
Figure 5-6 KCCQ symptom burden at baseline 
 
Most participants felt at least some burden from all of the three physical 
symptom categories.  Oedema represented the lowest overall burden for 
participants, with almost 30% either not having any symptoms, or rating the 
burden of oedema as “not bothersome at all”.  This contrasts to both fatigue 
and dyspnoea, with only 7.8% and 4.4% respectively, reporting no burden.  12.3% 
of participants felt moderately bothered by oedema, with 20.4% and 24.4% 
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reporting oedema to be “quite a bit” and “extremely bothersome”, respectively.  
A higher proportion of participants found fatigue to be “quite a bit” and 
“extremely bothersome” at 33.6 and 31.7%, respectively.  An even higher 
proportion of burden was reported due to dyspnoea, with “quite a bit” and 
“extremely bothersome” reported by 29.4 and 39.3%, respectively.   
Self-efficacy 
The KCCQ asks patients to reflect on how their understanding of heart failure.  
Specifically, they are asked who they should contact if their symptoms were to 
deteriorate and their understanding of what action they can take themselves to 
prevent deterioration in symptoms.  Although this is only applicable to patients 
with a known diagnosis of heart failure, these questions are useful to gain a 
baseline assessment of a patients understanding of a heart failure treatment.  
There were a wide variety of responses to “How sure are you that you know 
what to do, or whom to call, if your heart failure gets worse”.  Just over one 
third of participants, 99 (36.5%), answered “not at all” or “not very sure” to this 
question.  A further 30 (11.1%) were “somewhat sure”.  142 (52.2%) felt either 
“mostly” or “completely sure”.  This is somewhat surprising, as only 120 (44.1%) 
of participants had a known previous diagnosis of heart failure.  I suspect that 
some participants answered this question thinking they would contact their own 
general practitioner, rather than a heart failure nurse, in the event of a 
deterioration in their symptoms.   In response to the question “How well do you 
understand what things you are able to do to keep your heart failure symptoms 
from getting worse?”, over half (137 participants) again answered that they 
“mostly” or “completely understand”.  These answers would be expected from 
patients who have previously been through the heart failure liaison service, as 
education on this subject is an integral part of the liaison service.  Again, it is 
somewhat surprising that such a high proportion answered this question with 
positive answers.   
Quality of life 
There are three questions pertaining to general quality of life assessment in the 
KCCQ.  These include “How much has heart failure limited your enjoyment of 
life?”, “If you had to spend the rest of your life with your heart failure the way 
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it is right now, how would you feel about this?”, and “How often have you felt 
down in the dumps because of your heart failure?”.  77 (28.6%) participants felt 
that heart failure had extremely limited their enjoyment of life.  A further 130 
(48.4%) felt that heart failure had limited their enjoyment of life “moderately” 
or “quite a bit”.  Most participants would have been dissatisfied if they had to 
spend the rest of their lives with heart failure as it was at the time of the 
questionnaire, with 62 (23%) somewhat, 54 (20.0%) mostly, and 110 (40.7%) 
extremely dissatisfied.  Most participants felt discouraged as a result of their 
heart failure symptoms, with 93 (34.2%) occasionally, 70 (25.7%) most, and 45 
(16.5%) all of the time.   
Social limitation 
The KCCQ asks patients to rate how limited they are in getting to or performing 
a variety of social activities.  The distribution of responses to these questions 
are represented in Figure 5-7.  The social activities reported include hobbies or 
recreational activities, working or doing household chores, visiting family or 
friends, and intimate or sexual relationships.  There was a high proportion of 
participants reporting extreme limitation in all of these activities.  20.4 and 
40.8% of participants felt “quite a bit” and “extremely limited”, respectively, 
when participating in hobbies or recreational activities.   21.9 and 31.1% of 
participants felt “quite a bit” and “extremely limited”, respectively, when 
visiting family or friends.  25.6 and 40.4% of participants felt “quite a bit” and 
“extremely limited”, respectively, when working or doing household chores.  6.7 
and 33.9% of participants felt “quite a bit” and “extremely limited”, 
respectively, when participating in intimate or sexual relationships, although 
50.8% of participants were limited for other reasons or did not do this activity. 
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Figure 5-7 KCCQ Social Limitation at baseline 
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Summary scores 
As detailed above, summary scores are available for the various sub-domains and 
also overall.  The overall summary score is often used in clinical trials to track 
changes in heart failure specific quality of life.  The sub-domain summary scores 
and overall scores are detailed in Table 5-4.  Also detailed in Table 5-4 are the 
summary scores reported in the original results paper describing and validating 
the KCCQ.179 
Table 5-4 KCCQ sub-domain scores 
 PCHF cohort KCCQ 
responsiveness 
cohort 
KCCQ reliability  
cohort 
Setting/ patient group Inpatient/ ADHF Inpatient/ ADHF Outpatient/ CHF 
n 272 39 39 
Score    
Physical limitation 34.8 (25.1) 34.7 64.4 
Total symptoms 35.1 (22.8) 31.3 76.6 
Social limitation 31.6 (29.4) 31.1 59.2 
Self-efficacy 56.0 (31.6) 67.6 83.3 
Quality of life 36.4 (25.2) 30.5 64.5 
Clinical summary score 34.9 (21.4) 33.0 70.5 
Overall summary score 34.5 (21.1) 31.8 66.2 
Values are expressed as mean (±SD), or mean.   
ADHF= acute decompensated heart failure; CHF= chronic heart failure; KCCQ= Kansas City Cardiomyopathy  
Questionnaire; PCHF= Palliative Care in Heart Failure. 
The summary scores from my cohort (labelled PCHF) are very consistent with the 
cohort of patients hospitalised due to heart failure that were used to assess the 
responsiveness of the KCCQ.  There are particularly similar mean results for the 
Physical and Social Limitation sub-domain scores.  The mean Physical Limitation 
scores in my cohort and the KCCQ responsiveness cohort were 34.8 and 34.7, 
respectively.  The mean Social Limitation scores in my cohort and the KCCQ 
cohort were 31.6 and 31.1, respectively.  The mean Clinical Summary Score also 
showed good concordance with the KCCQ cohort, at 34.9 and 33.0 respectively.  
The two main discrepancies, were between the Quality of Life and Self-efficacy 
scores.  In the PCHF cohort, the QOL summary score mean was 36.4, and was 
lower in the KCCQ cohort at 30.5.  The reverse was true when comparing the 
Self-efficacy scores between the two cohorts, with the mean Self-efficacy score 
being much lower in my cohort at 56.0 versus 67.6 in the KCCQ cohort.  All of 
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the sub-domain and summary scores were lower in my cohort and the KCCQ in-
patient cohort compared to the outpatient, chronic heart failure cohort.     
The distribution of the KCCQ Overall Summary Scores is shown in Figure 5-8.  
The Overall Summary score was also similar in my cohort to the KCCQ cohort, at 
34.5 and 31.8, respectively.  The Overall Summary Score is important, as this 
allows for comparison between different cohorts, and change in clinical 
condition over time.  The KCCQ Overall Summary Score is one of the most 
responsive markers to change in clinical status in heart failure when measured 
over time.   
 
Figure 5-8 Distribution of KCCQ Overall Summary Scores at Baseline 
 
Comparison of KCCQ Overall Summary Score with other cohorts can be seen in 
Figure 5-9.  The difference in KCCQ Overall Summary Score between patients 
hospitalised due to heart failure, represented in orange, and chronic heart 
failure patients in the community is clear.  The Efficacy of Vasopressin 
Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) provides a 
useful comparison.112  This was a multi-centre randomised controlled clinical 
trial of which 1458 participants had a KCCQ performed at baseline.  As this study 
was a pharmacotherapy trial of patients with HF-REF, there are some differences 
between this and my cohort.  Namely, lower age and ejection fraction, and a 
higher incidence of previous hospitalisation for heart failure in the EVEREST 
study versus my cohort.  However, despite these differences in baseline 
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characteristics, there was a very similar mean KCCQ Overall Summary Score 
between EVEREST and PCHF at 31.6 and 34.5.  The clear difference in KCCQ 
Overall Summary Score between patients admitted to hospital with heart failure 
and chronic heart failure can be seen.  This highlights both the potential 
responsiveness to change of the KCCQ Overall Summary Score, and the similarity 
between my cohort and other acute heart failure cohorts.   
 
 
Figure 5-9 Comparison mean KCCQ Overall Summary Score selected cohorts 
Orange columns = hospitalised heart failure cohorts, blue columns = community heart failure cohorts.  
PCHF= Palliative care in heart failure; KCCQ179= Kansas City Cardiomyopathy Questionnaire; EVEREST112 
= Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan ;  Barnes et al183 ; 
Spertus et al254; RED-HF255 = Reduction of Events With Darbepoetin Alfa in Heart Failure Trial; SHIFT71 
= Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial; GISSI-HF256= Gruppo Italiano per 
lo Studio della Sopravvivenza nell’Infarto miocardico-heart failure; HF-ACTION257 = Heart Failure: A 
Controlled Trial Investigating Outcomes of Exercise Training ; MADIT-CRT79= Multicenter Automatic 
Defibrillator Implantation Trial With Cardiac Resynchronization Therapy ; PARADIGM-HF258= Prospective 
comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure 
trial. 
 
Selected baseline characteristics for participants in different severity categories 
of KCCQ Overall Summary Score are shown in Table 5-5.  The KCCQ severity 
categories appeared to divide the cohort more evenly with 43% and 35% being in 
either moderate or severe categories.  This is a higher proportion than reported 
in the EVEREST study, which only had 9% in the severe group and 32% in 
moderate.  This perhaps reflects when the KCCQ was completed, at baseline in 
my study and after one week in EVEREST.  The other main difference is that 
EVEREST was a randomised controlled clinical trial and my cohort was 
unselected.  There were no differences between severity groups in my study in 
terms of age, sex, blood pressure, heart rate, or body mass index.   Past medical 
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history was similar between the three groups, with the exception of higher 
prevalence of diabetes with increasing severity of KCCQ Overall Severity group 
(p=0.0101).  There were clear differences in NYHA class between the different 
KCCQ groups, with more severe KCCQ having a higher proportion of NYHA III/IV 
than moderate and none/mild groups (p<0.0001).  This finding is in keeping with 
previous studies comparing KCCQ summary score to NYHA class.179, 234    There 
were no significant differences between groups regarding echocardiographic or 
laboratory findings.  The EVEREST study reported similar ejection fraction 
between groups of KCCQ severity, in keeping with my study, but higher levels of 
BNP with lower scores in KCCQ.  Again, this difference perhaps reflects the 
difference in timing of sampling of blood and the KCCQ in both studies, with 
higher BNP levels expected across all groups of participants expected the closer 
to admission a sample is taken, such as in my study.  Participants with higher 
KCCQ Overall Summary score category had higher proportion of oedema on 
physical examination.  This is to be expected as the presence of oedema results 
in a higher KCCQ Symptom Score, and therefore a higher KCCQ Overall Summary 
score.  The KCCQ Summary Score severity categories appeared to discriminate 
well the severity of other PROMs.  There were worse mean scores across all 
PROMs, with a stepwise deterioration in mean score from none/mild to 
moderate to severe KCCQ Overall Summary severity categories (p<0.0001 for all 
PROMs).   
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Table 5-5 Baseline characteristics per KCCQ severity group 
 None/ mild Moderate Severe p  
 n=60 n=117 n=95   
Age- yr 75.78 ± 10.10 76.12 ± 9.84 72.98 ± 11.27 0.0749 
Female sex- n (%) 29     (48.3) 51     (43.6) 48     (50.5) 0.5878 
Systolic blood pressure- 
mmHg 
140.92 ± 27.07 141.48 ± 28.81 131.62 ± 26.23 0.0241 
Heart rate- beats/min 87.86 ± 23.62 84.81 ± 24.47 89.93 ± 28.10 0.3496 
Body-mass index- kg/m 27.92 ± 7.19 27.30 ± 6.01 28.77 ± 7.08 0.2913 
Past Medical history- n(%) 
Hypertension 43 (71.7) 75 (64.1) 66 (69.5) 0.5327 
Myocardial infarction 20 (33.3) 50 (42.7) 41 (43.2) 0.4097 
Atrial fibrillation 31 (51.7) 64 (54.7) 49 (51.6) 0.8802 
Diabetes 14 (23.3) 33 (28.2) 42 (44.2) 0.0101 
CVA/TIA 11 (18.3) 22 (18.8) 19 (20.0) 0.9612 
COPD 11 (18.3) 28 (23.9) 30 (31.6) 0.1627 
Depression 6 (10.2) 12 (10.3) 19 (20.2) 0.0755 
Symptoms- n (%)     
NYHA functional class    <0.0001 
Class I 0 (0.0)  0 (0.0)  0 (0.0)   
Class II 34 (56.7) 33 (28.2) 15 (15.8)  
Class III 22 (36.7) 67 (57.3) 52 (54.7)  
Class IV 4 (6.7) 17 (14.3) 28 (29.5)  
Examination- n (%)     
Elevated JVP (> 4cm)  38 (70.4) 71 (68.9) 67 (79.8) 0.2226 
Third Heart Sound  14 (23.7) 23 (19.7) 22 (23.2) 0.7608 
Pulmonary crackles  48 (81.4) 92 (78.6) 72 (76.6) 0.7833 
Pleural effusion  18 (30.5) 40 (34.2) 37 (39.8) 0.4783 
Peripheral Oedema  46 (78.0) 81 (69.2) 79 (84.0) 0.04 
Echocardiography     
Ejection fraction, % 39.32 ± 17.28 40.34 ± 17.41 38.94 ± 15.07 0.8182 
LVIDD/BSA2 2.97 ± 0.59 2.96 ± 0.56 2.96 ± 0.56 0.998 
LV mass/BSA2 115.89 ± 31.98 122.89 ± 41.52 115.97 ± 34.23 0.4312 
E/e’ 17.17 ± 7.64 17.95 ± 7.56 17.03 ± 7.59 0.6649 
Laboratory     
Sodium (mmol/l) 137.0 [134.0, 139.0] 138.0 [135.0, 140.0] 138.0 [135.0, 140.0] 0.5852 
Urea (mmol/l) 8.1 [5.6, 11.2] 8.8 [6.6, 12.1] 8.5 [6.3, 14.2] 0.3013 
Creatinine (umol/l) 92.5 [70.0, 124.0] 103.0 [75.0, 141.0] 97.0 [71.0, 136.0] 0.2631 
BNP (pg/ml) 642.0 [448.0, 1288.5] 733.0 [451.0, 1192.0] 749.0 [378.0, 1619.0] 0.9267 
Haemoglobin (g/L) 125.5 [111.5, 137.0] 122.0 [107.0, 138.0] 120.0 [107.0, 134.0] 0.5473 
PROMS     
HADS-A score 5.07 ± 3.64 6.54 ± 4.23 9.74 ± 4.99 <0.0001 
HADS-D score 3.69 ± 3.01 6.71 ± 3.11 9.52 ± 4.37 <0.0001 
KCCQ summary score 64.87 ± 12.04 36.72 ± 7.21 12.64 ± 6.89 <0.0001 
ESAS summary score 25.28 ± 19.45 34.90 ± 17.55 53.19 ± 19.72 <0.0001 
SF12-physical score 38.90 ± 8.42 30.02 ± 7.63 25.40 ± 7.46 <0.0001 
SF12-mental score 51.52 ± 9.42 43.62 ± 9.77 33.60 ± 10.66 <0.0001 
Continuous variables are expressed as mean± standard deviation or median [ interquartile range], categorical variables are expressed as n (%). 
BNP= Brain-Type natriuretic peptide; BSA= body surface area; CVA= cerebrovascular accident; ESAS= Edmonton Symptom Assessment Scale; 
HADS-A= Hopsital anxiety and depression scale- anxiety; HADS-D= Hospital anxiety and depression scale- depression; JVP= jugular venous 
pressure; KCCQ= Kansas City Cardiomyopathy Questionnaire; LVIDD = left ventricular internal diameter diastole; NYHA = New York Heart 
Association; PROMs= patient reported outcome measures; SF12= Short Form 12 questionnaire; TIA = transient ischaemic attach. 
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5.3 Edmonton symptom assessment scale 
The ESAS is a PROM often used in PC to monitor the symptom burden of patients 
with cancer.227  The ESAS is often used clinically as a trigger tool to prompt a 
further detailed assessment of symptom burden.  The ESAS consists of ten Likert 
scales from 0-10 inclusive, with each scale representing a different symptom.  
The symptoms included in this PROM include shortness of breath, tiredness, 
drowsiness, lack of appetite, anxiety, depression, pain, nausea, and the 
patients’ overall assessment of their own wellbeing.  There is also an additional 
space for respondents to fill in any other symptoms they may have as the tenth 
symptom.  An overall summary score is then created by totalling the sum of the 
individual scores.  Although a number of studies have used differing cut-offs to 
categorise each symptom as mild/ moderate/ severe, there is no consensus 
regarding this.259   I have chosen to use a pragmatic and intuitive approach to 
categorise each individual symptom as follows: 0-4 = none/mild; 5-7 = moderate; 
8-10 = severe.  This principle has previously been applied to patients with heart 
failure and allows for comparison.129  A similar principle was applied to the ESAS 
overall summary score, with 0-33 being classified as none-mild, 34-66 as 
moderate, and 67-100 as severe burden. 
Symptom distribution 
A breakdown of the different symptom scores are expressed in Table 5-6.  The 
range of responses for every symptom was 0-10. The symptom with the highest 
median score was dyspnoea, with a median (IQR) of 7 [4-9].  This is not 
surprising given most patients completed this questionnaire on the first few days 
of a hospital admission for decompensated heart failure.  The next highest 
median [IQR] score was bother tiredness and the patients’ assessment of their 
general wellbeing, at 5 [4-8] and 5 [3-7].  Anxiety, pain, depression, and 
drowsiness all had lower median scores, between 2-3.  Nausea appeared to be 
the least common/ problematic symptom of the 9 assessed, with a median [IQR] 
of 0 [0-3].   
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Table 5-6 ESAS symptom distribution 
The distribution, expressed as a percentage, of the different severity categories 
for each symptom is shown in Figure 5-10.   Again, it is quite clear that shortness 
of breath or dyspnoea is the most problematic symptom, with 54% falling into 
the severe category, 21.9% in moderate, and only 24.2% in the none/ mild 
category.  A similar proportion of symptom burden/ severity was seen regarding 
tiredness, with 48.5% falling into the severe category, 29.2% moderate, and only 
22.4% with only none/mild burden.  The patients’ own assessment of their 
overall wellbeing and drowsiness had similar distribution of patients in terms of 
severity of symptom burden.  Overall wellbeing was reported in the severe range 
for 30.1%, moderate for 33.8% and none/mild in 36.1%.  Lack of appetite, 
anxiety, depression, and pain all had higher proportions of patients in the 
none/mild range, with 50.4, 54.9, 59.9, and 63.9%, respectively.  The lowest 
burden from any of the symptoms assessed was nausea, with only 22% in the 
moderate or severe range. 
Although ESAS has primarily been used in cancer patients, there are some 
studies starting to use this symptom assessment scale in heart failure.  One such 
study, which allows interesting comparison, is by Evangelista et al, who 
performed the ESAS in 36 patients who had been admitted to hospital with heart 
failure.129  Interestingly, they found that the symptom with the highest median 
score was pain, with a median [IQR] of 6 [0-7].  This compares to a median [IQR] 
of 2 [0-5] in my cohort at baseline.  Most other symptoms had median scores of 
4, with the exception of Loss of Appetite and Nausea, both with median scores 
of 3. 
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Figure 5-10 ESAS symptom severity distribution at baseline 
 
An ESAS summary score can be generated by totalling all of the individual 
symptom scores.  The ESAS summary score has a potential range of 0-100.  The 
distribution of ESAS summary scores is shown in Figure 5-11.  The mean (±SD) 
and median [IQR] total summary scores at baseline were 39.18 (±21.64) and 
38.89 [22-56.67].  This was higher than the median [IQR] reported by Evangelista 
et al at 34.00 [29.00-40.75].  This higher symptom burden in my cohort perhaps 
reflects the larger sample size.  Another difference between the cohorts was 
there was a much higher proportion of patients who were NYHA class III in my 
cohort versus the cohort reported by Evangelista et al, at 52 versus 31 %.  There 
was also a much higher proportion of NYHA class IV patients in my study at 18% 
versus 0%.  The distribution of ESAS summary score severity categories is 
detailed in Figure 5-15.  Using the cut offs described previously, 40.1% of 
patients had ESAS summary scores in the none/mild category, 50.2% in the 
moderate, and 9.7% in the severe. 
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Figure 5-11 Distribution of ESAS summary scores at baseline 
 
Comparison of selected baseline characteristics by ESAS severity group is 
provided in Table 5-7.  ESAS severity groups had similar baseline characteristics 
with a few notable exceptions including age, history of myocardial infarction, 
depression, NYHA class, and PROMs summary scores.  Patients who scored in the 
severe ESAS summary category were younger than those in non/mild or 
moderate (p=0.0034).  Patients in moderate or severe categories were more 
likely to have had a previous myocardial infarction or a diagnosis of depression.  
ESAS severity category did not discriminate NYHA class as clearly as KCCQ 
Overall Summary severity categories, with similar proportions of NYHA III/IV 
between ESAS severity categories moderate and severe.  However, there was a 
lower proportion of participants in NYHA class IV who scored in the none/mild 
severity for ESAS.  Participants in severe severity category for ESAS had worse 
scores on all other PROM mean scores, with a stepwise worsening of mean score 
going from none/mild to moderate to severe.  The exception to this was the 
SF12-Physical summary score, where moderate and severe ESAS categories had 
similar mean scores.  
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Table 5-7 Baseline characteristics per ESAS severity group 
 None/ mild Moderate Severe p  
 n=108 n=135 n=26   
Age- yr 74.99 ± 10.23 76.13 ± 10.05 68.58 ± 12.19 0.0034 
Female sex- n (%) 49     (45.4%) 63     (46.7%) 14     (53.8%) 0.7379 
Systolic blood pressure- 
mmHg 141.64 ± 27.59 136.40 ± 28.25 132.85 ± 26.24 0.2088 
Heart rate- beats/min 86.91 ± 26.85 86.08 ± 24.31 94.58 ± 27.38 0.3 
Body-mass index- kg/m 28.12 ± 6.68 27.75 ± 6.61 29.00 ± 7.18 0.6814 
Past Medical history- n(%) 
Hypertension 67     (62.0%) 99     (73.3%) 17     (65.4%) 0.1642 
Myocardial infarction 31     (28.7%) 66     (48.9%) 12     (46.2%) 0.0052 
Atrial fibrillation 58     (53.7%) 70     (51.9%) 15     (57.7%) 0.8521 
Diabetes 31     (28.7%) 45     (33.3%) 13     (50.0%) 0.1165 
CVA/TIA 15     (13.9%) 32     (23.7%) 5      (19.2%) 0.1567 
COPD 21     (19.4%) 37     (27.4%) 10     (38.5%) 0.0972 
Depression 6      (5.7%) 24     (17.8%) 6      (23.1%) 0.0076 
Symptoms- n (%)     
NYHA functional class    0.0005 
Class I 0 (0.0)  0 (0.0)  0 (0.0)   
Class II 45 (41.7) 29 (21.5) 7 (26.9)  
Class III 55 (50.9) 71 (52.6) 13 (50.0)  
Class IV 8 (7.4) 35 (25.9) 6 (23.1)  
Examination- n (%)     
Elevated JVP (> 4cm)  67     (69.1%) 92     (78.6%) 15     (62.5%) 0.1358 
Third Heart Sound  23     (21.5%) 28     (20.7%) 7      (26.9%) 0.7813 
Pulmonary crackles  82     (76.6%) 107    (79.9%) 20     (76.9%) 0.8217 
Pleural effusion  33     (30.8%) 51     (38.3%) 11     (42.3%) 0.3678 
Peripheral Oedema  80     (74.8%) 104    (77.6%) 19     (73.1%) 0.8178 
Echocardiography     
Ejection fraction, % 40.32 ± 16.43 39.16 ± 16.80 40.19 ± 16.71 0.856 
LVIDD/BSA2 2.96 ± 0.52 2.96 ± 0.60 2.94 ± 0.52 0.9936 
LV mass/BSA2 114.64 ± 29.37 121.93 ± 41.30 117.70 ± 41.83 0.4312 
E/e’ 17.81 ± 8.35 17.00 ± 6.96 18.30 ± 7.82 0.621 
Laboratory     
Sodium (mmol/l) 138.0 [136.0, 140.0] 138.0 [134.0, 140.0] 137.5 [135.0, 140.0] 0.2201 
Urea (mmol/l) 8.2 [6.1, 11.8] 8.8 [6.5, 12.2] 10.9 [7.5, 14.2] 0.2643 
Creatinine (umol/l) 95.5 [72.0, 133.5] 98.0 [71.0, 135.0] 109.5 [87.0, 151.0] 0.1446 
BNP (pg/ml) 612.0 [394.5, 1207.5] 798.0 [451.0, 1478.0] 754.5 [424.0, 1866.0] 0.1658 
Haemoglobin (g/L) 122.0 [107.0, 139.0] 122.0 [109.0, 134.0] 119.0 [96.0, 128.0] 0.4221 
PROMS     
HADS-A score 5.00 ± 3.72 8.07 ± 4.44 12.73 ± 4.48 <0.0001 
HADS-D score 4.77 ± 3.40 8.15 ± 3.79 10.44 ± 4.52 <0.0001 
KCCQ summary score 45.51 ± 20.59 28.54 ± 17.38 18.98 ± 18.81 <0.0001 
ESAS summary score 17.78 ± 9.66 48.99 ± 9.94 77.13 ± 9.65 <0.0001 
SF12-physical score 33.46 ± 9.88 28.30 ± 8.08 28.18 ± 7.85 <0.0001 
SF12-mental score 48.46 ± 10.69 39.10 ± 10.73 29.61 ± 9.05 <0.0001 
Continuous variables are expressed as mean± standard deviation or median [ interquartile range], categorical variables are expressed as n (%). 
BNP= Brain-Type natriuretic peptide; BSA= body surface area; CVA= cerebrovascular accident; ESAS= Edmonton Symptom Assessment Scale; 
HADS-A= Hopsital anxiety and depression scale- anxiety; HADS-D= Hospital anxiety and depression scale- depression; JVP= jugular venous 
pressure; KCCQ= Kansas City Cardiomyopathy Questionnaire; LVIDD = left ventricular internal diameter diastole; NYHA = New York Heart 
Association; PROMs= patient reported outcome measures; SF12= Short Form 12 questionnaire; TIA = transient ischaemic attach.   
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5.4 Short form 12  
The SF12 questionnaire, is a general quality of life questionnaire, based upon 
the longer Short Form 36 questionnaire.  Both the SF12 and 36 questionnaires 
are designed to provide eight separate domains of different aspects of general 
health, and also provide two summary scores.  These summary scores, the SF12-
Physical Function and SF12-Mental well-being aggregate scores are useful for 
comparison between populations.  Higher scores indicate better physical and 
mental health.  The SF12 is a validated and shorter version of the SF36.  The 
SF12 is able to reliably reproduce the overall summary scores generated from 
the SF36 but has the advantage of reduced participant burden due to a shorter 
form.193  The eight domains that make up the SF12 include: physical functioning; 
physical role; bodily pain; general health; vitality; social functioning; emotional 
role; and mental health.  An example of the SF12 questionnaire is provided in 
appendix 4.   
Although the SF12 produces a score for each of the above sub-domains, the SF36 
provides more reliable sub-domain scores, and it is recommended by the 
developers of the SF12 and those who have validated the SF12 that the two 
summary scores are used for comparison purposes.  The mean (SD) and median 
[IQR] scores for SF12-Physical Function aggregate score at baseline were 30.31 
(9.18) and 30.33 [23.98-36.16], respectively.  The distribution of scores for the 
Physical Function summary score at baseline are shown in Figure 5-12.  The 
mean (SD) and median [IQR] scores for the SF12-Mental wellbeing aggregate 
score at baseline were 41.79 (12.06) and 42.22 [32.82-50.36].   The distribution 
of scores for the Mental Wellbeing summary score at baseline are shown in 
Figure 5-13. 
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Figure 5-12 Distribution of SF-12 Aggregate Physical function scores at baseline 
 
Figure 5-13 Distribution of SF-12 Mental Wellbeing summary scores at baseline 
 
SF12 has been validated in a large population sample in the United Kingdom, 
which included both participants with no known disease and patients with 
chronic disease including heart failure.193  This sample included a community 
sample of over 9000 participants.  The mean (SD) values for both SF12-Physical 
Function and SF12-Mental well-being aggregate scores were both 50.00 (9.72).  
In this sample there were 68 participants with a diagnosis of heart failure.  
These participants had much lower scores of 31.47 (12.19) and 38.36 (12.46) for 
SF12-Physical Function and SF12-Mental well-being aggregate scores, 
respectively.  The SF12 has also been administered to a large sample of 476 
chronic heart failure patients in the United States of America.254  This study 
reported mean (SD) scores of 35 (11) and 49 (12) for SF12-Physical Function and 
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SF12-Mental well-being aggregate scores, respectively.  The results of the SF12 
in my cohort are similar to those seen in previous cohorts of patients with heart 
failure, and are much lower than what is seen in the general population.  
Using the cut-offs previously described, 123 (49.4%), 91 (36.5%), and 35 (14.1%) 
participants would be classified in none/mild, moderate and severe categories of 
the SF12-Physical Function aggregate score, respectively.  199 (79.9%), 37 
(14.9%), and 13 (5.2%) would be classified in none/mild, moderate and severe 
categories of the SF12-Mental wellbeing aggregate score, respectively.  Selected 
baseline characteristics are provided per severity category for both SF12-
Physical Function and SF12-Mental well-being aggregate scores in Table 5-8 and 
Table 5-9, respectively.    Baseline characteristics were similar between the 
three groups of severity for both the SF12-Physical Function and SF12-Mental 
well-being aggregate scores.  A higher proportion of participants in the 
none/mild category of the SF12-Physical function were female compared to the 
moderate or severe groups.  There was also a higher proportion of participants 
with a third heart sound in the severe category for SF12-Mental wellbeing 
compared to moderate or mild/none.  The main differences between the groups 
for both summary scores, were in the other mean PROMs scores, with the 
exception of mean SF12-Physcial and mental aggregate scores.  
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Table 5-8 Baseline characteristics per SF12-physical severity group 
 None/ mild Moderate Severe p  
 n=123 n=91 n=35   
Age- yr 75.16 ± 10.40 73.47 ± 10.99 75.22 ± 9.28 0.4668 
Female sex- n (%) 67 (54.5) 32 (35.2) 14 (40.0) 0.0154 
Systolic blood pressure- 
mmHg 140.38 ± 24.42 137.08 ± 32.22 129.46 ± 27.25 0.1249 
Heart rate- beats/min 88.12 ± 25.02 86.14 ± 26.11 85.43 ± 25.34 0.792 
Body-mass index- kg/m 28.05 ± 7.85 28.20 ± 5.39 28.52 ± 5.62 0.9338 
Past Medical history- n(%) 
Hypertension 83 (67.5) 61 (67.0) 27 (77.1) 0.506 
Myocardial infarction 41 (33.3) 41 (45.1) 18 (51.4) 0.0765 
Atrial fibrillation 64 (52.0) 48 (52.7) 19 (54.3) 0.9721 
Diabetes 34 (27.6) 34 (37.4) 18 (51.4) 0.0257 
CVA/TIA 23 (18.7) 18 (19.8) 6 (17.1) 0.9419 
COPD 27 (22.0) 28 (30.8) 8 (22.9) 0.3197 
Depression 15 (12.3) 12 (13.2) 7 (20.6) 0.4536 
Symptoms- n (%)     
NYHA functional class    0.074 
Class I 0 (0.0)  0 (0.0)  0 (0.0)   
Class II 42 (34.1) 26 (28.6) 9 (25.7)  
Class III 63 (51.2) 51 (56.0) 14 (40.0)  
Class IV 18 (14.6) 14 (15.4) 12 (34.3)  
Examination- n (%)     
Elevated JVP (> 4cm)  77 (72.0) 58 (70.7) 25 (86.2) 0.2407 
Third Heart Sound  26 (21.3) 19 (20.9) 8 (22.9) 0.9708 
Pulmonary crackles  92 (75.4) 72 (80.0) 29 (82.9) 0.557 
Pleural effusion  42 (34.4) 29 (32.6) 15 (42.9) 0.5499 
Peripheral Oedema  92 (75.4) 71 (78.9) 29 (82.9) 0.6124 
Echocardiography     
Ejection fraction, % 39.25 ± 16.56 42.29 ± 16.91 33.54 ± 14.44 0.0279 
LVIDD/BSA2 3.00 ± 0.56 2.86 ± 0.55 3.05 ± 0.60 0.1116 
LV mass/BSA2 113.52 ± 28.64 126.04 ± 47.61 117.58 ± 31.67 0.1183 
E/e’ 16.66 ± 6.64 17.52 ± 7.87 18.70 ± 9.86 0.3748 
Laboratory     
Sodium (mmol/l) 138.0 [135.0, 140.0] 137.0 [134.0, 139.0] 138.0 [136.0, 140.0] 0.2392 
Urea (mmol/l) 8.0 [6.0, 11.7] 8.7 [6.4, 14.3] 9.2 [7.3, 14.8] 0.0972 
Creatinine (umol/l) 91.0 [70.0, 130.0] 104.0 [74.0, 148.0] 107.0 [77.0, 140.0] 0.0651 
BNP (pg/ml) 598.0 [418.0, 1192.0] 733.0 [388.0, 1403.0] 911.0 [525.0, 1697.0] 0.2497 
Haemoglobin (g/L) 125.0 [113.0, 139.0] 115.0 [103.0, 135.0] 117.0 [107.0, 133.0] 0.0575 
PROMS     
HADS-A score 6.84 ± 4.29 8.27 ± 5.19 7.11 ± 4.83 0.091 
HADS-D score 6.02 ± 3.95 8.18 ± 4.41 7.65 ± 3.52 0.0006 
KCCQ summary score 43.91 ± 22.05 26.54 ± 16.32 20.95 ± 14.30 <0.0001 
ESAS summary score 34.68 ± 21.72 45.12 ± 20.56 44.32 ± 19.78 0.0009 
SF12-physical score 37.68 ± 5.84 25.79 ± 2.79 16.18 ± 3.79 <0.0001 
SF12-mental score 42.46 ± 11.91 39.63 ± 13.14 45.05 ± 8.39 0.0528 
Continuous variables are expressed as mean± standard deviation or median [ interquartile range], categorical variables are expressed as n (%). 
BNP= Brain-Type natriuretic peptide; BSA= body surface area; CVA= cerebrovascular accident; ESAS= Edmonton Symptom Assessment Scale; 
HADS-A= Hopsital anxiety and depression scale- anxiety; HADS-D= Hospital anxiety and depression scale- depression; JVP= jugular venous 
pressure; KCCQ= Kansas City Cardiomyopathy Questionnaire; LVIDD = left ventricular internal diameter diastole; NYHA = New York Heart 
Association; PROMs= patient reported outcome measures; SF12= Short Form 12 questionnaire; TIA = transient ischaemic attach.   
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Table 5-9 Baseline characteristics per SF12-mental severity group 
 None/ mild Moderate Severe p  
 n=199 n=37 n=13   
Age- yr 75.30 ± 10.23 72.27 ± 11.97 69.53 ± 7.41 0.0552 
Female sex- n (%) 90 (45.2) 17 (45.9) 6 (46.2) 0.9951 
Systolic blood pressure- 
mmHg 137.58 ± 28.83 139.58 ± 24.43 132.54 ± 26.83 0.7413 
Heart rate- beats/min 86.52 ± 24.52 84.31 ± 24.32 101.85 ± 36.74 0.085 
Body-mass index- kg/m 27.96 ± 6.52 28.44 ± 6.40 30.63 ± 9.74 0.3731 
Past Medical history- n(%) 
Hypertension 136 (68.3) 24 (64.9) 11 (84.6) 0.4075 
Myocardial infarction 77   (38.7) 19 (51.4) 4   (30.8) 0.2748 
Atrial fibrillation 107 (53.8) 19 (51.4) 5   (38.5) 0.5559 
Diabetes 64   (32.2) 17 (45.9) 5   (38.5) 0.2572 
CVA/TIA 38   (19.1) 6   (16.2) 3   (23.1) 0.8492 
COPD 47   (23.6) 10 (27.0) 6   (46.2) 0.1875 
Depression 22   (11.2) 9   (24.3) 3   (23.1) 0.0625 
Symptoms- n (%)     
NYHA functional class    0.2087 
Class I 0 (0.0)  0 (0.0)  0 (0.0)   
Class II 68 (34.2) 7 (18.9) 2 (15.4)  
Class III 98 (49.2) 23 (62.2) 7 (53.8)  
Class IV 33 (16.6) 7 (18.9) 4 (30.8)  
Examination- n (%)     
Elevated JVP (> 4cm)  124 (72.1) 27  (75.0) 9    (90.0) 0.4473 
Third Heart Sound  39   (19.7) 5    (13.5) 9    (69.2) <0.0001 
Pulmonary crackles  155 (78.3) 27  (75.0) 11  (84.6) 0.7675 
Pleural effusion  69   (34.8) 11  (30.6) 6    (50.0) 0.4719 
Peripheral Oedema  150 (75.8) 30  (83.3) 12  (92.3) 0.26 
Echocardiography     
Ejection fraction, % 39.41 ± 17.01 42.86 ± 13.82 32.46 ± 15.92 0.1448 
LVIDD/BSA2 2.93 ± 0.56 3.01 ± 0.57 3.10 ± 0.71 0.49 
LV mass/BSA2 118.81 ± 38.01 119.53 ± 42.50 122.43 ± 29.06 0.9575 
E/e’ 17.48 ± 7.84 15.98 ± 6.93 17.18 ± 5.67 0.5881 
Laboratory     
Sodium (mmol/l) 138.0 [135.0, 140.0] 138.0 [135.0, 140.0] 138.0 [135.0, 139.0] 0.8865 
Urea (mmol/l) 8.7 [6.3, 12.2] 8.5 [6.2, 13.9] 10.5 [6.4, 15.8] 0.59 
Creatinine (umol/l) 97.0 [72.0, 140.0] 102.0 [77.0, 132.0] 110.0 [71.0, 136.0] 0.819 
BNP (pg/ml) 710.0 [444.0, 1329.0] 521.0 [388.0, 1044.0] 1619.0 [646.0, 2010.0] 0.0957 
Haemoglobin (g/L) 122.0 [109.0, 137.0] 122.0 [97.0, 133.0] 126.0 [107.0, 130.0] 0.5969 
PROMS     
HADS-A score 6.21 ± 4.07 11.60 ± 4.10 13.92 ± 4.15 <0.0001 
HADS-D score 5.98 ± 3.40 10.00 ± 3.89 14.69 ± 3.84 <0.0001 
KCCQ summary score 38.87 ± 20.65 20.02 ± 13.10 5.58 ± 4.56 <0.0001 
ESAS summary score 34.61 ± 18.97 59.75 ± 19.18 62.64 ± 17.73 <0.0001 
SF12-physical score 30.57 ± 9.91 29.83 ± 5.38 27.79 ± 5.04 0.5382 
SF12-mental score 46.21 ± 8.94 26.34 ± 2.53 18.10 ± 1.78 <0.0001 
Continuous variables are expressed as mean± standard deviation or median [ interquartile range], categorical variables are expressed as n (%). 
BNP= Brain-Type natriuretic peptide; BSA= body surface area; CVA= cerebrovascular accident; ESAS= Edmonton Symptom Assessment Scale; 
HADS-A= Hopsital anxiety and depression scale- anxiety; HADS-D= Hospital anxiety and depression scale- depression; JVP= jugular venous 
pressure; KCCQ= Kansas City Cardiomyopathy Questionnaire; LVIDD = left ventricular internal diameter diastole; NYHA = New York Heart 
Association; PROMs= patient reported outcome measures; SF12= Short Form 12 questionnaire; TIA = transient ischaemic attach.   
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5.5 Zarit Burden Interview 
The Zarit Burden Interview consists of 22 questions, which are self-administered 
by the caregiver, with possible answers provided, with a possible score of 0-4 for 
each question.195  A total score is generated with a potential range of 0-88.  
Higher summary scores for the ZBI indicate higher burden.  Cut-offs have been 
suggested by the developers of the ZBI with 0-21 indicating little or no burden, 
21-40 mild-moderate burden, 41-60 moderate-severe, and 61-88 severe burden.  
93 (34.2%) caregivers were available and/or willing to complete the ZBI.  The 
mean (SD) and median [IQR] scores for the ZBI at baseline were 19.32 (14.05) 
and 16.00 [09.00-28.00], with a range of 0-58.  The distribution of scores at 
baseline is shown in Figure 5-14.   Using the above cut-offs, 57 (61.3%) reported 
little or no burden, 25 (26.9%) reported mild-moderate burden, 11 (11.8%) 
reported moderate-severe burden, and no caregivers reported severe burden.  
The ZBI has been used in numerous other conditions and is one of the most 
commonly used caregiver strain assessments.195 The ZBI has also been used in 
heart failure, with one study of 50 patients with heart failure and their primary 
caregivers reporting a similar mean (SD) ZBI score of 16.0 (14.4).260  Although the 
ZBI mean scores are similar between this and my study, the low proportion of 
caregivers with high levels of burden is surprising given the high symptom and 
quality of life burden reported by participants themselves.  This could reflect 
the smaller sample size of the ZBI.   
 
 
Figure 5-14 Distribution of Zarit Burden Interview summary scores at baseline 
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5.6 Summary scores 
The distribution of severity score categories is provided in Figure 5-15.  The 
KCCQ severity categories used classified the highest proportion of participants as 
either moderate or severe (77.9%).  This was followed by the ESAS, which using 
the cut-offs previously described, categorised 59.9% of participants as moderate 
or severe.  The ESAS cut-offs used classified fewer participants as severe 
compared to the KCCQ, with 9.7 and 34.9%, respectively.  The SF-12 Physical 
summary score categories classified a similar proportion of participants as 
none/mild, moderate or severe, as the ESAS.  The three PROMs which 
predominantly assess mood (SF-12 Mental wellbeing, HADS-Depression, and 
HADS-Anxiety) had similar distributions of severity scores, with most participants 
being classed as none/mild (74.5-81.6%).  A similar proportion of participants 
were classified as moderate or severe (18.3-25.5%) on the mood assessment 
PROMs.  That there was such similarity between the SF-12 Mental wellbeing and 
both HADS assessments is suggestive that the cut-offs used in SF-12 Mental 
Wellbeing are appropriate.  Although the KCCQ classified a high proportion of 
participants as severe, or moderate, the cut-offs used are justifiable as they 
have been used in large cohorts of both patients admitted to hospital with heart 
failure and chronic heart failure patients.184, 234  In both cohorts, a KCCQ Overall 
Summary score of less than 25 was associated with poor outcomes including 
increased mortality and increased readmissions.  In an analysis of the EVEREST 
study, KCCQ score of less than 25 was the strongest predictor of persistently 
impaired QOL (assessed as KCCQ less than 45) or death at 6 months follow-up.112   
Overall, 114 (41.9%) of participants scored severe in any of the PROMs at 
baseline assessment.  Of these, most scored severe in one PROM (n = 59, 51.8%).  
A further 38 (33.3%) participants scored severe in two PROMs.  10 (8.8%) of those 
in the severe overall category scored severe in three PROMs, with 4 and 3 
participants scoring severe in 4 and 5 PROMs respectively.   
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Figure 5-15 Baseline PROM severity categories 
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5.7 Summary 
In this chapter, I have shown that patients admitted to hospital because of heart 
failure suffer from a number of physical and psychological symptoms, as 
reported using reproducible and objective PROMs.   The most common physical 
symptoms were shortness of breath and fatigue, followed by drowsiness and lack 
of appetite.  Although less frequent, pain and nausea were not uncommon.  
Patients with higher symptom burden and lower mood or worse anxiety were 
more likely to have worse quality of life, as anticipated.  Higher scores for 
depression and anxiety were present compared to the general population.  
Interestingly, very few of the known predictors of prognosis were statistically 
significantly different between the groups of severity for any of the PROMs.  
Notable exceptions were age in the HADS Depression and Anxiety, and ESAS, 
with worse severity category being associated with lower age.  Worse NYHA class 
was associated with worse KCCQ, ESAS and HADS-Anxiety severity category.  
Measures of heart structure and function, such as left ventricular size, reduced 
ejection fraction, or elevated BNP, were not associated with worsening severity 
category of any PROM.  The only exception to this being HADS-Anxiety severe 
category having higher left ventricular indexed size, higher BNP and lower 
ejection fraction (although the differences in BNP and ejection fraction did not 
reach statistical significance).  This suggests that severity of physiological 
dysfunction does not necessarily correlate with severity of symptom burden or 
QOL impairment. 
Of all of the PROMs used, the KCCQ appeared to be the most sensitive at 
identifying patients with severe impairment, as defined as a KCCQ summary 
score less than 25.  Perhaps the KCCQ is not specific for severe impairment, and 
is over-classifying patients into this group?  The results of the KCCQ in the 
current study are comparable with other hospitalised cohorts, as demonstrated 
earlier, and the cut-off value of 25 has been shown to identify patients with 
heart failure at risk of reduced life expectancy and unfavourable future QOL.  
The KCCQ cut-offs used also correlated well with NYHA classification, as 
previously shown, indicating that the results of the KCCQ are in keeping with 
other published cohorts.  Patients with severe KCCQ were also more likely to 
have worse scores in all of the other PROMs, with statistically significant 
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separation of scores for each PROM between all of the categories of KCCQ 
severity.   The ESAS also identified a group of patients with worse scores in all 
other PROMs measured.   
This chapter has also highlighted the importance of using multiple different 
types of PROMs to describe the multi-faceted influence heart failure has on 
patients’ lives, and therefore, potential palliative care needs.  Although the 
KCCQ did appear to have the highest sensitivity for identifying patients with 
heart failure with severe impairment of quality of life, it did not identify all 
patients who scored severely at baseline.  Of the 114 (41.9%) of patients who 
scored severely in any domain at baseline, 95 (83%) of these scored severely in 
KCCQ. 
The change over time in symptom burden, mood disturbance, and QOL will be 
explored further in the following chapter.  
 
 
 138 
 
Chapter 6 Follow up- the patient journey 
6.1 Introduction 
This chapter describes the follow-up of participants.  Participants had two types 
of follow-up, actively through study visits, and passively through linkage with 
medical records and the Greater Glasgow and Clyde SafeHaven.  The Greater 
Glasgow and Clyde SafeHaven has details of every hospital admission and death 
within the Greater Glasgow and Clyde health board, in which the study was 
performed.  Details of cause and location of both hospitalisation and deaths are 
available through coding using the Scottish Morbidity Record.  This chapter will 
describe the proportion of participants who met the definition of PC needs and 
compare baseline demographics with those who did not. 
6.2 Follow up-study visits 
All participants agreeing to take part in the PROM aspect of the study were 
invited to attend for study visits every 4 months for the duration of the study.  
The minimum number of potential study visits was two for the last participant 
recruited, and the maximum number of potential study visits was 7 for the first 
participant recruited.  The first study visit took place on the 14th of May 2013 
and the last on the 25th of June 2015.  There were a total of 691 study visits 
carried out during this time period.  Flexible appointments were offered at 4 
months +/- one week in attempt to achieve maximum retention of participants.  
Given the nature of the study and the participants involved, participants were 
offered home visits or to attend the research facility at the British Heart 
Foundation Glasgow Cardiovascular Research Centre.  37.0% of all study visits 
were carried out in the participants’ home.  Prior to each study visit, 
participants were posted the same questionnaire pack containing the PROMs, as 
described earlier.  A detailed medical history, physical examination, and 
laboratory tests were taken, as detailed in study visit case report form.  Where 
available, caregivers were invited to complete the Zarit Burden Interview 
caregiver strain questionnaire.   
Retention in the study was good, with the proportion of participants attending 
demonstrated in Figure 6-1.  190 (69.9%) participants attended the 4 month 
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study visit.  Of the 82 who did not attend, 23 were due to death, 4 due to 
deteriorating health, 11 did not want to attend, and 44 failed to attend or 
provide a reason.  As the time from recruitment increased, unsurprisingly, the 
proportion of participants not attending due to death increased.  The proportion 
of participants not attending due to death steadily increased from 8.5% at the 4-
month study visit, to 35.6% at the 24-month visit.  As there was a variable 
follow-up period for study assessments for participants, from minimum 8 months 
to maximum 28 months, the proportion of participants who were unable to 
attend a visit for this reason increased over time.   The proportion of 
participants where a study visit was not possible due to the time they entered 
the study rose steadily from 24 (8.8%) at the 12-month visit, to 124 (45.6%) at 
the 24-month visit.  Participants did not attend for a variety of other reasons, 
including fatigue with assessments, a feeling of having too many appointments, 
or due to deteriorating health.  However, most commonly there was no reason 
available or given for no attendance.  The proportion of participants who failed 
to attend for reasons other than death or visit not possible increased as the 
study progressed.  59 (23.7%) participants who could potentially have attended 
(excluding those who died) the 4-month study visit did not attend.  This 
proportion increased over time, and 17 (33.3%) of participants who could 
potentially have attended (excluding participants who died or could not have 
had a study visit due to time of entry to the study) at the 24-month visit.  
Overall, of the number of possible study visits (excluding missed visits due to 
death or late entry into the study), 78% of study visits were completed.  In total, 
including the inpatient assessment, there were 963 patient assessments.    
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Figure 6-1 Attendance at study visits 
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6.3 Passive follow-up  
Participants provided consent to be passively followed up through medical 
record linkage, which is available through the Greater Glasgow and Clyde 
SafeHaven service.  Both services utilise the Scottish Morbidity Record linked to 
each patient, which records details of hospitalisations and deaths, amongst 
other data. 
The minimum follow-up through data linkage was 368 days, and the maximum 
was 1056 days.  The median [IQR] and mean (±SD) follow up in days for the 272 
participants who completed the questionnaire aspect of the study were 774.5 
[608.0-912.5] and 754.3 (±190.8), respectively. 
6.3.1 Hospitalisations 
Details of hospitalisations, including cause and length of stay were available 
through analysis of the Scottish Morbidity Record via the Greater Glasgow 
SafeHaven records.  During the follow-up period, 217 (79.8%) participants were 
readmitted to hospital.  Of those hospitalised, the range of number of 
hospitalisations was 1 to 32.  The median number of readmissions was 3 [2-5].  
The total number of unscheduled or emergency hospitalisations during the 
follow-up period was 503.  Of these, 183 (36.4%) were for cardiovascular causes 
(heart failure, myocardial infarction, arrhythmia, stroke or other cardiovascular 
causes).  The most common cardiovascular reason for hospitalisation was heart 
failure (56.8%), followed by arrhythmia (16.9%).   4.9% of cardiovascular 
readmissions were due to myocardial infarction.  The majority of repeat 
hospitalisations were not due to cardiovascular causes, with 320 (63.6%) due to 
non-cardiovascular causes.   
6.3.2 Mortality 
During the follow-up period from 9th January 2013 – 1st December 2015, there 
were 103 deaths, or 37.9% of participants.  The survival of the 272 participants 
in the cohort who completed the questionnaire aspect of the study is 
demonstrated in Figure 6-2.  The mortality was similar in this cohort to other 
cohorts of patients hospitalised because of heart failure locally and nationally.26, 
261  Figure 6-2 highlights the high mortality associated with heart failure 
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following a hospitalisation due to decompensation.  23.1 and 35.7% of 
participants had died by one and two years following recruitment, respectively.   
Cause and location of death will be explored in more detail in following chapter. 
 
Figure 6-2 Kaplan-Meier mortality 
 
6.4 Patient journey- patients with palliative care needs 
Details of the proportion of participants who scored severe in each of the PROMs 
are shown in Table 6-1.  At baseline, a high proportion of participants were 
graded as overall severe, defined as scoring severe in any PROM, with 41.9%.  
Most of these participants were severe as evaluated by the KCCQ (34.9%).  The 
next most common contributing PROM was the SF-12 Physical PROM with 35 
(14.1%) participants, followed by the ESAS summary score with 26 (9.7%) 
participants.  The three mood assessments, SF-12 Mental, HADS Anxiety and 
Depression, scored similar proportions of participants as severe at baseline, with 
5.2%, 6.5%, and 3.7%, respectively.  The proportion of participants who attended 
study visits that were categorised as severe overall fell from baseline to the 4-
month assessment at 27.8%.  This proportion remained fairly constant for the 
remainder of the study, for the patients who attended study visits, at between 
24 and 34%.   Throughout the study, the KCCQ and SF-12 Physical PROMs 
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contributed most to the classification of overall severity. Between 15 and 23% of 
participants who attended study visits were scored as severe on KCCQ.  Between 
12 and 20% of participants who attended study visits were scored as severe on 
SF-12 Physical.   
Table 6-1 PROM severity per study visit 
 
Baseline 
4  
month 
8  
month 
12 
month 
16 
month 
20 
month 
24 
month 
 n=272 n= 187 n=159 n= 136 n=94 n= 61 n= 35 
Severe PROM 
HADS-
Anxiety 
17 (6.5) 4 (2.3) 4 (2.6) 3 (2.3) 1 (1.2) 1 (1.7) 2 (6.2) 
HADS-
Depression 
10 (3.7) 4 (2.2) 7 (4.5%) 2 (1.6) 3 (3.3) 5 (8.2) 2 (5.9) 
KCCQ 
overall 
95 (34.9) 28 (15.0) 27 (17.0) 24 (17.6) 14 (15.1) 14 (23.0) 6 (17.6) 
ESAS overall 26 (9.7) 13 (7.1) 13 (8.2) 13 (9.6) 7 (7.5) 5 (8.2) 5 (14.7) 
SF-12 
Physical 
35 (14.1) 28 (15.9) 30 (20.4) 17 (13.3) 10 (11.8) 10 (17.5) 6 (18.8) 
SF-12 Mental 13 (5.2) 5 (2.8) 5 (3.4) 5 (3.9) 0 (0.0) 3 (5.3) 1 (3.1) 
Overall 
Severe 
114 (41.9) 52 (27.8) 55 (34.6) 41 (30.1) 23 (24.4) 22 (36.0) 12 (34.3) 
Values expressed as n (%) 
ESAS= Edmonton symptom assessment scale; HADS= hospital anxiety depression scale; PROM= patient 
reported outcome measure; SF-12= short form 12. 
 
 
 
The patient journey for each participant is detailed in Figure 6-3, Figure 6-4, 
Figure 6-5, and Figure 6-6.  Participants were classified at each potential study 
visit as “severe” or “not severe” for those who attended the visit.  As discussed 
in Chapter 3, participants were classified as “overall severe” if they scored 
severe burden in any PROM.  For participants who did not attend study visits, 
reasons were detailed as either “missed” for those who did not attend, “not 
possible” for those who could not have had a study visit at that time point due 
to their recruitment date, and “deceased”.   Using the severity criteria and the 
definition of probable PC needs detailed in Chapter 3, the population can be 
divided into two groups: those meeting the definition of PC needs (Figure 6-3), 
and those without not meeting the definition (Figure 6-4, Figure 6-5, and Figure 
6-6). Due to the nature of the patient population being studied, and the length 
of active follow-up, missed visits were inevitable.  I have elected to include 
participants with missed visits in my analysis as to exclude them would remove a 
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large proportion of the patient population.  Another important reason for 
including these patients in the analysis is that these participants could have 
missed study visits due to deteriorating health or hospitalisation, and therefore I 
would be potentially excluding the participants with the highest need.  For the 
purpose of describing the prevalence of PC needs, I have assumed that during  a 
missed visit a participant had the same status as the last known status, as 
determined by PROMs.  Another possible way to address missing study visit data 
is to assume that a participant missed a study visit due to deteriorating health 
and classify them as “severe” for that visit.  I have elected not to do this as I 
feel this will potentially over classify participants as having PC needs. A further 
option to address missed visits would be to assume a study visit was “not 
severe”, again, I have elected not to do this, as I felt this would potentially 
under-classify participants with likely PC needs. 
Analysis of Figure 6-3, Figure 6-4, Figure 6-5, and Figure 6-6, reveals two broad 
groups, those with persistently impaired status or those who died following a 
severe status, and those who had a predominantly not-severe status or had 
improvement in status.  Of those identified as likely having PC needs, 47 (64.5%) 
participants died following at least one study visit, with no known recovery of 
overall status.  A further 26 (35.6%) of those classified as having likely PC needs 
had at least two consecutive study visits with severe overall status, without 
known recovery.   The fluctuating nature of heart failure can be seen in these 
figures, with some participants changing severity category over time from 
severe, to not severe, and back to severe.  A good example of this is patient 
number 1149.  The patient journey figures are also important to understand 
that, although the mortality is high, many patients with heart failure do well and 
can improve.   Many participants had severe overall impairment at baseline, but 
improved as time progressed.  This highlights the importance of this study and of 
performing multiple serial assessments, rather than a single one-off assessment 
in hospital.   
Using the definition described in Chapter 3, 73 (26.8%) participants met the 
definition for PC needs.  Of patients, 47 died following a study visit with severe 
impairment (of any PROM), without known improvement in their status.  26 
participants in the PC needs group had two or more consecutive visits with 
severe impairment of any PROM, without known improvement in their status.   
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 STUDY VISIT 
Patient Baseline 4 Month 8 Month 12 month 16 month 20 Month 24 Month 28 Month 
1004 Severe Severe Deceased Deceased Deceased Deceased Deceased Deceased 
1008 Severe Severe Severe Deceased Deceased Deceased Deceased Deceased 
1011 Severe Missed Deceased Deceased Deceased Deceased Deceased Deceased 
1013 Severe Deceased Deceased Deceased Deceased Deceased Deceased Deceased 
1014 Severe Severe Deceased Deceased Deceased Deceased Deceased Deceased 
1017 Severe Deceased Deceased Deceased Deceased Deceased Deceased Deceased 
1019 Severe Not Severe Severe Severe Severe Severe Severe Missed 
1026 Severe Deceased Deceased Deceased Deceased Deceased Deceased Deceased 
1030 Not Severe Not Severe Severe Severe Severe Severe Severe Severe 
1032 Not Severe Severe Severe Missed Missed Deceased Deceased Deceased 
1036 Severe Severe Not Severe Not Severe Not Severe Severe Severe Not Possible 
1038 Severe Missed Deceased Deceased Deceased Deceased Deceased Deceased 
1043 Severe Deceased Deceased Deceased Deceased Deceased Deceased Deceased 
1044 Not Severe Not Severe Severe Severe Severe Severe Severe Not Possible 
1052 Severe Deceased Deceased Deceased Deceased Deceased Deceased Deceased 
1067 Severe Missed Missed Missed Deceased Deceased Deceased Deceased 
1069 Severe Severe Severe Severe Severe Severe Severe Not Possible 
1071 Not Severe Severe Severe Severe Severe Severe Severe Not Possible 
1077 Not Severe Severe Not Severe Severe Severe Severe Severe Not Possible 
1078 Severe Missed Severe Severe Severe Missed Severe Not Possible 
1081 Severe Severe Severe Severe Not Severe Severe Severe Not Possible 
1082 Severe Severe Severe Missed Missed Missed Missed Deceased 
1083 Not Severe Not Severe Severe Missed Severe Deceased Deceased Deceased 
1085 Severe Severe Severe Severe Missed Deceased Deceased Deceased 
1091 Severe Severe Severe Severe Deceased Deceased Deceased Deceased 
1094 Severe Severe Deceased Deceased Deceased Deceased Deceased Deceased 
1096 Severe Severe Severe Severe Missed Severe Not Possible Not Possible 
1098 Severe Missed Missed Deceased Deceased Deceased Deceased Deceased 
1105 Severe Severe Missed Missed Missed Missed Not Possible Not Possible 
1110 Not Severe Missed Severe Missed Severe Severe Deceased Deceased 
1112 Not Severe Not Severe Not Severe Severe Severe Severe Deceased Deceased 
1116 Not Severe Not Severe Severe Severe Severe Severe Not Possible Not Possible 
1119 Severe Deceased Deceased Deceased Deceased Deceased Deceased Deceased 
1124 Severe Missed Missed Missed Deceased Deceased Deceased Deceased 
1130 Severe Missed Missed Not Possible Deceased Deceased Deceased Deceased 
1132 Severe Severe Severe Missed Missed Missed Not Possible Not Possible 
1142 Not Severe Severe Severe Not Severe Severe Severe Deceased Deceased 
1151 Severe Severe Severe Severe Severe Severe Not Possible Not Possible 
1157 Severe Not Severe Missed Severe Missed Not Possible Deceased Deceased 
1166 Severe Missed Deceased Deceased Deceased Deceased Deceased Deceased 
1167 Severe Severe Deceased Deceased Deceased Deceased Deceased Deceased 
1174 Severe Missed Missed Deceased Deceased Deceased Deceased Deceased 
1182 Severe Severe Deceased Deceased Deceased Deceased Deceased Deceased 
1198 Severe Severe Severe Severe Deceased Deceased Deceased Deceased 
1205 Severe Severe Deceased Deceased Deceased Deceased Deceased Deceased 
1216 Severe Missed Severe Severe Missed Not Possible Not Possible Not Possible 
1225 Not Severe Not Severe Not Severe Severe Deceased Deceased Deceased Deceased 
1233 Severe Severe Missed Missed Not Possible Not Possible Not Possible Not Possible 
1234 Severe Severe Severe Deceased Deceased Deceased Deceased Deceased 
1235 Severe Not Severe Not Severe Severe Deceased Deceased Deceased Deceased 
1249 Severe Severe Severe Severe Not Possible Not Possible Not Possible Not Possible 
1252 Severe Severe Severe Severe Not Possible Not Possible Not Possible Not Possible 
1256 Severe Severe Severe Severe Not Possible Not Possible Not Possible Not Possible 
1258 Not Severe Severe Severe Severe Not Possible Not Possible Not Possible Not Possible 
1261 Severe Severe Severe Severe Deceased Deceased Deceased Deceased 
1266 Severe Deceased Deceased Deceased Deceased Deceased Deceased Deceased 
1269 Severe Severe Severe Not Possible Not Possible Not Possible Not Possible Not Possible 
1271 Severe Missed Severe Deceased Deceased Deceased Deceased Deceased 
1278 Not Severe Severe Severe Deceased Deceased Deceased Deceased Deceased 
1281 Severe Severe Severe Not Possible Not Possible Not Possible Not Possible Not Possible 
1283 Not Severe Severe Severe Deceased Deceased Deceased Deceased Deceased 
1285 Severe Deceased Deceased Deceased Deceased Deceased Deceased Deceased 
1290 Severe Severe Severe Not Possible Not Possible Not Possible Not Possible Not Possible 
1295 Severe Deceased Deceased Deceased Deceased Deceased Deceased Deceased 
1298 Severe Deceased Deceased Deceased Deceased Deceased Deceased Deceased 
1301 Not Severe Severe Severe Not Possible Not Possible Not Possible Not Possible Not Possible 
1304 Severe Severe Severe Not Possible Not Possible Not Possible Not Possible Not Possible 
1305 Severe Deceased Deceased Deceased Deceased Deceased Deceased Deceased 
1306 Severe Deceased Deceased Deceased Deceased Deceased Deceased Deceased 
1315 Severe Deceased Deceased Deceased Deceased Deceased Deceased Deceased 
1319 Severe Severe Not Possible Not Possible Not Possible Not Possible Not Possible Not Possible 
1051 Severe Missed Missed Missed Missed Deceased Deceased Deceased 
1135 Not Severe Severe Missed Missed Missed Missed Deceased Deceased 
 
Figure 6-3 Patient journey- patients with PC needs 
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STUDY VISIT 
Patient Baseline 4 Month 8 Month 12 Month 16 Month 20 Month 24 month 30 Month 
1005 Severe Severe Not Severe Deceased Deceased Deceased Deceased Deceased 
1007 Not Severe Not Severe Severe Severe Not Severe Not Severe Not Severe Not Severe 
1039 Severe Severe Missed Severe Severe Severe Not Severe Not Possible 
1074 Severe Severe Severe Not Severe Not Severe Not Severe Not Severe Not Possible 
1079 Severe Not Severe Not Severe Not Severe Severe Severe Not Severe Deceased 
1095 Severe Missed Severe Severe Severe Not Severe Not Possible Not Possible 
1100 Not Severe Not Severe Severe Severe Not Severe Not Severe Not Possible Not Possible 
1115 Severe Severe Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible 
1149 Not Severe Severe Not Severe Severe Severe Not Severe Not Possible Not Possible 
1171 Severe Missed Severe Severe Not Severe Deceased Deceased Deceased 
1189 Severe Severe Severe Not Severe Not Severe Not Possible Not Possible Not Possible 
1222 Severe Severe Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible 
1001 Not Severe Not Severe Not Severe Deceased Deceased Deceased Deceased Deceased 
1002 Not Severe Severe Missed Not Severe Not Severe Not Severe Not Severe Missed 
1006 Not Severe Not Severe Deceased Deceased Deceased Deceased Deceased Deceased 
1009 Not Severe Not Severe Not Severe Not Severe Missed Missed Missed Missed 
1010 Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe 
1012 Not Severe Not Severe Not Severe Not Severe Not Severe Deceased Deceased Deceased 
1015 Severe Not Severe Missed Not Severe Missed Severe Not Severe Not Severe 
1018 Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe 
1020 Severe Not Severe Not Severe Not Severe Deceased Deceased Deceased Deceased 
1021 Not Severe Missed Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe 
1022 Not Severe Not Severe Missed Not Severe Missed Missed Missed Missed 
1023 Not Severe Not Severe Not Severe Not Severe Deceased Deceased Deceased Deceased 
1024 Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe 
1025 Not Severe Missed Deceased Deceased Deceased Deceased Deceased Deceased 
1027 Not Severe Missed Missed Missed Missed Missed Missed Missed 
1029 Not Severe Not Severe Deceased Deceased Deceased Deceased Deceased Deceased 
1033 Not Severe Not Severe Not Severe Not Severe Missed Not Severe Not Severe Not Possible 
1034 Not Severe Missed Deceased Deceased Deceased Deceased Deceased Deceased 
1035 Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Possible 
1037 Not Severe Missed Missed Missed Deceased Deceased Deceased Deceased 
1040 Severe Missed Missed Missed Missed Missed Missed Not Possible 
1041 Not Severe Not Severe Severe Not Severe Not Severe Not Severe Not Severe Not Possible 
1042 Severe Missed Missed Missed Missed Missed Missed Not Possible 
1045 Not Severe Not Severe Missed Not Severe Not Severe Severe Not Severe Not Possible 
1046 Not Severe Missed Missed Missed Missed Missed Missed Not Possible 
1048 Severe Missed Missed Missed Missed Missed Missed Not Possible 
1049 Not Severe Withdrawn Deceased Deceased Deceased Deceased Deceased Deceased 
1050 Not Severe Not Severe Not Severe Missed Deceased Deceased Deceased Deceased 
1053 Not Severe Not Severe Not Severe Not Severe Deceased Deceased Deceased Deceased 
1054 Severe Missed Missed Not Severe Not Severe Not Severe Not Severe Not Possible 
1055 Not Severe Missed Missed Deceased Deceased Deceased Deceased Deceased 
1056 Not Severe Missed Missed Missed Missed Missed Missed Deceased 
1057 Severe Missed Missed Missed Missed Missed Missed Not Possible 
1058 Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Possible 
1059 Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Possible 
1060 Severe Not Severe Missed Missed Missed Missed Missed Not Possible 
1061 Not Severe Withdrawn Deceased Deceased Deceased Deceased Deceased Deceased 
1063 Not Severe Withdrawn Deceased Deceased Deceased Deceased Deceased Deceased 
1064 Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Possible 
1065 Severe Missed Missed Missed Missed Missed Missed Not Possible 
1068 Severe Not Severe Not Severe Not Severe Not Severe Not Severe Missed Missed 
1070 Severe Not Severe Not Severe Severe Not Severe Not Severe Severe Not Possible 
1072 Not Severe Not Severe Not Severe Not Severe Not Severe Severe Not Severe Not Possible 
1073 Severe Missed Not Severe Not Severe Not Severe Not Severe Missed Not Possible 
1075 Not Severe Not Severe Missed Missed Missed Missed Missed Missed 
1076 Severe Not Severe Not Severe Not Severe Severe Not Severe Not Severe Not Possible 
1080 Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Possible 
1084 Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Possible 
1086 Not Severe Deceased Deceased Deceased Deceased Deceased Deceased Deceased 
1087 Severe Not Severe Severe Not Severe Not Severe Deceased Deceased Deceased 
1088 Not Severe Missed Missed Missed Missed Missed Missed Not Possible 
1089 Not Severe Not Severe Deceased Deceased Deceased Deceased Deceased Deceased 
1090 Not Severe Missed Missed Deceased Deceased Deceased Deceased Deceased 
Figure 6-4 Patient journey- patients without PC needs A 
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STUDY VISIT 
Patient Baseline 4 Month 8 Month 12 Month 16 Month 20 Month 24 month 30 Month 
1093 Severe Not Severe Not Severe Not Severe Not Severe Severe Missed Not Possible 
1097 Not Severe Not Severe Severe Not Severe Not Severe Not Severe Not Possible Not Possible 
1099 Severe Missed Missed Missed Missed Missed Not Possible Not Possible 
1101 Not Severe Not Severe Missed Not Severe Not Severe Not Severe Not Possible Not Possible 
1102 Not Severe Severe Not Severe Missed Missed Missed Not Possible Not Possible 
1103 Severe Missed Missed Missed Missed Missed Not Possible Not Possible 
1104 Not Severe Not Severe Missed Not Severe Not Severe Missed Not Possible Not Possible 
1106 Not Severe Missed Missed Missed Missed Missed Not Possible Deceased 
1107 Not Severe Not Severe Severe Not Severe Not Severe Not Severe Not Possible Not Possible 
1108 Not Severe Deceased Deceased Deceased Deceased Deceased Deceased Deceased 
1109 Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible 
1111 Not Severe Not Severe Missed Missed Not Severe Not Severe Not Possible Not Possible 
1113 Not Severe Missed Deceased Deceased Deceased Deceased Deceased Deceased 
1114 Not Severe Missed Not Severe Severe Not Severe Not Severe Deceased Deceased 
1118 Not Severe Missed Missed Missed Missed Missed Not Possible Not Possible 
1120 Not Severe Missed Missed Missed Deceased Deceased Deceased Deceased 
1121 Not Severe Missed Missed Missed Missed Missed Not Possible Not Possible 
1122 Severe Missed Severe Missed Missed Missed Not Possible Not Possible 
1123 Not Severe Deceased Deceased Deceased Deceased Deceased Deceased Deceased 
1125 Not Severe Not Severe Not Severe Missed Missed Missed Not Possible Not Possible 
1126 Severe Not Severe  Missed Severe Not Severe Severe Not Possible Not Possible 
1127 Not Severe Missed Missed Missed Missed Missed Not Possible Not Possible 
1129 Severe Not Severe Deceased Deceased Deceased Deceased Deceased Deceased 
1131 Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible 
1133 Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible 
1134 Severe Not Severe Deceased Deceased Deceased Deceased Deceased Deceased 
1136 Not Severe Not Severe Not Severe Not Severe Missed Missed Missed Missed 
1137 Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible 
1138 Not Severe Not Severe Deceased Deceased Deceased Deceased Deceased Deceased 
1139 Not Severe Deceased Deceased Deceased Deceased Deceased Deceased Deceased 
1140 Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible 
1141 Not Severe Deceased Deceased Deceased Deceased Deceased Deceased Deceased 
1143 Not Severe Deceased Deceased Deceased Deceased Deceased Deceased Deceased 
1144 Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible 
1145 Not Severe Not Severe Not Severe Not Severe Not Severe Missed Not Possible Not Possible 
1146 Not Severe Missed Not Severe Not Severe Not Severe Severe Not Possible Not Possible 
1147 Not Severe Not Severe Missed Missed Missed Missed Not Possible Not Possible 
1152 Not Severe Not Severe Not Severe Not Severe Deceased Deceased Deceased Deceased 
1154 Not Severe Deceased Deceased Deceased Deceased Deceased Deceased Deceased 
1155 Not Severe Not Severe Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible 
1156 Not Severe Not Severe Not Severe Not Severe Not Severe Missed Not Possible Not Possible 
1158 Not Severe Not Severe Not Severe Not Severe Missed Not Possible Not Possible Not Possible 
1160 Not Severe Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible 
1161 Not Severe Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible 
1162 Severe Not Severe Missed Not Severe Not Severe Not Possible Not Possible Not Possible 
1163 Severe Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible 
1164 Not Severe Missed Missed Missed Missed Deceased Deceased Deceased 
1165 Severe Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible 
1168 Not Severe Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible 
1169 Severe Missed Missed Missed Missed Not Possible Not Possible Not Possible 
1172 Not Severe Not Severe Missed Not Severe Not Severe Not Possible Not Possible Not Possible 
1173 Not Severe Not Severe Missed Not Severe Not Severe Deceased Deceased Deceased 
1175 Not Severe Not Severe Deceased Deceased Deceased Deceased Deceased Deceased 
1176 Not Severe Not Severe Severe Not Severe Not Severe Not Possible Not Possible Not Possible 
1178 Not Severe Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible 
1179 Not Severe Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible 
1180 Not Severe Not Severe Not Severe Not Severe Missed Not Possible Not Possible Not Possible 
1181 Severe Missed Missed Missed Missed Missed Missed Missed 
1183 Not Severe Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible 
1184 Not Severe Severe Not Severe Not Severe Not Severe Deceased Deceased Deceased 
1185 Not Severe Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible 
1187 Severe Not Severe Severe Not Severe Not Severe Not Possible Not Possible Not Possible 
1188 Severe Not Severe Severe Not Severe Not Severe Not Possible Not Possible Not Possible 
1190 Severe Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible 
1191 Not Severe Not Severe Not Severe Not Severe Severe Not Possible Not Possible Not Possible 
Figure 6-5 Patient journey- patients without PC needs B 
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 STUDY VISIT 
Patient Baseline 4 Month 8 Month 12 Month 16 Month 20 Month 24 month 30 Month 
1192 Not Severe Not Severe Not Severe Severe Not Severe Not Possible Not Possible Not Possible 
1194 Not Severe Not Severe Not Severe Not Severe Severe Not Possible Not Possible Not Possible 
1195 Not Severe Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible 
1196 Not Severe Missed Missed Missed Missed Not Possible Not Possible Not Possible 
1197 Not Severe Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible 
1200 Not Severe Not Severe Severe Not Severe Severe Not Possible Not Possible Not Possible 
1201 Not Severe Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible 
1202 Severe Not Severe Not Severe Not Severe Severe Not Possible Not Possible Not Possible 
1203 Not Severe Not Severe Missed Deceased Deceased Deceased Deceased Deceased 
1206 Not Severe Deceased Deceased Deceased Deceased Deceased Deceased Deceased 
1207 Severe Not Severe Not Severe Deceased Deceased Deceased Deceased Deceased 
1208 Severe Not Severe Not Severe Not Severe Not Severe Deceased Deceased Deceased 
1209 Severe Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible 
1212 Severe Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible 
1218 Not Severe Missed Missed Missed Missed Not Possible Not Possible Not Possible 
1219 Not Severe Missed Missed Missed Not Possible Not Possible Not Possible Not Possible 
1220 Not Severe Missed Missed Missed Not Possible Not Possible Not Possible Not Possible 
1221 Not Severe Deceased Deceased Deceased Deceased Deceased Deceased Deceased 
1223 Not Severe Missed Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible 
1224 Not Severe Missed Missed Missed Not Possible Not Possible Not Possible Not Possible 
1227 Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible 
1228 Not Severe Not Severe Not Severe Deceased Deceased Deceased Deceased Deceased 
1229 Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible 
1230 Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible 
1236 Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible 
1237 Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible 
1238 Not Severe Not Severe Not Severe Severe Not Possible Not Possible Not Possible Not Possible 
1239 Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible 
1240 Not Severe Not Severe Missed Missed Not Possible Not Possible Not Possible Not Possible 
1242 Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible 
1243 Not Severe Missed Missed Missed Not Possible Not Possible Not Possible Not Possible 
1245 Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible 
1246 Not Severe Severe Not Severe Severe Not Possible Not Possible Not Possible Not Possible 
1250 Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible 
1251 Not Severe Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible 
1254 Not Severe Missed Missed Missed Not Possible Not Possible Not Possible Not Possible 
1255 Severe Not Severe Missed Severe Not Possible Not Possible Not Possible Not Possible 
1257 Not Severe Missed Missed Missed Not Possible Not Possible Not Possible Not Possible 
1262 Severe Not Severe Missed Missed Not Possible Not Possible Not Possible Not Possible 
1263 Not Severe Missed Deceased Deceased Deceased Deceased Deceased Deceased 
1265 Not Severe Not Severe Not Severe Not Possible Deceased Deceased Deceased Deceased 
1267 Not Severe Not Severe Severe Not Possible Not Possible Not Possible Not Possible Not Possible 
1268 Severe Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible Not Possible 
1272 Not Severe Not Severe Severe Not Possible Not Possible Not Possible Not Possible Not Possible 
1273 Severe Missed Missed Not Possible Not Possible Not Possible Not Possible Not Possible 
1277 Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible Not Possible 
1279 Not Severe Missed Missed Not Possible Not Possible Not Possible Not Possible Not Possible 
1280 Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible Not Possible 
1282 Severe Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible Not Possible 
1286 Severe Not Severe Deceased Deceased Deceased Deceased Deceased Deceased 
1287 Not Severe Not Severe Severe Not Possible Not Possible Not Possible Not Possible Not Possible 
1288 Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible Not Possible 
1291 Not Severe Not Severe Not Severe Deceased Deceased Deceased Deceased Deceased 
1292 Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible Not Possible 
1293 Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible Not Possible 
1294 Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible Not Possible 
1299 Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible Not Possible 
1302 Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible Not Possible 
1303 Severe Missed Missed Not Possible Not Possible Not Possible Not Possible Not Possible 
1307 Not Severe Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible Not Possible 
1308 Severe Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible Not Possible 
1310 Not Severe Missed Missed Deceased Deceased Deceased Deceased Deceased 
1313 Not Severe Not Severe Not Possible Not Possible Not Possible Not Possible Not Possible Not Possible 
1316 Not Severe Missed Not Possible Not Possible Not Possible Not Possible Not Possible Not Possible 
1317 Not Severe Missed Not Possible Not Possible Not Possible Not Possible Not Possible Not Possible 
1321 Not Severe Missed Deceased Deceased Deceased Deceased Deceased Deceased 
1322 Not Severe Deceased Deceased Deceased Deceased Deceased Deceased Deceased 
 
 
Figure 6-6 Patient journey- patients without PC needs C 
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6.4.1 Days alive and out of hospital 
As there is no universally accepted tool to determine if a patient with heart 
failure has PC needs, a sensitivity analysis is required to determine if the criteria 
I have used to define PC needs are appropriate.  Examination of the patient 
journey as determined by the amount of time lost per patient to hospitalisation 
or death is an appropriate measure.  The DAOH should be lower in the patients 
deemed to have PC needs. 
The DAOH per PC needs group are described in Table 6-2.  Patients classified as 
having PC needs spend much fewer days alive and out of hospital during the 
study.  The median DAOH for the entire follow-up period was 394 [172-586] days 
in the PC needs group and 638 [420-809] days in the not PC needs group 
(p<0.001).  As every participant had at least one year of passive follow-up, a 
more useful comparison is DAOH at one year from recruitment date.  The median 
DAOH at one year was 282 [159-333] in the PC needs group, compared to 346 
[296-357] in the not PC needs group (p<0.001).  Perhaps the most striking 
difference between the two groups was in the proportion of total follow-up 
spent alive and out of hospital.  The median proportion DAOH for the PC needs 
group was only 0.59 [0.23-0.93], compared to 0.97 [0.75-0.99] in the not PC 
needs group (p<0.001).   
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Table 6-2 Days alive out of hospital 
 All 
Participants 
PC Needs Not PC Needs p 
 n=272 n=73 n=199  
DAOH 
DAOH total follow-up, 
days 
581 [345-783] 394 [172-586] 638 [420-809] <0.001 
DAOH 1 year, days 333 [256- 355] 282 [159- 333] 346 [296, 357] <0.001 
DAOH proportion of 
potential follow-up, % 
94 [49- 98] 59 [23- 93] 97 [75- 99] <0.001 
QOL adjusted DAOH 
QOL adjusted DAOH, 
days 
230 [93- 425] 77 [24- 138] 312 [172- 492] <0.001 
QOL adjusted DAOH 
percentage of follow-
up, % 
31 [13- 58] 12 [3- 22] 47 [25- 68] <0.001 
Symptom adjusted DAOH 
Symptom adjusted 
DAOH, days 
360 [169- 545] 190 [73- 270] 439 [278- 585] <0.001 
Symptom adjusted 
DAOH percentage of 
follow-up, % 
51 [23- 74] 23 [10- 42] 63 [41- 79] <0.001 
DAOH= days alive out of hospital; QOL= quality of life. 
 
Another important sensitivity analysis is adjusting each day alive out of hospital 
for QOL, as described in Chapter 3.  The QOL adjusted DAOH results are shown in 
Table 6-2, Figure 6-7, and Figure 6-8.  The median number of overall good days, 
or QOL adjusted DAOH for the whole cohort was 230 [93-425] for the duration of 
follow-up.  There were much fewer QOL adjusted DAOH in the PC needs versus 
Not PC needs group, with median QOL adjusted DAOH of 77[24-138] and 312 
[172-492] (p< 0.001), respectively.   As follow-up duration varied for each 
participant, a more useful metric is to calculate the proportion of potential 
follow-up which was spent with good QOL, as described in Chapter 3 and 
expressed as a percentage.  The median proportion QOL adjusted DAOH for the 
whole cohort was 31 % [13-58].  There was a significant difference in the 
proportion of QOL adjusted DAOH compared to potential follow-up between the 
groups of PC need, with patients in the PC needs group spending 12 [3-22] % of 
follow-up with good days out of hospital, compared to 47 [25-68] % in the not PC 
needs group. 
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Figure 6-7 QOL adjusted DAOH- histogram 
 
 
Figure 6-8 QOL adjusted DAOH box plot 
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Another important sensitivity analysis is to adjust each DAOH for symptom 
burden, as described in Chapter 3.  The results of the symptom adjusted DAOH 
are shown in Table 6-2, Figure 6-9, and Figure 6-10.  The median number of 
overall good days, after adjusting DAOH for symptom burden, for the whole 
cohort was 360 [169-545] for the duration of follow-up.  There were much fewer 
symptom adjusted DAOH in the PC needs versus not PC needs group, with 
median symptom adjusted DAOH of 190 [73-270] and 439 [278-585] (p< 0.001), 
respectively.   The median proportion symptom adjusted DAOH for the whole 
cohort was 51 % [23-74].  There was a significant difference in the proportion of 
symptom adjusted DAOH compared to potential follow-up between the groups of 
PC need, with patients in the PC needs group spending  23 [10-42] % of follow-up 
with good days out of hospital, compared to 63 [41-79] % in the not PC needs 
group. 
The striking, and statistically significant, differences in DAOH, QOL and symptom 
adjusted DAOH between the two groups of PC need would suggest that the 
criteria used are appropriate.   
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Figure 6-9 Symptom adjusted DAOH histogram per PC needs group 
 
 
Figure 6-10 Symptom adjusted DAOH box plot per PC needs group 
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6.5 Baseline demographics clinical features per PC needs group 
A description of the baseline demographics and physical examination findings 
per PC needs group is provided in Table 6-3.   Participants in the PC needs group 
were younger than those in not-PC needs group, with median ages of 73.6 [66.6-
80.5] and 76.6 [70.6-83.0], respectively, although this difference did not reach 
statistical significance.  There was a lower proportion of female participants in 
the probable PC needs group compared to the unlikely PC needs group, with 37.0 
and 50.8% (p= 0.0438), respectively.  Both systolic and diastolic blood pressure 
were lower overall in the probable PC needs group.  Other physiological 
measures were similar between the two groups.   
Symptoms of heart failure were similar between the two groups.  Orthopnoea 
was reported by participants in 82.2 and 72.4% of participants in both the 
probable and unlikely PC needs groups, respectively.  Paroxysmal nocturnal 
dyspnoea was reported in 79.5 and 68.3% participants in both the probable and 
unlikely PC needs groups, respectively.  Ankle swelling was a more commonly 
reported symptom in participants in the probable compared to unlikely PC needs 
group, at 84.9 and 73.4% (p= 0.0463), respectively.  A similar proportion of ankle 
swelling was found on physical examination findings, with 86.3 and 72.6 % (p= 
0.0186) of probable and unlikely PC needs, respectively.  There was a significant 
difference between the two groups in proportion of participants in each NYHA 
class with a higher proportion in NYHA class III/IV in the probable compared to 
unlikely PC needs group.  28.8 compared to 14.1% of the probable compared to 
unlikely PC needs groups were NYHA class IV, respectively.     
Physical examination findings were similar between the two groups, with similar 
proportions of elevated jugular venous pressure, third heart sound, murmur, 
pulmonary crackles, and clinical pleural effusions.   
 155 
 
Table 6-3 Baseline demographics per PC needs group 
 All participants PC needs Not PC needs p  
 n = 272 n =73 n = 199  
Age- yr 76.0 [69.8, 82.4]  73.6 [66.6, 80.5] 76.6 [70.6, 83.0] 0.0628 
Female sex- n (%) 128 (47.1)  27 (37.0) 101 (50.8) 0.0438 
Race or ethnic group- n (%)    0.6667 
White 266 (97.8)  71 (97.3) 195 (98.0)   
Black 1     (0.4)  0   (0.0) 1     (0.5)   
Asian 5     (1.8)  2   (2.7) 3     (1.5)   
Other 0     (0.0)  0   (0.0)  0     (0.0)  
     
Systolic blood pressure- 
mmHg 
134 [118, 155]  127 [112, 152] 136 [120, 158] 0.0214 
Diastolic blood pressure- 
mmHg 
75 [64, 90]  72 [60, 82] 78.0 [65, 92] 0.027 
Heart rate- beats/min 82 [68, 102]  81 [71, 100] 82 [68, 103] 0.9054 
Body-mass index- kg/m 27.0 [23.5, 31.6]  28.1 [23.6, 31.6] 26.2 [23.5, 31.6] 0.3237 
     
Symptoms- n (%)     
NYHA class    0.0194 
Class I 0 (0.0)  0 (0.0)  0     (0.0)   
Class II 82 (30.1)  20     (27.4) 62   (31.2)   
Class III 141 (51.8)  32     (43.8) 109 (54.8)   
Class IV 49 (18.0)  21     (28.8) 28   (14.1)   
HF symptoms     
Orthopnoea  204 (75.0)  60     (82.2) 144 (72.4) 0.0971 
PND  194 (71.3)  58     (79.5) 136 (68.3) 0.0726 
Ankle swelling  208 (76.5)  62     (84.9) 146 (73.4) 0.0463 
Wheeze  62 (22.8)  14     (19.2) 48   (24.1) 0.3892 
Palpitations  10 (3.7)  2      (2.7) 8     (4.0) 0.619 
     
Signs- n (%)     
Elevated JVP (> 4cm)  176 (73.0)  50     (75.8) 126  (72.0) 0.5578 
Third Heart Sound  59   (21.8)  17     (23.3) 42    (21.2) 0.7134 
Murmur  149 (55.0)  43     (58.9) 106  (53.5) 0.4306 
Pulmonary crackles  212 (78.5)  53     (72.6) 159  (80.7) 0.1496 
Basal§  210 (99.1)  53     (100) 157  (98.7) 0.412 
Middle§ 45   (21.2)  15     (28.3) 30    (18.9) 0.1458 
Apex§ 9     (4.2)  3       (5.7) 6      (3.8) 0.5552 
Pleural effusion  95   (35.3)  26     (35.6) 69    (35.2) 0.9498 
Right  59   (62.1)  16     (61.5) 43    (62.3) 0.9443 
Left  59   (62.1)  15     (57.7) 44    (63.8) 0.5863 
Peripheral Oedema  206 (76.3)  63     (86.3) 143  (72.6) 0.0186 
Ankle*  206 (100.0)  63     (100) 143  (100) NA  
Knee*  125 (60.7)  40     (63.5) 85    (59.4) 0.5833 
Thigh*  64   (31.1)  21     (33.3) 43    (30.1) 0.641 
Sacrum*  43   (20.9)  13     (20.6) 30    (21.0) 0.9553 
Abdomen*  35   (17.0)  12     (19.0) 23    (16.1) 0.6018 
Ascites  40   (14.8)  14     (19.2) 26    (13.1) 0.2131 
Values are expressed as median [ interquartile range] 
HF= heart failure; JVP= jugular venous pressure; NYHA = New York Heart Association; PND= paroxysmal 
nocturnal dyspnoea. 
§ percentage of patients with pulmonary crackles 
* percentage of patients with peripheral oedema 
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6.5.1 Past medical history 
The past medical history of participants with probable PC needs compared to 
those with unlikely PC needs is shown in Table 6-4.  There was a higher 
proportion, although not statistically significant, of participants with a prior 
diagnosis of heart failure in the probable compare to unlikely PC needs group, at 
52.1 and 41.2%, respectively.  Prior hospitalisation for heart failure was more 
common in the probable compare to the unlikely PC needs group, although this 
was not statistically significant.  However, participants in the probable PC needs 
group had a higher prevalence of heart failure hospitalisation in the preceding 6 
months compared to those in the unlikely PC needs group, at 13.7 and 6.0% 
respectively (p=0.04). 
Cardiovascular co-morbidities were common, as reported earlier, with similar 
proportions of atrial fibrillation, hypercholesterolemia, hypertension, peripheral 
arterial disease, and cerebrovascular disease.  41 (56%) participants in the PC 
needs groups had suffered a previous myocardial infarction, compared to 70 
(35.2%) in the unlikely PC needs group (p 0.0018).  Cardiac resynchronisation 
therapy was rare in both groups, and overall, as were ICDs.   Only 8 participants 
had a cardiac resynchronisation therapy device, and only 4 had an ICD.  There 
were no statistically significant differences between the two groups in terms of 
device therapy.  The low proportion of ICDs and cardiac resynchronisation 
therapy is notable.   Many patients in the cohort will not have met the criteria 
for such devices, based upon QRS duration and ejection fraction.  For some 
other patients, the index study visit was their first presentation with heart 
failure, and cardiac resynchronisation is only indicated after optimisation of 
therapy.  
Non-cardiovascular co-morbidities were also common, although not as common 
as cardiovascular co-morbidities.  Most non-cardiovascular co-morbidities had a 
similar prevalence between the two groups of PC need including COPD, asthma, 
depression, cancer, hypothyroidism, osteoarthritis, and anaemia.  Previously 
diagnosed diabetes mellitus was more common in the probable versus unlikely 
PC needs group, at 42.5 and 29.1% (p 0.038), respectively.   
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Table 6-4 Past medical history per PCneeds group 
 All participants PC needs Not PC needs p  
 n = 272 n =73 n = 199  
History of HF- n (%)     
HF diagnosis prior to 
admission 
120 (44.1)  38    (52.1) 82   (41.2) 0.1103 
HF hospitalisation 73 (26.8)  27    (71.1) 46   (56.1) 0.1185 
HF hospitalisation 
preceding 6 months 
22 (8.1)  10    (13.7) 12   (6.0) 0.0398 
     
Cardiovascular- n (%)     
Treated Hypertension  184 (67.6)  51    (69.9) 133 (66.8) 0.6361 
Myocardial Infarction  111 (40.8)  41    (56.2) 70   (35.2) 0.0018 
PCI  38   (14.0)  15    (20.5) 23   (11.6) 0.0581 
CABG  42   (15.4)  13    (17.8) 29   (14.6) 0.5129 
Hypercholesterolaemia  88   (32.4)  26    (35.6) 62   (31.2) 0.4859 
Atrial Fibrillation/Flutter  144 (52.9)  41    (56.2) 103 (51.8) 0.5189 
Cerebrovascular disease 
(CVA/TIA)  
52   (19.1)  11    (15.1) 41   (20.6) 0.3037 
Peripheral Arterial Disease  37   (13.6)  10    (13.7) 27   (13.6) 0.9778 
Primary prevention ICD  4     (1.5)  2      (2.7) 2     (1.0) 0.2949 
Pacemaker  18   (6.6) 5      (6.8) 13   (6.5) 0.9258 
Conventional§  10   (55.6)  4      (80.0) 6     (46.2) 0.1955 
CRT-P§  3    (16.7)  0      (0.0) 3     (23.1) 0.2393 
CRT-D§  5    (27.8)  1      (20.0) 4     (30.8) 0.6477 
Valve replacement  11  (4.0)  2      (2.7) 9     (4.5) 0.5083 
     
Non-cardiovascular-n 
(%) 
    
Diabetes Mellitus  89  (32.7)  31     (42.5) 58   (29.1) 0.038 
COPD  69  (25.4)  22     (30.1) 47   (23.6) 0.2736 
Asthma  23  (8.5)  6      (8.2) 17   (8.5) 0.9323 
Depression  37  (13.7)  13     (17.8) 24   (12.2) 0.2325 
Cancer  31  (11.4)  7      (9.6) 24   (12.1) 0.5698 
Hypothyroidism  35  (12.9)  9      (12.3) 26   (13.1) 0.8723 
Osteoarthritis  27  (9.9)  6      (8.2) 21   (10.6) 0.5684 
Anaemia  77  (28.3)  23     (31.5) 54   (27.1) 0.4783 
CABG= coronary artery bypass graft; COPD= chronic obstructive pulmonary disease; CRT-P= cardiac 
resynchronisation therapy- pace; CRT-D= cardiac resynchronisation therapy- defibrillator; CVA= cerebrovascular 
accident; HF= heart failure; ICD= implantable cardioverter defibrillator; PCI= percutaneous coronary intervention; 
TIA= transient ischaemic attack. 
§ percentage of patients with pacemaker 
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6.5.2 Drug history- medications started prior to admission 
The medications participants were taking prior to admission and those started 
during admission and on discharge are detailed in Table 6-5 and Table 6-6.  
Medications prior to the index admission were similar between the two groups of 
PC need.  There were similar proportions of disease modifying therapies such as 
beta-blockers or RAAS blockers.  Hydralazine, nitrates, and ivabradine were 
rarely prescribed prior to admission in both groups.  The only statistically 
significant difference in drug prescription prior to admission was the PC needs 
group had a higher proportion prescribed aspirin compared to the group without 
PC needs, 54.8 and 36.2%, respectively.  This is in keeping with the previous 
finding of a higher proportion of previous myocardial infarction in the PC needs 
group, as detailed in Table 6-4.  Similarly, there was a higher proportion of 
prescriptions for the anti-platelet drug, clopidogrel, in the PC needs group, 
although this did not reach statistical significance.  The proportions of non-
cardiovascular drugs were similar between the two PC needs groups.   
The mainstay of pharmacological treatment in hospital for the treatment of 
symptoms was furosemide, with most participants receiving either a one off or 
regular intravenous furosemide followed by oral.  There were no differences 
between the two PC needs groups regarding treatment with furosemide.  Other 
medications used in the treatment of acute decompensated heart failure include 
vasodilators, such as intravenous nitrates, and inotropic agents, such as 
dobutamine and dopamine.  The number and proportion of participants who 
were treated with these medications was very low, with 6 (2.2%) treated with 
intravenous nitrates, 4 (1.5%) with dobutamine, and 9 (3.3%) with dopamine.  
There were no differences between the two PC needs groups other than a higher 
proportion of participants in the PC needs group were treated with dopamine (p 
0.002).   
 159 
 
Table 6-5 Pharmacological therapy on admission- per PC needs group 
 All participants PC needs Not PC needs p  
 n = 272 n =73 n = 199  
Cardiovascular      
ACEI  108 (39.7)  29 (39.7)  79   (39.7)  1.000  
ARB  40   (14.7)  10 (13.7)  30   (15.1)  0.849   
Beta-blocker  152 (55.9)  42 (57.5)  110 (55.3)  0.784  
MRA  23   (8.5)  8   (11.0)  15   (7.5)  0.460  
Hydralazine  8     (2.9)  4   (5.5)  4     (2.0)  0.217  
Ivabradine  1     (0.4)  1   (1.4)  0     (0.0)  0.268   
Anti-arrhythmic  4     (1.5)  2   (2.7)  2     (1.0)  0.292  
Calcium channel-blocker  68   (25.0)  14 (19.2)  54   (27.1)  0.208  
Long-acting nitrates  33   (12.1)  11 (15.1)  22   (11.1)  0.403  
Statin  171 (62.9)  52 (71.2)  119 (59.8)  0.091  
Diabetic medication  70   (25.7)  22 (30.1)  48   (24.1)  0.349  
Insulin§ 27   (38.6)  6   (27.3)  21   (43.8)  0.290  
Sulphonylurea§  33   (47.1)  12 (54.5)  21   (43.8)  0.447  
Biguanide§ 41   (58.6)  14 (63.6)  27   (56.3)  0.610  
Glitazone§ 3     (4.3)  0   (0.0)  3     (6.3)  0.547  
Other§ 8     (11.4)  0   (0.0)  8     (16.7)  0.050  
Diuretics  172 (63.2)  53 (72.6)  119 (59.8)  0.065  
Digoxin  26   (9.6)  9   (12.3)  17   (8.5)  0.357  
Aspirin  112 (41.2)  40 (54.8)  72   (36.2)  0.008  
Clopidogrel  26   (9.6)  10 (13.7)  16   (8.0)  0.168  
Warfarin  78   (28.7)  22 (30.1)  56   (28.1)  0.764  
Nicorandil  25   (9.2)  9   (12.3)  16   (8.0)  0.343  
 
Non-cardiovascular 
    
Bronchodilator  86   (31.6)  29 (39.7)  57  (28.6)  0.105  
Steroid tablets*  9     (10.7)  2   (6.9)  7    (12.7)  0.488  
Beta-agonist 
inhalers*  
71   (86.6)  23 (82.1)  48  (88.9)  0.498 
Anti-cholinergic 
inhalers*  
45   (57.0)  17 (65.4)  28  (52.8)  0.340  
 
Steroid inhalers*  48   (60.8)  22 (78.6)  26  (51.0)  0.018  
Antidepressants  42   (15.4)  15 (20.5)  27  (13.6)  0.185  
SSRI±  17   (40.5)  8   (53.3)  9    (33.3)  0.326  
TCA±  19   (45.2)  6   (40.0)  13  (48.1)  0.750  
MAOI ± 3     (7.1)  1   (6.7)  2    (7.4)  1.000  
Other±  5     (11.9)  1   (6.7)  4    (14.8)  0.639  
NSAIDs  8     (2.9)  0   (0.0)  8    (4.0)  0.114  
Vitamins  28   (10.3)  9   (12.3)  19  (9.5)  0.504  
Antihistamines  11   (4.0)  5   (6.8)  6    (3.0)  0.172  
Values are expressed as n (%). 
ACE= angiotensin converting enzyme; ARB= angiotensin receptor blocker; MRA= mineralocorticoid receptor 
antagonist; MAOI= monoamine oxidase inhibitor; SSRI= selective serotonin reuptake inhibitor; TCA= tricyclic 
antidepressant. 
§ percentage of diabetic medication 
* percentage of bronchodilator medication 
± percentage of antidepressant medication 
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Prescription of disease modifying therapies was high on discharge from hospital, 
with 243 (89%) participants taking an ACEi or ARB.  192 (70.6%) participants were 
prescribed a beta-blocker on discharge, and 91 (33.5%) a mineralocorticoid 
receptor antagonist.  These medications are only indicated in patients with a 
reduced ejection fraction, 183 (67.3%) participants had an ejection fraction less 
than 50%. 
Table 6-6 Medications started during admission or on discharge- per PC needs group 
 All participants PC needs Not PC needs p  
 n = 272 n =73 n = 199  
Cardiovascular      
ACEI  152 (55.9)  39 (53.4)  113 (56.8)  0.680   
ARB  91 (33.5)  24 (32.9)  67 (33.7)  1.000  
Beta-blocker  192 (70.6)  48 (65.8)  144 (72.4)  0.297  
MRA  91 (33.5)  24 (32.9)  67 (33.7)  1.000  
Hydralazine  9 (3.3)  5 (6.8)  4 (2.0)  0.061  
Ivabradine  1     (0.4)  1   (1.4)  0     (0.0)  0.268   
Anti-arrhythmic  7 (2.6)  2 (2.7)  5 (2.5)  1.000 
Calcium channel-blocker  28 (10.3)  5 (6.8)  23 (11.6)  0.368  
Long-acting nitrates  30 (11.1)  11 (15.3)  19 (9.5)  0.193  
Statin  160 (59.0)  42 (58.3)  118 (59.3)  0.890 
Diuretics (exc. 
Furosemide)  
22 (8.1)  8 (11.0)  14 (7.0)  0.318  
Furosemide  265 (97.4)  70 (95.9)  195 (98.0)  0.390  
IV once-off  49 (18.0)  15 (20.5)  34 (17.1)  0.503  
IV regular  182 (66.9)  48 (65.8)  134 (67.3)  0.806  
Oral once-off  3 (1.1)  1 (1.4)  2 (1.0)  0.118  
Oral regular  242 (89.0)  60 (82.2)  182 (91.4)  0.031  
Digoxin  76 (27.9)  20 (27.4)  56 (28.1)  1.000  
Aspirin  96 (35.4)  30 (41.7)  66 (33.2)  0.200  
Clopidogrel  31 (11.4)  7 (9.7)  24 (12.1)  0.671  
Warfarin  106 (39.1)  23 (31.9)  83 (41.7)  0.161  
Nicorandil  18 (6.6)  4 (5.6)  14 (7.0)  0.788 
Inotropes / vasodilators      
IV Nitrate  6 (2.2)  2 (2.7)  4 (2.0)  0.661  
Dobutamine  4 (1.5)  2 (2.7)  2 (1.0)  0.292  
Dopamine  9 (3.3)  7 (9.6)  2 (1.0)  0.002  
IV other  6 (2.2)  1 (1.4)  5 (2.5)  1.000  
Values are expressed as n (%). 
ACE= angiotensin converting enzyme; ARB= angiotensin receptor blocker; MRA= mineralocorticoid receptor 
antagonist; IV= intravenous.  
 
 
  
 161 
 
6.5.3 Investigations 
 Electrocardiogram 
Details of the ECG findings on admission to hospital are represented in Table 6-7.  There 
were a number of abnormalities in both groups, the most common being the presence of 
atrial fibrillation on the admission ECG, with a prevalence of 51% in both the probable 
and unlikely PC needs groups, respectively.   A similar proportion of participants had a 
bundle branch block in both groups, at 32.9 and 28.6%, in the probable and unlikely PC 
needs groups, respectively.  Median QRS duration was higher in the probable PC needs 
group compared to the unlikely PC needs group at 106 [94-128] and 100 [86-130], 
although this did not reach statistical significance.  The only significant difference 
between the groups was a higher proportion of pathological Q waves being present in the 
probable PC needs versus unlikely PC needs group, at 35.6 and 20.2% (p= 0.0087), 
respectively.  This finding is in keeping with the higher prevalence of myocardial infarction 
seen in the probable PC needs group. 
Table 6-7 ECG findings per PC needs group 
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Chest X-ray 
Chest X-ray findings are detailed in Table 6-8.  There were similar frequencies of 
abnormalities commonly found in decompensated heart failure between the two 
groups of PC need.  These included cardiomegaly, upper lobe venous diversion, 
interstitial oedema, alveolar oedema and pleural effusions.  There was a higher 
proportion of participants in the unlikely PC group who had bilateral compared 
to unilateral pleural effusions, although the clinical significance of this is 
unclear.   
Table 6-8 Chest X-ray findings per PC needs group 
 All 
participants 
PC needs Not PC needs p  
 (n = 272) (n =73) (n = 199)  
CXR during admission - 
n(%) 
267 (98.2) 
71     (97.3) 196    (98.5) 0.5026 
Cardiomegaly (CTR > 0.5)  248 (92.9)  65     (91.5) 183    (93.4) 0.6097 
Upper lobe venous 
diversion  
245 (91.8)  64     (90.1) 181    (92.3) 0.5624 
Interstitial oedema 
(Kerley B lines)  
112 (41.9)  32     (45.1) 80      (40.8) 0.5337 
Alveolar oedema (patchy 
consolidation)  
104 (39.0)  24     (33.8) 80      (40.8) 0.2991 
Pleural effusions  140 (52.4)  33     (46.5) 107    (54.6) 0.2409 
Right§  31   (22.1)  7       (21.2) 24      (22.4)  0.0282 
Left§  16   (11.4)  8       (24.2) 8        (7.5)    
Bilateral§ 93   (66.4)  18     (54.5) 75      (70.1)   
CTR= cardiothoracic ratio; CXR= chest X-ray.  
§ percentage of patients with pleural effusions 
  
Laboratory results 
Laboratory results per PC needs group are detailed in Table 6-9.  Median BNP 
levels were higher in PC compared to no PC needs group, with 807 [471-1810] 
compared to 680 [417-1329] pg/ml, respectively, although this did not reach 
statistical significance (p=0.183).   A higher proportion (although not significant) 
of participants in the PC needs group compared to the no PC needs group had 
detectable troponin, with 65.9 and 48.4%, respectively.  Although median 
troponin levels were numerically higher in the PC needs group compared to the 
not PC needs group, at 0.06 [0.02-0.13] and 0.02 [0.02-0.11] µg/L, respectively, 
this difference was not statistically significant.  Measures of renal function 
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(urea, creatinine, eGFR) were similar between the two groups.  A numerically 
higher proportion of participants had renal impairment, as determined by eGFR 
less than 60 ml/min, in the PC needs group, with 63% compared to 57% in the 
not PC needs group, although this was not significant.  The only biochemical 
blood tests which were statistically significant between the two groups were 
potassium and bilirubin, although, as results for both groups were mostly within 
the normal limits, this likely represents a statically rather than clinically 
important difference. 
Haematology tests were similar between the two groups of PC need.  
Haemoglobin was similar in the group with PC needs compared to the not PC 
needs group, with median haemoglobin of 120 [109-136] and 123 [109-138] g/L, 
respectively.     
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Table 6-9 Laboratory results per PC needs group 
 All participants PC needs Not PC needs p  
 n = 272 n =73 n = 199  
Biochemistry      
BNP level (pg/ml) 724 [420, 1405]  807 [471, 1810]  680 [417, 1329]  0.183 
TnI (µg/L) 0.04 [0.02, 0.12]  0.06 [0.02, 0.13]  0.02 [0.02, 0.11]  0.271 
TnI ≤ 0.02 µg/L - n(%) 129 (49.6)  30 (44.1)  99 (51.6)  0.500 
Sodium (mmol/l) 138 [135, 140]  138 [134, 140]  138 [135, 140]  0.609 
Potassium (mmol/l) 4.2 [3.8, 4.6]  4.3 [4.0, 4.6]  4.1 [3.8, 4.5]  0.035 
Chloride (mmol/l) 103 [99, 106]  103 [98, 106]  103 [99, 107]  0.317 
Urea (mmol/l) 8.5 [6.4, 12.4]  8.5 [6.4, 14.3]  8.5 [6.3, 12.0]  0.257 
Creatinine (umol/l) 99 [73, 136]  104 [73, 132]  96 [72, 136]  0.268 
eGFR (ml/min Derived) 62 [40, 82]  55 [38, 80]  63 [40, 82]  0.647 
eGFR <= 60 ml/min- 
n(%) 
159 (58.5)  46 (63.0)  113 (56.8)  0.406 
Bilirubin (mmol/l) 16 [10, 23]  13 [9, 21]  17 [11, 26]  0.034 
AST (mmol/l) 24 [18, 34]  25 [16, 34]  24 [18, 34]  0.768 
ALT (mmol/l) 20 [13, 36]  22 [10, 39]  20 [14, 33]  0.974 
Alk Phos (mmol/l) 99 [76, 128]  104 [76, 130]  98 [73, 128]  0.611 
Albumin (mmol/l) 34 [31, 36]  33 [31, 36]  34 [31, 36]  0.201 
TSH (mU/l) 1.60 [0.94, 2.60]  1.50 [0.85, 2.60]  1.60 [0.95, 2.60]  0.629 
T4 (pmol/L) 14.00 [0.19, 
16.00]  
14.40 [12.00, 
16.10]  
13.50 [0.18, 
16.00]  
0.077 
Urate (mmol/l) 0.51 [0.41, 0.65]  0.55 [0.44, 0.69]  0.51 [0.41, 0.63]  0.093 
Glucose (mmol/l) 6.5 [5.6, 8.3]  6.5 [5.7, 7.9]  6.5 [5.5, 8.6]  0.940 
 
Haematology  
    
Haemoglobin (g/L) 122 [109, 136]  120 [109, 133]  123 [109, 138]  0.444 
WCC (x109/L) 8.1 [6.4, 10.6]  7.6 [6.2, 9.9]  8.3 [6.6, 10.6]  0.265 
HbA1c (mmol/mol) 41 [38, 48]  43 [39, 51]  40 [37, 48]  0.062 
MCV (fl) 90.9 [86.1, 95.5]  91.5 [87.3, 95.0]  90.1 [85.9, 95.6]  0.441 
Platelets (x109/L) 216 [164, 273]  225 [156, 297]  209 [166, 269]  0.494 
Lymphocytes (x109/L) 1.20 [0.83, 1.60]  1.20 [0.73, 1.76]  1.20 [0.87, 1.60]  0.967 
Values are expressed as median [interquartile range] unless specified. 
ALT= alanine aminotransferase ; AST= aspirate aminotransferase; eGFR= estimated glomerular filtration rate; 
HbA1c= haemoglobin A1c; MCV= mean corpuscular volume; BNP= Brain-Type natriuretic peptide; TnI= troponin I; 
TSH= thyroid stimulating hormone. 
 
Echocardiography 
Details of the echocardiographic assessment, per PC needs group, are shown in 
Table 6-10.  Left ventricular volumes (systolic and diastolic), were larger in the 
probable compared to unlikely PC needs groups, which reached statistical 
significance for both systolic and diastolic volumes.  Other measures of left 
ventricular size were similar between the two groups.  The mean indexed (for 
body surface area) left ventricular internal diameters in diastole were 3.04 
(±0.66) and 2.94 (±0.52) cm, in the PC compared to no PC needs groups, 
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respectively.   A similar, and again not significant, finding was seen in the 
indexed left ventricular internal diameter in systole.  Left ventricular mass, 
indexed for body surface area, was similar between the two groups, with mean 
mass of 118 (±34) and 119 (±38) in the two groups.   
Measures of left ventricular function, including ejection fraction as measured by 
Simpson’s Biplane method, were similar between the two PC needs groups.  
Ejection fraction was lower in the PC needs group, but this was not statistically 
significant, with a mean ejection fraction of 37.6 (±16.9) and 40.4 (16.4), 
respectively.  The markers of diastolic impairment, and prognostic markers, E/e’ 
and left atrial size were similar in both groups.  The only statistically significant 
difference in diastolic function between the two groups, was deceleration time, 
with a shorter deceleration time in the probable compared to unlikely PC needs 
group.  89 (32.7 %) patients participating in the PROM part of the study had an 
ejection fraction  50%, with similar proportions between the two groups of PC 
need.  
Markers of right ventricular structure and function were very similar between 
the groups, with the only statistically significant difference being a larger mean 
inferior vena cava size in the probable compared to unlikely PC needs group, at 
2.4 (±0.6) and 2.2 (±0.6) cm, respectively.  This is perhaps in keeping with a 
higher prevalence of peripheral oedema reported and found on examination.   
There were no differences in the frequency or severity of valvular heart disease 
between the two groups. 
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Table 6-10 Echocardiographic findings per palliative care needs group 
 All 
participants 
PC needs Not PC needs p  
 n = 272 n =73 n = 199  
LV structure     
LViDDi, cm/m2 2.96 ±0.56 3.04 ± 0.66 2.94 ± 0.52 0.2033 
LViSDi, cm/m2 2.37 ±0.68 2.43 ± 0.78 2.34 ± 0.65 0.3267 
LVDVi, ml/m2 75 ±32 83 ± 37 71.36 ± 29.36 0.0227 
LVSVi, ml/m2 49 ±31 58± 35 46 ± 29 0.0185 
LV mass index, mg/ m2 119 ±37 118 ± 34 119 ± 38 0.856 
LV systolic function     
LVEF Biplane 
assessment 
218 (80.1) 
59  (80.8%) 159  (79.9%) 0.8658 
LVEF estimated 54 (19.9) 14  (19.2%) 40    (20.1%) 0.8658 
LVEF, % 39.63 ±16.55 37.56 ±16.90 40.38 ±16.40 0.2135 
EF  50% 89 (32.7)  21 (28.8)  68 (34.2)  0.467 
S-Lateral, m/s 5.54 ±1.99 5.37 ± 1.80 5.61 ± 2.06 0.4063 
     
LV diastolic function     
E, m/s 1.05 ±0.34 1.07 ± 0.34 1.04 ± 0.35 0.5278 
a, m/s 0.73 ±0.34 0.62 ± 0.30 0.76 ± 0.34 0.0959 
E/a ratio 1.69 ±1.12 2.02 ± 1.27 1.59 ± 1.06 0.1086 
E’-Lateral, m/s 0.08 ±0.05 0.08 ± 0.03 0.08 ± 0.06 0.9545 
E’-Septal, m/s 0.06 ±0.05 0.06 ±0.02 0.05 ±0.06 0.9875 
E’-Average, m/s 0.07 ±0.08 0.08 ± 0.11 0.07 ± 0.06 0.3248 
E/E’, cm/s 17.45 ±7.57 17.20 ± 6.82 17.54 ± 7.85 0.7489 
DT, ms 194.1 ±72.94 174.0 ±60.11 201.45 ± 75.94 0.0077 
LAVi, ml/m2  57 ±18 59.46 ±18.56 55.53 ± 17.93 0.1365 
     
RV structure/ function     
RViDD, cm 3.53 ±0.72 3.60 ± 0.80 3.51 ± 0.69 0.379 
TV Peak Gradient, ms 2.85 ±0.57 2.88 ± 0.53 2.83 ± 0.58 0.5538 
RV Systolic Pressure, 
mmHg 
48.29 ±14.34 49.24 ±13.58 47.90 ± 14.65 0.5373 
IVC Diameter, mm 2.24 ±0.56 2.38 ± 0.56 2.18 ± 0.56 0.0251 
TAPSE, mm 18 ±6 16.56 ± 5.94 18.16 ± 5.73 0.1011 
RA Volume, ml 23.32 ±7.8 23.38 ± 7.91 23.30 ± 7.71 0.9404 
     
Valvular disease     
Valve disease 228 (83.8) 61   (83.6) 167    (83.9) 0.9434 
Significant Valve 
Disease* 
65   (23.9) 19   (26.0) 46     (23.1) 0.6178 
Significant TR§ 21   (7.7) 5     (6.8) 16     (8.0) 0.7444 
Continuous variables are expressed as mean ± standard deviation unless specified, categorical variables are 
expressed as n (%). 
DT = deceleration time; IVC = inferior vena cava; LAV ; left atrial volume index; LV = left ventricle; LVEF ; left 
ventricular ejection fraction; LViDDi= left ventricular internal diastolic dimension indexed; LVDVi = left 
ventricular diastolic volume indexed; LVISDi= left ventricular internal systolic dimension indexed; LVSVi = left 
ventricular systolic volume indexed; RV = right ventricle; RViDD= right ventricular internal diameter diastole; 
TAPSE = tricuspid annular plane systolic excursion; TV= tricuspid valve;  
*  Defined as ≥ moderate-severe left sided valve disease. 
§ defined as ≥ moderate-severe tricuspid regurgitation. 
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6.6 Patient reported outcome measures 
HADS 
The distribution of baseline summary scores for both the HADS Anxiety and 
Depression summary scores, per PC needs category are displayed in Figure 6-11 
and Table 6-11.  263 (96.7%) participants completed the HADS questionnaires at 
baseline.  The median HADS Anxiety summary score was higher in the probable 
PC needs group compared to the unlikely PC needs group at 9.5 [6.0-13.0] and 
6.0 [3.0-9.0] (p<0.001), respectively.  A statistically significant, higher 
proportion of participants were classified as having either moderate or severe 
impairment on the HADS Anxiety summary score in the PC needs group compared 
to the not PC needs group.  Most participants (81.9%) were graded as none/mild 
impairment in the not PC needs group, compared to 54.3% in the PC needs 
group.   
 
Figure 6-11 HADS summary scores per PC needs category 
 
A similar difference in baseline HADS Depression summary scores were also seen, 
with higher baseline scores in the PC needs group.  The median scores for the 
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probable and unlikely PC needs at baseline were 9.0 [7.0-12.0] and 6.0 [3.0-9.0] 
(p<0.001), respectively.  A similar trend was present in baseline distribution of 
severity as determined by the HADS Depression scale.  Similar proportions of 
participants were classified as severe in the two PC needs groups, with 3 and 7 
participants.  However, most participants in the not PC needs group were 
classified as none/mild depression at baseline (88.8%).  This was a higher 
proportion compared to those in the PC needs group, where 62% were classified 
as none/mild depression and 33.8% classified as moderate. 
Table 6-11 HADS summary score and severity category per PC needs group 
 PC needs Not PC needs p 
 n= 73 n = 199  
n with HADS Anxiety 70 (95.9) 193 (97.0)  
HADS Anxiety Summary 
Score, median[IQR] 
9.5 [6.0-13.0] 6.0 [3.0-9.0] <0.0001 
 
HADS Anxiety Severity 
category, n (%) 
  <0.0001 
 
None/mild 38   (54.3) 158  (81.9)   
Moderate 22   (31.4) 28    (14.5)   
Severe 10   (14.3) 7      (3.6)   
n with HADS Depression 71 (97.3) 196 (98.5)  
HADS Depression Summary 
Score, median[IQR] 
9.0 [7.0-12.0] 6.0 [3.0-9.0] <0.0001 
 
HADS Depression Severity 
category, n (%) 
  <0.0001 
 
None/mild 44   (62.0) 174  (88.8)   
Moderate 24   (33.8) 15    (7.7)   
Severe 3     (4.2) 7      (3.6)   
HADS= hospital anxiety and depression scale; PC = palliative care. 
 
KCCQ 
The distribution of baseline overall summary scores for the KCCQ per PC needs 
group are shown in Figure 6-12.  The distribution of the composite scores which 
make up the overall summary score, the summary score, and KCCQ severity 
category by PC needs group, are detailed in Table 6-12.  Every participant 
completed the KCCQ.  This is due to the KCCQ allowing for a missing value or 
response, where the other PROMs do not.  All of the composite scores of the 
KCCQ were lower in the PC needs group compared to the not PC needs group, 
with the exception of the Self-efficacy score.  The median self-efficacy scores in 
the PC needs and not PC needs groups were 50.0 [25.0-75.0] and 62.5 [37.5-
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87.5] (p=0.158). Figure 6-12 demonstrates the lower baseline KCCQ summary 
score in the PC versus not PC needs groups, with median scores of 15.9 [8.3-
27.3] and 38.5 [26.0-51.8] (p<0.0001).  There was also a much higher proportion 
of participants graded as severe by the KCCQ summary score at baseline in the 
PC versus not PC needs groups, with 68.5 and 22.6%, respectively.  There was a 
much lower proportion of participants classified as none/mild in the PC 
compared to not PC needs groups, at 8.2 and 27.1%, respectively.   
 
 
Figure 6-12 KCCQ summary score per PC category 
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Table 6-12 KCCQ summary scores and severity category per PC needs category 
 PC needs Not PC needs p 
 n= 73 n = 199  
KCCQ completed 73 (100) 199 (100)  
Symptom stability score 0.0 [0.0-25.0] 25.0 [0.0-75.0] 0.0006 
Symptom frequency score 18.8 [6.2-31.2] 33.3 [18.8-52.1] <0.0001 
Symptom burden score 25.0 [0.0-33.3] 41.7 [25.0-58.3] <0.0001 
Total symptom score 17.7 [8.3-32.3] 40.6 [21.9-54.2] <0.0001 
Self-Efficacy score 50.0 [25.0-75.0] 62.5 [37.5-87.5] 0.158 
Quality of life score 16.7 [8.3-33.3] 41.7 [16.7-58.3] <0.0001 
Social limitation score 7.3 [0.0-16.7] 33.3 [14.6-58.3] <0.0001 
Clinical score 17.7 [9.9-30.7] 39.6 [25.0-51.6] <0.0001 
Summary score 15.9 [8.3-27.3] 38.5 [26.0-51.6] <0.0001 
KCCQ Overall Severity 
category, n (%) 
  <0.0001 
 
None/mild 6      (8.2) 54     (27.1)   
Moderate 17    (23.3) 100   (50.3)   
Severe 50    (68.5) 45     (22.6)   
Values are expressed as median [IQR] or n (%). 
KCCQ= Kansas City Cardiomyopathy Questionnaire; PC = palliative care. 
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ESAS 
The distribution of baseline overall summary scores for the ESAS per PC needs 
group are shown in Figure 6-13.  The distribution of different symptom scores 
which make up the overall ESAS summary score and ESAS severity category by PC 
needs group, are detailed in Table 6-13.  Most participants (98.9%) completed 
the ESAS at baseline.  The median score for every individual symptom was higher 
in the PC needs group when compared to the not PC needs group, with the 
exception of nausea.  The median score for nausea was 0 [0-4] and 0 [0-2] for 
probable and unlikely PC needs groups, respectively.  The symptoms with the 
highest scores in the PC needs group were those often characteristic of heart 
failure, namely tiredness and shortness of breath, with median scores of 8 [5-9] 
and 8 [6-9], respectively.  Patients rated their overall wellbeing as particularly 
poor in the PC needs group, with a median overall wellbeing score of 7 [4-8].  
The overall summary score was higher in the PC compared to not PC need, with 
median scores of 52.6 [35.8-62.6] and 34.0 [18.0-49.0], respectively.  A 
statistically significant higher proportion of participants were in the severe 
category for ESAS summary score in the PC compared to not PC group, as shown 
in Table 6-13.  13 (18.1%) of the PC group compared to 13 (6.6%) of the not PC 
needs group were classified as severe according to the ESAS. 
 172 
 
 
 
Figure 6-13 ESAS summary score per PC needs category 
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Table 6-13 ESAS summary score and severity category per PC needs category 
 PC needs Not PC needs p 
 n= 73 n = 199  
n with ESAS 72 (98.6) 197 (99.0)  
Pain 4.0 [0.0-6.0] 1.0 [0.0-4.0] 0.0004 
Tiredness 8.0 [5.0-9.0] 5.0 [3.0-8.0] <0.0001 
Drowsiness 6.0 [3.0-8.0] 4.0 [1.0-7.0] 0.0012 
Nausea 0.0 [0.0-4.0] 0.0 [0.0-2.0] 0.078 
Lack of appetite 4.0 [0.0-8.0] 3.0 [0.0-6.0] 0.0414 
Shortness of breath 8.0 [6.0-9.0] 6.0 [3.0-8.0] <0.0001 
Depression 5.0 [2.0-8.0] 1.0 [0.0-5.0] <0.0001 
Anxiety 4.0 [2.0-8.0] 2.0 [0.0-5.0] <0.0001 
Overall wellbeing 7.0 [4.0-8.0] 4.0 [2.0-6.0] <0.0001 
ESAS summary score 52.6 [35.8-62.6] 34.0 [18.0-49.0] <0.0001 
ESAS Overall Severity 
category, n (%) 
  <0.0001 
 
None/mild 14     (19.4) 94     (47.7)   
Moderate 45     (62.5) 90     (45.7)   
Severe 13     (18.1) 13     (6.6)   
Values are expressed as median [IQR] or n (%). 
ESAS= Edmonton Symptom Assessment Scale; PC = palliative care. 
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SF-12 
The distribution of baseline summary scores for both the SF-12 Physical and 
Mental summary scores, per PC needs category are displayed in Figure 6-14 and 
Table 6-14.  249 (91.5%) participants completed the SF-12 questionnaire at 
baseline, 70 (95.9%) and 179 (89.9%) of the PC group and not PC needs group, 
respectively.  Median scores for the various components of the aggregate 
physical and mental scores are shown in Table 6-14, with all medians being 
lower (worse) in the PC compared to not PC needs group at baseline.   
 
Figure 6-14 SF-12 summary scores per PC needs category 
 
The median aggregate physical scores were 26.9 [21.3-31.2] and 32.2 [24.5-37.6] 
(p <0.0001) for the PC and not PC needs groups respectively, as shown in Figure 
6-14 and Table 6-14.  The median aggregate mental score was also lower in the 
PC compared to not PC needs group, although the overall scores were higher 
than the aggregate physical scores as shown in Figure 6-14.  A higher proportion 
of participants were classified as moderate or severe for SF-12 Physical 
aggregate score in the PC compared to not PC needs group, with 21.4 and 14.3% 
compared to 32.4 and 11.2%, respectively.  Fewer participants were classified as 
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moderate or severe using the aggregate mental wellbeing score in either PC 
needs group, compared to the aggregate physical burden score.  Most 
participants in the not PC needs group were classified as none/mild (86.0%).  A 
higher proportion of participants in the PC compared to not PC needs group were 
classified as either moderate or severe using the aggregate mental wellbeing 
score, with 21.4 and 14.3% compared to 12.3 and 1.7%, respectively. 
Table 6-14 SF-12 summary scores and severity category per PC needs category 
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ZBI 
The summary scores and severity categories for the ZBI are detailed in Table 
6-15.  93 (34.1%) of participants’ caregivers completed the ZBI caregiver burden 
questionnaire, with 27 (37.0%) and 66 (33.2%) of caregivers for participants in 
the PC and not PC needs groups, respectively.  Baseline caregiver burden was 
higher in the PC compared to not PC needs group, with median scores of 24.0 
[15.0-38.0] and 12.0 [6.0-22.0] (p0.0008), respectively.  Most caregivers in the 
not PC needs group (72.7%) were classified as none/mild severity using the ZBI, 
compared to 33.3% of caregivers in the PC needs group.  Similarly, a higher 
proportion of caregivers were classified as moderate or severe in the PC 
compared to not PC needs, as shown in Table 6-15. 
Table 6-15 Zarit Burden Interview summary score and severity category per PC needs category 
 PC needs Not PC needs p 
 n=73 n=199  
n with ZBI 27   (37.0) 66    (33.2)  
ZBI summary score 24.0 [15.0-38.0] 12.0 [6.0, 22.0] 0.0008 
 
ZBI Severity Category   0.0018 
None/mild 9      (33.3) 48    (72.7)   
Moderate 12    (44.4) 13    (19.7)   
Severe 6      (22.2) 5      (7.6)   
Values are expressed as median [IQR] or n (%). 
ZBI= Zarit burden interview; PC = palliative care.   
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6.7 Access to palliative care services 
Electronic patient records, PC registries, and hospice records were searched to 
identify participants who accessed specialist PC either as an inpatient or 
outpatient.  Details of participants who accessed hospice care were also 
recorded.   Of the 272 participants who participated in the whole study, 33 
(12.1%) accessed specialist PC services.  Of the 73 participants who met the 
definition of PC needs, 19 (26.0%) accessed specialist PC services, compared to 
14 (7.0%) of the 199 participants who did not meet the definition of PC needs   
(p< 0.001).  Very few participants accessed hospice care, either as an inpatient 
or an outpatient.  Of the 272 participants who participated in the whole study, 
only 6 (2.2%) accessed some form of hospice care.  5 (6.8%) of participants who 
met the diagnosis of PC needs accessed hospice care, compared to only one 
participant (0.5%) of those who did not meet the definition of PC need 
(p=0.007).   Some participants who accessed PC services or hospice care may 
have accessed these services due to established referral pathways from other 
conditions, such as cancer.  It was not possible to determine from electronic 
records the reason for referral. 
The proportion who accessed specialist PC services or hospice care is lower than 
reported in other cohorts.  A recent analysis of the Rochester epidemiology 
project in the United States of America analysed access to palliative and hospice 
care in patients with heart failure between 2003 and 2012.109  The proportions of 
patients with heart failure who accessed PC over the 9 years of study are shown 
in Figure 6-15.  Of the 1369 patients with heart failure studied, there were 698 
deaths.  Over the 9 years of study, there was a dramatic increase in the 
proportion of participants who accessed specialist PC services, with 43.6% 
accessing PC during a similar follow-up period to my study.  There was also a 
dramatic difference in the proportion of patients who accessed hospice care, 
with 42.2% of patients with heart failure in the Rochester Epidemiological study 
compared to only 2.2% in my study over a similar follow-up period.   
Interestingly, fewer patients with heart failure were hospitalised in the last 
month of life or died in hospital latterly in the Rochester project.  These data 
are retrospective and not from RCT data, therefore, it is not possible to say that 
increased PC access resulted in fewer heart failure patients dying in hospital.   
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Figure 6-15 Trends in hospice enrolment and palliative care consultations Rochester USA 
Reproduced with permission from Shannon M. Dunlay et al. Circ Heart Fail. 2015;8:489-496.109 
 
Although this study is informative for comparison, the healthcare systems in the 
United States of America and the United Kingdom are quite different, 
particularly in funding and access to hospice care.  Perhaps a more useful 
comparison is the heart failure audit of England and Wales between 2013 and 
2014.53  This audit included 55 040 patients admitted to hospital because of 
heart failure.  Of these, only 4% of patients accessed PC services.  This 
proportion was lower than the proportion referred and seen by specialist PC 
services in my study.  There is a large discrepancy between the number of 
patients who met the definition of PC need in my cohort and the number who 
accessed PC services, although those in the PC needs group were more likely to 
access PC than those not in the PC needs group.   
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6.8 Summary 
Participants were reviewed frequently and systematically in this study, with a 
total of 963 individual patient assessments.  As well as this active follow-up, 
participants were followed-up passively using record linkage for a minimum of 1 
year, maximum of 2.9 years, and a median of 2.1 years.  PROMs were repeated 
systematically at every patient contact, giving this study a unique opportunity to 
chart the fluctuation and severity over time in how patients viewed their own 
health.  The number, frequency, high retention in the study, and depth of 
assessment, make this study the most in depth assessment of PC needs in 
patients with heart failure.  Using the definition of PC needs described earlier, a 
large proportion of patients in this cohort had PC needs.  72 (27%) of participants 
met the criteria for PC needs.  Participants who were classified as having PC 
needs had fewer DAOH, and a much lower proportion of the total follow-up was 
spent alive and out of hospital, suggesting that the criteria used to define PC 
needs is appropriate.  Furthermore, patients meeting the criteria for the 
definition of PC needs had much worse QOL and symptom adjusted DAOH, again 
confirming that the group identified was appropriate. 
There were few differences between the two groups of PC need in terms of 
conventional markers of severity of heart failure.  Although natriuretic peptide 
levels were higher in the PC needs group, the difference did not reach statistical 
significance.  Left ventricular size was larger in the PC needs group, but this only 
reached statistical significance when measured as an estimated diastolic and 
systolic volume, rather than internal diameter.  Systolic function, as measured 
by ejection fraction, was lower in the group with PC needs, but again, this did 
not reach statistical significance.   Other common prognostic biomarkers were 
similar between the two groups.   
Baseline demographics were similar between the two groups of PC need, with 
some notable exceptions.  A history of myocardial infarction or diabetes was 
more common in the PC needs group, as was prescription of the anti-platelet 
aspirin in keeping with higher proportions of prior myocardial infarction.  
Participants classified as having PC needs were more often NYHA class IV then 
II/III.  Systolic and diastolic blood pressures were lower on admission, and a 
clinical finding of oedema was more prevalent in the PC needs group.    
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Pharmacotherapy prescriptions were similar between the two groups of PC need, 
including proportions of patients treated with disease modifying therapies such 
as RAAS inhibitors, beta-blockers, and MRAs.  Although infrequently prescribed in 
either group, participants in the PC needs group had a higher prevalence of 
inotropic prescriptions. 
The most marked differences between the two groups at baseline were the 
summary scores, severity categories, and individual components of each PROM.  
Participants that were classified as having PC needs had worse scores on each 
PROM, and were more often classified as severe rather than mild or moderate.  
Caregiver burden, where available, was higher in the PC needs group, again with 
a higher proportion classified as having severe burden in the PC needs group.   
Despite the patients in this population having a limited life expectancy 
associated with high symptom burden and low quality of life, very few 
participants accessed specialist PC services.  Even fewer participants accessed 
hospice care.  There appeared to be a marked discrepancy between participants 
who met the definition of PC needs and who accessed PC services.  Furthermore, 
participants who accessed specialist PC services may have been referred due to 
another co-morbid condition such as cancer, although this was not possible to 
ascertain from electronic records.   
Prediction of patients who met the definition of PC needs from baseline 
characteristics and PROMs will be explored in more detail in the following 
chapter. 
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Chapter 7 Predicting patients with PC needs 
In this chapter I will assess whether it is possible to predict, from the baseline 
hospital admission data, patients who met the definition of PC needs.  
Guidelines would suggest that poor functional state, frequent hospitalisations 
despite optimal therapy, cardiac cachexia, and a clinical judgement of 
approaching EOL, should be used to determine if a patient requires PC. 3  The 
most recent ESC guidelines also discuss using performance status as a method of 
monitoring palliative patients, but do not discuss this as a method to identify 
patients who should receive PC.262  During the course of each index hospital 
admission I asked the treating cardiologist or physician to assess whether they 
thought the patient had more or less than one year to live.  I also asked them 
whether they thought the patient had PC needs.  I will describe whether 
predicted poor prognosis, predicted PC needs, predictive model for mortality, 
performance status, or patient reported outcome measures can predict patients 
who met the definition of PC needs. 
7.1 Physician prediction of palliative care needs and prognosis 
The questionnaire given to the treating doctor is shown in Appendix 6. Of the 
272 patients who participated in the whole study, a physician prediction of PC 
need was available in 264 (97.1%).  The treating physician asked was a 
cardiologist in 91% of cases and a general internal physician in 9%.  The grade of 
physician who completed the questionnaire was consultant (33.3%), specialist 
registrar (61.7%), staff grade doctor (4.2%), and senior house officer (0.8%).  
The results of physician prediction of PC needs compared to patients who did or 
did not meet the definition of PC needs are shown in Table 7-1.   61 patients 
were estimated to have PC needs, of these, 22 met the definition of PC needs.  
The sensitivity of physician prediction of PC needs was 36.1%: the specificity 
was 75.4%, with an area under the receiver operating curve (AUROC) of 0.56 
(95% CI 0.49 to 0.62).  The positive and negative predictive values of the 
physician prediction of PC needs were 30.6 and 79.7%, respectively. 
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Table 7-1 Physician prediction of PC needs 
Physician predicted 
PC needs 
PC needs  
 Yes No Total 
Yes 22 39 61 
No 50 153 203 
Total 72 192 264 
 
The results of physician prediction of poor prognosis (defined as less than one 
year) compared to those who met the definition of PC needs are shown in Table 
7-2.  262 physicians gave an estimate of prognosis.  75 patients were predicted 
to have a prognosis less than one year, of these 26 met the definition of PC 
needs, giving a sensitivity of 34.7%.  187 patients were predicted to have a 
prognosis of greater than a year, of these, 141 did not meet the criteria for the 
definition of PC needs, giving a specificity of 75.4%.  The AUROC was 0.55 (95% 
CI 0.49 to 0.61).  The positive and negative predictive values of physician 
prediction of prognosis at predicting PC needs were 36.1 and 74.2%, 
respectively.  These results are very similar, although there were different 
proportions of patients in each category, to the physician prediction of PC 
needs.  This suggests that for the physicians asked, their assessment of PC need 
was linked to their assessment of prognosis.   
Table 7-2 Physician prediction prognosis vs PC needs group 
Physician predicted 
prognosis < 1 year 
PC needs  
 Yes No Total 
Yes 26 49 75 
No 46 141 187 
Total 72 190 262 
 
An analysis of the accuracy of the treating physician in predicting prognosis is 
shown in Table 7-3.  262 physicians completed the assessment of prognosis, and 
tried to predict which patients they thought had a prognosis of less than one 
year.  Of these 262 participants, there were 100 deaths.  Of the 75 predicted to 
have a poor prognosis, 47 died, giving a sensitivity of 62.7%.  Of the 187 
predicted to have a better prognosis (deemed survival greater than one year), 
134 were alive at the end of follow-up, giving a specificity of 71.7%.  The AUROC 
was 0.67 (95% CI 0.61 to 0.74).  The positive and negative predictive values of 
physician prediction of prognosis at predicting PC needs were 47.0 and 82.7%, 
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respectively.   A comparison of physician prediction of prognosis less than one 
year versus survival at one year is shown in Table 7-4.  There were 54 deaths 
during the first year of follow-up.  The sensitivity was understandably lower at 
42.7%.  The specificity was high at 88.2%.  Positive and negative predictive 
values were 59.3 and 79.3%, respectively.  The AUROC was 0.65 (05% CI 0.59-
0.72).   
Table 7-3 Physician prediction prognosis vs survival 
Physician predicted 
prognosis < 1 year 
Died during follow-up  
 Yes No Total 
Yes 47 28 75 
No 53 134 187 
Total 100 162 262 
 
Table 7-4 Physician prediction prognosis versus survival 1 year 
Physician predicted 
prognosis < 1 year 
Died during 1st year of follow-up  
 Yes No Total 
Yes 32 43 75 
No 22 165 187 
Total 54 208 262 
 
 
These results suggest that physicians were better at predicting prognosis than 
they were at predicting which patients had PC needs, as defined earlier.  The 
similarities in sensitivity and specificity of physician prediction of prognosis and 
PC needs at identifying patients with PC needs suggests that physicians link 
prognosis to PC need. 
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7.2 Physician completed assessments of palliative care need 
During the baseline assessment, I completed the AKPS and the NAT-PD-HF 
assessments.  These are both assessments which are completed by physician.  
The AKPS is an end of the bed assessment, whereas the NAT-PD-HF is an 
assessment based upon discussions with the patient (and caregiver where 
available). 
7.2.1 Australia Modified Karnofski Performance Scale 
The AKPS is a functional, bedside assessment commonly used in patients with 
cancer to monitor PC need.230  The physician marks a score between 0 and 100, 
indicating physical performance.  Higher scores indicate better performance.  An 
example of the AKPS is shown in page 18 of the case report form, Appendix 3.  
All participants had an AKPS assessment completed.  The overall mean and 
median were 72.6 (15.3) and 70 [60-80], respectively.  The range of scores were 
from 40 to 100.  A score of 40 indicates a participant is in bed more than 50% of 
the time.  Patients in the PC needs group had lower scores on the AKPS 
compared to those who did not meet the definition of PC needs, with mean 
values of 65.9 (14.0) and 75.0 (15.0) (p<0.001), respectively.  Median values 
were also lower in the PC need group compared to the not PC need group, at 60 
[60-80] and 80 [60-90] (p<0.001), respectively.   
7.2.2 Needs Assessment Tool-Progressive Disease- Heart Failure 
The NAT-PD-HF is a single page assessment which can be completed by any 
member of the healthcare team.  This has specifically been developed for use in 
patients with heart failure, and aims to identify patients with heart failure who 
have PC needs.  An example of the NAT-PD-HF is provided in page 19 of the case 
report form, Appendix 3.  The NAT-PD-HF is divided into three sections: patient 
well-being assessment; ability to care for the patient; and caregiver wellbeing 
assessment.  Each section has specific questions, which the healthcare 
professional answers whether they have no concern, some/potential concern, or 
significant concern.  I have classified the NAT-PD-HF overall as significant level 
of concern if any of the responses were answered “significant level of concern”.   
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The results of the NAT-PD-HF are detailed in Table 7-5 and Table 7-6.  
Participants in the PC needs group scored a higher percentage of “significant 
concern” in the first three questions regarding patient wellbeing.  These were 
“Is the patient experiencing unresolved physical symptoms?”, “Does the patient 
have problems with daily living activities?”, and “Does the patient have 
psychological symptoms that are interfering with wellbeing?”.  There was also a 
small, but statistically significant difference regarding caregiver wellbeing in the 
question “Is the caregiver or family experiencing grief over the impending or 
recent death of the patient that is interfering with their wellbeing or 
functioning?”  Other than these questions, there were no statistically significant 
differences between patients who met the diagnostic criteria for PC needs and 
those who did not.  For the purposes of using the NAT-PD-HF as a potential tool 
to identify patients with heart failure with PC needs, I defined ‘significant level 
of concern’ as assessed by the NAT-PD-HF, as scoring ‘significant concern’ for 
any of the questions regarding patient wellbeing (Table 7-5). 
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Table 7-5 NAT-PD-HF patient wellbeing component 
 All participants PC needs Not PC needs p 
 No concern Some 
concern 
Significant 
concern 
No 
concern 
Some 
concern 
Significant 
concern 
No 
concern 
Some 
concern 
Significant 
concern  
PATIENT WELLBEING           
1. Is the patient experiencing unresolved physical symptoms? 107 (39.5) 
 
110 (40.6) 
 
54 (19.9) 
 
15 (20.5) 
 
32 (43.8) 
 
26 (35.6) 
 
92 (46.5) 
 
78 (39.4) 
 
28 (14.1) 
 
< 0.001 
 
2. Does the patient have problems with daily living activities? 109 (40.1) 
 
114 (41.9) 
 
49 (18.0) 
 
16 (21.9) 
 
33 (45.2) 
 
24 (32.9) 
 
93 (46.7) 
 
81 (40.7) 
 
25 (12.6) 
 
< 0.001 
 
3. Does the patient have psychological symptoms that are 
interfering with wellbeing? 
197 (73.0) 
 
62 (23.0) 
 
11 (4.1) 
 
41 (56.9) 
 
27 (37.5) 
 
4 (5.6) 
 
156 (78.8) 
 
35 (17.7) 
 
7 (3.5) 
 
< 0.001 
 
4. Does the patient have concerns about how to manage 
his/her medication and treatment? 
208 (77.0) 
 
54 (20.0) 
 
8 (3.0) 
 
52 (71.2) 
 
52 (71.2) 
 
2 (2.7) 
 
156 (79.2) 
 
35 (17.8) 
 
6 (3.0) 
 
0.336 
 
5. Does the patient have concerns about spiritual or existential 
issues? 
245 (90.4) 
 
20 (7.4) 
 
6 (2.2) 
 
61 (83.6) 
 
11 (15.1) 
 
1 (1.4) 
 
184 (92.9) 
 
9 (4.5) 
 
5 (2.5) 
 
0.017 
 
6. Does the patient have financial or legal concerns that are 
causing distress or require assistance? 
257 (94.5) 
 
14 (5.1) 
 
1 (0.4) 
 
67 (91.8) 
 
5 (6.8) 
 
1 (1.4) 
 
190 (95.5) 
 
9 (4.5) 
 
0 (0.0) 
 
0.232 
 
7. From the health delivery point of view, are there health 
beliefs, cultural or social factors involving the patient or family 
that are making care more complex? 
260 (95.6) 
 
7 (2.6) 
 
5 (1.8) 
 
71 (97.3) 
 
1 (1.4) 
 
1 (1.4) 
 
189 (95.0) 
 
6 (3.0) 
 
4 (2.0) 
 
0.876 
 
Values are expressed as n(%)           
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Table 7-6 NAT-PD-HF caregiver wellbeing component 
 All participants PC needs Not PC needs p 
 No  
concern 
Some 
concern 
Significant 
concern 
No 
concern 
Some 
concern 
Significant 
concern 
No 
concern 
Some 
concern 
Significant 
concern  
ABILITY OF CAREGIVER OR FAMILY TO CARE FOR PATIENT           
1. Is the caregiver or family distressed about the patient’s physical 
symptoms? 
50 (39.1) 
 
59 (46.1) 
 
19 (14.8) 
 
11 (28.9) 
 
18 (47.4) 
 
9 (23.7) 
 
39 (43.3) 
 
41 (45.6) 
 
10 (11.1) 
 
0.127 
 
2.Is the caregiver or family having difficulty providing physical 
care? 
83 (64.8) 
 
33 (25.8) 
 
12 (9.4) 
 
20 (52.6) 
 
13 (34.2) 
 
5 (13.2) 
 
63 (70.0) 
 
20 (22.2) 
 
7 (7.8) 
 
0.143 
 
3. Is the caregiver or family having difficulty coping? 97 (75.8) 
 
27 (21.1) 
 
4 (3.1) 
 
27 (71.1) 
 
9 (23.7) 
 
2 (5.3) 
 
70 (77.8) 
 
18 (20.0) 
 
2 (2.2) 
 
0.538 
 
4. Is the caregiver have difficulty managing the patient’s 
medication and treatment regimes? 
111 (86.7) 
 
16 (12.5) 
 
1 (0.8) 
 
34 (89.5) 
 
4 (10.5) 
 
0 (0.0) 
 
77 (85.6) 
 
12 (13.3) 
 
1 (1.1) 
 
0.842 
5. Does the caregiver or family have financial or legal concerns 
that are causing distress or require assistance? 
118 (93.7) 
 
7 (5.6) 
 
1 (0.8) 
 
35 (94.6) 
 
1 (2.7) 
 
1 (2.7) 
 
83 (93.3) 
 
6 (6.7) 
 
0 (0.0) 
 
0.334 
 
6. Is the family currently experiencing problems that are 
interfering with their functioning or inter-personal relationships, 
or is there a history of such problems? 
117 (92.9) 
 
7 (5.6) 
 
2 (1.6) 
 
33 (89.2) 
 
4 (10.8) 
 
0 (0.0) 
 
84 (94.4) 
 
3 (3.4) 
 
2 (2.2) 
 
0.262 
 
CAREGIVER WELLBEING           
1. Is the caregiver or family experiencing physical, practical, 
spiritual, existential or psychological problems that are interfering 
with their wellbeing or functioning? 
20 (16.5) 
 
101 (83.5) 
 
0 (0.0) 
 
5 (14.3) 
 
30 (85.7) 
 
0 (0.0) 
 
15 (17.4) 
 
71 (82.6) 
 
0 (0.0) 
 
0.791 
 
2. Is the caregiver or family experiencing grief over the impending 
or recent death of the patient that is interfering with their 
wellbeing or functioning? 
104 (83.2) 
 
16 (12.8) 
 
5 (4.0) 
 
26 (70.3) 
 
7 (18.9) 
 
4 (10.8) 
 
78 (88.6) 
 
9 (10.2) 
 
1 (1.1) 
 0.012 
Values are expressed as n(%) 
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7.3 Multivariable model 
To identify independent predictors that could potentially be used to highlight 
patients at risk of developing PC needs, markers of prognosis, physician 
completed assessments, and PROMs from baseline were compared by calculating 
univariable and multivariable odds ratios and 95% confidence intervals.  The 
prognostic variables used were age, sex, NYHA classification, eGFR, history of 
diabetes, systolic blood pressure, ejection fraction, natriuretic peptide, and 
serum sodium.  These variables were the most commonly used in a recently 
published systematic review of prognostic models in heart failure, both acute 
and chronic.263  I have also included physician completed assessments, namely 
the AKPS and NAT-PD-F, and also the PROMs.  Patients were classified as having 
“significant level of concern” overall on the NAT-PD-HF if they scored 
“significant” in any of the patients wellbeing components of the NAT-PD-HF.  I 
categorised the PROMs into severity category, as this could be more useful in 
clinical practice to identify patients with potential PC needs.  As many of the 
PROMs had comparatively few patients classified as severe at baseline, other 
than KCCQ, the PROMs were grouped by “none/mild” and “moderate/severe”.   
The results of the multivariable analysis are shown in Table 7-7.   
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Table 7-7 Univariable and multivariable analysis of predictors of PC needs 
Variable n Univariate 
odds ratio 
Univariate 
95% CI 
Univariate 
p-value 
n Multivariate 
odds ratio 
Multivariate 
95% CI 
Multivariate 
p-value 
Prognostic variables 
Age (per year increase)  262 0.98 (0.95, 1.02) 0.337 231 1.01 (0.97, 1.05) 0.520 
Gender (Female)  262 0.66 (0.35, 1.22) 0.185 231 0.48 (0.21, 1.10) 0.084 
Diabetes Mellitus  262 1.89 (0.98, 3.64) 0.058 231 1.30 (0.57, 2.95) 0.528 
NYHA Class  262   0.043 231   0.110 
Class III vs II  262 0.87 (0.43, 1.74) 0.685 231 0.36 (0.14, 0.93) 0.036 
Class IV vs II  262 2.25 (0.95, 5.28) 0.064 231 0.45 (0.13, 1.54) 0.201 
Systolic blood pressure (per mmHg 
increase) 
262 0.99 (0.98, 1.00) 0.089 231 0.99 (0.98, 1.01) 0.328 
eGFR (per ml/min increase)  262 1.00 (0.99, 1.01) 0.971 231 1.00 (0.99, 1.02) 0.910 
Ejection Fraction (per 5% decrease < 50)  262 0.99 (0.87, 1.13) 0.905 231 1.07 (0.90, 1.26) 0.453 
Log BNP level (pg/ml) (per unit increase)  262 1.14 (0.74, 1.75) 0.557 231 1.28 (0.73, 2.22) 0.385 
BMI (per kg/m2  increase) 262 1.01 (0.96, 1.06) 0.712 231 1.05 (0.98, 1.12) 0.174 
Sodium (per mmol/l increase)  262 0.99 (0.93, 1.05) 0.640 231 1.00 (0.93, 1.08) 0.952 
Physician completed assessment 
AKPS Score(per 10 unit increase) 272 0.96 (0.94, 0.98) < 0.001 231 0.98 (0.94, 1.01) 0.138 
NAT-PD-HF - Significant Level of 
Concern  
272 0.43 (0.24, 0.77) 0.004 231 0.90 (0.35, 2.32) 0.830 
PROMs 
HADS Depression Severity (Mod/Sev)  267 4.85 (2.53, 9.32) < 0.001 231 1.61 (0.61, 4.23) 0.337 
HADS Anxiety Severity (Mod/Sev)  263 3.80 (2.09, 6.90) < 0.001 231 1.74 (0.66, 4.62) 0.264 
KCCQ Overall Summary Score Severity  272   < 0.001 231   < 0.001 
Moderate vs Mild/None  272 1.53 (0.57, 4.11) 0.399 231 1.41 (0.40, 4.91) 0.592 
Severe vs Mild/None  272 10.00 (3.93, 25.4) < 0.001 231 7.18 (1.77, 29.1) 0.006 
ESAS-R Severity (Mod/Sev)  269 3.78 (1.98, 7.22) < 0.001 231 2.04 (0.82, 5.11) 0.127 
SF-12 Physical Severity (Mod/Sev)  249 2.83 (1.57, 5.07) < 0.001 231 1.28 (0.58, 2.84) 0.543 
SF-12 Mental Severity (Mod/Sev)  249 3.42 (1.79, 6.53) < 0.001 231 0.78 (0.30, 2.06) 0.618 
AKPS= Australia Modified Karnofsky Performance Scale; BNP= brain type natriuretic peptide; eGFR= estimated glomerular filtration rate; ESAS= Edmonton Symptom Assessment Scale; 
HADS= Hospital Anxiety and Depression Scale; KCCQ= Kansas City Cardiomyopathy Questionnaire; NAT-PD-HF= Needs Assessment Tool Progressive Disease Heart Failure. 
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Of the 272 patients who participated in the study, 231 had complete data for the 
purposes of the multivariable analysis.  None of the conventional predictors of 
prognosis, when measured at admission, predicted patients who were 
subsequently classified as having PC needs.  Neither of the physician completed 
assessments, the AKPS and NAT-PD-HF, predicted PC needs in a multivariable 
analysis.  The only variables which independently predicted PC need at baseline, 
were a severe score on KCCQ (KCCQ < 25), and NYHA class II.  That NYHA class II 
is an independent predictor of PC needs is counter-intuitive.  After analysis for 
correlation between variables, NYHA class and KCCQ severity were strongly 
correlated.  I therefore, removed NYHA class from the multivariable analysis due 
to collinearity of these variables.  The results of the multivariable analysis using 
categorical variables for each PROM is shown in Table 7-8.  The multivariable 
analysis was repeated using continuous variables for each PROM summary score, 
as shown in Table 7-9. 
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Table 7-8 Multivariable analysis of prediction of PC need using categorical PROM variables  
Variable n Multivariate 
odds ratio 
Multivariate 
95% CI 
Multivariate 
p-value 
Prognostic variables 
Age (per year increase) 231 1.01 (0.97, 1.05) 0.695 
Gender (Female)  231 0.45 (0.20, 1.02) 0.056 
Diabetes Mellitus  231 1.27 (0.57, 2.84) 0.558 
Systolic blood pressure (per mmHg 
increase) 
231 0.99 (0.98, 1.01) 0.282 
eGFR (per ml/min increase) 231 1.00 (0.99, 1.01) 0.980 
Ejection Fraction (per 5% decrease < 50)  231 1.06 (0.90, 1.24) 0.473 
Log BNP level (pg/ml) (per unit increase)  231 1.16 (0.68, 2.00) 0.584 
BMI (per kg/m2 increase) 231 1.04 (0.97, 1.10) 0.278 
Sodium (per mmol/l increase)  231 0.99 (0.92, 1.07) 0.852 
Physician completed assessment 
AKPS Score (per 10 unit increase) 231 0.98 (0.95, 1.01) 0.186 
NAT-PD-HF - Significant Level of 
Concern  
231 0.94 (0.38, 2.36) 0.901 
PROMs 
HADS Depression Severity (Mod/Sev)  231 1.60 (0.63, 4.08) 0.322 
HADS Anxiety Severity (Mod/Sev)  231 1.89 (0.74, 4.85) 0.186 
KCCQ Overall Summary Score Severity  231   0.002 
Moderate vs Mild/None  231 0.96 (0.30, 3.12) 0.950 
Severe vs Mild/None  231 4.37 (1.25, 15.3) 0.021 
ESAS-R Severity (Mod/Sev)  231 1.91 (0.78, 4.68) 0.159 
SF-12 Physical Severity (Mod/Sev)  231 1.34 (0.61, 2.94) 0.460 
SF-12 Mental Severity (Mod/Sev)  231 0.79 (0.31, 2.00) 0.612 
AKPS= Australia Modified Karnofsky Performance Scale; BNP= brain type natriuretic peptide; eGFR= estimated 
glomerular filtration rate; ESAS= Edmonton Symptom Assessment Scale; HADS= Hospital Anxiety and Depression 
Scale; KCCQ= Kansas City Cardiomyopathy Questionnaire; NAT-PD-HF= Needs Assessment Tool Progressive Disease 
Heart Failure. 
 
 
 192 
 
Table 7-9 Multivariable analysis of prediction of PC need continuous PROM variables 
Variable n Multivariate 
odds ratio 
Multivariate 
95% CI 
Multivariate 
p-value 
Prognostic variables 
Age (per year increase)  231 1.00 (0.96, 1.04) 0.941 
Gender (Female)  231 0.51 (0.23, 1.11) 0.088 
Diabetes Mellitus  231 1.39 (0.63, 3.10) 0.415 
Systolic blood pressure (per mmHg 
increase) 
231 0.99 (0.97, 1.00) 0.149 
eGFR (per ml/min increase)  231 1.00 (0.99, 1.02) 0.709 
Ejection Fraction (per 5% decrease < 50)  231 1.04 (0.89, 1.22) 0.622 
Log (BNP level (pg/ml)) (per unit increase) 231 1.12 (0.66, 1.91) 0.674 
BMI (per kg/m2 increase) 231 1.02 (0.96, 1.09) 0.468 
Sodium (per mmol/l increase)  231 0.98 (0.91, 1.05) 0.558 
Physician completed assessment 
AKPS Score (per 10 unit increase) 231 0.98 (0.95, 1.01) 0.241 
NAT-PD-HF - Significant Level of 
Concern  
231 0.81 (0.33, 1.99) 0.641 
PROMs 
HADS Depression summary score (per unit 
increase) 
231 0.99 (0.89, 1.11) 0.896 
HADS Anxiety summary score (per unit 
increase) 
231 1.04 (0.94, 1.15) 0.493 
KCCQ Overall Summary Score (per unit 
increase) 
231 0.97 (0.94, 1.00) 0.029 
ESAS-R summary score (per unit increase) 231 1.00 (0.98, 1.02) 0.941 
SF-12 Physical summary score (per unit 
increase) 
231 0.99 (0.93, 1.04) 0.649 
SF-12 Mental summary score (per unit 
increase) 
231 0.97 (0.92, 1.02) 0.234 
AKPS= Australia Modified Karnofsky Performance Scale; BNP= brain type natriuretic peptide; eGFR= estimated 
glomerular filtration rate; ESAS= Edmonton Symptom Assessment Scale; HADS= Hospital Anxiety and Depression 
Scale; KCCQ= Kansas City Cardiomyopathy Questionnaire; NAT-PD-HF= Needs Assessment Tool Progressive Disease 
Heart Failure. 
 
Using a backwards selection method, a best fit multivariable model was created 
first using categorical variables for each PROM, then using continuous variables 
for each PROM summary score.  The results of these best fit models are shown in 
Table 7-10 and Table 7-11, respectively.  The independent predictors of PC 
needs, when assessed at baseline were KCCQ less than 25, HADS anxiety score of 
moderate or severe, lower AKPS score, and male sex, when using the PROMs as 
categorical variables.  When using the PROMs as continuous variables, the 
strongest independent predictors of PC need were lower KCCQ summary score, 
lower AKPS score, and male sex.   
The AUROC for the multivariable model using PROM data as categorical variables 
was 0.80.  The AUROC for the multivariable model using PROM data as 
continuous variables was 0.81. Therefore, categorical variables were used in the 
final model for ease of interpretation.   
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Table 7-10 Multivariable model prediction PC needs- categorical PROM variables 
Variable n Multivariate 
odds ratio 
Multivariate 
95% CI 
Multivariate 
p-value 
Gender (Female)  231 0.39 (0.19, 0.80) 0.010 
AKPS Score (per 10 unit increase) 231 0.97 (0.95, 1.00) 0.020 
HADS Anxiety Severity (Mod/Sev)  231 2.14 (1.02, 4.46) 0.044 
KCCQ Overall Summary Score Severity  231   < 0.001 
Moderate vs Mild/None  231 1.21 (0.40, 3.70) 0.738 
Severe vs Mild/None  231 6.90 (2.33, 20.4) < 0.001 
AKPS= Australia Modified Karnofsky Performance Scale; HADS= Hospital Anxiety and Depression Scale; KCCQ= 
Kansas City Cardiomyopathy Questionnaire. 
 
 
Table 7-11Multivariable model prediction PC needs- continuous PROM variables 
Variable n Multivariate 
odds ratio 
Multivariate 
95% CI 
Multivariate 
p-value 
Gender (Female)  231 0.44 (0.22, 0.88) 0.020 
AKPS Score (per 10 unit increase)  231 0.97 (0.95, 1.00) 0.026 
KCCQ Overall Summary Score  (per unit 
increase) 
231 0.95 (0.93, 0.97) < 0.001 
AKPS= Australia Modified Karnofsky Performance Scale; KCCQ= Kansas City Cardiomyopathy Questionnaire. 
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7.4 Summary 
Common prognostic predictors in heart failure, when assessed in the first few 
days of admission, did not predict patients that met the definition of PC needs.  
Physician completed tools used in other terminal conditions to monitor PC 
needs, namely the AKPS and NAT-PD-HF, identified patients who went on to 
meet the definition of PC needs.  Only AKPS was predictive of PC needs after 
multivariable analysis.  All of the PROMs, assessed in the first few days of 
admission, were predictive of PC needs, but only the KCCQ was an independent 
predictor of PC needs after multivariable analysis.   
Physicians’ clinical acumen had a modest correlation in identifying patients with 
PC needs during an index heart failure hospitalisation.  Physicians were better at 
predicting prognosis than predicting PC needs.  Two best-fit multivariable 
models were created (using backwards selection), one with categorical and one 
with continuous variables for baseline PROMs.  Both models had similar AUROC 
values.  Both models had greater accuracy for predicting patients with PC needs 
than physician assessment.  The model using continuous PROM variables is 
perhaps more useful clinically as there is only one PROM required, and one 
physician completed assessment.   
That KCCQ was the strongest predictor of PC needs, is somewhat of a self-
fulfilling prophecy as participants had to have a severe PROM (either before 
death, or persistently severe without improvement) to meet our chosen 
definition of PC needs, and KCCQ had the highest proportion of participants 
categorised as severe.  However, this information has been shown to be 
clinically relevant.  Clinicians will know that if a patient has a low summary 
score during an admission due to heart failure, they are at risk of not only 
reduced days alive out of hospital, but also persistently impaired QOL.  These 
data are in keeping with the analysis of the large, multicentre, acute heart 
failure study EVEREST.112  The authors of this study used different, although 
similar, criteria for the definition of PC needs.  They defined PC needs as 
persistently impaired QOL (defined as KCCQ less than 45 at one-week post 
discharge and at 6 months) or death before 6 months.  In a multivariable 
analysis, they found that KCCQ less than 25 was the strongest predictor of PC 
need (i.e. meeting the above definition).   The EVEREST authors found that some 
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predictors of prognosis also predicted PC need, whereas my study did not.  
There are a number of possible explanations for this.  Firstly, their definition of 
PC needs included death, whereas my study used severe impairment preceding 
death.  Secondly, the cohort studied in EVEREST were exclusively HF-REF, and 
most prognostic variables and models have been tested and validated in HF-PEF, 
where my study included all ejection fractions.  Thirdly, I assessed prognostic 
variables close to day of admission, where EVEREST assessed on day of 
discharge.  Markers such as natriuretic peptide are potentially more powerful 
predictors of prognosis on discharge than admission.264, 265  This potentially 
reflects the dynamic physiological changes which can occur during a heart 
failure hospitalisation, such as reduction in natriuretic peptide or improvement 
in renal function with diuresis.  It would appear that a KCCQ score taken either 
on admission or discharge is predictive of patients with heart failure who have or 
will go on to develop PC needs.    
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Chapter 8 Heart failure at end of life 
In this chapter I will evaluate EOL in patients in with heart failure.  I will 
describe how and where patients with heart failure died, and compare those 
with and without PC needs, as defined in Chapter 3.  I will also compare 
preferred place of death to actual place of death.  Lastly, I will assess EOL care 
by reporting the results of the EOL questionnaire VOICES.    
8.1  Mortality 
Of 272 participants, during the mean follow-up of 2.1 years, there were 103 
(37.9%) deaths.  Of the whole cohort of 313 patients, there were 118 (36.5%) 
deaths.  15 (36.7%) of the patients who did not participate in the questionnaire 
or active follow-up aspects of the study died.  There were no statistically 
significant differences between those who participated in the whole study and 
those who did not.    The Kaplan-Meier survival analysis per PC needs group is 
shown in Figure 8-1.   
 
Figure 8-1 Kaplan-Meier overall survival per PC needs group 
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There is clear separation of the survival curves for overall mortality between the 
two PC groups, this occurred early and continued throughout the follow-up 
period.  Participants in the PC needs group had higher mortality rates than those 
in the no PC needs group, p <0.0001.  This is not surprising as I have used 
mortality as a component of the definition of PC needs.  If participants had a 
severe impairment on any PROM and died without known recovery of status, 
they were in the PC needs group.  The total mortality for the follow up period 
was understandably higher in the PC needs group compared to the no PC needs 
group, with 47 (64.4%) and 56 (28.1%) (p<0.0001). 
8.1.1 Cause of death 
Cause of death was available through record linkage with the Scottish Morbidity 
Record via the Greater Glasgow and Clyde SafeHaven.  Cause and location for 
death was available for 108 (91.5%) of all deaths in the cohort, and 96 (93.2%) of 
participants who completed the PROM and active follow-up phases of the study.  
Details regarding cause and location of death were not available in 10 (8.5%) 
participants, due to inaccuracies in record linkage at the time the death 
certificate was produced.  Cause of death was defined as the primary reason for 
death documented on the official death certificate. The International 
Classification of Diseases (ICD) version 10, was used to classify cause of death.266   
Details of recorded cause of death for the whole cohort are detailed in Table 
8-1.  Causes of death were more likely to be from cardiovascular than non-
cardiovascular causes, with 65 (60.2%) and 43 (39.8), respectively.  There were 
no differences between participants who completed the PROM component of the 
study and those who did not (p=0.536).  Of the cardiovascular causes, the most 
common cause of death recorded was myocardial infarction, with 49.2%.  The 
next most common cardiovascular cause recorded as the primary cause of death 
was heart failure, with 15.4%.  Arrhythmia and stroke were infrequent 
cardiovascular causes of death, with 3.1 and 9.2%, respectively.  The most 
common non-cardiovascular causes of death recorded were those classified as 
diseases of the respiratory system or cancer, with 32.6 and 18.6%.  The 
proportion of non-cardiovascular causes is higher than has been reported in RCTs 
of patients with heart failure.267   However, there has been a rise in the 
proportion of deaths attributable to non-cardiovascular deaths with increasing 
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use of disease modifying therapy, such as beta-blocker therapy.  Another 
difference between this cohort and other reported studies is the low proportion 
of participants who had a primary cause of death recorded as heart failure, with 
only 9.3% overall.  There are a number of possible explanations for these 
discrepancies.  Firstly, my cohort was unselected and had an older, and likely 
frailer population with a greater proportion of co-morbidities.  Secondly, most 
RCTs adjudicate deaths, which did not happen with my cohort, potentially 
leading to a lower classification of heart failure as the primary cause of death.  
Lastly, my cohort included not only HF-REF, but also HF-PEF.  RCTs of HF-PEF 
have a higher proportion of non-cardiovascular death than those of HF-REF.   
Table 8-1 Cause of death all - participants 
 
The causes of death per group of PC need are detailed in Table 8-2.  There were 
no significant differences in cause of death between the two groups of PC need. 
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Table 8-2 Causes of death per PC need group 
 All 
participants 
PC needs Not PC 
needs 
p  
 n = 272 n =73 n = 199  
All deaths 103 (37.9) 47 (64.4) 56 (28.1)  
Cause of death available 96 (93.2) 46 (97.9) 50 (89.3)  
Cardiovascular  59 (61.5)  29 (63.0)  30 (60.0)  0.835 
Heart failure* 8 (13.6)  4 (13.8)  4 (13.3)  0.871 
Myocardial infarction* 31 (52.5)  14 (48.3)  17 (56.7)   
Arrhythmia * 1 (1.7)  1 (3.4)  0 (0.0)   
Stroke * 5 (8.5)  2 (6.9)  3 (10.0)   
Other CV * 14 (23.7)  8 (27.6)  6 (20.0)  
Non-Cardiovascular  37 (38.5)  17 (37.0)  20 (40.0)  0.871 
Diseases of the respiratory system§  14 (37.8)  9 (52.9)  5 (25.0)  0.259 
Neoplasms§  7 (18.9)  3 (17.6)  4 (20.0)   
Diseases of the GU system§  5 (13.5)  2 (11.8)  3 (15.0)   
Infectious and parasitic diseases§  4 (10.8)  0 (0.0)  4 (20.0)   
Diseases of the digestive system § 3 (8.1)  2 (11.8)  1 (5.0)   
Primary disorders of muscles§  1 (2.7)  1 (5.9)  0 (0.0)   
Unspecified fall§  1 (2.7)  0 (0.0)  1 (5.0)  
T2DM § 1 (2.7)  0 (0.0)  1 (5.0)   
Polyarteritis with lung involvement§  1 (2.7)  0 (0.0)  1 (5.0)   
Values are expressed as n (%). 
CV= cardiovascular; GU = genitourinary; T2DM = Type 2 diabetes mellitus. 
* = % of CV deaths 
§ = % of non-CV deaths 
 
 
8.1.2 Place of care and death 
Preferred place of care/death 
All participants who took part in the PROM stage of the study were asked to 
consider, in a hypothetical scenario, where they would prefer to be cared for in 
the event of a deterioration in their health.  Participants were given the 
following options as answers; home, hospital, care facility, hospice, or 
undecided.  Participants were then asked to consider, again in a hypothetical 
scenario, where they would prefer to spend the last few days and hours of their 
life in the event of a deterioration in their health.  Again participants were given 
the following options as possible answers; home, hospital, care facility, hospice, 
or undecided.   
The answers provided at baseline are provided in Table 8-3.  256 (94.1%) of 
participants gave answers to the above questions regarding preferred place of 
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care and death.  Most participants expressed a preference to be cared for, and 
indeed spend their last few days and hours, at home if possible, with 61.3 and 
55.9%, respectively.  A similar proportion of participants wished to spend their 
last few days or hours in a hospital (8.2%), care facility (5.9%), or hospice (6.3%). 
Table 8-3 Preferred place of care and death 
 All 
participants 
Probable 
PC needs 
Unlikely PC 
needs 
p  
 n = 272 n =73 n = 199  
Answered questions 256 (94.1) 70 (95.9) 186 (93.5)  
Preferred place of care    0.389 
Home 157 (61.3)  40 (57.1)  117 (62.9)   
Hospital 17   (6.6)  3 (4.3)  14 (7.5)   
Care facility  24   (9.4)   6 (8.6)  18 (9.7)   
Hospice 6     (2.3)  3 (4.3)  3 (1.6)   
Undecided 52   (20.3)  18 (25.7)  34 (18.3)   
Preferred place of death    0.263 
Home 143 (55.9)  35 (50.0)  108 (58.1)   
Hospital 21   (8.2)   6 (8.6)  15 (8.1)   
Care facility  15   (5.9)   2 (2.9)  13 (7.0)   
Hospice 16   (6.3)  4 (5.7)  12 (6.5)   
Undecided 61   (23.8)  23 (32.9)  38 (20.4)   
Values are expressed as n (%). 
PC = palliative care. 
 
 
 
A comparison between preferred place of death in my cohort and other heart 
failure cohorts is shown in Figure 8-2.  In their study, Formiga et al asked 80 
patients admitted to hospital with decompensated heart failure to consider their 
place of care if recovery seemed unlikely.42  Of these, 50% wanted to be cared 
for at home, a further 40% wanted to continue care in hospital, and 10% were 
unsure.  Of those who preferred to be cared for in hospital, 53% of these said 
this due to worry regarding the burden they would place on their caregivers.  As 
part of their study, Stachan et al asked 107 patients admitted to hospital with 
decompensated heart failure to consider their preferred place for death.165  This 
was a highly selected cohort, consisting of patients with NYHA class IV symptoms 
and an ejection fraction less than 25%.  Most patients in this cohort expressed a 
preference for EOL care at home (44%), with a further 26% expressing a wish for 
EOL care in hospital.  25% of this cohort were undecided regarding their 
preference for EOL care location.  A higher proportion of participants in my 
study expressed a wish to spend their EOL at home (60%), with a similar 
proportion undecided to that reported by Strachan et al, at 24%.  Much fewer 
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participants expressed a wish for EOL care to take place in hospital in my study, 
at only 8%.  
 
Figure 8-2 Preferred place of death comparison other cohorts 
 
Actual place of death 
The details of location of death were available for 92% of all participants in the 
study, and 93% of those who completed PROMs.  The actual place of death for 
the whole cohort are shown in Table 8-4.  Most participants (68.5%) died in 
hospital, compared to only 18 (16.7%) at home and a further 14 (14.6%) in other 
facilities such as care homes or hospices.   A higher proportion of patients who 
did not agree to take part in the whole study and complete PROMs or attend 
follow-up died in hospital, although this difference was not statistically 
significant.   
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Table 8-4 Location of death- all participants 
 All 
participants 
Completed  
PROMS 
Did not 
complete 
PROMS 
p  
 n = 313 n =272 n = 41  
All deaths 118 (37.7) 103 (37.9) 15 (36.6)  
Location of death available 108 (91.5) 96 (93.2) 12 (80.0) 0.086 
Location of death     
Home 18 (16.7)  17 (17.7)  1 (8.3)  0.804 
Hospital 74 (68.5)  65 (67.7)  9 (75.0)   
Other  16 (14.8)  14 (14.6)  2 (16.7)   
Values are expressed as n (%). 
PROMS= patient reported outcome measures. 
 
The actual location of death for the participants who took part in the whole 
study, broken down into those who met the definition of PC need and those who 
did not, are shown in Table 8-5.  Again, most participants died in hospital, with 
67.7% of the cohort.  Only 17 (17.7%) participants died at home, with a further 
14 (14.6%) dying at other care facilities.  A higher percentage of participants 
died in other facilities in the group who met compared to those who did not 
meet the definition of PC need, with 19.6 and 10.0%, respectively.   The 
differences in place of death by palliative care need group did not reach 
statistical significance as shown in Table 8-5. 
 
Table 8-5 Location of death per PC need group 
 All 
participants 
PC  
needs 
Not PC 
needs 
p  
 n = 272 n =73 n = 199  
All deaths 103 (37.9) 47 (64.4) 56 (28.1)  
location of death available 96 (93.2) 46 (97.9) 50 (89.3)  
Location of death     
Home 17 (17.7)  7 (15.2)  10 (20.0)  0.394 
Hospital 65 (67.7)  30 (65.2)  35 (70.0)   
Other  14 (14.6)  9 (19.6)  5 (10.0)  
Values are expressed as n (%). 
 
A comparison of actual place of death in cohorts of patients with heart failure is 
shown Figure 8-3.  Place of death was reported in the Assessment and Treatment 
with Lisinopril and Survival (ATLAS)38 and Sudden Cardiac Death in Heart Failure 
Trial (SCD HeFT)39 RCTs, where 53 and 58% died in hospital, respectively.   A 
recent study assessing place of death by using death certificates in three 
European countries in 2007, reported similar proportion of patients with a 
primary diagnosis of heart failure who died in hospital.40  Most deaths in patients 
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with heart failure in Finland, France, and England occurred in hospital, with 
58%, 61%, and 68% respectively.  The proportion of patients who died at home 
ranged from 20-35%, with the lowest proportion of home deaths in these studies 
in England.  A similar proportion of participants in my study died in hospital, 
although this was even higher than previously reported at 68%.  Furthermore, a 
lower proportion of participants in my study died at home compared to other 
studies reporting place of death in patients with heart failure.   
 
 
Figure 8-3 Actual place of death comparison other cohorts 
ATLAS= Assessment and Treatment with Lisinopril and Survival; PCHF= palliative care in heart failure; 
SCD-HeFT= Sudden Cardiac Death in Heart Failure Trial. 
 
Of the 96 deaths where location of death was available, data regarding 
preferred place of death was known at baseline in 94 participants.  Of these 72 
(76.5%) expressed a preferred place of death and 22 (23.5%) were either 
undecided or did not have a preferred place of death.  A comparison of location 
of death compared to preferred place of death is shown in Table 8-6.   As 
described above, most participants expressed a preference to spend their EOL at 
home.  Of the 50 participants who expressed a wish to die at home, and who had 
location of death data available, only 9 (18%) achieved their preferred place of 
death.  Most (n= 37, 74%) died in hospital.  Overall, only 18 (25%) of the 72 
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patients who expressed a preference for location of EOL, achieved their 
preferred place of death. 
 
Table 8-6 Preferred place versus actual place of death 
 Preferred place of death 
 Home Hospital Care home Hospice  Undecided 
Location of death      
Home 9   (18.0) 3 (30.0) 2 (40.0) 0 (0.0) 3   (13.6)  
Hospital 37 (74.0) 6 (60.0) 2 (40.0) 5 (71.4) 13 (59.1)  
Other*  4   (8.0) 1 (10.0) 1 (20.0) 2 (28.6) 6   (27.3)  
Values are expressed as n (%). 
* Either care home or hospice. 
 
 
 
8.2 End of life care assessment- VOICES 
The VOICES questionnaire has been designed and used by the Department of 
Health to assess EOL care, from the perspective of informal caregivers.101  The 
VOICES questionnaire is a postal questionnaire which describes care in the last 
three months of life, the last two days of life, and care at the EOL.  The 
questionnaire is designed to be completed by caregivers after what is perceived 
to be adequate grieving time, but still close enough to a death to allow accurate 
reflection.  For this reason, the authors advise posting the questionnaire 6-12 
months following a death.    
8.2.1 Completion of VOICES questionnaire 
The proportion of participants’ caregivers who completed the VOICES 
questionnaire is displayed in Figure 8-4.   Of the 272 participants who took part 
in the study and completed PROMs, 103 died during follow-up.  Of these, 61 
were eligible to participate in the VOICES EOL survey.  42 participants were 
excluded, either because the timing of their death would not allow 6 months’ 
lag before posting the questionnaire, or the participants had no known or 
available caregiver.  Of the 61 VOICES questionnaires posted, 17 were returned.  
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Figure 8-4 VOICES questionnaire CONSORT diagram 
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15 caregivers returned the reply slip stating they did not wish to participate in 
this part of the study and a further 29 did not return any of the VOICES 
documentation.  OF the 17 VOICES questionnaires returned, 7 were from 
caregivers who met the definition of PC needs, and 10 were from caregivers of 
participants who did not meet the definition of PC needs.   
8.2.2 VOICES results- assessment of care in last 3 months of life 
Of those completing the VOICES questionnaire, the reported length of illness was 
between 1 and 6 months in 5.9%, between 6 and 12 months in 17.7%, and over 1 
year in 82.4%.  14 (82.4%) caregivers reported that their relative or friend spent 
some time at home in the last 3 months of life, with a further 2 (11.8%) spending 
that time in a care home, and 1 respondent reporting their relative or friend did 
not spend any time in either. 
Community care 
A summary of the evaluation of community services in the last three months of 
life is shown in Table 8-7.  Most informal caregivers felt that the community care 
services worked well together, with 61.6% of respondents reporting that care 
worked well together to some extent or definitely.  One caregiver did not feel 
that care services worked well together, and one caregiver did not know.  Three 
caregivers felt that their relative or friend did not receive any care services in 
the community in the las three months of life.   50% of respondents felt they got 
as much support in the community as they wanted, with a only one caregiver 
reporting they got support but not as much as they wanted or required.  One 
caregiver felt they did not get enough support, even though they tried to get 
more.  28.6% of caregivers did not get enough support, but did not seek 
additional support.  Most patients who tried to see their general practitioner 
(GP) got to see their preferred GP most (18.8%), a lot (18.8%), or some of the 
time (31.2%).  2 caregivers reported that their relative almost never got to see 
their preferred GP.  Most caregivers felt they were able to discuss their fears or 
worries with the GP, with only 12.5% % reporting they tried to discuss these but 
were not able to do so.  One care giver reported having fears or worries, but did 
not attempt to discuss these with the GP.  Caregivers generally reported good 
access to home visits, with 67.7% reporting very easy or fairly easy access to 
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getting a GP home visit.  2 caregivers felt it was fairly difficult getting a home 
visit, no caregivers felt it was very difficult to get a home visit.  Out of hours 
care was generally rated highly by caregivers.  84.9% of respondents reported 
excellent or good care provided in the community out of hours, with only 3 
caregivers reporting fair or poor care.  
Table 8-7 Community care in the last 3 months of life 
 All 
participants 
PC 
needs 
Not PC 
needs 
p  
Care services worked well together  
Yes, definitely 5 (38.5)  2 (40.0) 3 (37.5)  1.000 
Yes, to some extent 3 (23.1)  1 (20.0) 2 (25.0)  
No, they did not work well together 1 (7.7)  0 1 (12.5)  
Did not receive any care 3 (23.1) 2 (40.0) 1 (12.5)  
Don’t know 1 (7.7) 0 1 (12.5)  
Got enough help and support at home from services  
Yes, as much as we wanted 7 (50.0)  2 (33.3)  5 (62.5) 0.394 
Yes, some but not as much as we 
wanted 
1 (7.1) 1 (16.7)  0   
No, although we tried to get more  1 (7.1) 1 (16.7)  0  
No, but we did not ask for more  4 (28.6)  2 (33.3)  2 (25.0)  
Did not need help 1 (7.1) 0 1 (12.5)  
Saw preferred GP 
Always or almost always 3 (18.8)  1 (14.3)  2 (22.2)  0.575 
A lot of the time 3 (18.8)  2 (28.6) 1 (11.1)  
Some of the time 5 (31.2)  3 (42.9) 2 (22.2)   
Never or almost never 2 (12.5)  1 (14.3)  1 (11.1)  
Did not try to see a particular GP 3 (18.8) 0 3 (33.3)  
Did not have to see GP 0 0   
Able to discuss fears or worries with GP 
No fears or worries to discuss 3 (18.8) 0 3 (33.3) 0.148 
Yes, as much as I wanted 9 (56.2) 5 (71.4) 4 (44.4)  
Yes, but not as much as I wanted 1 (6.2) 1 (14.3) 0  
No, although I tried to discuss 2 (12.5)  0  2 (22.2)  
No, but I did not try to discuss 1 (6.2) 1 (14.3) 0  
Ease of getting a home visit 
Very easy 5 (31.2) 2 (28.6) 3 (33.3) 0.650 
Fairly easy 6 (37.5) 2 (28.6) 4 (44.4)  
Fairly difficult 2 (12.5) 1 (14.3) 1 (11.1)  
Very difficult 0  0  0   
Don’t know 1 (6.2) 0 1 (11.1)  
Wanted home visit, but GP would not 0 0 0  
Does not apply, did not want home visit 2 (12.5) 2 (28.6) 0  
Out of hours care 
Excellent 6 (49.2) 2 (33.3)  4 (50.0)  0.867 
Good 5 (35.7) 3 (50.0) 2 (25.0)  
Fair 1 (7.1)  0  1 (12.5)   
Poor 2 (14.3) 1 (16.7) 1 (12.5)   
Don’t know 0 0 0  
GP= general practitioner; PC= palliative care. 
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Pain relief in last 3 months 
Caregivers were asked to report on how adequately pain was controlled in the 
various healthcare settings that their relative was cared for in the last three 
months of life.  A summary of the assessment of pain control are shown in Table 
8-8.   Most patients appeared to have suffered from pain in the last three 
months of life.  42.8% of caregivers reported that pain was only relieved 
partially or not at all in the community.  A similar proportion of caregivers 
reported only partial pain relief in the four patients cared for in care homes 
(50%).   Of the 14 patients who spent some of their last three months in hospital, 
2 did not experience any pain.  Of those who spent time in hospital and 
experienced pain, 58.3% of caregivers reported inadequate pain relief.  Only two 
participants with caregivers who completed the VOICES questionnaire spent any 
time in a hospice.  Of these, only one caregiver reported that their relative or 
friend experienced pain, and this was relieved partially.  There were no 
statistically significant differences between the two groups of PC need regarding 
pain relief in the last 3 months of life.   
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Table 8-8 Pain control in the last 3 months of life 
 All participants PC needs Not PC needs p  
 n = 17 n =7 n = 10  
Pain control at home  
Does not apply, not 
pain 
3 (21.4) 1 (16.7) 2 (25.0) 1.000 
Completely, all of the 
time 
4 (28.6) 2 (33.3) 2 (25.0)  
Completely, some of 
the time 
1 (7.1) 1 (16.7) 0  
Partially 5 (35.7)  2 (33.3) 3 (37.5)  
Not at all 1 (7.1) 0 1 (12.5)  
Don’t know 0 0 0  
Pain control in Care home  
Does not apply, not 
pain 
0 0 0 1.000 
Completely, all of the 
time 
1 (25.0) 0 1 (33.3)   
Completely, some of 
the time 
1 (25.0) 0 1 (33.3)   
Partially 2 (50.0)  1 (100.0)  1 (33.3)   
Not at all 0 0 0  
Don’t know 0 0 0  
Pain control in Hospital 
Does not apply, not 
pain 
2 (14.3) 1 (20.0) 1 (11.1)  0.850 
Completely, all of the 
time 
5 (35.7) 1 (20.0) 4 (44.4)  
Completely, some of 
the time 
0  0 0   
Partially 6 (42.9) 3 (60.0)  3 (33.3)   
Not at all 1 (7.1) 0 (0.0) 1 (11.1)  
Don’t know 0 0 0  
Pain control in Hospice 
Does not apply, not 
pain 
1 (50.0) 0  1 (50.0) na 
Completely, all of the 
time 
0  0  0   
Completely, some of 
the time 
0  0  0   
Partially 1 (50.0) 0  1 (50.0)  
Not at all 0 0 0  
Don’t know 0 0 0  
na= not applicable; PC= palliative care. 
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Respect and dignity in last three months of life 
As part of the VOICES questionnaire, informal caregivers are asked to report 
whether they felt specific healthcare professionals treated their relatives or 
friends with respect and dignity.  The results of these questions are displayed in 
Table 8-9.  No caregivers reported that their friend or relative was never treated 
with respect by any healthcare professional.  Of those cared for by community 
nurses, 66.7% of caregivers felt the healthcare professionals treated their 
relative or friend with respect and dignity always or most of the time.  Only one 
caregiver reported their friend or relative being treated with respect and dignity 
some of the time.  81.3% of caregivers reported that their relative or friends’ GP 
treated them with respect and dignity always or most of the time, with 3 
caregivers reporting some of the time.  Of the four participants who were cared 
for in a care-home in the last three months of life, all four were treated with 
respect and dignity, either always or most of the time.  Hospital doctors and 
nurses were evaluated similarly regarding their treatment of relatives or friends 
of caregivers, with 78.5 and 78.6% of caregivers reporting treatment with 
respect and dignity always or most of the time, respectively.  Of the two 
participants, with caregivers completing the VOICES questionnaire, who were 
cared for in a hospice, hospice staff were reported to treat the two participants 
with respect and dignity always.   
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Table 8-9 Respect and dignity shown to patient in last 3 months of life 
 All participants PC needs Not PC needs p  
 n = 17 n =7 n = 10  
Community nurse 
Always 5 (55.6)  2 (50.0) 3 (60.0)  1.000 
Most of the time 1 (11.1)  1 (25.0) 0  
Some of the time 1 (11.1)  0  1 (20.0)  
Never 0  0 0  
Don’t know 2 (22.2) 1 (25.0) 1 (20.0)  
General practitioner  
Always 11 (68.8)  4 (57.1)  7 (77.8)  0.342 
Most of the time 2 (12.5)  2 (28.6)  0 (0)   
Some of the time 3 (18.8) 1 (14.3)  2 (22.2)   
Never 0  0  0   
Don’t know 0 0 0  
Care home staff 
Always 2 (50.0)  0  2 (66.7)  1.000 
Most of the time 2 (50.0) 1 (100.0)  1 (33.3)  
Some of the time 0  0  0   
Never 0  0  0   
Don’t know 0 0 0  
Hospital doctor 
Always 8 (57.1) 3 (60.0%) 5 (55.6) 0.287 
Most of the time 3 (21.4) 0 3 (33.3)  
Some of the time 3 (21.4) 2 (40.0%) 1 (11.1)  
Never 0  0  0   
Don’t know 0 0 0  
Hospital nurse 
Always 9 (64.3) 3 (60.0) 6      (66.7) 1.000 
Most of the time 2 (14.3) 1 (20.0) 1      (11.1)  
Some of the time 3 (21.4) 1 (20.0) 2      (22.2)  
Never 0  0  0   
Don’t know 0 0 0  
Hospice doctor 
Always 1 (50.0)  0  1 (50.0)  na 
Most of the time 1 (50.0) 0 1 (50.0)  
Some of the time 0  0  0   
Never 0 0 0  
Don’t know 0 0 0  
Hospice nurse 
Always 2 (100.0)  0  2 (100.0)  na 
Most of the time 0 0 0  
Some of the time 0  0  0   
Never 0 0 0  
Don’t know 0 0 0  
na= not applicable; PC= palliative care. 
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Overall care in the last three months of life 
As part of the VOICES questionnaire, informal caregivers were asked to make an 
assessment of care from various healthcare professionals and make an overall 
assessment of care in the last three months of life of their friend or relative.  
Caregivers were asked to make an assessment of standard of care by selecting an 
answer from poor, fair, good, excellent, or don’t know.  The results of these 
questions are shown in Table 8-10 and Table 8-11.   
Table 8-10 Assessment of care in last three months 
 Community 
nurse 
GP Care 
home  
staff 
Hospital 
doctor  
Hospital 
nurse  
Hospice 
care 
 n = 9 n =16 n = 4 n = 13 n = 13 n = 2 
Assessment of care       
Excellent 5 (55.6)  7 (43.8)  3 (75.0)  5 (38.5) 6 (46.2) 1 (50.0)  
Good 1 (11.1)  4 (25.0)  1 (25.0) 4 (30.8) 4 (30.8) 0 
Fair 1 (11.1)  1 (6.2) 0  1 (7.7) 2 (15.4) 1 (50.0) 
Poor 1 (11.1) 4 (25.0) 0  3 (23.1) 1 (7.7) 0 
Don’t know 1 (11.1) 0 0 0 0 0 
Values are expressed as n (%). 
GP= general practitioner. 
 
Care from community nurses was generally rated highly, with 6 (66.7%) 
caregivers evaluating care delivered by community nurses as excellent or good. 2 
(22.2%) rated fair or poor standard of care by community nurse in the last three 
months of life.  GPs were rated highly, many caregivers felt the care delivered 
by GPs was excellent or good, 43.8% and 25.0%, respectively.  Of the four 
participants in care-homes who had a caregiver complete the VOICES 
questionnaire, all four caregivers rated the care received there as either 
excellent (3 caregivers) or good (1 caregiver).  Hospital doctors were rated 
similarly to community nurses and GPs, with 38.5 and 30.8% of caregivers rating 
hospital doctors’ care in the last three months of life as either excellent or 
good.  3 (23.1%) hospital doctors were rated as poor by caregivers.  Hospital 
nurses were rated highly overall, with 77.0% being rated by caregivers as 
delivering excellent or good care in the last three months of life, with only one 
caregiver reporting poor care, and a further 2 (15.4%) reporting fair care.  Of the 
 213 
 
two participants who accessed hospice care with caregivers who completed the 
VOICES questionnaire, one reported excellent care and one fair care. 
Table 8-11 Overall assessment of care in last 3 months of life 
 All PC needs Not PC needs p 
 n = 17 n =7 n = 10  
Overall Care last 3 
months 
   0.164 
Outstanding 2 (11.8) 1 (14.3) 1 (10.0)  
Excellent 4 (23.5)  2 (26.8)  2 (20.0)   
Good 5 (29.4)  3 (42.9)  2 (20.0)  
Fair 5 (29.4) 0 5 (50.0)   
Poor 1 (5.9) 1 (14.3) 0   
Don’t know 0 0 0  
Values are expressed as n (%). 
PC= palliative care. 
 
The caregivers’ evaluation of overall care is shown in Table 8-11, including 
distribution of care assessment by palliative care needs group.  This particular 
question in the VOICES questionnaire had the additional option of rating care as 
outstanding, in addition to the options available in Table 8-10.  Again, more 
caregivers felt that overall care was positive, with 64.2% reporting good- 
outstanding care.  2 (11.8%) caregivers felt care was outstanding, 4 (23.5%) felt 
care was excellent, and 5 (29.4%) felt care was good.  5 (29.4%) and 1 (5.9%) 
caregivers reported overall care in the last three months of life of their friend or 
relative as fair and poor, respectively.  There was no statistical difference in the 
proportion of participants in each care standard category between those with PC 
needs and those without.  This may have been due to small numbers of 
responses received for the VOICES questionnaire. 
8.2.3 Assessment of care in last two days of life 
Caregivers completing the VOICES questionnaire were also asked to reflect on 
various aspects of care in the last two days of life of their relative or friend.  
The results of these questions, overall and by PC needs group, are shown in 
Table 8-12 and Table 8-13.   
Caregivers were asked to reflect on location care took place in the last two days 
of life.  5 (29.4%) reported care taking place at home all of the time, 3 (17.6%) 
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in a care home, 7 (41.2%) in hospital, and 2 (11.8%) in a hospice.  This proportion 
is different to the location of death recorded by the whole cohort, perhaps 
reflecting the presence of an informal caregiver, enabling a higher proportion of 
participants to spend their last two days at home.  Most felt were treated with 
respect and dignity by doctors in the last two days of life, with 10 (66.7%) 
treated with respect and dignity either always or most of the time.  No caregiver 
reported their friend or relative never being treated with respect and dignity in 
the last two days.  2 (13.3%) were treated with respect and dignity only 
sometimes in the last two days of life.  Caregivers reported a higher proportion 
of patients being treated with respect and dignity by nurses in the last two days 
of life, with 93.4% of caregivers reporting nurses treated their relatives with 
respect and dignity either always or most of the time.   
Most caregivers reported that their friends or relatives received enough help to 
meet their personal care needs in the last two days of life.  Only two caregivers 
reported feeling that there was not enough support to meet these needs.  A 
similar proportion of caregivers reported that there was enough nursing support 
in the last two days of life, again with 2 (13.4%) caregivers reporting that there 
was not enough nursing support.  Most caregivers (73.4%) reported there was 
enough privacy at the bed space in the last two days of life.  Two caregivers 
reported that they did not think there was enough privacy.    
There were no statistically significant differences between the groups of 
palliative care need in the caregiver perceived standards of care described in 
Table 8-12. 
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Table 8-12 Assessment of care in last 2 days of life 
 All 
participants 
PC 
needs 
Not PC 
needs 
p  
Location of care last 2 days of life 
At home all the time 5 (29.4)  3 (42.9) 2 (20.0)  0.762 
Care home all the time 3 (17.6)  1 (14.3) 2 (20.0)  
Hospital all the time 7 (41.2)  3 (42.9) 4 (40.0)  
Hospice all the time 2 (11.8) 0 2 (20.0)  
Other 0 0 0  
Treated with dignity and respect by doctors last 2 days of life 
Always 9 (60.0)  4 (66.7)  5 (55.6) 1.000 
Most of the time 1 (6.7) 0 1 (11.1)   
Some of the time 2 (13.3) 1 (16.7) 1 (11.1)  
Never 0 0 0  
Don’t know 3 (20.0) 1 (16.7) 2 (22.2)  
Treated with dignity and respect by nurses last 2 days of life 
Always 10 (66.7) 5 (83.3)  5 (55.6)  0.139 
Most of the time 4 (26.7) 0 4 (44.4)  
Some of the time 1 (6.7) 1 (16.7) 0   
Never 0 0 0  
Don’t know 0 0 0  
Enough help to meet personal care needs in last 2 days  
Strongly agree 2 (13.3) 1 (16.7) 1 (11.1) 0.944 
Agree 8 (53.3) 3 (50.0) 5 (55.6)  
Neither agree nor disagree 2 (13.3) 1 (16.7) 1 (11.1)  
disagree 1 (6.7) 0  1 (11.1)  
Strongly disagree 1 (6.7) 1 (16.7) 0  
Does not apply 1 (6.7) 0 1 (11.1)  
Don’t know 0 0 0  
Enough nursing care to meet needs in last 2 days 
Strongly agree 4 (26.7) 2 (33.3) 2 (22.2) 1.000 
Agree 7 (46.7) 3 (50.0) 4 (44.4)  
Neither agree nor disagree 1 (6.7) 0 1 (11.1)  
disagree 1 (6.7) 0  1 (11.1)  
Strongly disagree 1 (6.7) 1 (16.7) 0  
Does not apply 0 0 0  
Don’t know 1 (6.7) 0 1 (11.1)  
Enough privacy bed space last 2 days 
Strongly agree 4 (26.7) 2 (33.3)  2 (22.2)  1.000 
Agree 7 (46.7) 3 (50.0) 4 (44.4)  
Neither agree nor disagree 1 (6.7) 0  1 (11.1)   
disagree 1 (6.7) 0 1 (11.1)   
Strongly disagree 1 (6.7) 1 (16.7) 0  
Does not apply 0 0 0  
Don’t know 1 (6.7) 0 1 (11.1)   
 PC= palliative care. 
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15 caregivers answered the VOICES questions regarding pain relief in the last two 
days of life.  Of the 13 participants who experienced pain, most received good 
or excellent pain relief in the last two days of life, 4 (30.7%) and 5 (38.5%), 
respectively.   3 (23%) caregivers reported that pain relief was poor in the last 
two days of life.  A similar proportion of caregivers reported adequate control of 
other symptoms in the last two days of life, with 5 (33.3%) reporting this as 
excellent and 5 (33.3%) good.  A further 5 (33.3%) caregivers rated symptom 
control in the last two days of life as either fair or poor. 
Caregivers were asked to rate EOL care in terms of the emotional and spiritual 
support that their friend or relative received in the last two days of life, the 
proportion of answers given are shown in Table 8-13.  Two caregivers did not 
know what this was. Just over half of caregivers (8 caregivers) reported that 
their relative or friend received excellent or good emotional support in the last 
two days of life.  5 rated the standard of emotional support given in the last two 
days as either fair or poor.  11 caregivers reported that they felt spiritual 
support was required.  Of these, 1 (9.1%) and 4 (36.4%) caregivers reported 
excellent and good spiritual support in the last two days of life, respectively.  4 
(36.4%) caregivers rated the quality of spiritual support as either fair or poor. 
Caregivers were asked to rate the amount of support that was provided to 
enable achievement of preferred place of death.  15 caregivers answered this 
question, with one stating this was not applicable, and another reporting they 
did not know the answer to this question.  Of the other 13 caregivers, 4 (30.8%) 
rated support for preferred place of death as excellent, 5 (38.5%) as good, 3 
(23.1%) as fair, and 1 (7.8%) as poor.   
There were no statistically significant differences between the groups of PC 
need regarding evaluation of EOL care in the last two days of life, as 
demonstrated in Table 8-13. 
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Table 8-13 Assessment of symptom and emotional support last 2 days of life 
 All 
participants 
PC 
needs 
Not PC 
needs 
p  
Pain relief in last 2 days of life 
Excellent 4 (26.7)  2 (33.3) 2 (22.2)  1.000       
Good 5 (33.3)  2 (33.3) 3 (33.3)   
Fair 0 0 0  
Poor 3 (20.0) 1 (16.7) 2 (22.2)   
Does not apply 3 (20.0) 1 (16.7) 2 (22.2)   
Don’t know 0 0 0  
Relief of other symptoms in last 2 days of life 
Excellent 5 (33.3)  2 (33.3) 3 (33.3)  1.000 
Good 5 (33.3)  2 (33.3) 3 (33.3)   
Fair 3 (20.0) 1 (16.7) 2 (22.2)   
Poor 2 (13.3) 1 (16.7) 1 (11.1)  
Does not apply 0 0 0  
Don’t know 0 0 0  
Emotional support in last 2 days of life 
Excellent 4 (26.7)  2 (33.3) 2 (22.2)  0.760 
Good 4 (26.7) 1 (16.7) 3 (33.3)   
Fair 2 (13.3) 1 (16.7) 1 (11.1)  
Poor 3 (20.0) 2 (33.3) 1 (11.1)  
Does not apply 0 0 0  
Don’t know 2 (13.3) 0 2 (22.2)   
Spiritual support in last 2 days of life 
Excellent 1 (6.7) 1 (16.7) 0 0.811 
Good 4 (26.7) 2 (33.3) 2 (22.2)   
Fair 2 (13.3) 1 (16.7) 1 (11.1)  
Poor 2 (13.3) 1 (16.7) 1 (11.1)  
Does not apply 4 (26.7) 1 (16.7) 3 (33.3)   
Don’t know 2 (13.3) 0 2 (22.2)   
Support to achieve preferred place of care in last 2 days of life 
Excellent 4 (26.7) 2 (33.3) 2 (22.2) 1.000 
Good 5 (33.3)  2 (33.3) 3 (33.3)   
Fair 1 (6.7) 0 1 (11.1)  
Poor 3 (20.0) 2 (33.3) 1 (11.1)  
Does not apply 1 (6.7) 0 1 (11.1)  
Don’t know 1 (6.7) 0 1 (11.1)  
 PC= palliative care. 
 
8.2.4 Assessment of communication at end of life 
As part of the VOICES questionnaire caregivers were asked to reflect on how well 
health professionals communicated with both patients and their caregivers 
leading up to death, and with caregivers following death.  The distribution of 
answers to these questions are shown in Table 8-14.  Caregivers were asked to 
comment on whether their friend or relative knew that they were likely to die.  
57% reported that their friend or relative certainly or probably did know they 
were going to die.  6 (35.5%) caregivers felt that their friend or relative probably 
did not know they were likely to die, and one felt that their friend or relative 
definitely did not know they were likely to die.   Caregivers often did not know 
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whether or not their friend or relative was told they were dying in a sensitive 
way.  Most caregivers (47.1%) responded that their relative did not know they 
were dying. 
Caregivers were asked whether they were contacted in enough time before their 
friend or relative died.  2 (11.8%) caregivers reported that they were not.  Most 
other caregivers were either with their friend or relative already or were 
contacted in enough time (76.4%).  Caregivers were asked if the news of the 
death of their friend or relative was broken in a sensitive manner, and all 
reported that it was.  13 (76.5%) caregivers felt they were given enough support 
at the time of death, either definitely or to some extent.  One caregiver 
reported not getting enough support at the time of death. 
Caregivers were asked to reflect on whether they thought they or their relatives 
or friends were involved in decisions about their health as much as they would 
have wanted.  Most caregivers (85.7%), felt that their relative or friend were 
involved with decision making as much as they would have wanted.  2 (13.3%) 
caregivers, felt that their relative or friend would have liked to be more 
involved in decision making processes.  11 (64.7%) caregivers felt they were 
involved in decision making as much as they would have liked, with a further 5 
(29.4%) feeling they would have liked to be more involved, and one caregiver 
reported feeling that they were too involved.  2 (17.6%) caregivers reported that 
some decisions were not in keeping with their friend or relative’s wishes, 
although most felt this was not the case or not applicable (82.3%).   
Of the caregivers completing the VOICES questionnaire, none accessed any 
formal bereavement counselling, with half stating they would have liked to. 
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Table 8-14 Assessment of communication at end of life 
 All 
participants 
PC 
needs 
Not PC 
needs 
p  
Did patient know they were likely to die 
Yes, certainly 4 (23.5)  1 (14.3) 3 (30.0)  0.735       
Yes, probably 4 (23.5)  1 (14.3) 3 (30.0)   
Probably not 6 (35.5) 3 (42.9) 3  
No, definitely 1 (5.9) 1 (14.3) 0  
Not sure 2 (11.8) 1 (14.3) 1 (10.0)   
Did the person who broke news he/she was likely to die do so sensitively  
Yes, definitely 1 (5.9) 1 (14.3) 0 0.166 
Yes, to some extent 1 (5.9) 0 1 (10.0)   
No, not at all 0 0 0  
Don’t know 4 (23.5)  0 4 (40.0)  
Does not apply, they did not know he/she was 
dying 
3 (17.6) 2 (28.6) 1 (10.0)  
Does not apply, they did not tell him/her they 
were dying 
8 (47.1) 4 (57.1) 4 (40.0)  
Were you contacted in enough time to see him/her before he/she died 
Yes 4 (23.5)  1 (14.3) 3 (30.0)  0.637 
No 2 (11.8) 1 (14.3) 1 (10.0)   
I was there already 9 (52.9) 5 (71.4) 4 (40.0)  
It was not clear they were going to die soon 2 (11.8) 0 2 (20.0)  
I could not have got there anyway 0 0 0  
Were family given enough support at the time of death 
Yes, definitely 7 (41.2) 3 (42.9) 4 (40.0) 1.000 
Yes, to some extent 6 (35.3) 3 (42.9) 3 (30.0)   
No, not at all 1 (5.9) 0 1 (10.0)  
Don’t know 3 (17.6) 1 (14.3) 2 (20.0)  
After his/her death did staff deal with the family in a sensitive manner 
Yes 15 (88.2) 7 (100.0) 8 (80.0) 0.485 
No 0  0 0  
Don’t know 0 0 0  
Does not apply 2 (11.8) 0 2 (20.0)  
Over the past 3 months was he/she involved in decision about his/her care as much as you 
wanted 
Involved as much as wanted to be 12 (70.6) 6 (85.7) 6 (60.0) 0.338 
Would have liked to be more involved 2 (11.8)  1 (14.3) 1 (10.0)   
Would have liked to be less involved 0 0 0  
Don’t know 3 (17.6) 0 3 (30.0)  
Over the past 3 months, were you involved in decision about his/her care as much as you 
wanted 
Involved as much as wanted to be 11 (64.7) 5 (71.4) 6 (60.0) 1.000 
Would have liked to be more involved 5 (29.4) 2 (28.6) 3 (30.0)   
Would have liked to be less involved 1 (5.9) 0 1 (10.0)  
Don’t know 0 0 0  
Were any decision made about his/her care that he/she would not have wanted 
Yes 3 (17.6) 2 (28.6) 1 (10.0) 0.404 
No 11 (64.7) 5 (71.4) 6 (60.0)   
Don’t know 3 (17.6) 0 3 (30.0)  
Have you talked to anyone from health or social services or a bereavement service?  
Yes 0 0 0 1.000 
No, but I would have liked to 8 (50.0)  4 (57.1) 4 (40.0)   
No, but I did not want to 8 (50.0)  3 (42.9) 5 (50.0)  
Not sure 0 0 0  
 PC= palliative care. 
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8.3 Summary 
Despite the numerous advances in the treatment of heart failure, particularly 
HF-REF, patients admitted to hospital in this cohort were a very high risk group, 
in terms of mortality risk.  During a median follow-up of 2.1 years, 37.9% of the 
cohort died.  Unsurprisingly, the participants who met the definition of PC needs 
had a much higher mortality rate, with 64.4% versus 28.1% dying during follow-
up, p<0.001.  This difference likely reflects the use of mortality in the definition 
of PC needs (which is appropriate), however, death was not a mandatory 
condition to meet the definition.  Most deaths in my cohort were classified as 
cardiovascular, with the highest proportion of deaths being further sub-classified 
as due to myocardial infarction.  A lower than expected proportion of deaths 
were classified as due to heart failure.  This is perhaps due to the non-
adjudicated nature of the deaths.  Despite cardiovascular deaths being more 
common, there was still a high proportion of deaths classified as non-
cardiovascular (39%).  Of these, most were classified as due to respiratory 
disease, followed by cancer, with 37.8% and 18.9% of non-cardiovascular deaths 
respectively due to these causes.  This proportion of non-cardiovascular deaths 
perhaps reflects the nature of the population studied, with an elderly population 
with a high proportion of co-morbidities.   
As previously described in other smaller studies, most patients with heart 
failure, when asked, expressed a preference to spend their EOL at home.  
Despite this preference for place of death, most patients in my study did not die 
at home.  By far the most common location of death was hospital.  This was a 
consistent finding with other studies which have recorded place of death in 
patients with heart failure, although an even higher proportion of hospital 
deaths was seen in my study.  This is potentially an area where PC could have a 
positive influence.268  However, this needs to be explored further in adequately 
powered RCTs. 
Although only 17 informal caregivers completed the VOICES questionnaire, this 
still provides a useful, although not exhaustive, insight into EOL care in patients 
with heart failure.  In general, most caregivers were positive about the care 
received in the community by their relative or friend in the last three months of 
life.  Most felt the various services available in the community worked well 
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together, and out of hours care was viewed positively.  Most caregivers felt their 
relative or friend could access their preferred GP during working hours.  4 out of 
14 caregivers did not feel like they had enough access to support services in the 
last three months of life, although they did not seek additional support, perhaps 
suggesting they were not aware of extra support that may have been available.  
Pain was only partially relieved between 36 and 50% of the time, depending on 
care setting.  Overall, most caregivers felt that their relative or friend was 
treated with respect and dignity, with no caregiver reporting this never 
happened.   
Caregivers mostly reported positively regarding care in the last two days of life.  
However, 2 (13.4%) caregivers felt there was not enough nursing support or help 
to meet the personal needs of their relative or friend in the last two days of life.  
2 caregivers also reported not enough privacy at the bed-space in the last two 
days of life.  20% of caregivers felt relief of pain or other symptoms was poor.  
Emotional and spiritual support was also rated as fair or poor in 5 (33.3%) and 4 
(26.7%) patients, respectively.  One quarter of caregivers felt support to achieve 
preferred place of death was fair or poor, in keeping with the observed 
discrepancy between preferred and actual place of death.  Although 
communication at EOL was rated highly in general, 6 (35.5%) caregivers felt their 
relative or friend did not know they were dying.  A further 5 (29.4%) caregiver 
felt they would have liked to have been more involved in decisions about care.  
No caregivers reported accessing any form of bereavement service, with half of 
respondents reporting they would have liked to have accessed this service.   
A useful comparison can be made between my study and the National Survey of 
Bereaved People in England, 2015.103  In the most recent cycle of this survey, 
the VOICES questionnaire was completed by 21 320 bereaved relatives.  Overall 
care in the last three months of life was rated as either good, excellent, or 
outstanding in 74.9%.  25.1% of caregivers reported overall care as either fair or 
poor.   The overall rating of care in the last three months was less favourable 
from the 17 caregivers in my study who completed the VOICES questionnaire.  Of 
these, 35.3% rated overall care to be fair or poor.   
An important reason for using the VOICES EOL questionnaire in this study was to 
determine if this could be used as a potential outcome measure in a subsequent 
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RCT of early PC in heart failure.  I have found the return rate to be particularly 
low, lower than reported in the DOH EOL surveys.  This was surprising as, unlike 
the Department of Health survey, I had previously made contact with most of 
the caregivers who the questionnaire was posted to and in most cases 
established a rapport.  I was aware that many participants in my study did not 
have an informal caregiver or close friend or relative, which would result in low 
return rate.   I also found the timing of the VOICES questionnaire difficult to 
administer, as this was quite prescriptive.  The questionnaire itself is large, and 
perhaps represents too high a participant burden.  My opinion regarding the 
VOICES EOL questionnaire is that it would not be useful as an outcome measure 
in an RCT, in its current form, although it may be informative.     
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Chapter 9 Discussion  
9.1 Main findings of the study 
Heart failure is common and associated with significant morbidity and mortality.  
There have been a number of evidence based therapies which have been shown 
to improve prognosis and reduce morbidity, particularly in patients with HF-REF.  
Despite these improvements, for many patients, heart failure is a life-limiting 
disease.  There has recently been more focus on providing PC and treatments for 
patients with organ failure, including heart failure.  This has been recognised by 
numerous editorials, and now is acknowledged in international guidelines.3, 269  
However, the extent of patients which have, or would potentially benefit from, 
a palliative intervention has not been described.  I believe that this study and 
thesis has systematically addressed this important research and clinical 
question. 
I have systematically reviewed the published literature available describing the 
potential PC needs in patients with heart failure.  My search strategy identified 
over 60 publications, including more recently published RCTs.   Half of the 
studies identified used qualitative research methods and half used either 
quantitative or a mix of the two methodologies.  Many of the studies identified 
described highly selected cohorts, either patients with exclusively NYHA class 
III/IV or patients already attending or referred to PC services.  Most of the 
cohorts did not fully describe the patient population studied in detail, with 
important data such as severity of heart failure (including ejection fraction and 
NYHA clas), drug history, or natriuretic peptide levels missing.  Most of the 
studies identified described only a ‘snap-shot’ assessment, at one time-point.  
This methodology would not capture the potential fluctuation that heart failure 
is thought to have, and ultimately would not describe the patient journey.  
Another key weakness of the current literature identified was the focus on 
exclusively patients with HF-REF.  HF-REF is the most prevalent type of heart 
failure and appears to have the highest mortality associated, however, the 
proportion of patients with HF-PEF is potentially increasing and 
underrepresented in the studies identified.  Even though HF-REF was studied 
more often, descriptions of proportions of patients receiving disease modifying 
therapies were lacking.  This is crucial to report in any study describing either 
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the prevalence of PC needs or the effect of PC on patients with heart failure, as 
pharmacotherapy can improve QOL.  My study and thesis addressed these issues, 
and ultimately, provides a description of the prevalence of PC needs in a 
contemporary and very well described cohort of patients admitted to hospital 
because of heart failure. 
A total of 829 unselected, near-consecutive, patients with suspected heart 
failure were screened for inclusion in the study.  Of these, 313 met the ESC 
diagnostic criteria for definition of heart failure.  Of these 313 patients with 
confirmed heart failure, 272 (86.9%) agreed to participate in the whole study 
and complete the PROMs at baseline and at follow-up visits.  The 41 patients 
who declined or were unable to take part in the PROM and follow-up parts of the 
study were older, with a higher proportion women and with lower BMI.  There 
were no other statistically significant differences at baseline between those who 
participated and those who did not in the whole study. 
The patients enrolled in the study were elderly with a median age of 76, and had 
numerous co-morbidities.  Just under half of participants were women (47%), 
and most participants were white, reflecting the catchment area for the 
Western Infirmary, Glasgow.  The most common co-morbidities were 
hypertension, ischaemic heart disease, atrial fibrillation, diabetes mellitus, and 
COPD.  Most patients were NYHA class III (52%), with 30% class II, and 18% class 
IV.  Pulmonary rales was the most common finding on physical examination, with 
79%, followed by peripheral oedema (76%).  That 30% of patients were NYHA 
class II (symptoms on mild exertion) is in some ways surprising, as one would 
expect patients admitted to hospital to be symptomatic on minimal exertion or 
at rest (NYHA class III/IV).  However, these findings are in keeping with a recent 
study which reported that most patients admitted to hospital due to heart 
failure are comfortable at rest, but short of breath on exertion, compared to 
those that are short of breath at rest.270    
Most patients in the study had HF-REF (67.3%), in keeping with previous studies 
locally, and in keeping with a large contemporary meta-analysis.61, 250  Valve 
disease was common, with significant valve disease (defined as ≥ moderate-
severe aortic or mitral valve lesion) present in 23.9% of patients.  Markers of 
disease severity, namely ejection fraction and BNP, were very similar between 
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my cohort and other large unselected heart failure cohorts.  Prescription levels 
of disease modifying therapy were high in my cohort.  70.5% of patients who 
took part in the PROMs and follow-up parts of the study were prescribed either 
ACEI/ARB, with 70.6% prescribed a beta-blocker, and 33.5% a MRA.  Very few 
participants had an ICD or CRT device before the index admission.   
In this study I have completed one of the most detailed quantitative assessments 
describing the influence heart failure has on the lives of patients.  I have used 
PROMs to describe the patients’ perspective, rather than the often reported 
investigators perspective.  I have made detailed assessments of QOL (using two 
different measures), mood disturbance (using two measures), symptom burden, 
and caregiver burden.  Although each of these different PROMs have been used 
in patients with heart failure before, this breadth of assessment has not been 
used in such a large and well defined cohort as this one.  I have shown that 
patients with heart failure suffer from a variety of symptoms, including some 
symptoms which are more commonly associated with other terminal conditions 
(like cancer) such as pain and nausea.  During the index hospitalisation 114 
(41.9%) participants had PROMs scores in the severe range of at least one PROM.  
Of these participants, 48.2% had severe impairment of at least two PROMs.  The 
KCCQ, which has been widely used in a number of studies and cohorts of 
patients with heart failure, appeared to be the most sensitive PROM at 
identifying patients with severe impairment, with 34.9% of participants having 
severe impairment at baseline.  This compared to 9.7% in the severe category in 
the ESAS, 14.1% in SF-12-Physical, 6.5% in HADS- Anxiety, 5.2% in SF-12-Mental, 
and 3.7% in HADS-Depression.  The mean KCCQ scores in my cohort were 
consistent with other hospitalised cohorts of patients with heart failure, 
suggesting that the results are robust and genuine.  The importance of using a 
variety of PROMs to assess different facets of influence of heart failure on 
patients’ lives is demonstrated by the difference between the number of 
patients who were severe in any category and those who were severe in KCCQ.  
Participants were offered follow-up visits, either in the study centre or at home, 
every 4 months for the duration they were in the study, with a minimum of 8 
months and a maximum of 28 months.  At each study visit all of the PROMs were 
completed/ offered to each participant, and caregiver where available.  There 
were a total of 691 study visits, giving a total number of assessments during the 
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study of 963.  37% of all study visits were carried out in patients’ homes.  This 
allowed this study to have a very high retention rate given the length of the 
study and the age and frailty of the participants. Excluding patients who did not 
attend due to death, 78% of potential study visits were completed.  This makes 
this study one of the most in-depth longitudinal studies assessing the patient 
journey in patients with heart failure.  This, combined with the unselected 
recruitment and rigorous diagnostic process, makes this study unique.   
Participants were followed-up actively at study visits and also passively, using 
medical record linkage.  This resulted in a very complete follow-up for 
hospitalisations, and deaths.  In keeping with other cohorts, and data based on 
death certificates, participants in this study were at risk of early death following 
or during their index admission.  During the follow-up period there were 103 
deaths, 37.9% of the participants who participated in the PROMs aspect of the 
study.    Most deaths were cardiovascular (61.5%).  This relatively high 
proportion of non-cardiovascular deaths for a heart failure cohort perhaps 
reflects the high proportion of participants with co-morbidities.  Participants 
were asked where there preferred place of death would be, in a hypothetical 
scenario.  In keeping with other studies, most participants stated a preference 
to spend their EOL at home.  However, there was a stark mismatch between 
preferred place of death and actual place of death.  Of the 94 patients who 
died, where place of death was known, 50 (53%) stated a preference to spend 
their EOL at home.  Of these, 37 (74%) died in hospital.  Most participants 63 
(67%) died in hospital.  The proportion of patients with heart failure dying in 
hospital is similar to that reported in a recent study reporting place of death in 
three countries in Europe (including England and Wales) in 2007.40  My study is 
the largest study of unselected patients with heart failure to compare preferred 
to actual place of death.   EOL care was also evaluated using the VOICES 
questionnaire.  Unfortunately, there was a lower than expected response rate, 
possible due to a lack of informal caregiver for many participants.  Of the 61 
VOICES EOL questionnaires posted to informal caregivers of deceased 
participants, 17 (27.9%) were returned.  The VOICES questionnaire does still 
provide useful insight into the EOL care in patients with heart failure.  11 
(64.7%) respondents reported overall care in the last three months of life to be 
either good, excellent, or outstanding.  Only 2 (11.8%) felt that care was 
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outstanding.  6 (35.3%) informal caregivers felt that overall care was either fair 
or poor.  These results are worse than the latest National EOL Survey in England 
and Wales, completed by 21 320 bereaved caregivers.103  In that survey, overall 
care was rated as good-excellent in 74.1%.  Whether this discrepancy is due to 
my cohort being exclusively of patients with heart failure is unclear.  It is not 
possible to make direct comparisons due to the large discrepancy in size 
between the two surveys.  The results of the VOICES questionnaire in my study, 
combined with the discrepancy between preferred and actual place of care, do 
suggest that improvements could be made in EOL care. 
As described above, participants were followed-up actively, between 8 and 28 
months following their index heart failure hospitalisation.  At each of these 
assessments, each PROM was repeated.  By classifying patients as having severe 
impairment (defined as scoring in the severe category in any PROM) or not-
severe, I was able to describe the patient journey in detail.  Using this method, I 
was able to describe a group of patients who suffered from persistently severe 
impairment (of either QOL, symptom burden, or mood) over time, or died 
without improvement in their overall status.   Using these criteria to define PC 
need, 73 (26.8%) participants enrolled in the study had PC needs.   A higher 
proportion of patients in this group were men.  Physical examination findings 
were similar other than a higher proportion of patients presenting with signs of 
peripheral oedema, and patients in the PC needs group having lower median 
blood pressures.  There was a higher proportion of patients in NYHA class IV in 
the group meeting the definition of PC needs.  Patients in the PC needs group 
were more likely to have a past history of myocardial infarction or diabetes 
mellitus, and were more likely to have been admitted to hospital due to heart 
failure in the preceding 6 months.  The only difference in drug prescription prior 
to admission was a higher proportion of patients being prescribed aspirin in the 
PC needs group, in keeping with the higher proportion of previous myocardial 
infarction.  There were no differences in prescription of drugs on discharge or 
during admission, other than a higher use of the inotropic agent dopamine in the 
PC needs group.  Biochemical markers of disease severity, and predictors of 
prognosis, such as BNP and troponin, were higher in the PC needs group, 
although these differences did not reach statistical significance.  There were no 
statistically significant differences on laboratory testing during the index 
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admission between the two groups, other than a lower bilirubin level in the PC 
needs group.  The clinical significance of this difference is uncertain given both 
median bilirubin results were within the normal reference limits.  Ejection 
fraction was lower in the PC needs group, but this difference was not significant.  
LV indexed diastolic and systolic volumes were higher in the PC needs group 
(p=0.02).  There was a higher proportion of HF-REF in the PC needs group, 
although the difference was not significant.  There were no significant 
differences in left atrial or right ventricular size and function between the two 
groups.   
The most marked differences between the two groups of PC need were in the 
PROMs measured.  Patients in the PC needs group had worse overall summary 
scores across all PROMs, all of which were statistically significant.  There were 
also higher proportions of patients classified as moderate or severe by all PROM 
in the PC needs group.  Participants in the PC needs group not only had a 
reduced life expectancy, but also spent fewer DAOH.  An important additional 
analysis, adjusting DAOH for QOL and symptom burden, showed that patients in 
the PC needs group had much fewer good days spent alive and out of hospital.  
This confirms that the definition of PC needs is robust and appropriate to 
identify a group of patients who have persistently impaired lives with low QOL 
and a reduced life expectancy. 
Of the 272 patients who participated in the whole study, 33 (12.1%) accessed 
specialist PC services (SPCS), that is, they were on a specialist PC register.  Of 
the patients classified as having PC needs, 19 (26.0%) accessed SPCS, where 14 
(7.0%) of the 199 patients who were not in the PC needs group accessed SPCS, p 
<0.001.  Very few patients in either group accessed hospice care, either as an 
inpatient or day care services.  Only 6 of the 272 participants accessed any form 
of hospice care.  Although patients in the PC needs group were more likely to 
access SPCS, the majority of those identified as meeting the definition of PC 
needs did not.   
I have shown what many believe in clinical practice, that predicting which 
patients go on to develop PC needs is difficult.  I was able to formally assess this 
by asking the attending physician to try to predict if each patient had PC needs.  
The physicians’ predictions only correlated modestly with patients who met the 
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definition of PC needs.  The attending physicians were better at predicting 
prognosis at 1 year than predicting PC needs, although this correlation was also 
moderate.  I have also demonstrated that the most commonly used variables in 
predictive models for prognosis do not reliably identify or predict patients who 
have PC needs.  This finding i contrary to contemporary guidelines which suggest 
using physicians’ prediction of poor prognosis as one method for selecting 
patients who should be referred for specialist PC input.3  Using multivariable 
logistic regression analysis, I have shown that a combination of a PROM (low 
KCCQ summary score) and a structured physician completed assessment (low 
AKPS score) is more accurate at predicting patients with PC needs than 
physicians’ clinical assessment or prediction of prognosis.  The strongest 
independent predictor of PC needs, following multivariable analysis, was a KCCQ 
summary score of less than 25 (when using KCCQ as a categorical variable).   
This finding is consistent with the previous analysis of the acute heart failure 
study, EVEREST, in which KCCQ less than 25 during admission was the strongest 
predictor of persistently impaired QOL or death.112 
9.2 Strengths 
My study has a number of strengths which make this one of the most robust and 
detailed assessments of PC needs in patients with heart failure.  Firstly, 
screening was rigorous and systematic.  I screened for new heart failure 
admissions at least 5 days per week, for almost two years.   As well as personally 
reviewing all admissions to the medical receiving unit, I screened 
echocardiogram requests.  Given the median length of stay for a patient with 
heart failure was 9 days, I believe I was able to screen almost all patients with 
heart failure who were admitted to hospital in the Western Infirmary during the 
study.  I was very prescriptive when employing the ESC diagnostic criteria to 
diagnose heart failure, and therefore feel that all of the patients in this cohort 
had heart failure.  I used natriuretic peptides, echocardiography, CXR, and 
clinical examination to confirm or refute the diagnosis.  I believe this makes my 
cohort one of the most robust contemporary heart failure cohorts.  Furthermore, 
a detailed echocardiogram was performed, making assessment of left ventricular 
systolic and diastolic function, left and right ventricular size, and valve structure 
and function.  All echocardiograms were performed by myself, but blindly 
analysed by an expert in echocardiography (consultant cardiologist, Dr Piotr 
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Sonecki).   This was a crucial aspect of the screening process, particularly in 
making the diagnosis of HF-PEF, as this can be difficult and requires a number of 
assessments to be made.  These are often not routinely performed in clinical 
practice in the West of Scotland.   
Although a strictly consecutive cohort was not possible, as some patients are 
unable to consent due to cognitive impairment, and some patients refused 
consent, I was able to recruit a near-consecutive cohort of patients with heart 
failure.  This makes the results of this study more generalisable than most of the 
previous published studies assessing PC need in patients with heart failure. I 
have also reduced selection bias as much as possible by employing this strategy.   
In my systematic review of the literature I showed that most of the previous 
published studies of PC needs in patients with heart failure were from small, 
highly selected cohorts, often exclusively of HF-REF.   
Another issue identified in the systematic review of the current literature was 
the limited description available of use of pharmacotherapy and device therapy 
in previous studies describing PC needs.  I have extensively documented 
admission and discharge medications, including all potential disease modifying 
therapies.  The patients studied with HF-REF, where disease modifying therapies 
are available, were in general discharged from hospital on disease modifying 
therapy where tolerated.  This is important in any study assessing the PC needs 
of patients with heart failure, as these therapies could change the course of the 
condition and symptom burden.   
Another strength of my study was the size, with a large number of participants 
recruited, and long follow-up period with regular study assessments.  As 
described above, many of the studies reviewed focused on small numbers of 
highly selected cohorts, with resultant low power and high selection bias, and 
ultimately reduced generalisability.  I have recruited a large contemporary 
cohort, of well described patients with heart failure, and systematically 
followed them up over a median of 2.1 years.  A total of 691 study assessments 
were carried out, which gives this study a unique perspective into the patient 
journey. Patients were not only passively followed-up with record linkage to 
ensure as complete follow-up as possible, but they were offered active follow-up 
with study visits for a minimum of 8 months and a maximum of 28 months.  Only 
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two other studies describing the potential PC needs of patients with heart 
failure enrolled similar or greater number of patients.  The first enrolled 
community patients with heart failure.183  This study is important and 
informative, but lacks the robustness of diagnosis that my study offers.  The 
diagnosis was a clinical diagnosis of heart failure, which is flawed due to the 
variety of other conditions which can present with similar symptoms.  The 
analysis of the EVEREST study is also important, firstly due to its size, but also 
that participants had repeat assessments at one and 26 weeks.112  Although this 
was a highly selected clinical trial cohort, only including HF-REF, and used a 
different definition of PC needs (KCCQ summary score <45 on two measurements 
or death before week 26), the results were similar to my own.  In their 
multivariable analysis, the strongest predictor of PC needs was a KCCQ summary 
score of < 25 during baseline hospitalisation.   
Perhaps the greatest strength of my study was the use of quantitative measures 
to describe the effect heart failure has on patients’ QOL, symptoms, and mood.  
I used a combination of well validated and robust measures to give an overall 
assessment of the burden placed on patients by heart failure.  I also made an 
objective assessment of caregiver burden using a well validated questionnaire.  
Many studies have performed these assessments in patients with heart failure 
previously, however no study has performed all of these PROMs, and repeatedly 
over time, in an unselected cohort.  Using quantitative PROMs again increases 
the generalisability of the results.   
9.3 Weaknesses 
There are a number of unavoidable weaknesses in this study.  Perhaps the most 
important to address is the definition of PC needs.  There is no single assessment 
that categorises patients as having PC needs in heart failure.  There is a WHO 
definition of PC, and this defines what PC aims to do for a patient, but there is 
no universal definition of PC needs.  I have used this definition of PC to define a 
group of patients who I think had PC needs.  Not only did I adapt and interpret 
this definition of PC, but I also consulted with experts in both PC and heart 
failure, including the only consultant cardiologist in the UK with a specialist 
interest in PC (Dr Karen Hogg).  Through these discussions we were able to reach 
a consensus on how PC needs should be defined, as described in the methods 
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chapter.  I believe this definition is appropriate, incorporates the principles of 
the WHO definition of PC, and importantly, is intuitive for the practicing 
physician to understand.  Ultimately, the definition of PC needs I have chosen 
was designed to identify a group of patients who have the worst persistently 
impaired lives (as measured by frequent hospitalisations, poor QOL, high 
symptom burden) and a reduced life expectancy.  The reason for identifying 
these patients is that they are likely to be the group who would benefit most 
from a palliative intervention.  I have shown that the group identified as having 
PC needs had a worse patient journey, and ultimately had much fewer good days 
out of hospital with more days lost to either death, hospitalisation, or 
impairment of QOL.  
Another potential weakness of my study is the use of cut-off scores to define 
severity in each PROM.   For most of the PROMs there were published severity 
categories available, or cut-offs which were associated with worse outcomes.  
The ESAS was one PROM which, although used frequently in PC studies of 
patients with cancer, had no defined cut-off scores to categorise severity.  I 
have used an intuitive and common-sense approach to divide the overall score of 
the ESAS into thirds, with categories for none/mild impairment, moderate, and 
severe.  I believe the cut-offs or categories used are appropriate as patients with 
severe ESAS category had worse scores in all other PROM categories, and were 
more likely to be classified severe in other PROM categories.  Using cut-offs will 
invariably classify some patients who would have been close to the severe group 
in each PROM being labelled as not having PC needs.  Again, the purpose of this 
study was to try and describe a group of patients with persistently the worst 
QOL, symptom burden, and mood, and a reduced life expectancy, which may 
benefit from PC.  I believe this has been achieved and now this group of patients 
can be targeted for a palliative intervention in a RCT.  This is similar to the first 
use of ACEI in patients with heart failure.  First, the therapy was used in the 
most severe group, in the case of CONSENSUS, patients with NYHA class IV and 
low ejection fraction were targeted.  After a benefit was shown in this group, 
the therapy was trialled in other categories of patients (NYHA II, and patients 
without overt symptoms).   
Another potential weakness of the study was the number of patients who 
withdrew or were lost to active follow-up (failed to attend study visits).  I have 
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chosen not to exclude these patients.  I have done this as to eliminate these 
patients would reduce the overall generalisability of the study by introducing a 
form of selection bias, as only those who were fit/ able enough to complete 
follow-up would be assessed.  I feel excluding these patients would eliminate a 
large group of patients who were perhaps those with the highest need, as they 
may have missed study assessments due to deteriorating health.  There are 
various statistical ways of dealing with drop outs, or missed appointments.  One 
method is to impute an assumed value.  Another method would be to assume 
that a patient missed an appointment due to deteriorating health and classify 
them as “severe” for that missed assessment.    For the purposes of the defining 
patients with PC needs, I have not done this.  I have assumed that the patient’s 
overall status did not change from the previous assessment.   
Another potential weakness of the study was the time between assessments.  I 
elected to use 4 monthly assessments instead of shorter time intervals.  I did this 
for logistical reasons, based on the amount of time available for myself and the 
study nurse to complete the large number of assessments.  To increase the 
frequency of visits to 3 monthly, or more frequent, would have required me to 
truncate follow-up.  I felt 4 month visits allowed for the maximum number of 
follow-up visits and study duration. 
The VOICES survey had a low response rate compared to the published national 
VOICES surveys.  This reduces the value of the VOICES component of this study, 
but I believe this part of the study is still useful and informative about the 
caregivers’ perspective regarding EOL care.  I suspect the difference in 
methodology between my study and the VOICES national survey explains the low 
response rate in my study.  I only posted the VOICES questionnaire if I 
definitively knew that the deceased participant had an informal caregiver, 
whereas the VOICES national survey posted to registered next of kin. 
An unavoidable weakness of the study is the exclusion of patients with 
dementia.  Although these patients are potentially a group which are 
underserved by all services, and potentially have the highest levels of PC need, 
it would not be possible or appropriate to include these patients.  Firstly, they 
would be unable to participate, and secondly, they would be unable to complete 
the PROMs. 
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9.4 Future research based on this study 
One of the main objectives of this study was to identify a group of patients with 
heart failure who may benefit from a palliative intervention.   Not only have I 
described a group of patients who had either a sustained, severe impairment of 
QOL, symptom burden, or mood, or died following severe impairment, but I have 
also shown there is a marked discrepancy between these patients with PC needs 
and those who received PC.  Although there has now been a number of recent 
RCTs that are suggestive that a palliative intervention in patients with heart 
failure would be beneficial, these have been small studies, with ambiguous 
primary outcomes such as change in QOL.  To truly say that a patient has PC 
needs, we must prove that there is a benefit to patients from a palliative 
intervention.  My study will inform the design of a RCT which will answer this 
question.  I have identified a suitable target population, specifically those who 
met the definition of PC needs for such a study.  I have also shown that it is 
possible to identify these patients using a validated QOL questionnaire, the 
KCCQ, and a bedside physician completed assessment, the AKPS.  This study also 
provides crucially important data to power the sample size for any future RCTs 
testing a palliative intervention.  I have demonstrated the usefulness of the 
novel metric, DAOH, and more importantly, QOL adjusted DAOH.  This measure, 
used as the primary endpoint in a RCT of early PC in heart failure, will allow 
comparison of the patient journey between two groups.  I have also shown that 
patients are willing to discuss EOL preferences, and this is another potential 
endpoint in a RCT, comparing achieved preference for EOL care.  I believe this 
would be a more appropriate secondary endpoint, as palliative care needs are 
not limited to patients who die.  I found the VOICES EOL questionnaire to be 
very informative, but I feel this will be less useful in a RCT setting due to low 
return rates.   
I envisage an RCT comparing standard practice to early referral and utilisation of 
specialist PC services, in conjunction with usual care.  My study also provides 
some of the potential target areas for intervention, as individual patients would 
have different needs.  I have shown that some patients experience marked mood 
disturbance with low mood and anxiety, perhaps these patients could be 
targeted with cognitive-behavioural, pharmacological, and psychological 
therapies.  I have also shown that patients with heart failure experience a 
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variety of symptoms which could be specifically monitored and targeted, such as 
focused treatment of pain and nausea.  I have also demonstrated that some 
patients and their caregivers would have welcomed better communication 
between services, and better communication regarding their prognosis, 
treatment options, and EOL preferences. Some of these communication issues 
could potentially be addressed or highlighted through use of an appropriate 
anticipatory care plan.  Such an anticipatory care plan could be standardised in 
an RCT setting.   I believe that the NAT-PD-HF, although not identified as an 
independent predictor of PC need after multivariate analysis, would still be a 
very useful tool for monitoring the progress and highlighting specific needs of 
individual patients.  These specific and individual needs could be targeted by the 
PC and heart failure teams during the study.  Further research, based on the 
data gathered in my study, will be able to provide the construct validation for 
the NAT-PD-HF for such a purpose.   
9.5 Conclusions 
Patients admitted to hospital because of heart failure experience a variety of 
symptoms, frequently experience mood disturbance, and have markedly 
impaired QOL. Not only does heart failure impair the lives of patients, but also 
that of their caregivers.  I have demonstrated the fluctuating nature of the 
syndrome of heart failure by describing the patient journey in detail.  Following 
a hospitalisation due to heart failure, many patients have reduced number of 
good days spent out of hospital, with frequent and prolonged hospitalisations, 
reduced QOL, and reduced life expectancy.  26.8% of patients in this study met 
the definition PC needs.   Despite these apparent PC needs, very few patients 
accessed SPCS, and even fewer accessed hospice care.  Ultimately to prove a 
need for treatment, we should first prove a benefit.  My study provides the basis 
for the design of, and the justification for, a RCT which will test whether early 
PC can improve the lives of patients with a diagnosis of heart failure.   
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Appendices 
Appendix 1- Systematic review table 
Supplementary Appendix: Table 1A: Quantitative studies 
Study 
(year) 
Country 
Cohort description 
Aims Design 
 
Outcome 
measures 
Main Findings 
 Participants Recruitment n Age 
(mean
) 
Male 
(%) 
NYHA 
(%) 
Mean 
EF  
(%) 
HF 
diagnosis 
definition 
HF-PEF 
included 
Scott161 
(2000) 
USA 
 Outpatients 
with End 
Stage HF 
10 outpatient 
inotrope 
infusion 
programs. 
 
Selected 
Cohort. 
20 69 90 IV (100) NA NA NA Describe 
patient and 
caregiver 
HRQOL. 
 
Cross-
sectional. 
 
Quantitative. 
 
Telephone 
interview. 
QOL:  
 MLHF 
 QLI 
Mental health 
 MHI-5 
 
 
 1/3 of caregivers felt 
unprepared for the stress 
associated with caring for 
someone with end-stage 
HF. 
 Most felt positive regarding 
caregiving.  
 78% reported daily 
activities focused on ADL 
of patient, with 55% having 
to eliminate things from 
their schedule. 
 All pts reported physical 
burden, more so than 
emotional, particularly 
impairment in sexual 
activity, diet , walking, 
and climbing stairs. 
 55% of caregivers and 50% 
of pts experienced anxiety 
, with 65% and 45% 
respectively experiencing 
depression. 75% of patients 
fell below the age-
adjusted normative values 
for mental health scores. 
  Caregivers  18 63 11     Describe 
influence of 
caring on 
caregiver. 
 Caregiver 
preparedness: 
 QPS 
Caregiver 
Burden: 
 CRA 
Anderson11
3 
(2001) 
UK 
 Outpatients 
with end 
stage HF  
Heart failure 
clinic, tertiary 
centre. 
66 67 83 III/IV 
(49) 
29 NA NA Describe 
and 
compare 
symptoms 
Quantitative. 
 
Cross-
sectional. 
Self-designed 
questionnaire 
consisting of 
checklist of 20 
 PC and HF patients had 
similar number of 
symptoms per patient. 
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Consecutive 
patients. 
and service 
use between 
HF and 
palliative 
patients. 
different 
symptoms. 
 Symptom type differed 
between PC and HF 
patients. 
 HF patients less likely to 
access support services 
  Outpatient 
palliative 
patients 
(cancer or 
HIV) 
From 
Palliative care 
services and 
clinics 
213         
Fried134 
(2002) 
USA 
  CHF with 
reduced life 
expectancy 
Sequential 
charts 
screened from 
Cardiology, 
Pulmonary 
and Oncology 
outpatient 
practices, as 
well as 
inpatients. 
66 75 77 NA NA NA NA Describe 
patients’ 
preference 
for care in 
relation to 
burden of 
care. 
Quantitative, 
cross-
sectional. 
 
Interview at 
home. 
Self-designed 
questionnaire 
using 4 
scenarios: 
burden of 
treatment; 
possible 
outcomes; 
likelihood of 
outcomes. 
 Most patients would 
accept  a low burden 
treatment unless high 
likelihood of functional or 
cognitive impairment. 
  COPD with 
reduced life 
expectancy 
81      
  Cancer with 
reduced life 
expectancy 
79      
Barnes114 
(2006) 
UK 
CHF 
outpatients 
from 16 GP 
practices 
Identified and 
recruited by 
GPs 
 
Largely 
unselected 
cohort 
 
Age > 60 
540 NA 
80% >70 
39%> 80  
54 I/II (61) 
III/IV 
(39) 
NA Clinical 
diagnosis of 
HF 
NA Explore 
prevalence 
and burden 
of symptoms 
in elderly 
patients 
with CHF 
Quantitative,  
Longitudinal 
 
Qualitative 
interview for 
40 
participants 
QOL: 
 KCCQ 
 SF-36 
Mood: 
 GDS-5 
Symptoms 
 NYHA 
 
 Symptom burden high 
and common, 
particularly SOB and 
fatigue, which was 
experienced daily in 
half of participants   
 Over half of 
participants reported 
symptoms of 
depression  
Walke169 
(2007) 
USA 
 
CHF 
outpatients 
 
Sequential 
charts 
reviewed and 
patients 
contacted by 
telephone 
 
Selected 
cohort 
 
Age > 60 
59 75 63 III/IV(10
0) 
(100% 
EF= 
<20%) 
NA No Examine the 
prevalence 
and severity 
of symptoms 
over time 
Quantitative 
Longitudinal 
every 4 
months for 2 
years 
Symptoms 
 ESAS 
 Symptoms not only 
highly prevalent, but 
frequently reported as 
moderate or severe 
 >50% of HF patients 
reported physical 
discomfort, fatigue, 
and problems with 
appetite 
 Pain increased in 
severity over time in 
patients with HF 
 COPD 
outpatients 
 74 72 50 NA        
Fitzsimons
132 
(2007) 
UK 
HF inpatients Selected 
cohort 
Identified by 
clinical team 
6 na 67 III/IV(10
0) 
(100% 
EF= 
<30%) 
NA no Explore 
patient 
perceived 
PC needs of 
Mixed 
methods: 
quantitative 
QOL 
 SF-36 
Mood 
 HADS 
 Patients with HF 
reported poor physical 
and general health on 
SF-36 
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patients 
with non-
cancer 
diagnosis 
and 
qualitative,  
Cross-
sectional 
 
Semi-
structured 
interview 
 Depression and anxiety 
not reported at 
clinically significant 
levels on HADS 
 Themes important to 
patients identified 
through interview were 
physical deterioration, 
increased dependence, 
and family burden.  
Patients also 
experienced limited 
access to resources  
 Renal failure  6 NA 50 NA        
 Respiratory 
failure 
 6 NA 50 NA        
Bekelman1
16, 117  
(2007) 
USA 
CHF Recruited by 
Cardiologists 
at outpatient 
clinic 
60 75* 63 NA NA Cardiologist’
s clinical 
diagnosis of 
HF 
NA Identify the 
relationship 
between 
spiritual 
well-being 
and 
depression 
Cross-
sectional, 
quantitative 
Mood 
 GDS-SF 
Spiritual well-
being 
 FACIT-Sp 
QOL 
 KCCQ 
Physical 
symptoms 
 MSAS-SF 
 >30% of patients had 
clinically significant 
depression 
 Greater spiritual well-
being was associated 
with less depression 
 Depression was 
associated with a 
greater number of 
physical symptoms 
 
Gott137 
(2007) 
UK 
CHF in 
primary care 
Decedents 
with KCCQ 
assessments  
from larger 
longitudinal 
study of HF 
27 NA NA II (66) 
III (33) 
NA Clinical 
diagnosis of 
HF 
NA Assess 
change in 
QOL prior to 
death and 
dying 
trajectory  
Quantitative, 
longitudinal  
QOL 
 KCCQ 
 Physical function 
fluctuated in the 
months leading up to 
death  
 No clear dying 
trajectory was 
identified 
Opasich157 
(2008) 
Italy 
HF inpatients Selected 
cohort, 
inpatients 
with NYHA III-
IV 
46 71 57 III (26) 
IV (74) 
28 NA NA Explore 
physical and 
emotional 
symptoms 
mostly 
related to 
global 
health 
status in HF 
Cross-
sectional, 
quantitative 
 
ESAS repeated 
x2 daily for 5 
days 
QOL 
 KCCQ 
Symptoms 
 ESAS 
 Many symptoms 
identified, HF patients 
had poor global health 
status 
 Most distressing 
symptoms reported 
were general 
discomfort, tiredness, 
anorexia and dyspnoea 
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Goebel136 
(2009) 
USA 
CHF 
outpatients 
 Randomly 
sampled 
patients 
attending 
outpatient 
visits 
95 67 100 NA NA Clinical 
diagnosis of 
systolic or 
diastolic HF 
Yes Describe 
and 
compare 
symptoms of 
pain in 
patients 
with HF 
Cross-
sectional, 
quantitative 
Mood 
 PHQ-2 
 GAD-2 
Symptoms 
 BPI 
 Patients with HF 
experienced similar 
severity, interference, 
distress and location of 
pain to patients 
without HF 
 Pain is not an 
uncommon symptom in 
HF 
 Other 
outpatients 
 539 62 100         
Bekelman1
20 
(2009) 
USA 
CHF 
outpatients 
Selected 
patients from 
cardiology 
outpatient  
60 75* 63 NA NA Cardiologist’
s clinical 
diagnosis of 
HF 
NA Compare 
need for PC 
between HF 
and cancer 
population 
Cross-
sectional, 
quantitative 
Mood 
 GDS-SF 
Spiritual well-
being 
 FACIT-Sp 
QOL 
 KCCQ 
Physical 
symptoms 
 MSAS-SF 
 Similar physical 
symptoms , depression, 
and spiritual well-
being scores were 
reported between 
cancer and HF patients 
 Similar physical 
symptom burden, 
mood, and spiritual 
well-being scores were 
seen regardless of 
ejection fraction 
  Advanced 
cancer 
Oncology 
clinics 
30 64* 40         
Evangelist
a131 
(2009) 
USA 
CHF 
outpatients  
Tertiary HF 
clinic 
 
Selected 
cohort 
300 54 74 I (11) 
II (34) 
III (45) 
IV (12) 
32.3 NA No, 
inclusion 
EF <40% 
Describe the 
prevalence 
of pain in 
patients 
with HF and 
determine 
relationship 
of pain and 
QOL 
Cross-
sectional, 
quantitative 
QOL 
 MLWHF 
Pain 
 SF-36 
 Pain was common in 
CHF (67%) and more so 
in worse NYHA class 
(89% of NYHA IV) 
 Worse QOL (overall and 
physical) correlated 
with presence of pain 
O’leary156 
(2009) 
Ireland 
CHF 
outpatients 
Specialist HF 
clinic 
 
Selected 
cohort 
NYHA III/IV 
Deteriorating 
clinic 
condition 
 
50 77* 78 III/IV 
(100) 
28 NA NA Compare PC 
needs of 
patients 
with HF to 
patients 
with cancer 
Cross-
sectional, 
quantitative + 
qualitative 
interview 
QOL 
 SF-36 
Mood 
 HADS 
Symptoms 
 ESAS 
 Similar symptom 
burden was 
experienced between 
patients with HF and 
cancer 
 There was no 
difference between 
anxiety and depression 
scores between 
patients with cancer 
and HF 
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 Similar levels of QOL, 
with the exception of 
HF patients having 
better social 
functioning scores. 
 Cancer 
outpatients 
Referred to 
community 
specialist PC 
service 
50 75* 50         
Strachan16
5 
(2009) 
Canada 
HF inpatients ADHF from 5 
tertiary 
hospitals 
 
Selected 
cohort 
NYHA IV 
Age >55 
EF < 25% 
106 76 65 IV (100) NA NA no Identify 
opportunitie
s to improve 
EOL care in 
hospitalized 
patients 
with HF 
Cross-
sectional, 
quantitative 
 
Investigator 
designed 
questionnaire 
covering 5 
areas: 
 Medical + 
nursing 
care 
 Communi
cation + 
decision 
making 
 Social 
relations
hips + 
support 
 Advanced 
care 
planning 
 Most preferred place of 
death was home 
 Obstacles identified to 
achieving home death 
included burden (58%), 
no caregiver available 
(22%), pain (30%), and 
no health care services 
(48%) 
 Most expected to have 
a life expectancy of > 
1 year or did not know  
 46% wanted to know 
their prognosis 
 50% wanted to have a 
discussion about CPR, 
42% had not discussed 
CPR with anyone, 
 Most patients wanted 
some form shared 
decision making 
regarding CPR 
Allen112 
(2011) 
USA 
HF inpatients RCT inpatients 
with EF ≤ 40% 
Recruited 
from 359 sites 
 
Selected 
population 
1458 67 75 I (4) 
II (42) 
III (48) 
IV (6) 
27 Clinical 
signs of HF + 
low EF 
No Identify 
patients at 
risk of poor 
QOL and 
death 
following HF 
hospitalizati
on 
Quantitative 
 
Longitudinal 
QOL 
 KCCQ 
 High 6 month mortality 
(33%) 
 13.2% of survivors had 
persistently 
unfavorable QOL 
Raphael158 
(2011) 
UK 
HF outpatients 
with ICD 
Selected 
population 
with ICD  
54 72 80 Overall 
score 
mean 
1.8 
37 NA No Assess 
patients’ 
attitudes to 
and opinions 
of EOL care  
Quantitative  
 
Cross-
sectional 
EOL 
 Investigat
or 
designed 
questionn
aire 
 Most patients were 
aware of why ICD was 
implanted, but few 
were aware of options 
for device 
deactivation. 
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assessing 
ICD 
deactivat
ion 
 Most patients would 
like to be involved in 
any discussions about 
device deactivation, 
and advanced care 
planning. 
Bekelman1
18 
(2011) 
USA 
HF outpatients 
attending HF 
PC clinic 
Selected 
population 
50 51* 72 I (2) 
II (28) 
III (57) 
IV (13) 
28 NA NA Assess PC 
needs (QOL, 
symptoms, 
mood) 
serially in 
outpatients 
attending 
PC program  
Quantitative 
 
Longitudinal 
 
Retrospecti-ve  
QOL 
 KCCQ 
Mood 
 PHQ-9  
 GAD-7 
Symptoms 
 MSAS-SF 
 Common symptoms 
were depression(50%), 
anxiety (33%), pain 
(47%), fatigue (62%), 
dyspnea (46%), and 
sleep disturbance 
(44%). 
 Most of population not 
in terminal year of life, 
1 year mortality 14% 
 Advanced care 
discussed in 48%, 
Hospice and 
resuscitation discussed 
in 16% 
Habal140 
(2011) 
Canada 
HF oupatients 
attending 
heart function 
clinic in 
quaternary 
care academic 
centre 
Selected 
population 
 
LVSD 
41 57 83 I (17) 
II (39) 
III (29) 
IV (15) 
NA NA No Determine 
patients’ 
awareness, 
comprehensi
on, 
utilisation of 
ACD, 
determine 
knowledge 
of CPR and 
preference 
Quantitative 
 
Cross-
sectional 
Semi-
structured 
interview 
 Most (76%) did not 
know what an ACD was 
 Most would like to 
discuss ACD (78%) 
 Most would prefer full 
resuscitation at the 
time of interview 
 Of 19 patients with 
ICD, 47% would want 
ICD deactivation if 
deterioration of 
clinical condition, only 
2 patients recalled 
having previously 
discussed device 
deactivation 
Janssen147 
(2011) 
The 
Netherlan
ds 
Outpatients 
with severe 
HF 
Selected 
population, 
NYHA III/IV 
80 76 68 III/IV 
(100) 
na na na Assess the 
severity of 
symptoms, 
presence of 
co-
morbidities, 
and 
provision of 
Quantitative 
 
Cross-
sectional 
Symptoms 
 VAS 
Mood 
 HADS 
 Numerous symptoms 
were common, and 
rated as moderate to 
severe: Dyspnoea 
(75%); Fatigue (84%); 
Coughing (50%); 
weakness (85%); loss of 
appetite (45%); 
 Outpatients 
with COPD 
Selected 
population, 
105 66 62     
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GOLD stage 
III/IV 
services in 
outpatients 
with 
advanced 
COPD and 
HF 
insomnia (50%); low 
mood (53%); pain 
(41%); thirst (46%); 
frequent micturition 
(65%) 
 Symptom frequency 
and severity were 
similar between COPD 
and HF, although there 
was more severe 
dyspnoea in pts with 
COPD and more pain, 
itch and nocturnal 
micturition in pts with 
HF 
 Pts with both COPD 
and HF were generally 
satisfied with their 
management 
Janssen148 
(2012) 
The 
Netherlan
ds 
Caregivers of 
outpatients 
with severe 
HF 
Selected 
population, 
NYHA III/IV  
45 67 20 III/IV 
(100) 
(patient
s) 
na na na To assess 
caregiver 
burden as 
well as 
positive 
aspects of 
caregiving in 
advanced 
organ 
disease 
Quantitative 
 
Cross-
sectional 
Caregiver 
burden 
 FACQ PC 
Care 
dependency 
 CDS 
 Caregiver strain scores 
were relatively low 
 Scores were 
comparable across 
different conditions 
 Scores for positive 
caregiving appraisals 
and family well being 
were relatively 
positive 
 Caregivers of 
outpatients 
with advanced 
COPD 
 73 63 23     
 Caregivers of 
outpatients 
with advanced 
CRF 
 41 59 42     
Dunlay128 
(2012) 
USA 
New HF 
outpatients 
Olmstead 
County 
Unselected 
cohort, 
retrospective 
study 
608 74 55 I/II (35) 
III/IV 
(65) 
NA Framingham 
criteria 
Yes Assess use 
of ACD  
Quantitative 
 
Longitudinal 
Mood 
 PHQ-9 
QOl 
 SF-12 
Social support  
 ESSI 
EOL 
 Medical 
record  
 27% of participants 
died within mean 
follow up 1.8 years 
 Only 249 had an ACD 
 Of those with an ACD, 
less than half 
addressed CPR, 
mechanical ventilation 
or haemodialysis 
Howie-
Esquivel143 
(2012) 
USA 
HF inpatients Recruited as 
inpatient, 
screening NA 
47 63 64 II (21) 
III (34) 
IV (45) 
NA NA  Yes Assess 
communicat
ion wishes 
regarding 
Quantitative, 
Cross-
sectional 
QOL 
 KCCQ 
EOL 
 Most patients wished 
for more information 
about their condition 
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EOL care; 
identify 
relationship 
between 
communicat
ion and 
clinical 
characteristi
cs 
 Semi-
structure
d 
interview 
 44% wanted more 
information regarding 
prognosis 
 51% of patients could 
recall discussions 
regarding resuscitation 
during hospitalization 
Udeoji168 
(2012) 
USA 
HF outpatients Selected 
population, 
NHA IV 
excluded, HF-
REF only 
62 56* 82 na 33 na no 
 
Evaluate the 
prevalence 
and severity 
of pain in 
patients 
with HF 
Quantitative, 
Cross-
sectional 
Symptoms 
 ESAS 
 
 Symptoms were 
common and often 
reported as severe: 
pain (52%), fatigue 
(76%), reduced general 
wellbeing (84%), 
dyspnoea (76%), 
drowsiness (76%) 
Evangelist
a130 
(2012) 
USA 
HF outpatients 
referred for 
PC 
consultation 
Selected 
population, 
 
Tertiary 
centre, 
Patients with 
ICD/ VAD 
excluded, life 
expectancy < 
6 months 
excluded 
36 54 72 II (70) 
III (30) 
25 NA NA 1) Assess 
feasibility of 
referring pts 
recently 
hospitalized 
with HF to 
PC + 
standard 
care 
2) Compare 
PC 
consultation 
to standard 
care 
3) Examine 
relationship 
between 
clinical 
characteristi
cs and QOl, 
mood, 
symptom 
burden 
4) Assess 
multivariate 
model in 
predicting 
QOL, mood, 
Quantitative, 
longitudinal 
Symptoms 
 ESAS 
Mood 
 PHQ-9 
QOL 
 MLHF 
 PC consultation 
focused on ACP (100%), 
symptom management 
(81%), illness 
understanding (69%), 
and caregiver burden 
(50%) 
 Impaired QOL, mood 
disturbance, and 
symptom burden 
common in both groups 
 Pts referred to PC 
were similar to the 
control group regarding 
symptoms, QOl, and 
Mood at baseline 
 PC group showed 
better QOL, symptoms, 
and mood at 3 months 
            
 HF patients 
hospitalized 
Recruited 
from a larger 
RCT, selected 
population 
36 53 72 II (72) 
III (28) 
26 NA NA   
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Symptom 
burden 
Brunner-
La Rocca48 
(2012) 
Europe 
HF outpatients Pts 
participating 
in a RCT (BNP 
guided 
treatment) 
 
Selected 
population 
622 77 59 ≥ II (76) 35 Previous 
hospitalizati
on with CHF 
Yes  Assess 
willingness 
to trade 
survival 
time for 
QOL and 
resuscitatio
n 
preferences 
Quantitative, 
Longitudinal 
QOL 
 MLHF 
 SF-12 
Mood 
 GDS 
EOL 
 TTO tool 
 89% of participants 
completed time trade-
off questionnaire, 
although this 
decreased at 
subsequent visits  
 At baseline, 74% of pts 
were not willing to 
trade survival time for 
improved QOL, this 
increased significantly 
at month 12 and again 
at month 18 
 Willingness to trade 
survival time for 
increased QOL 
increased with age, 
female sex, GDS, 
reduced activity 
status, gout, 
constipation and 
oedema.  This was not 
reliably predictable 
from these factors 
however. 
 97% of pts completed 
the resuscitation 
questionnaire 
 39% did not wanting 
resuscitation, where 
51% did  
Malik152 
(2013) 
UK 
HF outpatients 
HF caregivers 
Recruited 
from 
outpatient 
clinics and 
inpatient 
wards 
 
Selected 
patients 
51 73 75 II (18) 
III (74) 
IV (8) 
25* NA NA Compare 
experiences 
of caring for 
breathless 
patient with 
lung cancer 
to HF and 
examine 
factors 
associated 
with 
caregiver 
burden  
Quantitative, 
cross-
sectional 
Caregiver 
burden 
 ZBI-12 
 COPE 
Mood 
 HADS 
QOL 
 SF-36 
Symptoms 
 POS-S 
 POS-C 
Performance 
 Both HF and lung 
cancer patients 
reported high levels of 
unmet needs, similar 
between both groups 
 Caregivers looking 
after more 
symptomatic pts 
reported positive 
caring experiences 
 Despite similar levels 
of symptoms and 
caregiver burden, HF 
          
 Lung cancer 
patients 
 50 70 71     
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Lung cancer 
caregivers 
 PPS patients had less 
access to PC services 
 
              
Herman141 
(2013) 
Czech 
Republic 
HF outpatients 
with ICD 
Selected 
population at 
ICD clinic in 
tertiary 
University 
centre, 
although 
consecutive 
screening at 
clinic 
112 68 84 I (12) 
II (81) 
III (7) 
32 NA No Examine the 
wishes of HF 
pts with ICD 
regarding 
ICD 
deactivation 
Quantitative, 
cross-
sectional 
EOL 
 Investigat
or 
designed 
questionn
aire 
regarding 
ICD 
deactivat
ion 
 46% of patients had 
never considered ICD 
deactivation during 
near- EOL situations 
 EOL ICD deactivation 
only discussed with 7% 
of pts 
 40% wanted more 
information regarding 
ICD deactivation 
 26% refused more 
information or further 
discussion regarding 
ICD deactivation 
Evangelist
a129 
(2014) 
USA 
HF outpatients Selected 
population, 
NYHA II-III, 
referred to PC 
services 
36 54 72 II (69) 
III (31) 
25 na na Describe PC 
services and 
levels of 
symptom 
burden 
experienced 
during 
initial PC 
consultation 
Quantitative, 
cross-
sectional 
Symptoms 
 ESAS 
 
 92% of pts reported at 
least one symptom, 
61% reported at least 
one severely distressful 
symptom. 
 Most commonly 
experienced 
moderate/ severe 
distressful symptoms 
were fatigue (77%), 
pain (78%), anxiety 
(50%), depression 
(39%), dyspnoea (39%), 
drowsiness (36%), 
anorexia (36%), nausea 
(14%), reduced well-
being (39%)  
Kavalierat
os149 
(2014) 
USA 
HF patients 
attending PC 
service 
Selected 
population 
already 
enrolled in PC 
service 
 
334 84* 41 Na Na Na Na Describe 
unresolved 
symptom 
and 
treatment 
needs in pts 
with HF and 
cancer 
Retrospective,  
Quantitative, 
cross-
sectional 
Symptoms 
 McCorkle 
Symptom 
Distress 
Scale 
Performance 
 PPS 
 Physical symptoms 
common (fatigue 60%, 
anorexia 30%, 
dyspnoea 25%) 
 28% of pts with HF had 
low PPS, with median 
score of 40 
 Cancer pts experienced 
greater frequencies of 
anorexia, pain, 
Cancer 
patients 
 697          
246 
attending PC 
service 
insomnia, anxiety, 
constipation, and 
nausea.  
 Dyspnoea more
commonly unresolved
in pts with HF.
Janssen146 
(2014) 
The 
Netherlan
ds 
Outpatients 
with severe 
HF 
Selected 
population, 
NYHA III/IV 
80 76 68 III/IV 
(100) 
na na na Explore the 
profiles of 
care 
dependency 
and 
compare 
between 
different 
conditions 
Quantitative, 
longitudinal 
Care 
dependency 
 CDS
 COPD and CHF pts had
higher baseline levels
of care dependency
 COPD pts were more
likely to experience
increase in care
dependency than CHF
or CKD pts
Outpatients 
with COPD 
Selected 
population, 
GOLD stage 
III/IV 
105 66 62 
Outpatients 
with CKD 
Requiring 
dialysis 
80 62 60 
Sidebotto
m163 
(2014) 
USA 
HF inpatients Tertiary care 
setting 
LVAD, 
transplant, 
actively dying 
pts excluded 
RCT early PC 
vs standard 
care 
232 73 53 NA NA NA NA Compare 
early 
inpatient PC 
use vs 
standard 
care in 
patients 
with HF, 
assess 
change in 
symptom 
burden, 
QOL, service 
use 
RCT 
Quantitative 
Longitudinal 
at baseline, 1 
and 3 months 
Symptoms 
 ESAS
QOL
 KCCQ
Mood
 PHQ-9
 Greater improvements
in symptom burden,
mood, and QOL seen in
early PC arm
 Pts in PC arm 2.87
times more likely to
complete a disease
specific ACP
Brannstro
m122 
(2014) 
Sweden 
HF outpatients Selected 
population 
RCT early PC 
vs normal 
therapy 
NYHA III/IV + 
≥1 HF 
hospitalization 
in preceding 6 
months 
72 NA ESC 
guidelines 
No Evaluate 
early PC 
versus 
normal care 
in pts with 
HF with 
regard to 
QOL, 
symptoms, 
and 
hospitalizati
ons 
RCT 
Quantitative 
Longitudinal 
assessment 
Symptoms 
 ESAS
QOL
 EQ-5D
 KCCQ
Resource
utilization
 Improved QOL and less
symptom burden seen
in PC treatment arm vs
control arm
 Less healthcare
utilization in PC arm
 PC arm 36 82 72 III (78) 
IV (22) 
 Control
arm
36 77 69 III (64) 
IV (31) 
ACD= advanced care directives; ADHF= acute decompensated heart failure; BNP= Brain-type natriuretic peptide; BPI= brief pain inventory; CDS= care dependency 
scale; CHF= chronic heart failure; CKD= chronic kidney disease; COPD= chronic obstructive pulmonary disease; COTE= care of the elderly; CPR= cardio-pulmonary 
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resuscitation; CPS= Caregiver preparedness scale questionnaire; CPR= cardiopulmonary resuscitation; CRA= caregiver reaction assessment; EF = ejection fraction; 
EOL= end of life; ESC= European Society of Cardiology; ESSI= ENRICHD Social Support Instrument; FACQ PC= family appraisal of caregiving questionnaire for 
palliative care; FACIT-Sp= Functional assessment of chronic illness therapy- spiritual well-being; GAD-2= generalized anxiety disorder scale; GDS-5= Geriatric 
Depression scale; GDS-SG = geriatric depression scale- short form; GOLD= Global initiative for chronic obstructive lung disease; GP= general practitioners; HF = 
heart failure; HIV= Human immunodeficiency virus; HRQOL = health related quality of life; ICD= implantable cardioverter defibrillator; LVAD= left ventricular assist 
device; MLHF= Minnesota Living with Heart Failure Questionnaire; MHI-5 = mental health inventory questionnaire; MSAS-SF = memorial symptoms assessment scale- 
short form; MND= motor neuron disease; NA= not available; NYHA = New York Heart Association; PC= palliative care; PHQ-2= Patient health questionnaire; POS-S= 
Palliative Care Outcome Scale- symptom; POS-C= Palliative Care Outcome Scale- Core; PPS= palliative performance scale; QLI= quality of life index questionnaire; 
QOL= quality of life; RCT= randomized controlled trial; TTO= time trade-off; VAD = ventricular assist device; VAS= visual analogue scale; ZBI-12= Zarit burden 
interview 
*= median 
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Supplementary appendix: Table 1B-Qualitative Studies 
Study 
(year) 
Country 
Cohort description 
Aims Design 
 
Main Findings 
 Participan
ts 
Recruitmen
t 
n Age 
(mean
) 
Male 
(%) 
NYHA 
(%) 
Mean 
EF  
(%) 
HF 
diagnosis 
definition 
HF-PEF 
included 
Lynn151 
(1997) 
USA 
Caregivers 
of HF 
inpatients 
Selected 
population, 
recruited as 
part of 
SUPPORT 
study, NYHA 
III/IV, 
expected 
reduced life 
expectancy  
102 na na na na na na Characterize 
experience of 
dying from the 
perspective of 
caregiver 
Qualitative 
interview, 
cross-
sectional 
 26% of HF pts died during first 
hospitalization 
 58% died in hospital, 27% died at home, 7% 
in a nursing home, and 3 % in a hospice 
 Caregivers reported high levels of severe 
dyspnoea (~65%), confusion (~15%) and pain 
(~45%) 
 ~50% of caregivers felt pt would have 
preferred comfort care at EOL 
 ~15% reported feelings that care was at odds 
with patients’ preference  
 ~40% of pts with HF received at least one of 
feeding tube, ventilator, or CPR in the last 3 
days of life  
Krumholz46 
(1998) 
USA 
HF 
inpatients 
Selected 
population, 
recruited as 
part of 
SUPPORT 
study, NYHA 
III/IV, 
expected 
reduced life 
expectancy  
936 Na 63 Na Na Na Na Describe the 
resuscitation 
preferences of pts 
admitted to 
hospital with HF 
Qualitative 
interview, 
Longitudinal 
assessment 
as inpatient 
and at 2 
months 
 63% viewed their QOL as fair/ poor 
 Most (67% estimated their  2 month survival 
at >90%) 
 23% reported not wanting CPR 
 Of 42 pts suffering cardiac arrest s inpatient, 
11 stated a wish not to be resuscitated, of 
these, 6 had resuscitation attempted 
 19% of pts changed resuscitation preferences 
after 2 months, 40% of those expressing 
wishes DNR changed their mind at 2 months 
Rogers159 
(2000) 
UK 
HF 
outpatient
s 
Outpatient 
cardiology and 
care of the 
elderly clinics 
 
Selected 
population 
targeting 
older patients 
27 69 74 II (26) 
III (44) 
IV (30) 
33 na na To explore pts 
understanding of 
HF, investigate 
their need for 
information and 
issues regarding 
communication 
Qualitative 
interview, 
cross-
sectional 
 Participants often sought further 
information regarding HF, prognosis and 
likely mode of death. 
 Pts described difficulties establishing good 
communication with doctors such as access 
to appointments, confusion, memory loss, 
and belief that doctors did not want to give 
pts too much information 
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Murray153 
(2002) 
UK 
HF 
outpatient
s and 
caregivers 
Selected 
population, 
NYHA IV,  
20 na na IV (100) na na na Compare illness 
trajectory and 
needs of pts with 
HF and lung 
cancer 
Qualitative 
interview, 
Longitudinal 
every 3 
months for 1 
year  
 Illness trajectory is different between lung 
cancer and HF, with HF affected by periods 
of acute deterioration, sudden death and no 
distinct terminal phase 
 HF pts and carers have less understanding of 
the condition and prognosis, and fewer 
opportunities to discuss EOL issues compared 
to pts with lung cancer 
 HF pts and carers have less access to support 
services such as PC, social and health 
services compared to lung cancer 
 Lung 
cancer 
outpatient
s and 
caregivers 
 20 na na     
Formiga42 
(2004) 
Spain 
ADHF 
inpatients 
 
Largely 
unselected 
cohort 
 
Recruited by 
investigator 
prior to 
discharge 
 
Age > 64 
80 79 42 II (10) 
III (74) 
IV (16) 
NA NA NA Describe EOL and 
CPR preferences 
of patients with 
ADHF 
Qualitative, 
cross-
sectional 
 42% did not want CPR 
 Only 3% had previously discussed CPR 
preference 
 50% would wish EOL care take place at 
home, 40% in hospital, 10% unsure 
 48% expressed a wish for spiritual support 
Willems171 
(2004) 
Holland 
HF 
outpatient
s 
Selected 
population 
 
NYHA >II 
EF < 25 
≥1 HF 
hospitalization 
31 72 74 I (4) 
II (19) 
III (70) 
IV (7) 
na na no Describe and 
explore the ideas 
and attitudes of 
pts with HF to 
dying 
Qualitative 
interview, 
Longitudinal 
every 4-6 
months for 1 
year 
 Most pts only thought about death during 
exacerbations  
 Few participants would consider suicide or 
euthanasia 
 Aspects considered appropriate dying 
included usefulness of pt, understanding 
prognosis, appropriate duration, and mental 
awareness, 
 All participants wanted life-prolonging 
therapy withheld when appropriate 
Boyd121 
(2004) 
UK 
HF 
outpatient
s/ 
community  
 
Selected 
population, 
NYHA IV 
20 74 55 IV (100) na na na Describe pt and 
caregivers views 
of health and 
social care in the 
last year of life 
Qualitative 
interview , 
Longitudinal 
every 3 
months 
 Pts with HF and their caregivers felt 
unsupported by services 
 Pts and their caregivers had little 
understanding of HF, the treatment options, 
or prognosis 
 QOL was impaired primarily by physical 
limitations and psychological morbidity 
 Pts and caregivers felt they had poor access 
to psychosocial care and the communication 
between primary and secondary care was 
poor 
 PC approach was rarely used 
 HF 
caregivers 
     
 Healthcare 
profession
als 
     
Murray154 
(2004) 
HF 
outpatient
Selected 
population, 
20 na na IV (100) na na na Explore spiritual 
needs, in context 
Qualitative 
interview, 
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UK s + 
caregivers 
NYHA IV of overall needs of 
pts with HF and 
compare to pts 
with inoperable 
lung cancer 
Longitudinal 
every 3 
months 
 HF pts experienced isolation, hopelessness 
and loss of confidence thought the last year 
of life 
 Many pts from both groups experienced 
spiritual needs in the last year of life 
 Pts were reluctant to raise spiritual needs 
with professionals, but were willing to 
discuss issues when prompted 
 Lung 
cancer 
outpatient
s + 
caregivers 
Identified by 
respiratory 
consultants 
       
Horne142 
(2004) 
UK 
HF 
outpatient
s 
Selected 
population 
from two 
teaching 
hospitals  
 
 
20 73 70 II (10) 
III (35) 
IV (55) 
na na na Explore the 
experiences of pts 
with advanced HF 
and identify needs 
for PC 
Qualitative 
interview, 
cross-
sectional 
 Reported problems included difficulty 
mobilizing, fatigue and difficulties 
performing activities of daily living 
 Relying on others, and feelings of burden, 
loneliness and isolation were identified as 
themes 
 Pts discussed dying and fears and 
frustrations at living with HF 
 None of the pts involved were referred to PC 
services 
Agard110 
(2004) 
Sweden 
HF 
outpatient
s 
Selected 
population, 
over 60 years 
 
University 
teaching 
hospital 
40 75 63 II (33) 
III (65) 
IV (2) 
na na na Explore pts with 
HF’s knowledge of 
their condition 
and attitude 
towards 
prognostic 
information 
Qualitative 
interview, 
cross-
sectional 
 Most pts had a limited understanding of their 
condition, but were satisfied with their level 
of understanding 
 Most did not want prognostic information 
Aldred111 
(2005) 
UK 
HF 
outpatient
s recently 
discharged 
from 
hospital 
Selected 
population, 
over 60 
10 72 70 II (20) 
III (60) 
IV (10) 
Na Na Na Explore the 
impact of HF on 
the lives of older 
pts with HF and 
their caregivers 
Qualitative 
interview, 
cross-
sectional 
 HF affect daily lives of pts and caregivers 
including every day activities 
 Pts felt concerned regarding the potential 
burden placed on caregivers 
 Lack of professional support contributed to 
social isolation of pts and caregivers 
 Pts and caregivers had limited understanding 
of HF and prognosis 
Brannstrom124 
(2006) 
Sweden 
House 
bound HF 
patients 
Selected 
population, 
NYHA III/IV 
plus deemed 
to be 
palliative 
4 79* 75 III (25) 
IV (75) 
Na ESC criteria na Understand 
meaning of living 
with severe HF in 
palliative 
advanced home 
care 
Qualitative 
interview, 
cross-
sectional 
 Themes identified included struggling to 
cope with unpredictability of condition; 
being aware of terminal condition; isolation; 
being positively dependent on professional 
care at home 
 Other sub themes identified include: 
dyspnoea; pain; difficulties mobilising; 
fatigue 
Barnes115 
(2006) 
UK 
Community 
HF patients 
Selected 
population,  
 
44 na na na na na na Explore patient’s 
and professionals 
attitudes towards 
communication of 
Qualitative 
interviews 
and focus 
group, 
 Main issue contributing to poor 
communication in primary care was 
diagnostic uncertainty 
 Terminology avoidance of the word ‘failure’  
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Subset of 
population 
recruited to 
larger study 
diagnosis, 
prognosis, and 
symptoms in HF 
  Patients had a poor understanding of their 
condition 
 Few pts had a discussion regarding prognosis 
with a healthcare provider 
Zapka172 
(2006) 
USA 
Communit
y HF 
patients 
Selected 
population, 
expected to 
be in last year 
of life 
38 na na na na na na Profile 
communication 
and 
recommendations 
reported by adults 
with terminal 
illness  
Qualitative 
interview, 
cross-
sectional 
 Pt’s with cancer were more likely to receive 
symptom management at home, be aware of 
their prognosis, and attend a hospice 
 Discussions regarding EOL care or ACD was 
low in both groups of pateints 
 Communit
y patients 
with 
cancer 
 52          
Formiga133  
(2007) 
Spain 
CHF 
inpatients 
Selected 
cohort, case 
note review of 
patients who 
died in 
hospital  
 
65 
81 
 
 
 
43 IV (100) NA Presence of 
impaired 
systolic or 
diastolic 
function + 
NYHA IV 
yes Assess caregiver’s 
opinion of EOL 
care 
Cross-
sectional, 
Qualitative 
 67 % of caregivers satisfied with overall EOL 
care , remaining thought it could be 
improved 
 45% thought symptoms could be controlled 
better in last 24 hours of life 
 14% thought pain was not controlled 
 45% thought dyspnoea was not controlled 
 Dementia  37 87 46        
Selman162 
(2007) 
UK 
HF 
inpatients 
and 
outpatient
s 
Selected 
population, 
HF-REF, NYHA 
III/IV 
20 69 80 III (80) 
IV (20) 
34 na no Generate data on 
patients’ and 
caregivers’ 
preferences 
regarding future 
treatments and 
EOL care; 
investigate 
communication 
between staff, 
patients and 
caregivers 
regarding EOL  
Qualitative 
interview, 
cross-
sectional 
 EOL care preferences varied widely 
 None of the pts or caregivers had discussed 
EOL care or ACD with their physician 
 Patients and caregivers were not aware of 
different EOL care options such as PC 
 Pts and caregivers were afraid and anxious 
regarding the diagnosis of HF, and lacked 
information regarding the diagnosis 
 EOL / ACD was rarely raised by staff  
Dougherty127 
(2007) 
USA 
HF 
outpatient
s 
contacted 
via 
telephone 
Selected 
population, 
expectancy 
less than 1 
year, AHA 
stage C/D 
24 68 88 na 29 na na Describe how 
patients with 
advanced HF view 
and plan for 
future care 
including EOL care 
Qualitative 
interview, 
cross-
sectional 
 Patients experienced distress from fatigue 
and reduced functional capacity 
 Patients did not actively plan for EOL  
 Patients wanted to discuss EOL care with 
care providers but initiation of discussions 
was difficult, leading to frustration 
 Less than 50% of patients received a life 
expectancy estimate from healthcare 
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providers, although patients did not find 
estimates of life expectancy helpful 
 Patients were unaware of ACD including ICD 
deactivation 
Brannstrom123 
(2007) 
Sweden 
Communit
y HF 
patients  
Selected 
population 
attending PC 
unit 
na na na III/IV 
(100) 
na na na Examine the 
meaning of being 
a caregiver to 
someone with 
severe HF 
Qualitative 
interview, 
cross-
sectional 
 Themes identified: caregivers alarmed and 
aware of the unpredictable nature of HF; 
caregivers burdened by responsibility; 
physical burden of caregiving; isolation; 
struggling to maintain household 
 Caregivers felt supported by the PC team 
Caregivers  4          
Caldwell125 
(2007) 
Canada 
HF 
outpatient
s 
Selected 
population 
attending 
tertiary care 
university 
centre,  
 
NYHA III/IV 
20 68 70 III (65) 
IV (35) 
28 na na Identify 
preferences of 
patients with HF 
regarding 
communication 
about EOL and 
prognosis 
Qualitative 
interview, 
cross-
sectional 
Themes identified: 
 Level of wellness- patients wanted 
information about prognosis and its 
implications at a time of good cognitive 
function 
 Opportunity to be informed- pts preferred 
doctors to initiate EOL discussions 
 Tell the truth- preference from pts for 
physicians to be honest regarding prognosis, 
treatments and outcomes 
 Hope- pts felt a need for truth to be 
balanced with hope 
Cortis126 
(2007) 
UK 
HF 
outpatient
s 
Selected 
population 
attending PC 
service 
 
Age > 80 
10 Range 
80-90 
50 II (20) 
III (40) 
IV (40) 
na na na Explore 
experiences of 
older pts with HF 
to understand PC  
and supportive 
needs 
Qualitative 
interview, 
cross-
sectional 
 Common physical symptoms experienced by 
pts included dyspnoea, falls, anorexia, 
insomnia, headaches, oedema, palpitations 
and fatigue 
 Coping with physical symptoms commonly 
lead to fear, anxiety and frustration 
 Pts reported loss of independence 
 Feelings of low self esteem and low self 
worth were reported by some pts as well as 
depression, low mood , and worry 
 Patients’ developed coping mechanisms 
including stoicism and acceptance 
 Pts worried about becoming a burden on 
others, but felt they were getting good 
standards of care from professionals 
Murray155 
(2007) 
UK 
HF 
outpatient
s 
Selected 
population, 
NYHA IV, older 
24 77 50 IV (100) na na na Identify and 
compare 
psychological, 
social, and 
spiritual needs of 
people with HF in 
the last year of 
Qualitative 
interview, 
Longitudinal 
every 3 
months 
 Decline of social, psychological wellbeing 
tracked decline in physical wellbeing in HF 
which was characterized by gradual decline 
punctuated by acute exacerbations with 
brief recovery 
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life and compare 
to lung cancer 
 Spiritual wellbeing fluctuated throughout 
the last year of patients’ lives 
 Cancer patients had a more gradual and 
obvious decline in physical wellbeing, 
tracked by decline in social wellbeing, 
whereas  psychological and spiritual 
wellbeing fluctuated with diagnosis, 
discharge after treatment and disease 
progression 
 Lung 
cancer 
outpatient
s 
  67 58       
Gott138 
(2008) 
UK 
Communit
y patients 
with HF 
Selected 
population, 
sample of 
larger study 
with NYHA 
III/IV 
40 77* 52 III/IV 
(100) 
na na na Examine older pts 
with HF’s views on 
EOL  
Qualitative 
interview, 
cross-
sectional 
 Fears about dying included pain and 
dyspnoea 
 Many pts did not want open awareness of 
EOL 
 Few patients had discussed ACD or prognosis 
with a physician 
 Thinking about EOL was anxiety provoking  
 A sudden death would be preferable for 
some pts studied 
 Pts with HF’s view of a ‘good death’ 
conflicted with conventional views held in 
PC delivery 
Stromberg166 
(2008) 
Sweden 
HF 
Outpatient  
Largely 
unselected 
population 
attending op 
cardiology 
clinic 
following 
recent HF 
hospitalization  
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70 70 na na ESC 2005 
guidelines 
na Explore elderly 
pts with HF’s 
thoughts 
regarding EOL in 
the immediate 
period following 
HF hospitalization 
Mixed 
methods: 
Quantitative 
QOL: 
EQ-5D 
 
Qualitative  
interview 
 
Cross-
sectional 
 During acute exacerbations 16% of pts were 
afraid of dying, and 4% suffered this feeling 
often 
 These fears did not change over 6 months 
following an exacerbation 
 Fear of death was correlated to higher levels 
of anxiety and depression, both during 
deterioration and 6 months later 
 Common themes regarding EOL were 
acceptance of death as a relief from 
suffering, fear of painful death, loss of 
independence and loss of dignity 
Ryan160 
(2009) 
Ireland 
HF 
outpatient
s 
Selected 
population 
attending 
outpatient 
clinic 
 
NYHA III/IV 
9 70 67 III/IV 
(100) 
na na na Describe pts’ 
experiences of 
living with 
advanced HF 
Qualitative 
interview, 
cross-
sectional 
Themes identified: 
 Patients lived with fear , particularly of 
suffering dyspnoea at night or of when the 
next HF exacerbation would be 
 Fatigue was a common problem reported 
 Patients felt hopeless  
 Frustration at living a restricted life due to 
HF symptoms 
 Social isolation commonly reported 
 Patients expressed frustration at using 
hospital services multiple times, but also at 
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lack of continuity when presenting to 
secondary care 
Thomas167 
(2009) 
USA 
HF 
inpatients 
and 
outpatient
s 
Selected 
population 
 
Age > 60  
57 na 70 na na na na Identify the 
determinants of 
doctors’ hospice 
discussions and 
impact of 
discussions on 
hospice referrals 
Qualitative 
interview, 
cross-
sectional 
 Common symptoms experienced by pts with 
HF included pain (29%), decreased activity 
levels (60%), depression (13%), and dyspnoea 
(32%).  These were similar to levels 
experienced by cancer and COPD pts, 
although pts with COPD suffered more 
dyspnoea 
 11% Pts with HF reported QOL as poor – 
worst ever 
 75% pts with HF rate health perception to be 
fair- poor 
 14% of clinicians reported life expectancy to 
pts with HF 
 Only 7% of HF pts had a discussion with 
doctor regarding hospice, common reasons 
being patient not terminally ill (55%), 
prognosis too uncertain (34%), or services 
would not benefit pt (13%) 
 Cancer 
inpatients 
 79 Na 57       
 COPD 
inpatients 
 79 Na 51       
Small164 
(2009) 
UK 
Family 
members 
of pts with 
HF 
Selected from 
larger study 
20 Na Na Na Na Na Na Explore carers’ 
views of EOL and 
bereavement for 
family members 
who recently died 
with HF 
Qualitative 
interview, 
cross-
sectional 
 Caregivers found difficulty discussing wishes 
of relatives for EOL care prior to death, 
making ACD difficult 
 Caregivers were generally against futile 
therapies, with an emphasis on QOL over 
length of life 
 Most would opt for a death at home, 
although not all would have preferred this 
 The sense that a relative had a ‘good death’ 
helped with bereavement, although 
caregivers were felt to have continuing 
needs 
 Deaths at home were considered to be 
‘good’ deaths 
 Only a small proportion of caregivers took up 
bereavement counselling 
Waterworth170 
(2010) 
New Zealand 
Communit
y patients 
with HF 
Recruited 
from primary 
care, or 
recently 
discharged 
from 
secondary 
care 
25 81 60 II (40) 
III (44) 
IV (16) 
Na Na Na Explore the 
experiences of 
older people with 
HF and transitions 
to dependence 
and EOL 
Qualitative 
interview, 
Longitudinal 
every 3-4 
months 
 Pts expressed fears of becoming a burden as 
they got older and progressed from 
independence to dependence to EOL 
 Pts believed they would receive good care at 
EOL from healthcare professionals 
 Pts with HF did not transition from 
independence – dependence- EOL in a linear 
fashion 
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Hupcey144 
(2011) 
USA 
Caregivers 
of pts with 
HF 
Spouses of pts 
admitted to 
hospital with 
decompensate
d HF 
45 Na Na Na Na Na Na Describe the 
experiences of 
spousal caregivers 
in caring for 
someone with HF 
to identify 
potential PC 
needs 
Qualitative 
interview, 
Longitudinal 
every month 
for 12-18 
months 
 Caregivers felt exhausted and stressed and 
experienced difficulties associated with not 
having their own health issues addressed 
 Caregivers often ignored their own health 
issues during times of exacerbation of their 
spouse’s HF 
 Psychosocial issues wre present for all 
spousal caregivers, both during HF 
exacerbations and at times of stability 
 Some caregivers experienced financial 
difficulties, and when present were 
persistent 
 All of the spousal caregivers had information 
needs, from acute treatments to ACD 
Bekelman119 
(2011) 
USA 
HF 
outpatient
s 
Selected 
population 
identified 
from 
University 
Hospital 
outpatient 
department 
33 64 70 II (33) 
III (39) 
IV (12) 
31 Na na Detail pts with HF 
and their 
caregivers’ needs 
and explore how 
PC may be useful 
to these pts 
 
Qualitative  
interview 
 
Cross-
sectional 
 Pts and caregivers reported a need to be 
able to adjust to limitations imposed on 
them by HF 
 Pts and caregivers frequently reported 
physical limitations as a common issue 
 Caregivers sought information regarding 
future course of the HF illness 
 Some pts expressed wishes to know more 
about prognosis 
 Pts suffered a number of diverse symptoms , 
particularly fatigue and dyspnoea.  Many pts 
were pessimistic regarding potential 
therapies for these symptoms.  Other 
symptoms included pain, dry mouth, and 
constipation 
 caregivers  19 59 5        
Gysels139 
(2011) 
UK 
HF 
outpatient
s 
Selected 
population, 
recruited from 
clinics 
 
NYHA III/IV 
10 69* 70 III/IV 
(100) 
Na Na Na Explore and 
compare patients’ 
experiences of 
dyspnoea between 
four conditions 
Qualitative  
interview 
 
Cross-
sectional 
 HF pts described dyspnoea in terms of the 
physical limitations it placed on their lives 
 Other common symptoms included oedema , 
pain, and fatigue 
 Disability was a common theme identified as 
a result of dyspnoea 
 Pts often thought about death 
 COPD 
outpatient
s 
 18 69* 30        
 Cancer 
outpatient
s 
 10 69* 50        
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 MND 
outpatient
s 
 10 42* 90        
Imes145 
(2011) 
USA 
HF 
outpatients 
Selected 
population, 
recruited from 
outpatient 
clinic 
 
NYHA III/IV 
Life 
expectancy < 
1 year 
14 68 88 III (96) 
IV (4) 
29 Na na Describe the 
experiences of pts 
living with severe 
HF as experienced 
by their partner 
Qualitative  
interview 
 
Cross-
sectional 
 Partners of pts with HF felt the pts’ disease 
affected their lifestyle by causing social 
isolation 
 Difficulties were experienced in planning for 
the future for both pt and caregiver 
 Caregivers felt under-prepared to manage 
the disease burden at home 
 EOL care and ACD was not actively discussed 
by healthcare providers 
 Despite having discussion with pts regarding 
EOL plans, there were frequently no ACD in 
place 
 Partners/ 
caregiver 
 14 65 79       
Gerlich135 
(2012) 
Germany 
HF 
outpatient
s 
Selected 
population, 
recruited from 
two hospitals 
outpatient 
department   
 
age > 70, 
patients with 
reduced life 
expectancy  
12 85 50 Na 
 
 
Na Na na Explore the needs 
of older patients 
with HF 
 
Qualitative  
interview 
 
Cross-
sectional 
 Pts wanted more information regarding their 
diagnosis and better communication 
regarding prognosis 
 Pts did not recognize HF as a life-limiting 
condition 
 Pts had no experience of PC services 
Kitko150 
(2013) 
USA 
Caregivers  Selected 
population, 
end-stage HF 
with LVAD 
10 62 20   na na Describe the 
experiences of 
caregivers of pts 
with end-stage HF 
with LVAD 
  
Qualitative  
interview 
 
Cross-
sectional 
Themes identified: 
 Adaptation to caregiver role 
 Caring for a spouse with HF 
  
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